-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, LoL/FQhwvavl41bKhBwMPV81JgdetrJ2jDgn0UYP5o56Gpj3lqkmw9R/pwOWacUP BEOn44/VQaiwDoo2ZxCOig== 0001144204-06-026579.txt : 20060628 0001144204-06-026579.hdr.sgml : 20060628 20060628172017 ACCESSION NUMBER: 0001144204-06-026579 CONFORMED SUBMISSION TYPE: SB-2/A PUBLIC DOCUMENT COUNT: 8 FILED AS OF DATE: 20060628 DATE AS OF CHANGE: 20060628 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PATRIOT SCIENTIFIC CORP CENTRAL INDEX KEY: 0000836564 STANDARD INDUSTRIAL CLASSIFICATION: COMMUNICATIONS EQUIPMENT, NEC [3669] IRS NUMBER: 841070278 STATE OF INCORPORATION: DE FISCAL YEAR END: 0531 FILING VALUES: FORM TYPE: SB-2/A SEC ACT: 1933 Act SEC FILE NUMBER: 333-134362 FILM NUMBER: 06930892 BUSINESS ADDRESS: STREET 1: 10989 VIA FRONTERA CITY: SAN DIEGO STATE: CA ZIP: 92127 BUSINESS PHONE: 8586745000 MAIL ADDRESS: STREET 1: 10989 VIA FRONTERA CITY: SAN DIEGO STATE: CA ZIP: 92127 FORMER COMPANY: FORMER CONFORMED NAME: PATRIOT FINANCIAL CORP DATE OF NAME CHANGE: 19920521 SB-2/A 1 v046258_sb2-a.htm
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
ON JUNE 26, 2006

REGISTRATION NO. 333-134362

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

AMENDMENT NO. 1 
TO
FORM SB-2

REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

PATRIOT SCIENTIFIC CORPORATION

(Name of small business issuer in its charter)

DELAWARE
3699
84-1070278
(State or Jurisdiction of Incorporation or Organization)
Primary SIC Code
(I.R.S. Employer Identification Number)

CARLSBAD CORPORATE PLAZA
6183 PASEO DEL NORTE, SUITE 180
CARLSBAD, CA 92011
(760) 547-2700
(Address and telephone number of principal executive offices)

THOMAS J. SWEENEY, CHIEF FINANCIAL OFFICER
PATRIOT SCIENTIFIC CORPORATION
CARLSBAD CORPORATE PLAZA
6183 PASEO DEL NORTE, SUITE 180
CARLSBAD, CA 92011
(760) 547-2700
(Name, address and telephone number of agent for service)

COPIES TO:
OTTO E. SORENSEN, ESQ.
LUCE, FORWARD, HAMILTON & SCRIPPS LLP
600 WEST BROADWAY, SUITE 2600
SAN DIEGO, CALIFORNIA 92101
(619) 236-1414
(619) 232-8311 (FAX)

APPROXIMATE DATE OF PROPOSED SALE TO
THE PUBLIC: AS SOON AS PRACTICABLE AFTER THE
EFFECTIVE DATE OF THIS REGISTRATION STATEMENT.

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. o
 
 
 
 

 
THE REGISTRANT HEREBY AMENDS THIS REGISTRATION STATEMENT ON SUCH DATE OR DATES AS MAY BE NECESSARY TO DELAY ITS EFFECTIVE DATE UNTIL THE REGISTRANT SHALL FILE A FURTHER AMENDMENT WHICH SPECIFICALLY STATES THAT THIS REGISTRATION STATEMENT SHALL THEREAFTER BECOME EFFECTIVE IN ACCORDANCE WITH SECTION 8(A) OF THE SECURITIES ACT OF 1933 OR UNTIL THE REGISTRATION STATEMENT SHALL BECOME EFFECTIVE ON SUCH DATE AS THE COMMISSION, ACTING PURSUANT TO SAID SECTION 8(A), MAY DETERMINE.
 
 
Title of Each Class of Securities to be Registered
 
Amount to be Registered
 
Proposed Maximum Offering Price Per Unit (3)
 
Proposed Maximum Aggregate Offering Price
 
Amount of Registration Fee
Common Stock, $0.00001 par value (1)
 
17,204,442
 
$0.84
 
$14,451,731.28
 
$1546.34
Common Stock, $0.00001 par value (2)
 
 
6,480,000
 
$0.84
 

$5,443,200.00
 
$582.42
TOTAL
 

23,684,442
 
 
 

$19,894,931.28
 
$2,128.76

(1)
Shares of the Registrant’s common stock, $.00001 par value per share, are being registered for resale on behalf of certain selling security holders. The common stock being registered was issued to the selling security holders between February 3, 2004 and March 23, 2006.
 
(2)
Shares of the Registrant’s common stock, $.00001 par value per share, are being registered for resale on behalf of certain selling security holders. The common stock being registered is issuable to the selling security holders on their exercise of warrants or options which were issued from April 26, 2004 through June 5, 2006.
 
(3)
Estimated solely for purposes of calculating the registration fee in accordance with Rule 457(c) under the Securities Act of 1933, as amended (the “Act”), based on the average of the closing bid and asked prices for the Registrant’s Common Stock (the “Common Stock”) as reported on the OTC Electronic Bulletin Board on May 12, 2006.
 
The information in this preliminary Prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the Securities and Exchange Commission (SEC) is effective. This preliminary Prospectus is not an offer to sell nor does it seek an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.
 

 
SUBJECT TO COMPLETION; AS FILED WITH THE SECURITIES AND
EXCHANGE COMMISSION ON JUNE 26, 2006

P R O S P E C T U S

PATRIOT SCIENTIFIC CORPORATION


The resale of up to 23,684,442 shares of common stock in the over-the-counter market at the prevailing market price or in negotiated transactions.
 
We will receive no proceeds from the sale of the shares by the Selling Shareholders.
 
TRADING SYMBOL
PTSC (Over-the-counter Electronic Bulletin Board)

THIS INVESTMENT INVOLVES A HIGH DEGREE OF RISK.
Please refer to Risk Factors Beginning on Page 1

THE SECURITIES AND EXCHANGE COMMISSION (SEC) AND STATE SECURITIES REGULATORS HAVE NOT APPROVED THESE SECURITIES OR DETERMINED IF THIS PROSPECTUS IS TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE. THIS PROSPECTUS IS NOT AN OFFER TO SELL THESE SECURITIES, NOR IS IT THE SOLICITATION OF AN OFFER TO BUY THESE SECURITIES, IN ANY STATE WHERE THE OFFER OR SALE OF THESE SECURITIES IS NOT PERMITTED.
 
Please read this Prospectus carefully. It describes our company, finances and products. Federal and state securities laws require that we include in this Prospectus all the material information that you will need to make an investment decision.
 
We have not authorized anyone to provide you with information that is different from that which is contained in this Prospectus.
 


 
TABLE OF CONTENTS

 
 
 
 
Page 
 
         
PROSPECTUS SUMMARY
    1  
About our Company
 
 
1
 
Warrant Shares We Are Registering
    1  
Additional Shares We Are Registering
    1  
Key Facts
    1  
 
RISK FACTORS
    1  
Patriot Has Reported Substantial Revenue In 2006 Which May Not Be Indicative Of Our Future Revenue Trends
    2  
Patriot Is Dependent Upon A Joint Venture In Which It Is A Passive Partner For Substantially All Of Its Revenues
    2  
Patriot’s Limited Sales And Marketing Capabilities Have Affected Our Revenue
    2  
Patriot May Experience Difficulties In The Completion Of Its Development Stage Products
    2  
Patriot Is Currently Involved In A Legal Dispute Which Could Impact Our Future Results Of Operations And Working Capital Position
    3  
A Successful Challenge To The Proprietary Nature Of Our Intellectual Property Would Have A Significant And Adverse Effect On Us
    3  
If A Large Number Of Patriot Shares Are Sold All At Once Or In Blocks, The Market Price Of Our Shares Would Most Likely Decline
    3  
The Market For Patriot’s Stock Is Subject To Rules Relating To Low-Priced Stock (“Penny Stock”) Which Limits Our Ability To Attract Competitive Funding
    3  
Our Share Price Could Decline As A Result Of Short Sales
    4  
Our Future Success Depends In Significant Part Upon The Continued Services Of Our Key Senior Management
    4  
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
    4  
 
PLAN OF DISTRIBUTION
    4  
SELLING SHAREHOLDERS
    5  
Selling Shareholders
    5  
OUR COMPANY
    6  
Background
    6  
AVAILABLE INFORMATION
    6  
 
BUSINESS
    6  
Technology
    7  
Our Microprocessor Technology
    8  
Our Licenses, Patents, Trade Secrets and Other Proprietary Rights
    11  
Research and Development
    13  
Marketing and Distribution
    14  
Dependence Upon Single Customers
    14  
Employees
    14  
Government Regulation
    14  
Description of Property
    15  
 
USE OF PROCEEDS
    15  
LEGAL PROCEEDINGS
    15  
 

 
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
    16  
Overview
    16  
Critical Accounting Policies
    17  
Results of Operations
    18  
Liquidity And Capital Resources
    21  
Recent Accounting Pronouncements
    22  
SELECTED FINANCIAL INFORMATION
    23  
MANAGEMENT
    25  
Committees of the Board Of Directors
    26  
Compliance with Section 16(a) of the Exchange Act
    27  
Code of Ethics
    27  
Indemnification of Officers, Directors and Others
    27  
EXECUTIVE COMPENSATION
    28  
Employment Contracts
    28  
Option Grants
    29  
Compensation of Directors
    30  
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
    30  
Certain Relationships and Related Transactions
    32  
MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS
    33  
DESCRIPTION OF SECURITIES
    33  
CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE
    34  
LEGAL OPINION
    34  
EXPERTS
    35  
         
INDEX TO FINANCIAL STATEMENTS
    F-1  
 

 
PROSPECTUS SUMMARY
 
About our Company
 
Patriot Scientific Corporation was organized under Delaware law on March 24, 1992, and is the successor by merger to Patriot Financial Corporation, a Colorado corporation, incorporated on June 10, 1987. Our address is Carlsbad Corporate Plaza, 6183 Paseo Del Norte, Suite 180, Carlsbad, CA 92011, and our telephone number is (760) 547-2700. Our home page can be located on the Internet at http://www.ptsc.com.
 
We develop, market, and sell microprocessors, our technology upon which the microprocessors are based, and complementary products which enable computers and other data processing devices to communicate. These products can be used to connect to the Internet or other telecommunication networks. We also have a patent for technology which, if fully developed, may allow radar to be used to penetrate the ground or structures to find various objects. Our strategy is to exploit our microprocessor technologies through product sales, licensing, and strategic alliances and to litigate against those who may be infringing on our patents.
 
We believe our financial resources are sufficient to support our operations during at least the next twelve months.
 
Warrant Shares We Are Registering
 
We are registering 6,480,000 shares issuable on the exercise of warrants or options issued between April 26, 2004 and June 5, 2006.
 
Additional Shares We Are Registering
 
We are also registering 17,204,442 shares that are issued and outstanding.
 
Key Facts
 
Shares being offered
 
23,684,442 (6.54 % of our shares currently outstanding as of April 17, 2006)
Total shares outstanding prior to the offering as of February 28, 2006
 
349,336,560
Total shares outstanding assuming completion of the offering
 
355,816,560
Total shares that would be outstanding assuming exercise of all outstanding options and warrants
 
425,329,628
Price per share to the public
 
Market price at time of resale
Total proceeds raised by offering
 
None.
Dividend policy
 
Patriot declared its first dividend on February 14, 2006 and another dividend on March 9, 2006. The Board of Directors may declare additional dividends in the future with due regard for the financial resources of Patriot and alternative applications of those financial resources.

 
Before purchasing any shares of our common stock, we urge you to carefully consider the following discussion of risks as well as other information contained in this Prospectus. The following are what we believe to be all our material risks. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations.
 

 
Patriot Has Reported Substantial Revenue In 2006 Which May Not Be Indicative Of Our Future Revenue Trends
 
During the first three quarters of fiscal 2006, the Company entered into license agreements, directly and through our joint venture with Technology Properties Limited, that generated license revenues of approximately $70,000,000 on a consolidated basis. Because of the uncertain nature of the negotiations that lead to license revenues, we cannot predict the amounts of future revenues from such agreements, or whether there will be future revenues from license agreements at all.

Patriot Is Dependent Upon A Joint Venture In Which It Is A Passive Partner For Substantially All Of Its Revenues
 
In June of 2005, we entered into a joint venture with Technology Properties Limited, pursuant to which Technology Properties Limited is responsible for the licensing and enforcement of Patriot’s microprocessor portfolio. This joint venture has been the source of virtually all of Patriot’s revenues since June of 2005. Therefore, given the absence of product sales on the part of Patriot or revenues from other sources, Patriot should be regarded as entirely dependent on the success or failure of the licensing and prosecution efforts of Technology Properties Limited on behalf of the joint venture.
 
Sales of our microprocessor products have resulted in limited revenues. Our other product lines have not generated enough revenue to support our company. We have experienced in the past and may experience in the future many of the problems, delays and expenses encountered by any early stage or small business, many of which are beyond our control. These include:
 
·      
substantial delays and expenses related to testing and development of our products and technologies,
 
·      
production and marketing problems encountered in connection with our products and technologies,
 
·      
competition from larger and more established companies, and
 
·      
lack of market acceptance of our products and technologies.
 
Patriot’s Limited Sales And Marketing Capabilities Have Affected Our Revenue
 
We currently have limited marketing capabilities and may need to hire additional sales and marketing personnel. We may not be able to recruit, train, or retain qualified personnel to sell and market our products and may not be able to develop a successful sales and marketing strategy. We also have very limited marketing experience. Any marketing efforts undertaken by us may not be successful or may not result in any significant sales of our products.
 
Patriot May Experience Difficulties In The Completion Of Its Development Stage Products
 
Our technologies and products are in various stages of development. We do not currently have in-house development personnel, nor have we retained independent researchers. Therefore, our development stage products may not be completed on a timely basis or at all. Additionally, even if we do recommence our development activities, our development stage products may not be completed due to the inherent risks of new product and technology development, limitations on financing, competition, obsolescence, the absence or loss of key personnel and other factors. Although we have licensed some of our technology at its current stage of development, we may not continue to be able to do so or that any revenues generated from licensing will be sufficient to support operations at their current level. Unanticipated technical obstacles can arise at any time and result in lengthy and costly delays or in a determination that further development is not feasible.
 

 
Patriot Is Currently Involved In A Legal Dispute Which Could Impact Our Future Results Of Operations And Working Capital Position
 
We are currently involved in a lawsuit with a former legal advisor, in which the former legal advisor is asserting a claim to a part of the proceeds we received under recently signed license agreements. We believe that this claim is without merit. However, if we do not prevail in this lawsuit, or settle the matter, the cost of the resolution of this matter could have a material and adverse effect on our results of operations and cash reserves.
 
A Successful Challenge To The Proprietary Nature Of Our Intellectual Property Would Have A Significant And Adverse Effect On Us
 
A successful challenge to our ownership of our technology or the proprietary nature of our intellectual property would materially damage our business prospects. We rely on a combination of patents, trademarks, copyrights, trade secret laws, confidentiality procedures and licensing arrangements to protect our intellectual property rights. We currently have eight U.S. patents, one European patent, and one Japanese patent issued. Any issued patent may be challenged and invalidated. Patents may not issue from any of our pending applications. Any claims allowed from existing or pending patents may not be of sufficient scope or strength to provide significant protection for our products. Patents may not be issued in all countries where our products can be sold so as to provide meaningful protection or any commercial advantage to us. Our competitors may also be able to design around our patents.
 
Vigorous protection and pursuit of intellectual property rights or positions characterize the fiercely competitive semiconductor industry, which has resulted in significant and often protracted and expensive litigation. Therefore, our competitors and others may assert that our technologies or products infringe on their patents or proprietary rights. Persons we believe are infringing our patents are vigorously defending their actions and have asserted that our patents are invalid. Problems with patents or other rights could increase the cost of our products or delay or preclude new product development and commercialization by us. If infringement claims against us are deemed valid or if our infringement claims are successfully opposed, we may not be able to obtain appropriate licenses on acceptable terms or at all. Litigation could be costly and time-consuming but may be necessary to protect our future patent and/or technology license positions or to defend against infringement claims.
 
If A Large Number Of Patriot Shares Are Sold All At Once Or In Blocks, The Market Price Of Our Shares Would Most Likely Decline
 
Our warrant holders are not restricted in the price at which they can sell common stock acquired through the exercise of warrants. Shares sold at a price below the current market price at which the common stock is trading may cause the market price to decline. The shares of common stock that are issuable on the exercise of our warrants represent a significant portion of our fully-diluted capitalization.
 
The Market For Patriot’s Stock Is Subject To Rules Relating To Low-Priced Stock (“Penny Stock”) Which Limits Our Ability To Attract Competitive Funding
 
Our common stock is currently listed for trading in the NASD Over-The-Counter Bulletin Board Market and is subject to the “penny stock rules” adopted pursuant to Section 15(g) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). In general, the penny stock rules apply to non-NASDAQ or non-national stock exchange companies whose common stock trades at less than $5.00 per share or which have tangible net worth of less than $5,000,000 ($2,000,000 if the company has been operating for three or more years). Such rules require, among other things, that brokers who trade “penny stock” to persons other than “established customers” complete certain documentation, make suitability inquiries of investors and provide investors with certain information concerning trading in the security, including a risk disclosure document, quote information, broker’s commission information and rights and remedies available to investors in penny stocks. Many brokers have decided not to trade “penny stock” because of the requirements of the penny stock rules, and as a result, the number of broker-dealers willing to act as market makers in such securities is limited. The “penny stock rules,” therefore, may have an adverse impact on the market for our common stock and may affect our ability to attract competitive funding.
 
 
Our Share Price Could Decline As A Result Of Short Sales
 
The downward pressure on the price of our common stock as our warrant holders exercise their warrants and sell material amounts of common stock could encourage short sales by the warrant holders or others. When an investor sells stock that he does not own, it is known as a short sale. The seller, anticipating that the price of the stock will go down, intends to buy stock to cover his sale at a later date. If the price of the stock goes down, the seller will profit to the extent of the difference between the price at which he originally sold it less his later purchase price. Short sales enable the seller to profit in a down market. Short sales could place significant downward pressure on the price of our common stock.
 
Our Future Success Depends In Significant Part Upon The Continued Services Of Our Key Senior Management
 
Our future success depends in significant part upon the continued services of our key senior management personnel. The competition for highly qualified personnel is intense, and we may not be able to retain our key managerial employees or attract and retain additional highly qualified technical and managerial personnel in the future. None of our employees is represented by a labor union, and we consider our relations with our employees to be good. None of our employees is covered by key man life insurance policies.
 
 
This Prospectus includes “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995, and we rely on the “safe harbor” provisions in those laws. The forward-looking statements in this Prospectus reflect our current views with respect to possible future events and financial performance. These forward-looking statements are subject to certain risks and uncertainties, including specifically the absence of significant revenues and financial resources until the current fiscal year, no assurance that the development of technology can be completed or that its completion will not be delayed, significant competition, the uncertainty of patent and proprietary rights, uncertainty as to royalty payments and indemnification risks, trading risks of low-priced stocks and those other risks and uncertainties discussed herein that could cause our actual results to differ materially from our historical results or those we anticipate. In this Prospectus, the words “anticipates,” “believes,” “expects,” “intends,” “future” and similar expressions identify certain forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made. Patriot undertakes no obligation to publicly release the result of any revision of these forward-looking statements to reflect events or circumstances after the date they are made or to reflect the occurrence of unanticipated events.
 
 
After the effective date of the registration statement of which this Prospectus is a part, each Selling Shareholder will be free to offer and sell his or her common shares at such times, in such manner and at such prices as he or she may determine. The types of transactions in which the common shares are sold may include transactions in the over-the-counter market (including block transactions), negotiated transactions, the settlement of short sales of common shares, or a combination of such methods of sale. The sales will be at market prices prevailing at the time of sale or at negotiated prices. Such transactions may or may not involve brokers or dealers. The Selling Shareholders have advised us that they have not entered into any agreements, understandings or arrangements with any underwriters or broker-dealers regarding the sale of their securities. The Selling Shareholders do not have an underwriter or coordinating broker acting in connection with the proposed sale of the common shares.
 
The Selling Shareholders may effect such transactions by selling common stock directly to purchasers or to or through broker-dealers, which may act as agents or principals. Such broker-dealers may receive compensation in the form of discounts, concessions, or commissions from the Selling Shareholders. They may also receive compensation from the purchasers of common shares for whom such broker-dealers may act as agents or to whom they sell as principals, or both (which compensation as to a particular broker-dealer might be in excess of customary commissions).
 
 
The Selling Shareholders and any broker-dealer that acts in connection with the sale of common shares may be “underwriters” within the meaning of Section 2(11) of the Securities Act. Any commissions received by such broker-dealers and any profit on the resale of the common shares sold by them while acting as principals may be deemed to be underwriting discounts or commissions.
 
Because the Selling Shareholders may be “underwriters” within the meaning of Section 2(11) of the Securities Act, the Selling Shareholders will be subject to prospectus delivery requirements.
 
Selling Shareholders also may resell all or a portion of their common shares in open market transactions in reliance upon Rule 144 under the Securities Exchange Act, provided they meet the criteria and conform to the requirements of such Rule.
 
 
Selling Shareholders
 
The following table sets forth certain information with respect to the Selling Shareholders as of February 28, 2006. Except as set forth below, none of the Selling Shareholders currently is an affiliate of ours, and none of them has had a material relationship with us during the past three years. None of the Selling Shareholders are or were affiliated with registered broker-dealers.
  
               
Amount and Percentage of Common Stock After the Sale 
 
Name
 
Beneficial Ownership of Common Stock as of February 28, 2006 
     
Maximum Number of Shares of Common Stock Offered for Sale 
 
Number 
 
% 
Caplan, Stan
 
2,904,096
 
(6)
 
1,147,751
 
1,756,345
 
____%
Daniels, Richard
 
3,795,862
     
3,795,862
 
-
 
____%
Gabourel, Victor
 
4,757,604
 
(1)
 
2,566,602
 
2,191,002
 
____%
Hawk Associates
 
2,422,496
 
(2)
 
1,222,496
 
1,200,000
 
____%
Mt. Savage Productions
 
1,000,000
 
(3)
 
1,000,000
 
-
 
0%
Opperman, Wayne
 
1,526,725
     
1,526,725
 
-
 
0%
Nunes, Daniel
 
2,100,000
     
500,000
 
1,600,000
 
____%
Zolin, James & Josephine
 
2,545,206
     
2,425,006
 
120,200
 
____%
Technology Properties Ltd.
 
3,700,000
 
(4)
 
3,500,000
 
200,000
 
0%
AMD Corporation
 
4,500,000
 
(5)
 
4,500,000
 
-
 
0%

(1)
Includes 180,000 shares of common stock issuable upon the exercise of issued warrants.
 
(2)
Frank Hawkins has ultimate voting and/or investment control over the securities owned by Hawk Associates. This amount includes 100,000 shares of common stock issuable upon the exercise of warrants dated March 1, 2006.
 
(3)
Includes 1,000,000 shares of common stock issuable upon the exercise of warrants. Elwood G. Norris has ultimate voting and/or investment control over the securities owned by Mt. Savage Productions.
 
(4)
Includes 3,500,000 shares of common stock issuable upon the exercise of warrants. Daniel Leckrone has ultimate voting and/or investment control over the securities owned by Technology Properties Ltd.
 
(5)
Harry Wollin, General Counsel and Senior Vice President of AMD has ultimate voting and/or investment control over the securities owned by AMD Corporation.
 
(6)
Included in this number are 193,548 restricted shares that were issued on March 23, 2006.
 

 
OUR COMPANY
 
Patriot Scientific Corporation was organized under Delaware law on March 24, 1992, and is the successor by merger to Patriot Financial Corporation, a Colorado corporation incorporated on June 10, 1987. In 1997, we emerged from the development stage primarily as a result of the acquisition of Metacomp Inc. Our address is 6183 Paseo Del Norte, Suite 180, Carlsbad, California 92011, and our telephone number is (760) 547-2700. Our home page can be located at http://www.ptsc.com.
 
We develop, market, sell, and license microprocessors and the technology incorporated within our microprocessors. We also have a patent for a technology which, if fully developed, might allow radar to penetrate the ground or structures to identify objects. We also owned gas plasma antenna technology which we sold for $250,000 in August 1999. In October 2003, we received a final royalty payment of $75,500 from the sale of the gas plasma technology. Our strategy is to exploit our microprocessor technologies through licensing, strategic alliances, and product sales and to litigate against those who we believe are infringing on our patents.
 
We believe our financial resources are sufficient to support our operations during at least the next twelve months.
 
Background
 
In February 1989, we completed our initial public offering under a registration statement on Form S-18 under the Securities Act of 1933. This offering raised gross proceeds of $50,000 and net proceeds of approximately $28,640 upon the sale of 2,500,000 units at $.02 per unit. Each unit sold in the public offering consisted of one common share and one Class A common stock purchase warrant exercisable to acquire one share of common stock and one Class B common stock purchase warrant. All Class A and Class B warrants have since been exercised or have lapsed.
 
On May 12, 1992, we redomiciled ourselves from Colorado to Delaware by merging into a wholly-owned Delaware subsidiary, Patriot Scientific Corporation, organized for that purpose. The reincorporation resulted in a reverse stock split. Three shares of the Colorado corporation, par value $.00001, were converted into one share of the Delaware corporation, par value $.00001. The reincorporation also effected a change in our charter and bylaws and a name change to Patriot Scientific Corporation.
 
In May 1993, we registered under the Securities Act of 1933 a total of 7,631,606 shares issuable upon the exercise of outstanding Class A and Class B common stock purchase warrants. Upon the exercise of those warrants, we received net proceeds of $3,343,915 and issued 7,538,102 common shares. None of such warrants remain outstanding.
 
Effective May 31, 1994, we entered into an asset purchase agreement and plan of reorganization with nanoTronics Corporation located in Eagle Point, Oregon and Helmut Falk. We issued a total of 8,500,000 restricted common shares to nanoTronics to acquire certain microprocessor technology of nanoTronics. The technology acquired was used to develop a sophisticated yet low cost microprocessor. 5,000,000 of the shares were issued on a non-contingent basis, and the remaining 3,500,000 shares were issued subject to the terms of an earnout escrow arrangement, which concluded on May 31, 1999.
 
Effective December 26, 1996, we acquired 96.9% of the outstanding shares of Metacomp, Inc., a California corporation, from 56 shareholders in exchange for the issuance of 1,272,068 shares of our common stock. Based on the closing price of our common stock of $1.375 on the date of the acquisition, the price of the acquisition was $1,749,094. This business combination was accounted for as a pooling-of-interests.
 
 
We file reports, proxy statements and other information with the SEC, and these reports may be inspected and copied at the public reference facility maintained by the SEC at 100 F Street, N.E., Washington, D.C. 20549. You may obtain information on the operation of the public reference room by calling the SEC at 1-800-SEC-0330. Copies of such material may be obtained from the Public Reference Section of the SEC’s Washington, D.C. office at prescribed rates.
 



 
We mail a copy of our Annual Report on Form 10-K along with a proxy statement to our shareholders prior to our annual meeting.
 
We have filed a registration statement on Form SB-2, of which this Prospectus is a part, with the SEC. This Registration Statement or any part thereof may also be inspected and copied at the public reference facility of the SEC.
 
Our filings may also be accessed through the SEC’s web site (http://www.sec.gov) or by visiting our web site at (http://www.ptsc.com) and linking to the SEC’s site. Our website is not part of this prospectus.
 
 
 
Our business involves the following technologies:
 
·      
Ignite microprocessor technology;
 
·      
A portfolio of patents covering the basic design architecture found in microprocessors used in a wide variety of end-user products including personal computers, servers, workstations, printers, routers, home theater systems, digital TVs, video game players, DVD Recorders/Players, mobile handsets/PDA's, portable media players, microwave ovens, dishwashers, medical equipment, automotive electronics, aircraft/aerospace electronics, and other modern microprocessor-based products found in consumer and business applications.; and
 
·     
Technology providing for remote power charging of electronic devices.
 
The stage of development of each of our technologies is as follows:
 
·      
Ignite microprocessor. This technology generated minor amounts of revenue in fiscal 2004 from the sale of development boards and microprocessors and from initial license fees. In 2005 it generated revenues of approximately $1,200,000 in connection with the sale of a license to Advanced Micro Devices, Inc (“AMD”). We run the technology on a 0.18-micron microprocessor, which is not in current production. We have ported the WindRiver VxWorks operating system and the Sun Microsystems personalJava virtual machine to the microprocessor. In addition, the technology is available for sale as intellectual property, which enables the prospective customer to incorporate the microprocessor functions with other parties’ applications to arrive at a system on a chip solution. We are currently evaluating the extent to which the Ignite technology may contribute significant revenue, if any, in the future as a product line in the form of microprocessor chips or intellectual property licenses. During at least the three years prior to June, 2005, we focused the majority of our efforts on the Ignite technology. The Ignite technology is targeted for the embedded controller and Java language processor marketplaces.
 
·     
Microprocessor patent portfolio. In the immediate future, we will be focusing our efforts primarily on the patent portfolio licensing and enforcement efforts being conducted on our behalf by the TPL Group. We currently anticipate that these efforts will be our principal source of revenue in the future, although we will continue to evaluate the Ignite microprocessor technology and the extent to which the Ignite technology may contribute significant revenue, if any, in the future as a product line in the form of microprocessor chips or as intellectual property licenses. See “BUSINESS - Our Licenses, Patents, Trade Secrets, and Other Proprietary Rights.”
 

 
·     
Remote power charging technology. In November, 2004, a patent application entitled “Remote Power Charging of Electronic Devices” was assigned to us. The patent application has 53 claims and has no conflicting prior art. We expect that it will be granted and that it should protect the essential systems, methods, apparatus and applications of the technology it describes. We anticipate that the Ignite microprocessor would be selected as the microprocessor to be used in products based on this technology. We are in the initial stages of evaluating this technology and its applicability and feasibility for further research and development, and we do not know whether it will be the basis for any commercial product or that it will generate any revenue for the Company.
 
Our Microprocessor Technology
 
General Background. Effective May 31, 1994, we entered into an asset purchase agreement and plan of reorganization with nanoTronics Corporation located in Eagle Point, Oregon, and Helmut Falk to acquire certain microprocessor technology. We used the technology we acquired from nanoTronics to develop a sophisticated yet low cost microprocessor by enhancing the microprocessor design, adding additional technical features to further modernize the design, and improving and testing the new design.
 
We initially fabricated a prototype 0.8-micron microprocessor in May 1996. The next generation was a 0.5-micron microprocessor that was delivered in September 1997. The 0.5-micron microprocessor was employed in demonstrations for prospective customers and was shipped in limited numbers to customers as an embedded microprocessor. In 1998 we introduced a 0.35-micron microprocessor whose features included a reduction in size and improved performance. In addition, in September 2000 we completed a VHDL model of this technology which enables customers to purchase intellectual property incorporating microprocessor functions with other parties’ applications to arrive at a system on a chip solution. By purchasing this software model, customers can significantly reduce their time to market by simulating results as opposed to trial and error commitments to silicon production. In 2003 we further reduced the size of our silicon production to 0.18-microns.
 
Industry Background. The semiconductor logic market has three major sectors:
 
·      
standard logic products;
 
·      
application specific standard products; and
 
·     
application specific integrated circuits.
 
Standard logic products, such as the Intel’s X86 and Pentium and Motorola’s 680X0 microprocessor families, are neither application nor customer specific. They are intended to be utilized by a large group of systems designers for a broad range of applications. Because they are designed to be used in a broad array of applications, they may not be cost effective for specific applications. Application specific integrated circuits are designed to meet the specific application of one customer. While cost effective for that application, application specific integrated circuits require large sales volumes of that application to recover their development costs. Application specific standard processors are developed for one or more applications but are not generally proprietary to one customer. Examples of these applications include modems, cellular telephones, other wireless communications devices, multimedia applications, facsimile machines and local area networks. We have designed our microprocessor to be combined with application specific software to serve as an embedded control product for the application specific standard processor market sector.
 
Application specific standard processors are typically used in embedded control systems by manufacturers to provide an integrated solution for application specific control requirements. Such systems usually contain a microprocessor or microcontroller, logic circuitry, memory and input/output circuitry. Electronic system manufacturers combine one or more of these elements to fit a specific application. The microprocessor provides the intelligence to control the system. The logic circuitry provides functions specific to the end application. The input/output circuitry may also be application specific or an industry standard component. The memory element, if not on the microprocessor, is usually a standard product used to store program instructions and data. In the past, these functions have been executed through multiple integrated circuits assembled on a printed circuit board. The requirements for reduced cost and improved system performance have created market opportunities for semiconductor suppliers to integrate some or all of these elements into a single application specific standard processor or chip set, such as the Ignite family of microprocessors. The Ignite family provides close integration of the microprocessor and input/output function with the logic circuitry, thereby providing an advanced application specific standard processor.
 

Embedded control systems enable manufacturers to differentiate their products, replace less efficient electromechanical control devices, add product functionality and reduce product costs. In addition, embedded control systems facilitate the emergence of completely new classes of products. Embedded control systems have been incorporated into thousands of products and subassemblies worldwide, including automotive systems, remote controls, appliances, portable computers and devices, cordless and cellular telephones, motor controls and many other systems.
 
Microprocessors are generally available in 4-bit through 64-bit architectures, which refers to the amount of data they can process. 4-bit microprocessors are relatively inexpensive, typically less than $1.00 each. Although they lack certain performance and features, they account for more than 40% of worldwide microcontroller volume. Also in general use today are 8-bit architectures, generally costing $1.00 to $10.00 each and accounting for an additional 40% of worldwide microcontroller volume. To date 16-bit, 32-bit and 64-bit architectures, with typical costs of over $10.00 each, have offered very high performance, but are generally considered to be expensive for high-volume embedded control applications. The use of 16-bit, 32-bit and 64-bit architectures offers fewer internal limitations, making programming easier and providing higher performance. Although generally more expensive per unit and requiring more support logic and memory, these devices offer many advantages for more sophisticated embedded control systems.
 
Electronic system designers, driven by competitive market forces, seek semiconductor products with more intelligence, functionality and control that can be used to reduce system costs and improve performance. For these needs, the Ignite product family was designed to be a sophisticated 32-bit microprocessor with advanced features. The Ignite product family uses a smaller number of transistors compared to other RISC (reduced instruction set computer) processors, which results in less power consumption and more economical prices compared to other embedded control applications. This creates the opportunity for the development of new, cost-effective applications.
 
Technology Description. Conventional high-performance microprocessors are register-based with large register sets. These registers are directly addressable storage locations requiring a complex architecture that consumes costly silicon. This conventional architecture provides processing power for computer applications but complicates and slows the execution of individual instructions and increases silicon size, thereby increasing the microprocessor cost.
 
Our technology is fundamentally different from most other microprocessors, in that the data is stored in groups and certain information is known to be at the top of a stack as opposed to being stored in a register. Our microprocessor employs certain features of both register and stack designs. The resultant merged stack-register architecture improves program execution for a wide range of embedded applications. Our design combines two processors in one highly integrated package, a microprocessing unit for performing conventional processing tasks, and an input-output processor for performing input-output functions. This replaces many dedicated peripheral functions supplied with other processors. The microprocessor's design simplifies the manipulation of data. Our architecture employs instructions that are shrunk from 32-bits to 8-bits. This simplified instruction scheme improves execution speed for computer instructions. Our architecture incorporates many on-chip system functions, thus eliminating the requirement of support microprocessors and reducing system cost to users.
 
The 0.8-micron microprocessor was designed to operate at a speed of 50Mhz; the 0.5-micron microprocessor at a speed of 100Mhz; the 0.35-micron microprocessor at 150MHz; and the 0.18-micron operates at a speed of 360Mhz. They are all compatible with a wide range of memory technology from low cost dynamic random access memory to high-speed static random access memory. The microprocessors can be packaged in various surface-mount and die-form packaging. There can be no assurance that the designed speed will be achieved with the production model of the 0.18-micron microprocessor or future versions or that all of the desired functions will perform as anticipated.
 
 
Our technology is not designed or targeted to compete with high-end processors for use in personal computers. It is targeted for embedded control applications. We believe that the features described above differentiate the Ignite family from other 8-bit to 64-bit microprocessors targeted for embedded control applications. Considering the reduced requirement for support microprocessors, the Ignite family is intended to be available at a high volume price that should be price competitive with high-end 8-bit microprocessor and general 16-bit microprocessor systems but with higher performance (speed and functional capability). The Ignite family has been designed to allow high-speed and high-yield fabrication using generally available wafer fabrication technology and facilities.
 
The Ignite Microprocessor as a Java Processor. We believe the Ignite microprocessor architecture is capable of being an efficient and cost effective Java programming language processor, because Java is designed to run on a stack-oriented architecture and the Ignite architecture executes the virtual stack machine internal to Java efficiently. Many Java byte codes or instructions require only a single 8-bit Ignite family instruction to be executed, providing a performance advantage over other more expensive processors that require six or more 32-bit instructions to do the same task. This feature allows the execution of Java programs with increased speed and reduced code size thereby enabling lower system memory costs. In addition, the incorporation of many on-chip system functions is expected to allow the Ignite family to perform most of the other functions required of an Internet computer device or Java accelerator, thereby eliminating components. Since Internet computers are designed to be inexpensive appliances for Internet access, cost, speed and performance are expected to be key requirements for designers. We believe the Ignite technology can compete favorably on the basis of such requirements, although we may not be able to successfully exploit Java related applications or that competitors will not create superior Java processors.
 
We have ported the Java operating environment to the Ignite family, which currently uses the C programming language for software support. We are a licensee of Sun Microsystems Inc. This enables us to develop and distribute products based on Sun's personalJava, a platform on which to run Java applications. We have also licensed from Wind River an operating system, VxWorks, and entered into a relationship with Forth Inc. (Forth) whereby Forth will provide software support and operating system development tools for the Forth Programming language. We believe this solution is competitive in the Java virtual machine and embedded applications markets. We believe that, if the implementation is successfully completed, the Ignite family will be competitive with Java microprocessors announced by competitors. However, we do not know whether implementation of this package of software or of a market for an Ignite family Java microprocessor will be successful.
 
Stage of Development. In early 1994, nanoTronics initiated production of a first generation of wafers at a contract fabrication facility using 6 inch wafers employing 0.8-micron double-metal CMOS technology. After the May 31, 1994 acquisition, we improved the original design, added new features and performed simulations and tests of the improved designs. In October 1995, a run of six wafers of second generation 0.8-micron microprocessors was fabricated by a contract fabrication facility. Subsequently, we tested these microprocessors, while completing a C computer language compiler and preparing application development tools. The compiler and application development tools are necessary to enable system designers to program the Ignite family for specific applications. We made corrections to the design suggested by the testing of prototype units and produced an additional run of second generation microprocessors from remaining wafers in May 1996. In July 1996, we employed these microprocessors in demonstration boards for use by developers and prospective customers and licensees.
 
In December 1997, we completed development of and started shipping a 0.5-micron microprocessor based on the Ignite technology and found that 0.5-micron double-metal CMOS technology improved operating speed, reduced power requirements, reduced physical size and reduced fabrication cost. In May 1998, we began a production run of a 0.35-micron microprocessor that further increased operating speed and cost performance over the previous generations of the Ignite family of microprocessors.
 
At each stage of development, microprocessors require extensive testing to ascertain performance limitations and the extent and nature of errors, if any. When significant limitations or errors are discovered, additional rounds of design modifications and fabrication are required prior to having functional and demonstrable microprocessors for prospective customers and licensees. Although our 0.5 and 0.35-micron microprocessors have been sent to prospective customers in anticipation of production orders, it is not certain that we, during our continued testing of these products, will not identify errors requiring additional rounds of design and fabrication prior to commercial production. Additional delays could have an adverse effect on the marketability of our Ignite technology and potential revenues from that source.
 
 
In September 2000, we completed the VHDL soft-core version of the Ignite microprocessor family. The hardware design inside a microprocessor, or silicon device, can be represented as a software program. This, in essence, replaces the old style of designing microprocessors using schematics. VHDL is the predominant software language used to design semiconductors. In addition to the design aspects, sophisticated simulation tools and PLD development kits can execute VHDL, allowing the designer to simulate the functionality of the entire design before committing to silicon. Also VHDL enables a designer to easily modify and enhance the design. A design represented in VHDL goes through a synthesis process whereby it is converted to the most basic element of a design, logical gates. This gate level representation in turn is used with computer aided engineering tools to translate the design into the most fundamental component of semiconductors, transistors. The characteristics of the transistors can be given as a library to a foundry. Therefore, a design represented in VHDL is technology and foundry independent and can be targeted for any given transistor geometry (such as 0.18, 0.25, or 0.35- micron) for any foundry of choice.
 
We have developed marketing materials, product manuals and application development tools for Ignite for use by Ignite licensees and customers. The manuals and tools are necessary to enable system designers to quickly and easily program the Ignite family for specific applications. We are not currently working on any additional tools for Ignite.
 
Competition. The semiconductor industry is intensely competitive and has been characterized by price erosion, rapid technological change and foreign competition in many markets. The industry consists of major domestic and international semiconductor companies, most of which have greater financial, technical, marketing, distribution, development and other resources than we do. The market for microprocessors and for embedded control applications is at least as competitive.
 
While our strategy is to target high-volume licensees and microprocessor customers requiring more sophisticated but low-cost, low-power consumption devices, we can still expect significant competition. We may also elect to develop embedded control system products utilizing our own architecture or by contract for other manufacturers.
 
We expect that the Ignite family, if successfully commercialized in the embedded controller market, will compete with a variety of 16/64-bit microprocessors including those based on intellectual property from ARM and MIPS and microprocessors from Hitachi, Motorola and IBM. As a Java processor, we expect our Ignite family will compete with a broad range of microprocessors including those incorporating co-processor accelerator technologies. The producers of these microprocessors have significantly greater resources than we do.
 
A new entrant, such as ours, is at a competitive disadvantage compared to these and other established producers. A number of factors contribute to this, including:
 
·       
the lack of product performance experience,
 
·       
lack of experience by customers in using application development systems,
 
·      
no record of technical service and support, and
 
·      
limited marketing and sales capabilities.
 
Our Licenses, Patents, Trade Secrets and Other Proprietary Rights
 
We rely on a combination of patents, copyright and trademark laws, trade secrets, software security measures, license agreements and nondisclosure agreements to protect our proprietary technologies. Our policy is to seek the issuance of patents that we consider important to our business to protect our inventions and technology.
 

 
We have seven U.S. patents issued dating back to 1989 on our microprocessor technology (the “Microprocessor Patents”). We have one microprocessor technology patent issued in five European countries plus one patent issued in Japan and one patent issued in Ireland. We may file additional applications under international treaties depending on an evaluation of the costs and anticipated benefits that may be obtained by expanding possible patent coverage. We also have one U.S. patent issued on ground penetrating radar technology and one U.S. patent issued on one of the communications products, as well as a pending patent application titled “Remote Charging of Wireless Devices.”
 
In addition to such factors as innovation, technological expertise and experienced personnel, we believe that a strong patent position is becoming increasingly important to compete effectively in the semiconductor industry. It may become necessary or desirable in the future for us to obtain patent and technology licenses from other companies relating to certain technology that may be employed in future products or processes. To date, we have not received notices of claimed infringement of patents based on our existing processes or products; but, due to the nature of the industry, we may receive such claims in the future.
 
In December 2003, we filed several lawsuits in United States District Courts against companies we contended were infringing on our patent No. 5,809,336 entitled “High Performance Microprocessor Having Variable Speed Clock.” In February 2004, these actions were consolidated into one action in the United States District Court for the Northern District of California. Also in February 2004, Intel Corporation filed a lawsuit against us in which they requested a declaratory judgment that their microprocessors, used by the defendants in our consolidated suit, did not infringe upon our patent. These actions are referred to collectively as the “Infringement Actions.”
 
Also in February 2004, we filed a lawsuit against Charles H. Moore (Moore) and Technology Properties Limited (TPL). These lawsuits contended that Russell Fish, the inventor from whom we obtained ownership interests in the patent referred to above, was the sole inventor of the technology described by the patent and requested that the Court declare inventorship and ownership on each of our granted patents related to the Infringement Litigation. This action is referred to as the “Inventorship Litigation.”
 
In July 2004, we entered into an agreement with Russell Fish. The agreement required Mr. Fish to provide certain assistance to the law firm we had retained in connection with the Inventorship Litigation. This agreement included a requirement that Mr. Fish waive the attorney-client privilege related to the attorney who had filed the Application for the patents in question. In return for his assistance, Mr. Fish was to receive a portion of the recovery under our litigation and licensing program under way at that time. On March 8, 2005, our law firm was disqualified from representing us in the Inventorship Litigation in part because the waiver from Mr. Fish was ineffective.
 
On June 7, 2005, we entered into a Master Agreement (the “Master Agreement”) with TPL and Moore which included the dismissal of the Inventorship Litigation.
 
Pursuant to the Master Agreement we agreed with TPL and Moore as follows:
 
·      
We entered into a patent license agreement (the “Intel License”) with Intel Corporation (“Intel”) pursuant to which we licensed certain rights in the Microprocessor Patents to Intel.
 
·      
We entered into an Escrow Agreement along with TPL pursuant to which the proceeds arising from the Intel License were allocated for the benefit of us and TPL. Pursuant to the Escrow Agreement, our initial capitalization obligations and those of TPL with regard to the JV LLC as described below were satisfied, our payment obligations and those of TPL with regard to the Rights Holders as described below were made, we received $6,672,349, and the remaining proceeds were allocated to or for the benefit of TPL.
 
·      
We caused certain of our respective interests in the Microprocessor Patents to be licensed to a limited liability company owned 50% by us and 50% by TPL (the “JV LLC”).
 
·      
The JV LLC engaged TPL to commercialize the Patents pursuant to a Commercialization Agreement among the JV LLC, TPL and us (the “Commercialization Agreement”).
 

 
 
·      
We paid $1,327,651 and TPL paid $1,000,000 to certain holders of rights in the Patents (“Rights Holders”) in exchange for the consent of such Rights Holders to the Transactions and a release of lien and transaction blocking rights.
 
·      
We agreed with TPL and Moore to settle or cause to be dismissed all litigation among all of us pursuant to a stipulated final judgment, including the Inventorship Litigation.
 
·      
We issued warrants to TPL to acquire $3,500,000 shares of our common stock at $0.125 per share. 1,400,000 warrants were exercisable upon issue; 700,000 warrants became exercisable on February 21, 2006 and 700,000 warrants became exercisable on February 22, 2006, when the Company’s stock price reached $0.50 and $0.75, respectively. On March 1, 2006, the remaining 700,000 warrants became exercisable when the Company’s stock price reached $1.00.
 
·       
We agreed with TPL and Moore to indemnify each other for, among other things, any inaccuracy or misrepresentation to any representation or warranty contained in the Master Agreement, any breach of the Master Agreement, certain liabilities relating to the respective interests of each of us in the Patents and the Transactions, and certain tax liabilities.
 
Pursuant to the Commercialization Agreement, the JV LLC granted to TPL the exclusive right to grant licenses and sub-licenses of the Patents and to pursue claims against violators of the Patents, in each case, on behalf of JV LLC, us, TPL and Moore, and TPL agreed to use reasonable best efforts to commercialize the Patents in accordance with a mutually agreed business plan. Pursuant to the Commercialization Agreement, the JV LLC agreed to reimburse TPL’s expenses incurred in connection with the commercialization of the Patents. All proceeds generated by TPL in connection with the commercialization of the Patents will be paid directly to the JV LLC. As of the date of this Prospectus, the implementation of the Commercialization Agreement has resulted in licenses with Intel, Hewlett-Packard, Casio, and Fujitsu.
 
Pursuant to the Master Agreement, we and TPL have entered into the Limited Liability Company Operating Agreement of the JV LLC (“LLC Agreement”). We and TPL each own 50% of the membership interests of JV LLC, and each have the right to appoint one member of the three (3) member management committee. The two (2) appointees are required to select a mutually acceptable third member of the management committee. Pursuant to the LLC Agreement, we and TPL must each contribute to the working capital of the JV LLC (in addition to the Patent licenses described above), and are obligated to make future contributions in equal amounts in order to maintain a working capital fund. The LLC Agreement provides that the JV LLC shall indemnify its members, managers, officers and employees to the fullest extent permitted by applicable law, for any liabilities incurred as a result of their involvement with the JV LLC, if the person seeking indemnification acted in good faith and in a manner reasonably believed to be in the best interest of the JV LLC.
 
We have one U.S. patent on our ground penetrating radar technology. No foreign application has been made. There are a large number of patents owned by others in the radar field generally and in the field of ground penetrating radar specifically. Accordingly, although we are not aware of any possible infringement and have not received any notices of claimed infringement, we may receive such claims in the future.
 
We do not know whether any patents will be issued from pending or future applications or that any patents that are issued will provide meaningful protection or other commercial advantages to us. Although we intend to protect our rights vigorously, these measures may not be successful.
 
We generally require all of our employees and consultants, including our management, to sign a non-disclosure and invention assignment agreement upon employment with us.
 
Research and Development
 
We are currently evaluating the feasibility and desirability of engaging in further development efforts focused on improvement of, and additional features for, the Ignite family of microprocessors either directly or through an alternative such as a joint venture, for example. The development of this technology has taken longer than anticipated and could be subject to additional delays. Therefore, we may not be able to timely or successfully market this technology.
 
 
We incurred research and development expenditures of $ 294,735 and $549,756 for our fiscal years ended May 31, 2005 and 2004, respectively. The majority of these expenditures have been devoted to our microprocessor technology. We believe that technical advances are essential to the success the Ignite technology and are currently evaluating whether we will continue to expend funds on research and development of our Ignite technology. It is not certain whether such research and development efforts, if continued in the future, will result in the design and development of a competitive technology in a timely manner.
 
Marketing and Distribution
 
Our products are marketed through a combination of direct sales and distributors. Approximate sales by principal geographic area (as a percentage of sales) for fiscal years ended May 31, 2005 and 2004 were as follows:
 
   
2005
 
2004
 
           
Domestic sales
   
100
%
 
92
%
               
Foreign sales
             
Europe
   
-
   
8
%
               
Total sales
   
100
%
 
100
%
               

All of our operating assets are located within the United States. While sales to certain geographic areas generally vary from year to year, we do not expect that changes in the geographic composition of sales will have a material adverse effect on operations.
 
Dependence Upon Single Customers
 
Ten percent (10%) or more of our consolidated net sales were derived from the following customers for the fiscal years ended May 31 as follows:
 
   
2005
 
2004
 
AMD
 
$
2,956,250
   
-
 
nTelesis
       
$
25,000
 
Blue Tech Inc.
         
18,000
 
Litton
         
9,000
 

All of the above sales were shipped against multiple purchase orders from each customer. nTelesis is owned by a former executive officer of the company who resigned in May, 2005.
 
We had no backlog as of May 31, 2005 or 2004.
 
Employees
 
We currently have five personnel. All are employed in general and administrative activities. We also engage additional consultants and part-time persons as needed from time to time.
 
Government Regulation
 
We believe our products are not subject to governmental regulation by any federal, state or local agencies that would affect the manufacture, sale or use of our products, other than occupational health and safety laws and labor laws which are generally applicable to most companies. We do not know what sort of regulations of this type may be imposed in the future, but do not anticipate any unusual difficulties in complying with governmental regulations which may be adopted in the future.
 

We have not incurred costs associated with environmental laws and do not anticipate such laws will have any significant effect on our future business.
 
Description of Property
 
We have one 3,300 square foot office space located at 6183 Paseo Del Norte, Suite 180, Carlsbad, California. The facility is leased through April, 2009. We have vacated one 10,300 square foot office located at 10989 Via Frontera, San Diego, California. That facility is leased through July 2006.
 
USE OF PROCEEDS
 
We will not receive any proceeds from the resale of the shares offered through this Prospectus.
 
 
Beatie and Osborne, LLP v. Patriot Scientific Corporation
 
Beatie and Osborne, LLP is a New York law firm that formerly represented the Company in the Inventorship Litigation and the Infringement Litigation. On March 8, 2005, Beatie and Osborne was disqualified by United States District Judge Jeremy Fogel in the Inventorship Litigation. Beatie and Osborne thereafter withdrew from the representation of the Company in the Infringement Litigation. Beatie and Osborne initiated litigation in the Supreme Court of New York on June 8, 2005 claiming breach of contract, quantum meruit, and unjust enrichment and alleging claims against the Company and former Company representatives, Jeffrey Wallin and Lowell Giffhorn for fraud and interference with contractual relationship. Beatie and Osborne claims a contingency fee under the terms of its contingency fee agreement with respect to licensing agreements entered into, and possibly with respect to license agreements to be entered into, by the Company. The Company denies any past, present, or future liability to Beatie and Osborne. The Company has caused a removal of the Beatie and Osborne lawsuit to the United States District Court for the Southern District of New York and have filed a motion to have the litigation transferred to the United States District Court for the Southern District of California. The transfer motion was denied on May 9, 2006, but Wallin and Giffhorn were ordered dismissed from the action at that time. The circumstances of the disqualification of Beatie and Osborne in the Inventorship Litigation and its withdrawal from the Infringement Litigation are claimed by the Company to have worked a forfeiture of any rights in Beatie and Osborne to a contingency fee of any kind. Further, the Company disputes that Beatie and Osborne’s efforts added any value to the Company’s licensing position or that they are entitled to any recovery under a quantum meruit analysis.
 
Patriot Scientific Corporation v. Russell Fish
 
On April 5, 2006, we filed a declaratory relief lawsuit against Russell Fish and The Fish Family Trust in the United States District Court for the Southern District of California. As a consequence of licensing agreements entered into by or on behalf of Patriot, Mr. Fish has presented demands for payment by us under his July 2004 agreement related to the Inventorship Litigation. We contend that Mr. Fish has been paid all sums that may have been owed to him. Our action seeks declaratory relief that no further sums are owed to Mr. Fish.
 
Also, on April 5, 2006, Fish and Robert Anderson, allegedly as trustee of The Fish Family Trust, filed a lawsuit against the Company in the District Court of Dallas County, Texas. The lawsuit is based on an alleged breach of the contract entered into on July 27, 2004 and seeks enforcement of the contract or damages.
 


Lowell Giffhorn Arbitration
 
On September 23, 2005, Lowell Giffhorn, a former executive officer and a former director of Patriot, submitted a demand for arbitration with the American Arbitration Association related to the termination of Mr. Giffhorn’s employment with the Company. Mr. Giffhorn asserts that the termination of his employment with the Company was unlawful, retaliatory, wrongful, violated public policy, violated the covenant of good faith and fair dealing and violated securities laws. Mr. Giffhorn has demanded damages of $1,500,000. The amount, if any, of ultimate liability with respect to the foregoing cannot be determined. Despite the inherent uncertainties of litigation, the Company at this time does not believe that Mr. Giffhorn’s claim will have a material adverse impact on its financial condition, results of operations, or cash flows.
 
Patent Litigation
 
Pursuant to its joint venture with Technology Properties Ltd., entered into in June 2005 (in settlement of inventorship/ownership litigation between the parties, and in return for a 50-50 sharing of net licensing and enforcement revenues), the Company granted Technology Properties Ltd. (TPL) the complete and exclusive right to enforce and license its microprocessor patent portfolio. The Company then dismissed its patent infringement claims against Fujitsu Computer Systems, Inc.; Matsushita Electric Corporation of America; NEC Solutions (America) Inc.; Sony Electronics Inc.; and Toshiba America Inc., which had been pending in the Federal District Court for the Northern District of California. Thereafter, TPL, on behalf of the TPL/Patriot joint venture, filed patent infringement actions against the foregoing defendants (except Sony) in the Federal District Court for the Eastern District of Texas, which litigation is currently pending. Litigation is not currently pending with regard to Fujitsu.
 
In February 2006, a license agreement was entered into with Fujitsu Corporation regarding the Company’s patent portfolio and in connection with that transaction, litigation involving Fujitsu and TPL and the Company in both California and Texas was dismissed.
 
FINANCIAL CONDITION AND RESULTS OF OPERATIONS
 
Overview
 
During the third quarter of the fiscal year ended May 31, 2005, and in the first three quarters of fiscal 2006, the Company entered into agreements for the licensing of its technology with Advanced Micro Devices Inc. (“AMD”), Intel Corporation, Hewlett Packard Company, Casio Computer Company and Fujitsu, Inc. respectively, among the largest of the microprocessor manufacturers. We believe these license agreements represent validation of the Company’s position that its intellectual property was and is being infringed by major manufacturers of microprocessor technology. Also, we believe the agreements demonstrate value of the Company’s intellectual property based upon “arms length” transactions with major electronics manufacturers.

In June 2005, the Company entered into a series of agreements with TPL and others to facilitate the pursuit of infringers, many of which are large scale, of its intellectual property. It is the intention of management that the recently signed license agreements will be used as a starting point to work toward more favorable terms in future negotiations. Management believes that utilizing the option of working through TPL, as compared to creating and using a Company licensing team for those activities, is a prudent way to achieve the desired results as the Company seeks to obtain fair value from the users of its intellectual property.

The Company continues to evaluate the development, marketing and sale of microprocessors, the technology behind the microprocessors and complementary products which enable computers and other data processing devices to communicate. These products can be used to connect to the Internet or other telecommunications networks.
 

 
Critical Accounting Policies
 
Our consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, which require us to make estimates and judgments that significantly affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. Actual results could differ from those estimates, and such differences could affect the results of operations reported in future periods. We believe the following critical accounting policies affect our most significant estimates and judgments used in the preparation of our consolidated financial statements.
 
1. Revenue Recognition
 
Accounting for revenue recognition is complex and affected by interpretations of guidance provided by several sources, including the Financial Standards Accounting Board (“FASB”) and the U.S. Securities and Exchange Commission (“SEC”). This guidance is subject to change. We follow the guidance established by the SEC in Staff Accounting Bulletin No. 104, as well as generally accepted criteria for revenue recognition, which require that, before revenue is recorded, there is persuasive evidence of an arrangement, the fee is fixed or determinable, collection is reasonably assured, and delivery to our customer has occurred. Applying these criteria to certain of our revenue arrangements requires us to carefully analyze the terms and conditions of our license agreements. Revenue from our technology license agreements is generally recognized at the time we enter into a contract and provide our customer with the licensed technology. We believe that this is the point at which we have performed all of our obligations under the agreement; however, this remains a highly interpretive area of accounting and future license agreements may result in a different method of revenue recognition. Fees for maintenance or support of our licenses are recorded on a straight-line basis over the underlying period of performance.
 
2. Assessment of Contingent Liabilities
 
We are involved in various legal matters, disputes, and patent infringement claims which arise in the ordinary conduct of our business. We accrue for estimated losses at the time when we can make a reliable estimate of such loss and it is probable that it has been incurred. By their very nature, contingencies are difficult to estimate. We continually evaluate information related to all contingencies to determine that the basis on which we have recorded our estimated exposure is appropriate.
 
3. Stock Options
 
The Company applies Accounting Principles Board (“APB”) Opinion 25, “Accounting for Stock Issued to Employees,” and related Interpretations in accounting for all stock option plans. Under APB Opinion 25, compensation cost has been recognized for stock options granted to employees when the option price is less than the market price of the underlying common stock on the date of grant.
 
SFAS No. 123, “Accounting for Stock-Based Compensation,” and SFAS No. 148, “Accounting for Stock-Based Compensation-Transition and disclosure,” require the Company to provide pro forma information regarding net income as if compensation cost for the Company’s stock option plans had been determined in accordance with the fair value based method prescribed in SFAS No. 123. To provide the required pro forma information, the Company estimates the fair value of each stock option at the grant date by using the Black-Scholes option-pricing model. SFAS No. 148 also provides for alternative methods of transition for a voluntary change to the fair value based method of accounting for stock-based employee compensation. The Company has elected to continue to account for stock based compensation under APB No. 25.
 
The Company applies SFAS No. 123 in valuing options granted to consultants and estimates the fair value of such options using the Black-Scholes option-pricing model. The fair value is recorded as consulting expense as services are provided. Options granted to consultants for which vesting is contingent based on future performance are measured at their then current fair value at each period end, until vested.
 

 
4. Debt Discount
 
We issue warrants as part of our convertible debentures and other financings. We value the warrants using the Black-Scholes pricing model based on expected fair value at issuance and the estimated fair value is recorded as debt discount. The debt discount is amortized to non-cash interest over the life of the debenture assuming the debenture will be held to maturity which is normally 2 years. If the debenture is converted to common stock previous to its maturity date, any debt discount not previously amortized is expensed to non-cash interest.
 
5. Patents and Trademarks
 
Patents and trademarks are carried at cost less accumulated amortization and are amortized over their estimated useful lives of four years. The carrying value of patents and trademarks is periodically reviewed and impairments, if any, are recognized when the expected future benefit to be derived from an individual intangible asset is less than its carrying value.
 
6. Income Taxes
 
Deferred income taxes are provided for by recognizing temporary differences in certain income and expense items for financial and tax reporting purposes. Deferred tax assets consist primarily of income tax benefits from net operating loss carry-forwards. A valuation allowance has been recorded to fully offset the deferred tax asset as it is more likely than not that the assets will not be utilized. The valuation allowance increased approximately $42,000 for the year ended May 31, 2005, from $14,732,000 at May 31, 2004 to $14,690,000 at May 31, 2005.
 
7. Accounting for Limited Liability Company
 
During the quarter ended August 31, 2005, we entered into a newly formed limited liability company with a third party. Although we do not control the limited liability company from a voting interest standpoint, we consider the limited liability company to be a variable interest entity, as that term is defined under accounting principles generally accepted in the United States of America (FIN 46(R)), and under such definition and interpretation of FIN 46(R), we are required to consolidate the results of the limited liability company with our own.
 
Results of Operations
 
Comparison of Fiscal Year 2005 and Fiscal Year 2004. In the third quarter of fiscal year 2005 we entered into an agreement with AMD that granted licenses for our Ignite microprocessor and for our patent portfolio of microprocessor technologies. The Ignite license called for payments totaling $1,220,000 with $300,000 paid upon closing of the agreement, $292,500 to be paid in the fourth quarter of fiscal 2005 and the remaining balance to be paid in the first three quarters of fiscal 2006. The revenues associated with the Ignite license were all recognized in fiscal 2005. The agreement also called for a maintenance fee totaling $100,000 connected with the Ignite license. That fee, payable in equal amounts of $25,000 on April 1, 2005, August 15, 2005, November 15, 2005 and February 15, 2006, is considered to support the Ignite license over a period of four years and is being recognized as revenue evenly over the four year period. The Ignite license contains provisions for royalties based upon deliveries of products using the technology. However, we cannot make reliable projections of quantities or the timing of shipments that could lead to royalty payments resulting from this agreement. The agreement with AMD also included a non-exclusive license for our portfolio of intellectual property. A one-time license fee amounting to $1,730,000 was agreed upon with equal payments of $432,500 to be paid on the following dates: April 1, 2005, August 15, 2005, November 15, 2005 and February 15, 2006. The entire amount of the license fee was recognized as revenue in fiscal 2005.
 
We continue to receive small orders for communications products that have reached the end of their life cycle. We no longer market these products but we do fill orders received, primarily from prior customers. We continue to fill small orders for microprocessor products from existing inventory that is carried at zero value.
 


Total sales from communications and microprocessor technology products decreased from approximately $74,000 to approximately $25,000 from the fiscal year ended May 31, 2004 to the fiscal year ended May 31, 2005.
 
Research and development expenses decreased from approximately $550,000 for the fiscal year ended May 31, 2004 to approximately $295,000 for the fiscal year ended May 31, 2005. The decrease was primarily due to staff reductions from five employees during the 2004 fiscal period to two employees during most of the 2005 fiscal period. Expenditures for tools and administrative expenses declined in the 2005 fiscal year as compared with the 2004 fiscal year. Also, depreciation expense for research and development declined from approximately $44,000 for the fiscal year ended May 31, 2004 to approximately $11,000 for the fiscal year ended May 31, 2005 as fixed assets became fully depreciated and were not replaced.
 
Selling, general and administrative expenses increased from approximately $1,254,000 for the fiscal year ended May 31, 2004 to approximately $2,600,000 for the fiscal year ended May 31, 2005. This significant increase resulted from multiple changes in our administrative operations. Legal fees increased from approximately $102,000 for the fiscal year ended May 31, 2004 to approximately $394,000 for the fiscal year ended May 31, 2005 as a result of our efforts to pursue infringers of our intellectual property as well as in support of administrative and strategic changes for our Company. Legal expenses amounting to approximately $371,000, were incurred by our attorneys and recognized as expenses by us in the fiscal year ended May 31, 2005 in connection with intellectual property enforcement efforts. Similar expenditures for the fiscal year ended May 31, 2004 amounted to approximately $21,000. A law firm involved in the Company’s intellectual property enforcement efforts has asserted a claim, which the Company disputes, for contingency fees payable in connection with the AMD agreement. The disputed fees have been accrued by us in the amount of $346,000, however payment is suspended as the disputed claim is litigated. Undisputed contingency fees in connection with the AMD agreement were recorded in the amount of approximately $208,000. We expect that resolution of legal matters that have led to unusually large legal expenses for the 2005 fiscal year will result in reduced legal expenses for the 2006 fiscal year. Total rent expense increased from approximately $181,000 for the fiscal year ended May 31, 2004 to approximately $281,000, primarily as a result of the accrual of rent expense liability on the unused portion of our leased space. Other General and Administrative expense categories increased in fiscal year 2005 as compared with fiscal year 2004 including the cost of insurance, transfer agent fees, and investor relations.
 
Marketing expenses increased from approximately $311,000 for the fiscal year ended May 31, 2004 to approximately $325,000 for the fiscal year ended May 31, 2005. The increase resulted from additional consulting costs and increases in telephone and other administrative costs associated with marketing activities. Partially offsetting the increases was a reduction of salary costs from approximately $165,000 for the fiscal year ended May 31, 2004 to approximately $134,000 for the fiscal year ended May 31, 2005.
 
Other income and expense items for the Company amounted to a net expense of approximately $2,413,000 for the fiscal year ended May 31, 2004 and increased to a net expense of approximately $2,781,000 for the fiscal year ended May 31, 2005. Other income in the amount of $75,000 was recorded in the fiscal year ended May 31, 2004 in connection with the final payment from the sale of gas plasma technology in 1999. Losses on the value of marketable securities amounted to approximately $45,000 for the fiscal year ended May 31, 2004 and approximately $21,000 for the fiscal year ended May 31, 2005. Interest expense increased from approximately $2,443,000 for the fiscal year ended May 31, 2004 to approximately $2,820,000 for the fiscal year ended May 31, 2005. That increase primarily resulted from an increase in non-cash interest expense associated with the conversion of debentures. The value of debt discount features recorded upon the issuance of a debenture is expensed as non-cash interest over the term of the debt. However as the debentures are converted to common stock any remaining balance of debt discount is recognized as non-cash interest in that period. Non-cash interest expense increased from approximately $2,294,000 for the fiscal year ended May 31, 2004 to approximately $2,679,000 for the fiscal year ended May 31, 2005.
 
The Company’s net loss for the fiscal year ended May 31, 2005 amounted to approximately $2,694,000 compared with a loss of approximately $4,150,000 for the fiscal year ended May 31, 2004.
 
Comparison of the Nine Months Ended February 28, 2006 and Nine Months Ended February 28, 2005.
 

 
During the third quarter of fiscal year 2006, our joint venture limited liability company signed agreements licensing our intellectual property with Hewlett Packard, Fujitsu and Casio for one time payments totaling $60,000,000. In June 2005, we entered into an agreement with Intel Corporation licensing our intellectual property for a one time payment of $10,000,000. These license revenues were recognized during the nine months ended February 28, 2006. It is not possible to predict when, if ever, we will again be successful in obtaining future license agreements. For the nine months ended February 28, 2005 license revenue consisted of approximately $2,950,000 from our one time licensing agreement with AMD. Product sales amounting to approximately $297,000 were also recorded in the nine month period ended February 28, 2006 in connection with communications products that are no longer marketed by the Company. Inventory associated with the sales of these communications products is carried at zero value. Cost of sales of approximately $103,000 consists of payments made to subcontractors for materials and labor in connection with the product sales. For the nine months ended February 28, 2005 the Company had no such product sales.
 
Research and development expenses amounted to approximately $226,000 for the nine months ended February 28, 2006 and approximately $236,000 for the nine months ended February 28, 2005. Expenses related to salaries, benefits, training and other employee expenses declined approximately $61,000 resulting from staff reductions. Consulting and related support expenses increased from approximately $12,500 during the nine months ended February 28, 2005 to approximately $65,000 for the nine months ended February 28, 2006, as research and development activities moved to outside contractors. Costs of components, supplies and equipment increased by approximately $5,000 for the nine months ended February 28, 2006 as compared with the nine months ended February 28, 2005 connected with product development and support of the Ignite product line. Depreciation for fixed assets associated with research and development activities declined from approximately $8,000 for the nine months ended February 28, 2005 to less than $500 for the nine months ended February 28, 2006, as equipment became fully depreciated and was not replaced.
 
Selling, general and administrative expenses increased from approximately $1,859,000 for the nine months ended February 28, 2005 to approximately $5,393,000 for the nine months ended February 28, 2006. Legal and accounting related expenses increased by approximately $541,000 for the nine months ended February 28, 2006 compared with the nine months ended February 28, 2005 related to legal matters in connection with intellectual property and formation of a limited liability company, the license agreement with Intel Corporation, and legal issues related to former employees and other corporate matters. In addition, salary costs increased approximately $505,000 for the nine months ended February 28, 2006 compared with the nine months ended February 28, 2005 as a result of changes in management personnel that included accrued severance costs. Other increases for the nine months ended February 28, 2006 as compared with the nine months ended February 28, 2005 included public relations and consultant expenses of approximately $124,000, insurance expenses of approximately $56,000 and travel expenses of approximately $55,000. Non cash general expenses of approximately $69,000 were recognized in connection with recording the issuance of warrants using the Black-Scholes method. Offsetting these increases were decreases in legal contingency fees of approximately $554,000, decreases in patent enforcement expenses of approximately $187,000. Finally, our newly created limited liability company, which we have consolidated since its creation in June 2005, incurred $1,500,000 in expenses paid to the other member of the limited liability company, as part of the quarterly fee to be paid to the other member in accordance with our limited liability company agreement and approximately $1,377,000 in legal and other operational expenses.
 
Settlement and license expenses amounting to approximately $3,855,000 were recorded during the nine months ended February 28, 2006 in connection with the agreements involving the formation of a limited liability company and, separately, a license agreement with Intel Corporation. The expenses consisted of both cash and non-cash elements related to incremental, direct costs of completing the transactions. In connection with the transactions, it was necessary for the Company to obtain the consent of certain debenture and warrant holders. The necessary consents, together with certain warrants held by the debenture holders and the release of their security interests in our intellectual property, were obtained in exchange for cash, new warrants and repriced warrants. The expenses resulted primarily from cash payments to debt holders of approximately $1,300,000, to co-owners of various intellectual property assets of approximately $960,000 and to a committee of the Company's board of directors of approximately $170,000. Non-cash expenses totaled approximately $1,400,000 and resulted primarily from the incremental value of the effect of repricing various warrants and granting other warrants in excess of the expense previously recognized for warrants granted to these security holders, as well as the value of the warrants reconveyed to the Company.
 

Other income and expense items for the Company amounted to a net expense of approximately $2,399,000 for the nine months ended February 28, 2005 and decreased to a net expense of approximately $2,179,253 for the nine months ended February 28, 2006. Other income for the nine months ended February 28, 2005 primarily resulted from a one-time settlement with a subtenant amounting to approximately $47,000. For the nine months ended February 28, 2006 other income primarily resulted from interest and dividends in the amount of approximately $262,000. Cash and non-cash interest expense declined from approximately $2,442,000 for the nine months ended February 28, 2005 to approximately $1,182,000 for the nine months ended February 28, 2006 as the amortization of debt discount has declined and the remaining debentures were converted during the nine months ended February 28, 2006. The value of debt discount features recorded upon the issuance of a debenture is expensed as non-cash interest over the term of the debt. However, as the debentures are converted into common stock, any remaining balance of debt discount is recognized as non-cash interest in that period. Non-cash interest expense decreased from approximately $2,323,000 for the nine months ended February 28, 2005 to approximately $413,000 for the nine months ended February 28, 2006. The Company charged approximately $723,000 to interest expense to record the beneficial conversion features of debentures converted to shares. During the nine months ended February 28, 2006, the Company recorded a loss on debt extinguishment of $1,260,688 related to the 7,000,000 warrants issued to a debenture holder as consideration for entering into the reset agreements.
 
During the nine months ended February 28, 2006, the Company recorded a provision for income taxes of $1,880,000 related to Federal alternative minimum tax and California state tax. Also, during the nine months ended February 28, 2006, the Company utilized approximately $33,400,000 of its available net operating loss carry-forwards to offset its taxable income arising in the quarter.
 
The Company recorded net income for the nine months ended February 28, 2006 of approximately $28,053,000 compared with a net loss of approximately $1,521,000 for the nine months ended February 28, 2005.
 
Liquidity And Capital Resources
 
The Company's cash, marketable securities and short-term investment balances increased from approximately $1,289,000 as of May 31, 2005 to approximately $24,658,000 as of February 28, 2006. As of February 28, 2006, we held two savings accounts which were restricted as collateral for our corporate credit cards and we held a short-term certificate of deposit amounting to approximately $202,000 as of May 31, 2005, which was restricted as collateral on our line of credit. Total current assets increased from approximately $3,612,000 as of May 31, 2005 to approximately $58,947,000 as of February 28, 2006. The increase in current assets results primarily from funds received and due from license fee agreements through our joint venture limited liability company. As of the filing date of this statement all license fees receivable have been received by the Company. Total current liabilities increased from approximately $1,644,000 as of May 31, 2005 to approximately $11,176,000 as of February 28, 2006. The improvement in the current position of the Company primarily resulted from the license agreements obtained by our joint venture limited liability company and with Intel Corporation which were recorded during the nine months ended February 28, 2006. Included within both our cash and current assets totals at February 28, 2006 is approximately $7,848,000 of cash, which is held by our joint venture limited liability company, which we consolidate for accounting purposes. As this cash has been invested by both us and the other member into this entity, its use is limited to the operations of the limited liability company.
 
During the nine months ended February 28, 2006, the Company’s operating activities generated approximately $30,724,000 of cash. The Company's net income, adjusted for non-cash expense items, primarily resulted from the license agreements obtained by our joint venture limited liability company and with Intel Corporation. The Company's operating activities used cash amounting to approximately $845,000 during the nine months ended February 28, 2005, primarily due to the Company's net loss as adjusted for non-cash expense items.
 
Investing cash flows consisted primarily of proceeds of investments sold, payment for investments acquired and capital expenditures. The Company used approximately $3,377,000 in net cash for investing activities during the nine months ended February 28, 2006 compared to $200,000 for the nine months ended February 28, 2005. The increase in cash used in investing activities primarily resulted from the purchase of marketable securities.
 
Cash used in financing activities consisted primarily of our joint venture limited liability company’s distribution to the other member of approximately $9,784,000. The Company used approximately $7,460,000 in net cash for financing activities for the nine months ended February 28, 2006 compared to receiving approximately $1,544,000 in net cash for the nine months ended February 28, 2005. Cash was provided by the exercise of common stock warrants and options amounting to approximately $679,000 during the nine months ended February 28, 2006 and approximately $706,000 during the nine months ended February 28, 2005. Additionally, cash in the amount of approximately $943,000 was provided by issuance of convertible debentures and common stock during the nine months ended February 28, 2005. No such transactions occurred during the nine months ended February 28, 2006.
 

Included in financing activities is $2,000,000 invested by the other member into a limited liability company, which we consolidate for financial reporting purposes. The limited liability company was created for the purposes of jointly pursuing infringers of our technologies. In connection with the creation of the limited liability company, both the other member and we have committed to funding the operations of the limited liability company, if necessary, up to an additional $4,000,000, with no more than $2,000,000 being required in any one year. The limited liability company agreement provides that the other member is to be paid a quarterly amount ranging between $500,000 and $1,000,000 (based upon a percentage of the working capital fund balance of the limited liability company) on a quarterly basis by the limited liability company for services performed by the other member.
 
In February, 2006, the Company announced a dividend of $0.02 per share of common stock for stockholders of record and qualified warrant holders as of February 24, 2006. The dividend resulted in an accrued liability amounting to $8,114,378 as of February 28, 2006. In March 2006 the Company announced a dividend of $0.04 per share of common stock for stockholders of record and qualified warrant holders as of March 31, 2006. The dividend is expected to result in a use of cash funds amounting to approximately $16,584,000 to be paid from net cash provided by operating activities.
 
The Company’s current working capital position as of February 28, 2006, is expected to provide the funds necessary to support the Company’s operations for the next 12 months. During the nine months ended February 28, 2006, we incurred significant cash and non-cash expenses related to the TPL and limited liability company transactions, which we expect to be of a nonrecurring nature. Given the unpredictable nature of our revenue stream, we have attempted to curb other non-strategic expenses. The Company is currently assessing various strategies to pursue in the future, which may include, among other things, expanding our commitment to research and development or making acquisitions of other technologies.
 
During recent years we have relied upon financing activities to provide the funds necessary for the Company’s operations including the sale of common stock and the issuance of debentures and notes payable for cash. In addition, we have issued stock and warrants and options for the purchase of the Company’s common stock in return for services. Although we have entered into various license agreements in fiscal 2006 that have resulted in our reporting significant revenue, we may not be able to achieve profitable operations in the future. Should the funds generated from these agreements be insufficient to fund our operations, we may be forced to curtail our operations or seek additional external funding. There can be no assurance that additional funding would be available to us or, if it is available, that it would be on terms favorable to us.

Subsequent Events
 
On June 5, 2006, the Company granted an option to acquire 1,500,000 shares of its common stock to its Chief Executive Officer at an exercise price of $0.165 per share. The option expires in August, 2007 and was fully vested as of the date of grant. As a result of the grant, the Company will record non-cash compensation expense of $1,527,019 in the first quarter of the fiscal year ended May 31, 2007.
 
Recent Accounting Pronouncements
 
In December 2004, the FASB issued SFAS 123R, Share Based Payment. This statement replaces SFAS No. 123 and supersedes APB Opinion 25. SFAS No. 123R requires that the cost of share-based payment transactions (including those with employees and non-employees) be recognized as compensation based on the estimated fair value of the equity instrument awarded. SFAS No. 123R applies to all share-based payment transactions in which an entity acquires goods or services by issuing (or offering to issue) its shares, options, or other equity instruments or by incurring liabilities in amounts based on the price of the entity’s shares or other equity instruments, or that require (or may require) settlement by the issuance of an entity’s shares or other equity instruments. This statement applies to all new awards granted during the fiscal year beginning after December 15, 2005 and to previous awards that are remodified or cancelled after such date. The Company has not yet fully evaluated the effect of adopting SFAS No. 123R on its financial statements.
 
In December 2004, the FASB issued SFAS No. 153, Exchange of Nonmonetary Assets, an amendment of APB Opinion No. 29, Accounting for Nonmonetary Transaction. SFAS No. 153 is based on the principle that exchanges of nonmonetary assets should be measured based on the fair market value of the assets exchanged. SFAS No. 153 eliminates the exception of nonmonetary exchanges of similar productive assets and replaces it with a general exception for exchanges of nonmonetary assets that do not have commercial substance. SFAS 153 is effective for nonmonetary asset exchanges in fiscal periods beginning after June 15, 2005. The Company does not believe that the provisions of SFAS No. 153 will have a material impact on its financial statements.
 
 
In May 2005, the FASB issued SFAS No. 154, Accounting Changes and Error Corrections, which replaces APB Opinion No. 20, Accounting Changes, and FASB Statement No. 3, Reporting Accounting Changes in Interim Financial Statements, and changes the requirements for the accounting for and reporting of a change in accounting principle. SFAS No. 154 requires retrospective application to prior periods’ financial statements of changes in accounting principle, unless it is impracticable to determine either the period-specific effects or the cumulative effect of the change. SFAS No. 154 is effective for accounting changes and correction of errors made in fiscal years beginning after December 15, 2005. Early adoption is permitted for accounting changes and correction of errors made in fiscal years beginning after the date SFAS No. 154 was issued. At the present time, the Company does not believe that adoption of SFAS No. 154 will have a material effect on its financial statements.
 
SELECTED FINANCIAL INFORMATION
 
The financial summary does not contain all the information that may be important to you. Therefore, we urge you to read all the information in this Prospectus, including the financial statements, and their explanatory notes before making an investment decision.
 
We derived the selected financial information from our consolidated financial statements (See section entitled “Financial Statements” in this Prospectus). Information as of and for the periods ended February 28, 2006 and 2005 is unaudited. Also, results of operations for the period ended February 28, 2006 are not necessarily indicative of the results which may be obtained for the fiscal year ending May 31, 2006. We urge you to read this selected financial information in conjunction with the section entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” as well as our consolidated financial statements and the related notes to the consolidated financial statements.
 
Results of Operations
 
   
Nine Months Ended
     
   
February 28, 2006 (Unaudited)
 
February 28, 2005 (Unaudited)
 
Increase
(Decrease)
 
Revenue
 
$
70,297,072
 
$
2,973,148
 
$
67,323,924
 
Cost of sales
 
$
103,351
 
$
-
 
$
103,351
 
Gross profit
 
$
70,193,721
 
$
2,973,148
 
$
67,220,573
 
Operating expenses:
                   
Research and development
 
$
225,564
 
$
236,296
 
$
(10,732
)
Selling, general and administrative
 
$
5,393,015
 
$
1,858,528
 
$
3,534,487
 
Settlement and license expense
 
$
3,855,132
 
$
-
 
$
3,855,132
 
Total operating expenses
 
$
9,473,711
 
$
2,094,824
 
$
7,378,887
 
Unrealized loss on marketable securities
 
$
1,201
 
$
14,500
 
$
(13,299
)
Interest expense
 
$
1,181,635
 
$
2,442,101
 
$
(1,260,466
)
Loss on debt extinguishment
 
$
1,260,688
 
$
-
 
$
1,260,688
 
Other income
 
$
264,271
 
$
57,552
 
$
206,719
 
Income (loss) before minority interest
 
$
58,540,757
 
$
(1,520,725
)
$
60,061,482
 
Minority interest in consolidated entity
 
$
(28,607,664
)
$
-
 
$
(28,607,664
)
Income (loss) before income taxes
 
$
29,933,093
 
$
(1,520,725
)
$
31,453,818
 
Provision for income taxes
 
$
1,880,000
 
$
-
 
$
1,880,000
 
Net income (loss)
 
$
28,053,093
 
$
(1,520,725
)
$
29,573,818
 
Basic income (loss) per common share
 
$
0.09
 
$
(0.01
)
$
0.10
 
Diluted income (loss) per common share
 
$
0.07
 
$
(0.01
)
$
0.08
 
 

   
Year Ended
 
Increase
(Decrease)
 
   
May 31,
2005
 
May 31,
2004
 
               
Revenue
 
$
2,982,586
 
$
76,417
 
$
2,906,169
 
Cost of sales
 
$
-
 
$
10,472
 
$
(10,472
)
Gross profit
 
$
2,982,586
 
$
65,945
 
$
2,916,641
 
Operating expenses:
                   
Research and development
 
$
294,735
 
$
549,756
 
$
(255,021
)
Selling, general and administrative
 
$
2,600,430
 
$
1,253,559
 
$
1,346,871
 
Total operating expenses
 
$
2,895,165
 
$
1,803,315
 
$
1,091,850
 
Gain on sale of technology
       
$
75,500
 
$
(75,500
)
Loss on marketable securities
 
$
(21,180
)
$
(45,354
)
$
(24,174
)
Interest expense
 
$
2,820,170
 
$
2,443,024
 
$
377,146
 
Other income
 
$
60,379
 
$
270
 
$
60,109
 
Net loss
 
$
(2,693,550
)
$
(4,149,978
)
$
(1,456,428
)
Basic income (loss) per common share
 
$
(0.01
)
$
(0.03
)
$
0.02
 
Diluted income (loss) per common share
 
$
(0.01
)
$
(0.03
)
$
0.02
 

Balance Sheet
 
   
February 28, 2006
(Unaudited)
 
 
May 31, 2005
 
Increase
(Decrease)
 
Cash and cash equivalents
 
$
20,478,619
 
$
591,426
 
$
19,887,193
 
Prepaid expenses and other current assets
 
$
111,383
 
$
121,758
 
$
(10,375
)
Accounts payable and accrued expenses
 
$
1,181,752
 
$
1,119,611
 
$
62,141
 
                     
 
 
   
February 28, 2006
(Unaudited) 
 
 
May 31, 2005
 
 
Increase
(Decrease)
 
Current assets
 
$
58,947,305
 
$
3,612,356
 
$
55,334,949
 
Current liabilities
 
$
11,176,130
 
$
1,643,764
 
$
9,532,366
 
Working capital
 
$
47,771,175
 
$
1,968,592
 
$
45,802,583
 
Long-term debt
 
$
--
 
$
45,942
 
$
(45,942
)
Stockholders’ equity
 
$
27,055,015
 
$
2,034,328
 
$
25,020,687
 

Cash Flows
 
   
Nine Months Ended
     
   
February 28, 2006 (Unaudited)
 
February 28, 2005 (Unaudited)
 
Increase
(Decrease)
 
Net cash provided by (used in):
                   
Operating activities
 
$
30,723,593
 
$
(845,433
)
$
31,569,026
 
Investing activities
 
$
(3,376,683
)
$
(200,000
)
$
3,176,683
 
Financing activities
 
$
(7,459,717
)
$
1,543,821
 
$
9,003,538
 
                     
                     


   
Year Ended
     
   
May 31,
2005
 
May 31,
2004
 
Increase
(Decrease)
 
Net cash provided by (used in):
                   
Operating activities
 
$
(628,326
)
$
(2,075,972
)
$
(1,447,646
)
Investing activities
 
$
(892,706
)
$
(28,623
)
$
(864,083
)
Financing activities
 
$
1,756,518
 
$
2,427,872
 
$
(671,354
)
                     

 
The following table and biographical summaries set forth information, including principal occupation and business experience, about our directors and the executive officers as of March 1, 2006:
 
NAME
 
AGE
 
POSITION, OFFICE and TERM
         
Helmut Falk, Jr.
 
49
 
Director (since December 1997)
Gloria Felcyn
 
58
 
Director (since October 2002)
Lowell W. Giffhorn
 
58
 
Director (since August 1999)
Carlton M. Johnson, Jr.
 
46
 
Director (since August 2001)
David H. Pohl
 
68
 
Director (since April 2001) / President and Chief Executive Officer
Thomas J. Sweeney
 
55
 
Chief Financial Officer/Secretary
James Turley
 
44
 
Director (since February 2006)

Biographical Information
 
Helmut Falk, Jr. Since 2000, Dr. Falk has worked at St. Francis Hospital in Mooresville, Indiana as a staff anesthesiologist and has been Chairman of its Pharmacy and Therapeutics Committee. From 1992 until 2000, Dr. Falk served as the Director of Anesthesia of, and served on the medical executive committee for, The Johnson Memorial Hospital in Franklin, Indiana. Dr. Falk received his D.O. from the College of Osteopathic Medicine of the Pacific in 1987 and his B.S. in Biology from the University of California, Irvine in 1983. Dr. Falk is the son of the late Helmut Falk, who was the sole shareholder of nanoTronics (we acquired all of the company’s assets on May 31, 1994) and the Chairman and CEO of the Company until his death in July 1995. Dr. Falk is also an heir to the Helmut Falk Estate, which is the beneficial owner of the Company's shares held by the Helmut Falk Family Trust.
 
Gloria Felcyn. Since 1982, Ms. Felcyn has been the principal in her own public accounting firm. Prior to establishing her own firm, Ms. Felcyn was employed by Main Hurdman & Cranston from 1969 through 1970 and at Price Waterhouse & Co. in the San Francisco and New York offices from 1970 through 1976. Subsequent to that, Ms. Felcyn worked in the field of offshore tax planning with a major real estate syndication company. Ms. Felcyn received her B.S. degree in Business Economics from Trinity University in 1968 and is a Certified Public Accountant and member of the American Institute of CPA’s.
 
Lowell W. Giffhorn. Since October 2005, Mr. Giffhorn has served as the Chief Financial Officer and, since December 2005, as a member of the Board of Directors of Omni USA, Inc., a developer and marketer of computational analytical software products for the laboratory testing industry. Since July 2005, Mr. Giffhorn has also served as the Chief Financial Officer of Imagenetix, Inc., a publicly held nutritional supplement company. Mr. Giffhorn was the Company’s Chief Financial Officer from May 1997 to June 2005, and has been a member of the Board since August 1999. From June 1992 to August 1996 and from September 1987 to June 1990, he was the Chief Financial Officer of Sym-Tek Systems, Inc. and Vice President of Finance for its successor, Sym-Tek, Inc., a major supplier of capital equipment to the semiconductor industry. Mr. Giffhorn obtained an M.B.A. degree from National University in 1975 and he obtained a B.S. in Accountancy from the University of Illinois in 1969. Mr. Giffhorn is also a director and chairman of the audit committee of DND Technologies, Inc., a publicly held company.
 
 
Carlton M. Johnson, Jr. Mr. Johnson is in-house legal counsel for Swartz Investments, LLC, a position he has held since June 1996. Mr. Johnson has been admitted to the practice of law in Alabama since 1986, Florida since 1982 and Georgia since 1997. He has been a shareholder in the Pensacola, Florida law firm of Smith, Sauer, DeMaria Johnson and as President-Elect of the 500 member Escambia-Santa Rosa Bar Association. He also served on the Florida Bar Young Lawyers Division Board of Governors. Mr. Johnson earned a degree in History/Political Science at Auburn University and Juris Doctor at Samford University - Cumberland School of Law. Mr. Johnson is also a director and member of the audit committee of Peregrine Pharmaceuticals, Inc., a publicly held company.
 
David H. Pohl. Mr. Pohl served as an officer of the Company from January 2001 to March 2002. He was elected President and Chief Executive Officer on June 13, 2005. Except for his service with the Company, Mr. Pohl has been in the private practice of law counseling business clients since 1997, and from 1995 to 1996 was Special Counsel to the Ohio Attorney General regarding investments in entrepreneurial firms by state pension funds. Previously, he was a senior attorney with a large U.S. law firm, and held positions as a senior officer and general counsel in large financial services corporations. Mr. Pohl earned a J.D. degree in 1962 from the Ohio State University College of Law, and also holds a B.S. in Administrative Sciences from Ohio State. Mr. Pohl is also a director and member of the audit committee of Peregrine Pharmaceuticals, Inc., a publicly held company.
 
Thomas J. Sweeney. Mr. Sweeney became the Company’s Chief Financial Officer on August 3, 2005. Since 2000, Mr. Sweeney has been a Partner in the San Diego office of Tatum CFO Partners, a national financial services firm. While a Partner of Tatum and for three and one-half years, Mr. Sweeney served as the Chief Financial Officer of New Visual Corporation, a publicly held development stage company in the telecommunications industry with more than 8,000 shareholders. Also while with Tatum, he served as the Chief Financial Officer of Mitchell International, Inc., a 700 person firm that is a provider of information software, print publications and total business solutions. Also while with Tatum, Mr. Sweeney worked in Johannesburg and Cape Town, South Africa on a project basis for an investment group that was organized under Astrata Group, Inc., a publicly held U.S. company, as it completed acquisitions of satellite technology subsidiaries. Earlier in his career Mr. Sweeney worked as an auditor for Ernst & Young LLP, where he earned his CPA certificate, and he also worked for the international consulting firm of McKinsey & Company. Mr. Sweeney earned his B.B.A. and M.B.A. degrees from The University of Texas at Austin and is a member of the American Institute of CPA’s.
 
James Turley. Since March 2004, Mr. Turley has served as the Editor-in-Chief of Embedded Systems Design, a global magazine for high-tech developers and managers, and Conference Chairman of the Embedded Systems Conferences, a series of electronics design shows. In addition, since August 2001, Mr. Turley has managed his own technology consulting and analysis business, Silicon Insider. From 1999 to 2001, he served as Senior Vice President of Marketing for ARC International, a microprocessor intellectual property company based in the UK. Mr. Turley has authored seven books on microprocessor chips, semiconductor intellectual property, computers, and silicon technology. He also serves on the board of directors and/or technical advisory boards of several high-tech companies in the U.S. and Europe.
 
There is no family relationship between any of our executive officers and directors.
 
Committees of the Board Of Directors
 
Our Board has standing Audit, Compensation, Nominating and Executive Committees.
 
Audit Committee. The Audit Committee is responsible for assisting the Board of Directors in monitoring and oversight of (1) the integrity of the Company’s financial statements and its systems of internal accounting and financial controls and (2) the independence and performance of the Company’s independent auditors. The Audit Committee, which met three times during fiscal 2005, is composed of two directors, both of whom were determined by the Board of Directors to be independent directors. During fiscal 2005 and to date, the Audit Committee has consisted of Ms. Felcyn (Chairman) and Mr. Johnson.
 
The Board of Directors has determined that Ms. Felcyn is an audit committee financial expert as defined in Item 401 of Regulation S-B promulgated by the SEC. The Board’s conclusions regarding the qualifications of Ms. Felcyn as an audit committee financial expert were based on her standing as a certified public accountant and her degree in business economics.
 
 
Compensation Committee. The Compensation Committee establishes the compensation philosophy for the company and has all the authority of the Board of Directors to act or exercise corporate powers with respect to the compensation of the executive officers and the administration of the company’s equity compensation plans. The Compensation Committee is composed of Mr. Johnson, as Chairman, Ms. Felcyn and Mr. Falk.
 
Executive Committee. The Executive Committee exercises certain powers of the Board of Directors between Board meetings. The Executive Committee is composed of Mr. Johnson (chairman), Mr. Falk and Ms. Felcyn.
 
Nominating Committee. On August 28, 2003, the Board created the Nominating Committee. The members of the Nominating Committee are Carlton M. Johnson, and David H. Pohl.
 
The Nominating Committee reviews and recommends to the Board, for nomination, candidates for election to the Board. During fiscal 2005 and 2006, the Nominating Committee did not hold any meetings. The entire Board acted in lieu of the Nominating Committee and in accordance with the policies that apply to the Nominating Committee.
 
Mr. Pohl is currently an officer of the Company, and, because Mr. Giffhorn was an officer of the Company until June 2005, neither Mr. Pohl nor Mr. Giffhorn are considered to be independent directors under the NASDAQ listing standards. Mr. Johnson is an independent director under the NASDAQ listing standards. Because of the small number of independent directors serving on the Board, the Board appointed Messrs. Pohl and Giffhorn to serve on the Nominating Committee.
 
Compliance with Section 16(a) of the Exchange Act
 
Section 16(a) of the Exchange Act requires our directors, executive officers and persons who beneficially own 10% or more of a class of securities registered under Section 12 of the Exchange Act to file reports of beneficial ownership and changes in beneficial ownership with the SEC. Directors, executive officers and greater than 10% shareholders are required by the rules and regulations of the Commission to furnish us with copies of all reports filed by them in compliance with Section 16(a).
 
Based solely on the Company’s review of copies of the Forms 3 and 4 and amendments thereto furnished to the Company by the persons required to make such filings during the 2005 fiscal year, and Forms 5 and amendments thereto furnished to the Company with respect to the 2005 fiscal year and the Company’s own records, the Company believes, that from the period June 1, 2004 through May 31, 2005, Mr. Pohl, Ms. Felcyn and Mr. Giffhorn each failed to file timely one Form 4 with the SEC to report changes in beneficial ownership.
 
Code of Ethics
 
The Company has adopted a Code of Ethics which applies to its principal executive and financial officers. The Code of Ethics will be provided to any person requesting it, without charge, by contacting the Company’s corporate office. (See Exhibit 14.1).
 
Indemnification of Officers, Directors and Others
 
As permitted by Delaware law, our certificate of incorporation provides that we will indemnify our officers, directors, employees and agents. This includes indemnification against attorneys’ fees and other expenses and liabilities they incur to defend, settle or satisfy any civil or criminal action brought against them arising out of their association with or activities on behalf of us. However, they will not be indemnified if they are adjudged to have acted with gross negligence or to have engaged in willful misconduct. We may also bear the expenses of such litigation for any such persons upon their promise to repay such sums if it is ultimately determined that they are not entitled to indemnification. Such expenditures could be substantial and may not be recouped, even if we are so entitled. We have provided for indemnification for liabilities arising under the Securities Act of 1933 as they may be permitted to directors, officers or persons controlling us. The SEC has informed us that such indemnification is against public policy and may be unenforceable.
 

 
 
There is shown below information concerning the compensation of our chief executive officer and the most highly compensated executive officers whose salary and bonus exceeded $100,000 (each a “Named Officer”) for the fiscal years ended May 31, 2005, 2004, and 2003.
 
           
Long-Term Compensation
       
Annual Cash Compensation
 
Awards
 
Payouts
 
 
Name and Principal Position
 
Fiscal Year
 
Salary
 
Bonus
 
Other Annual Compensation
 
Restricted Stock Award(s)
 
Securities Underlying Options/SARs
 
LTIP Payouts
 
 
All Other Compensation
Jeffrey E. Wallin
President and CEO (2)
 
2005
2004
2003
 
$146,317 (1)
$145,933 (1)
$127,650 (1)
 
Nil
Nil
Nil
         
250,000
673,000
250,000
       
                                 
Lowell W. Giffhorn
Exec. V.P., CFO
and Secy. (3)
 
2005
2004
2003
 
$148,227 (1)
$148,800 (1)
$150,779 (1)
 
Nil
Nil
Nil
         
650,000
239,000
115,000
       
                                 
Patrick O. Nunally
VP and CTO
 
2005
2004
2003
 
$122,734 (1)
$180,000 (1)
$189,521 (1)
 
Nil
Nil
Nil
         
200,000
173,000
400,000
     
 
 
$52,500 (4)

(1)
Included in Messrs. Wallin, Giffhorn, and Nunally is cash compensation of $400 per month for car allowance.
 
(2)
Mr. Wallin left the Company in June 2005. He was replaced by Mr. David H. Pohl who became the Company’s President and CEO on June 13, 2005.
 
(3)
Mr. Giffhorn left the Company in June 2005. He was replaced by Mr. Thomas J. Sweeney who became the Company’s CFO on August 3, 2005.
 
(4)
Amount represents payments through November 30, 2002 to Dr. Nunally for assignments to the Company of intellectual property rights. The rights were returned to Dr. Nunally in April 2003.
 
The Company maintains employee benefits that are generally available to all of its employees, including medical, dental and life insurance benefits and a 401(k) retirement savings plan. The Company did not make any matching contributions under the 401(k) plan for any of the above named officers during the fiscal years ended May 31, 2005, 2004 and 2003.
 
Employment Contracts
 
The Company had a consulting agreement dated March 18, 2004 with San Diego Millennia Consultants, Inc. whereby San Diego Millennia Consultants agreed to provide the services of Mr. Wallin to be the President and Chief Executive Officer of the Company. Mr. Wallin’s employment with the Company ended on June 12, 2005, and the Company’s agreement with San Diego Millennia Consultants terminated on that date. In September 2005, the Company agreed to pay Mr. Wallin approximately $148,700 in full settlement of all amounts owed to him under the consulting agreement.
 
The Company had an employment agreement dated September 1, 2004 with Mr. Giffhorn providing for his employment as Executive Vice President and Chief Financial Officer. Mr. Giffhorn’s employment with the Company ended on June 13, 2005. The Company did not pay Mr. Giffhorn any severance compensation or otherwise in connection with his termination of employment. The Company is currently in an arbitration proceeding adverse to Mr. Giffhorn related to the termination of his employment. (See “Legal Proceedings” Section for more information).
 


The Company entered into an employment agreement dated June 1, 2004, as amended on July 12, 2004, with Dr. Nunally regarding his employment as the Chief Technical Officer of the Company. Pursuant to the terms of the employment agreement, Dr. Nunally’s employment with the Company terminated on May 31, 2005.
 
The Company has an employment agreement with Mr. Sweeney. Under the terms of the agreement, Mr. Sweeney is paid a salary of $1,125 per day, subject to increase (in the Company’s sole discretion). Mr. Sweeney is also entitled to a cash bonus, stock options and severance pay, in each case, as may be determined by the Compensation Committee, in its sole discretion. During the course of Mr. Sweeney’s employment with the Company, Mr. Sweeney remains a partner of Tatum CFO Partners, LLP. As a partner of Tatum, Mr. Sweeney is to share with Tatum a portion of his economic interest in any stock options or equity bonus that the Company may pay him, to the extent specified in the Part-Time Engagement Resources Agreement between the Company and Tatum. Mr. Sweeney is eligible for any Company employment retirement and/or 401(k) plan and for vacation and holidays, consistent with the Company's policy as it applies to senior management. Either party may terminate the employment relationship upon at least 30 days' prior written notice, unless the Company has not remained current in its obligations under the employment agreement or the Part-Time Engagement Resources Agreement or if the Company engages in or asks Mr. Sweeney to engage in or to ignore any illegal or unethical conduct, in which case Mr. Sweeney may terminate his employment immediately.
 
Option Grants
 
Shown below is information on grants of stock options pursuant to the Company’s 1992, 1996, 2001 and 2003 Stock Option Plans to the Named Officers reflected in the Summary Compensation Table shown above.
 
Option Grants Table for Fiscal Year Ended May 31, 2005

 
 
Name
 
 
Number of Options Granted
 
Percent of Total Options Granted to Employees in Fiscal Year
 
 
Exercise Prices
 
 
 
Expiration Dates
                 
Jeffrey E. Wallin
 
250,000(1)
 
14.0%
 
$0.10
 
February 16, 2010
                 
Lowell W. Giffhorn
 
100,000(2)
 
5.6%
 
$0.07
 
December 15, 2009
   
300,000(1)
 
16.8%
 
$0.04
 
September 1, 2009
   
250,000(1)
 
14.0%
 
$0.10
 
February 16, 2010
                 
Patrick Nunally
 
200,000(3)
 
11.2%
 
$0.10
 
July 25, 2005

(1) Options are fully vested.
(2) Options are fully vested and were granted in recognition of his service on the Board.
(3) Options expired three months after termination of employment without being exercised.

Aggregated Option Exercises and Fiscal Year-End Option Values

Shown below is information on fiscal year-end values under the Company’s 1992, 1996, 2001 and 2003 Stock Option Plans to the officers reflected in the Summary Compensation Table shown above.
 
The following table sets forth certain information with respect to the Named Officers concerning exercised and unexercised stock options held as of May 31, 2005.
 
Name
 
 
Shares Acquired
on Exercise
 
Value Realized
 
Number of Unexercised Options
Held at May 31, 2005
 
Value of Unexercised In-The-Money Options
at May 31, 2005
 
           
Exercisable
 
Unexercisable
 
Exercisable
 
Unexercisable
 
Jeffrey E. Wallin
   
-
 
$
-
   
2,020,000
   
-
 
$
118,875
 
$
-
 
Lowell W. Giffhorn
   
-
 
$
--
   
1,120,000
   
-
 
$
82,550
 
$
-
 
Patrick Nunally
   
400,000
 
$
15,000
   
600,000
   
-
 
$
19,600
 
$
-
 
 

The fair market value of the unexercised in-the-money options at May 31, 2005 was determined by subtracting the option exercise price from the last sale price reported on the over the counter bulletin board on May 31, 2005.
 
The Company has not awarded stock appreciation rights to any of its employees. The Company has no long-term incentive plans.
 
Compensation of Directors
 
During the fiscal year ended May 31, 2005, options to purchase shares of Common Stock were issued to directors in respect of their service as directors in the following amounts: (i) options to acquire 200,000 shares to each of Mr. Pohl, Ms. Felcyn and Mr. Falk, (ii) options to acquire 300,000 shares to Mr. Johnson, and (iii) options to acquire 100,000 shares to Mr. Giffhorn. During the first quarter of the fiscal year ending May 31, 2006, the Company paid $60,000 to each of Mr. Pohl and Mr. Johnson, $40,000 to Ms. Felcyn and $10,000 to Mr. Falk. During the first quarter of the fiscal year ending May 31, 2006, options to purchase 500,000 shares of Common Stock were issued to each of Mr. Pohl and Mr. Johnson, options to purchase 250,000 shares of Common Stock were issued to Ms. Felcyn, and options to purchase 100,000 shares of Common Stock were issued to Mr. Falk. On February 3, 2006, the Board adopted a resolution which provides that each director will be paid compensation of $3,000 per month for his or her service as a director. The Company began making payments in February 2006. Expenses of the Company’s directors in connection with the attendance of board or committee meetings and company related activities are reimbursed by the Company.
 
 
The following table sets forth, as of February 28, 2006 (except as noted below), the stock ownership of each officer and director of the Company, of all officers and directors of the Company as a group, and of each person known by the Company to be a beneficial owner of 5% or more of its Common Stock. Except as otherwise noted, each person listed below is the sole beneficial owner of the shares and has sole investment and voting power over such shares. No person listed below has any option, warrant or other right to acquire additional securities of the Company, except as otherwise noted.
 
Title of Class
 
Name and Address of Beneficial Owner
 
Amount & Nature of Beneficial Ownership
 
Percent of Class
             
Common stock par value $0.00001
 
Gloria Felcyn, CPA
Carlsbad Corporate Plaza
6183 Paseo Del Norte, Suite 180
Carlsbad, CA 92011
 
744,700(1)
 
*
       
 
   
SAME AS ABOVE
 
Helmut Falk, Jr.
Carlsbad Corporate Plaza
6183 Paseo Del Norte, Suite 180
Carlsbad, CA 92011
 
2,918,231(2)
 
*
           
 
SAME AS ABOVE
 
David H. Pohl
Carlsbad Corporate Plaza
6183 Paseo Del Norte, Suite 180
Carlsbad, CA 92011
 
2,375,000(3)
 
*
       
 
 
 
SAME AS ABOVE
 
Carlton M. Johnson, Jr.
Carlsbad Corporate Plaza
6183 Paseo Del Norte, Suite 180
Carlsbad, CA 92011
 
975,000(4)
 
*
 
30

 
 
Title of Class
   
Name and Address of Beneficial Owner
   
Amount & Nature of Beneficial Ownership
   
Percent of Class
             
SAME AS ABOVE
 
James Turley
Carlsbad Corporate Plaza
6183 Paseo Del Norte, Suite 180
Carlsbad, CA 92011
 
200,000(4)
   
             
SAME AS ABOVE
 
Lowell W. Giffhorn
10875 Kemah Lane
San Diego, CA 92131
 
877,948(5)
 
*
             
SAME AS ABOVE
 
Thomas J. Sweeney
Carlsbad Corporate Plaza
6183 Paseo Del Norte, Suite 180
Carlsbad, CA 92011
 
0
 
*
 
 
             
SAME AS ABOVE
 
Lincoln Ventures, LLC
1125 Sanctuary Parkway,
Suite 275
Alpharetta, GA 30004
 
35,543,977(6)
 
9.99%(6)
 
 
             
SAME AS ABOVE
 
Swartz Private Equity, LLC
1125 Sanctuary Parkway,
Suite 275
Alpharetta, GA 30004
 
35,543,977(6)
 
9.99%(6)
 
 
       
 
   
SAME AS ABOVE
 
All directors & officers
As a group (7 persons)
* Less than 1%
 
8,090,879(7)
 
2.30%


1)
Includes 450,000 shares issuable upon the exercise of outstanding stock options.
 
2)
Includes 490,000 shares issuable upon the exercise of outstanding stock options.
 
3)
Includes 2,225,000 shares issuable upon the exercise of outstanding stock options (this includes 1,500,000 options granted on June 5, 2006 that will be included as a non-cash compensation expense of $1,527,019 in the first quarter of the fiscal year ended May 31, 2007).
 
4)
Represents shares issuable upon the exercise of outstanding stock options.
 
5)
Includes 820,000 shares issuable upon the exercise of outstanding stock options.
 
6)
Lincoln Ventures, LLC (“Lincoln”) and Swartz Private Equity, LLC (“SPE” and together with Lincoln, the “Reporting Person”) have shared voting power and shared dispositive power as to these shares. This number also includes 5,869,538 shares issuable upon exercise of outstanding warrants exercisable within 60 days of February 28, 2006. Lincoln and SPE each hold warrants to purchase Common Stock of the Company. The documents governing the terms of such warrants contain a provision prohibiting Lincoln and SPE, as applicable, from exercising warrants for shares of Common Stock if doing so would result in the Reporting Person and their affiliates beneficially owning shares of Common Stock that represent more than 9.99% of the outstanding shares of Common Stock as determined under Section 13(d) of the Securities Exchange Act of 1934. This number assumes that Lincoln and SPE may be deemed to be affiliated and under common control.
.
 
7)
Includes 3,660,000 shares issuable upon exercise of stock options.
 
Equity Compensation Plan Information

Plan category
 
Number of securities to be issued upon exercise of outstanding options, warrants and rights
 
Weighted average exercise price of outstanding options, warrants and rights
 
Number of securities remaining available for future issuance under equity compensation plans
 
               
Equity compensation plans approved by security holders
   
7,148,000
 
$
0.13
   
5,852,000
 
                     
Equity compensation plans not approved by security holders
   
109,122,581
 
$
0.04
   
-
 
                     
Total
   
116,570,581
 
$
0.05
   
5,852,000
 

 
Common shares issuable on the exercise of stock warrants have not been approved by the security holders and, accordingly, have been segregated in the above table.
 
Certain Relationships and Related Transactions
 
Other than those transactions described herein, there were no transactions, or series of transactions, during fiscal 2005 and 2004, nor are there any currently proposed transactions, or series of transactions, to which the Company is a party, in which the amount exceeds $60,000, and in which to its knowledge any director, executive officer, nominee, five percent or greater shareholder, or any member of the immediate family of any of the foregoing persons, has or will have any direct or indirect material interest other than as described below.
 
From June 10, 2002 through August 23, 2002, we issued to Gloria Felcyn, Trustee of the Helmut Falk Family Trust, two 8% Convertible Debentures with accumulative principal balances of $275,000 due June 10, 2004 through August 23, 2004. The initial exercise prices ranged from $0.0727 to $0.08616 and were subject to downward revisions if the price of our stock was lower on any three month anniversary of the debentures or on the date that a statement registering the resale of the common stock issuable upon conversion of the debentures became effective. Also, in conjunction with the debentures, we issued five year warrants to purchase up to 4,102,431 shares of our common stock at initial exercise prices ranging from $0.0727 to $0.08616 subject to reset provisions on each six month anniversary of the issuance of the warrants. If the price of our common stock is in excess of $0.20 per share, Ms. Felcyn has a two year option to purchase up to an additional $275,000 of 8% Convertible Debentures on the same terms. Ms. Felcyn converted the debentures into 6,810,102 shares of common stock in July and November 2003 and exercised the warrants into 4,102,431 shares of common stock in July 2003 and January 2004.
 
During October 2002 through December 2002, we entered into three 8% short-term notes with Gloria Felcyn, the trustee for the Falk Family Trust, aggregating $180,000 with initial maturity dates ranging from January 1 to January 31, 2003. In July 2003 we issued a new 8% short-term note in the amount of $200,354 with a maturity date of October 7, 2003 in exchange for cancellation of the three 8% short term notes issued in October through December 2002, the accrued interest on the canceled notes and an additional $10,000 in cash. In January 2004, as part of the exercise of the warrants, the $200,354 note was exchanged for four $25,000 6% notes and shares of common stock which were issued to the beneficiaries of the trust. The 6% notes have a one year and mature in January 2005, at which time they were repaid.
 



 
 
Our common stock is traded in the over-the-counter market and is quoted on the NASD OTC Bulletin Board system maintained by the National Association of Securities Dealers, Inc. Prices reported represent prices between dealers, they do not include markups, markdowns or commissions and do not necessarily represent actual transactions. The market for our shares has been sporadic and at times very limited.
 
The following table sets forth the high and low closing bid quotations for the Common Stock in the fiscal years ended May 31, 2006, 2005 and 2004.
 
   
   
HIGH
 
LOW
Fiscal Year Ending May 31, 2006
       
First Quarter
 
$0.18
 
$0.11
Second Quarter
 
$0.15
 
$0.09
Third Quarter
 
   $0.91
 
   $0.08
   
 
 
 
Fiscal Year Ending May 31, 2005
 
 
 
 
First Quarter
 
$0.09
 
$0.03
Second Quarter
 
$0.05
 
$0.03
Third Quarter
 
$0.25
 
$0.05
Fourth Quarter
 
   $0.18
 
   $0.07
   
 
 
 
Fiscal Year Ending May 31, 2004
 
 
 
 
First Quarter
 
$0.07
 
$0.04
Second Quarter
 
$0.08
 
$0.04
Third Quarter
 
$0.17
 
$0.03
Fourth Quarter
 
   $0.15
 
    $0.08

We have approximately 653 shareholders of record as of February 28, 2006. Because most of our common stock is held by brokers and other institutions on behalf of stockholders, we are unable to estimate the total number of stockholders represented by these record holders. Patriot paid its first dividend of $.02 per share on March 22, 2006. Patriot also declared a dividend of $0.04 per share to shareholders of record on March 31, 2006, which was paid on April 24, 2006. The Board of Directors may declare additional dividends in the future with due regard for the financial resources of Patriot and alternative applications of those financial resources.
 
 
Our authorized capital stock consists of 500,000,000 shares of common stock, $.00001 par value per share. At February 28, 2006, a total of 349,336,560 common shares were issued and outstanding. The holders of common stock are entitled to one vote for each share held. The affirmative vote of a majority of votes, cast at a meeting which commences with a lawful quorum, is sufficient for approval of most matters upon which shareholders may or must vote, including the questions presented for approval or ratification at the Annual Meeting. However, removal of a director from office or repeal of the certificate of incorporation in its entirety require the affirmative vote of a majority of the total voting power for approval, and certain other matters (such as shareholder amendment of the bylaws, and amendment, repeal or adoption of any provision inconsistent with provisions in the certificate of incorporation regarding indemnification of directors, officers and others, exclusion of director liability, and our election not to be governed by statutory provisions concerning business combinations with interested shareholders) require the affirmative vote of two-thirds of the total voting power for approval. Common shares do not carry cumulative voting rights, and holders of more than 50% of the common stock have the power to elect all directors and, as a practical matter, to control the company. Holders of common stock are not entitled to preemptive rights, and the common stock may only be redeemed at our election.
 
A special meeting of shareholders may be called by or at the request of:
 
·  
the Chairman of the Board (if one has been appointed by the Board),
 



 
·  
the President or any two directors, and
 
·  
persons owning in the aggregate not less than 20% of the issued and outstanding common shares entitled to vote in elections for directors.
 
After the satisfaction of requirements with respect to preferential dividends, if any, holders of common stock are entitled to receive, pro rata, dividends when and as declared by the board of directors out of funds legally available for that purpose. Upon our liquidation, dissolution or winding-up, after distribution in full of the preferential amount, if any, to be distributed to holders of the preferred stock, holders of common stock are entitled to share ratably in our assets legally available for distribution to our shareholders.
 
Our board of directors is authorized to issue 5,000,000 shares of undesignated preferred stock, $.00001 par value, without any further action by the stockholders. The board of directors may also divide any and all shares of preferred stock into series and fix and determine the relative rights and preferences of the preferred stock, such as the designation of series and the number of shares constituting such series, dividend rights, redemption and sinking fund provisions, liquidation and dissolution preferences, conversion or exchange rights and voting rights, if any. Issuance of preferred stock by the board of directors will result in such shares having dividend and/or liquidation preferences senior to the rights of the holders of common stock and could dilute the voting rights of the holders of common stock. There are currently no shares of preferred stock issued and outstanding.
 
Interwest Transfer Company, Inc., 1981 East 4800 South, Suite 100, Salt Lake City, Utah 84117, acts as our transfer agent and registrar for our common stock. Their telephone number is (801) 272-9294.
 
CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING
AND FINANCIAL DISCLOSURE
 
On November 21, 2005, Patriot received notice from Mayer Hoffman McCann P.C. ("Mayer Hoffman"), that they resigned effective November 21, 2005, as the Company's independent registered public accounting firm. Mayer Hoffman's reports on the consolidated financial statements of the Company and its subsidiaries for the two most recent fiscal years ended May 31, 2005, did not contain any adverse opinion or disclaimer of opinion, nor were they qualified or modified as to uncertainty, audit scope, or accounting principles, except only that their report for the fiscal year ending May 31, 2004 was modified as to an uncertainty regarding the Company's ability to continue as a going concern. On November 21, 2005, the Executive Committee of the Board of Directors of the Company, upon the recommendation of its Audit Committee, elected to engage Corbin & Company, LLP to serve as the Company's independent registered public accounting firm. On November 23, 2005, the Company was informed that it had been accepted as a client of Corbin & Company. During the Company's two most recent fiscal years ended May 31, 2005 and the subsequent interim period through November 21, 2005, there were no disagreements between the Company and Mayer Hoffman on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to Mayer Hoffman's satisfaction, would have caused them to make reference to the subject matter of the disagreement in their reports on the financial statements for such years. The Company has authorized Mayer Hoffman to respond fully to the inquiries of Corbin & Company concerning the subject matter of the reportable event and has provided Mayer Hoffman with a copy of the foregoing disclosures. During the Company's two most recent fiscal years ended May 31, 2005, and the subsequent interim period through November 23, 2005, the Company did not consult Corbin & Company with respect to the application of accounting principles to a specific transaction, either completed or contemplated, or the type of audit opinion that might be rendered on the Company's consolidated financial statements, or any other matters of reportable events as set forth in Items 304(a)(2)(i) and (ii) of Regulation S-B.
 
 
LEGAL OPINION
 
Luce, Forward, Hamilton & Scripps LLP, 600 West Broadway Street, Suite 2600, San Diego, California 92101 will pass on the validity of the common stock offered by us.
 


 
The financial statements as of and for the year ended May 31, 2005, included in this Prospectus and in the Registration Statement have been audited by Mayer Hoffman McCann P.C., independent certified public accountants, to the extent and for the periods set forth in their report appearing elsewhere herein and in the Registration Statement, and are included in reliance upon such report given the authority of said firm as experts in auditing and accounting. The financial statements as of and for the year ended May 31, 2004, included in this Prospectus and in the Registration Statement have been audited by Nation Smith Hermes Diamond, independent certified public accountants, to the extent and for the periods set forth in their report appearing elsewhere herein and in the Registration Statement, and are included in reliance upon such report given the authority of said firm as experts in auditing and accounting.
 


INDEX TO FINANCIAL STATEMENTS


Report of Mayer Hoffman McCann P.C., Independent Certified Public Accounting Firm
   
F-2
 
Report of Nation Smith Hermes Diamond, Independent Certified Public Accounting Firm
   
F-3
 
Consolidated Statements of Operations for the Years Ended May 31, 2005 and 2004
   
F-5
 
Consolidated Statement of Stockholders’ Equity (Deficit) for the Years Ended May 31, 2005 and 2004
   
F-6
 
Consolidated Statements of Cash Flows for the Years Ended May 31, 2005 and 2004
   
F-7
 
Summary of Accounting Policies
   
F-8-F-11
 
Notes to Consolidated Financial Statements
   
F-12-F-22
 
Consolidated Balance Sheets as of February 28, 2006 (unaudited) and May 31, 2005
   
F-23
 
Consolidated Statements of Cash Flows for the Nine Months ended February 28, 2006 and 2005 (unaudited)
   
F-25
 
Notes to Unaudited Consolidated Financial Statements
   
F-26-F-33
 
 
F-1


REPORT OF INDEPENDENT REGISTERED CERTIFIED PUBLIC ACCOUNTING FIRM



To the Board of Directors and Stockholders of
Patriot Scientific Corporation
San Diego, California

We have audited the accompanying consolidated balance sheet of Patriot Scientific Corporation as of May 31, 2005, and the related consolidated statements of operations, stockholders’ equity and cash flows for the year then ended. These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audit.
 
We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.
 
In our opinion, the consolidated financial statements referred to above, present fairly, in all material respects, the consolidated financial position of Patriot Scientific Corporation at May 31, 2005, and the consolidated results of its operations and its cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States of America.
 
/s/ Mayer Hoffman McCann P.C.    
 
San Diego, California
 
 
 
 
     
 August 18, 2005, except for notes 10 and 12, for which the date is September 12, 2005.
   
 
F-2

 
REPORT OF INDEPENDENT REGISTERED CERTIFIED PUBLIC ACCOUNTING FIRM


To the Stockholders and Board of Directors
Patriot Scientific Corporation
San Diego, California

We have audited the accompanying consolidated balance sheet of Patriot Scientific Corporation as of May 31, 2004, and the related consolidated statements of operations, stockholders’ equity and cash flows for the year then ended. These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audit.
 
We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.
 
In our opinion, the financial statements referred to above, present fairly, in all material respects, the consolidated financial position of Patriot Scientific Corporation at May 31, 2004, and the consolidated results of its operations and its cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States of America.
 
The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the 2004 financial statements, the Company has suffered recurring losses from operations, has negative cash flows and has negative working capital that raise substantial doubt about its ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
 
     
/s/ Nation Smith Hermes Diamond  
 
San Diego, California
 
 
 
 
     
July 8, 2004
   
 
F-3


PATRIOT SCIENTIFIC CORPORATION
CONSOLIDATED BALANCE SHEETS

May 31,
 
2005
 
2004
 
ASSETS (Notes 1, 4, 5 and 7)
             
               
Current Assets:
             
Cash and cash equivalents
 
$
591,426
 
$
355,940
 
Marketable securities and short term investments
   
697,524
   
22,646
 
Restricted short term investment (Note 4)
   
201,648
   
-
 
Licenses receivable (Note 3)
   
2,000,000
   
-
 
Prepaid expenses and other current assets
   
121,758
   
323,293
 
               
Total current assets
   
3,612,356
   
701,879
 
               
Property and equipment, net (Note 2)
   
21,376
   
68,389
 
               
Other assets
   
23,891
   
41,221
 
               
Patents and trademarks, net of accumulated amortization of $549,563 and $501,235
   
66,411
   
114,739
 
   
$
3,724,034
 
$
926,228
 
               
LIABILITIES AND STOCKHOLDERS’ EQUITY
             
               
Current liabilities:
             
Line of credit (Note 4)
 
$
100,000
 
$
-
 
Current portion of 8% convertible debentures, net of debt discount of $301,320 and $27,180 (Note 7)
   
421,847
   
145,320
 
Secured notes payable to affiliates (Note 5)
   
-
   
100,000
 
Accounts payable
   
268,458
   
134,600
 
Accrued liabilities and other (Note 6)
   
505,153
   
160,102
 
Current portion of capital lease obligation (Note 10)
   
2,306
   
8,020
 
Accrued contested fee payable (Note 3)
   
346,000
   
-
 
               
Total current liabilities
   
1,643,764
   
548,042
 
               
8  8%   Convertible Debentures, net of discount of  $111,559 and $2,047,966 (Note 7)
   
45,942
   
227,701
 
               
Long term portion of capital lease obligation (Note 10)
   
-
   
2,306
 
               
Total liabilities
   
1,689,706
   
778,049
 
               
Commitments and contingencies (Note 1, 3, 7 and 10)
             
               
Stockholders’ equity (Notes 7 and 8)
             
Preferred stock, $.00001 par value; 5,000,000 shares authorized: none outstanding
   
-
   
-
 
Common stock, $.00001 par value: 500,000,000 shares authorized: 280,492,013 and 171,156,363 issued and outstanding
   
2,805
   
1,712
 
Additional paid-in capital
   
54,569,091
   
49,990,485
 
Accumulated deficit
   
(52,537,568
)
 
(49,844,018
)
Total stockholders’ equity
   
2,034,328
   
148,179
 
               
   
$
3,724,034
 
$
926,228
 

See accompanying summary of accounting policies and notes to consolidated financial statements.



F-4


 
PATRIOT SCIENTIFIC CORPORATION
CONSOLIDATED STATEMENT OF OPERATIONS


Years Ended May 31,
 
2005
 
2004
 
Net sales (Note 11)
             
Product
 
$
25,077
 
$
74,017
 
Licenses and royalties
   
2,957,509
   
2,400
 
Net sales
   
2,982,586
   
76,417
 
               
Cost of sales
   
-
   
10,472
 
               
Gross profit
   
2,982,586
   
65,945
 
               
Operating expenses:
             
Research and development
   
294,735
   
549,756
 
Selling, general and administrative
   
2,600,430
   
1,253,559
 
Operating expenses
   
2,895,165
   
1,803,315
 
Operating income (loss)
   
87,421
   
(1,737,370
)
Other income (expense):
             
Sale of technology
   
-
   
75,500
 
Loss on marketable securities
   
(21,180
)
 
(45,354
)
Other income (Note 10)
   
60,379
   
270
 
Interest expense (Notes 4 and 7)
   
(2,820,170
)
 
(2,443,024
)
Other expense
   
(2,780,971
)
 
(2,412,608
)
Net loss
 
$
(2,693,550
)
$
(4,149,978
)
               
Basic and diluted loss per common share
 
$
(0.01
)
$
(0.03
)
               
Weighted average number of common shares outstanding
   
222,495,047
   
139,767,276
 

See accompanying summary of accounting policies and notes to consolidated financial statements.

F-5

 
PATRIOT SCIENTIFIC CORPORATION
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY  
 
     
Common Stock 
                   
 
Years Ended May 31, 2005 and 2004
 
 
Shares 
 
 
Amounts 
 
 
Additional Paid-in Capital 
 
 
Accumulated Deficit 
 
 
Stockholders’ Equity 
 
Balance, May 31, 2003
   
106,547,807
 
$
1,066
 
$
44,281,210
 
$
(45,694,040
)
$
(1,411,764
)
                                 
Issuance of common stock at $.025 and $.034 per share
   
1,800,752
   
18
   
50,422
   
-
   
50,440
 
Exercise of warrants and options at $.02 to $.04 per share
   
11,184,175
   
112
   
285,832
   
-
   
285,944
 
Issuance of common stock for services at $.04 and $.12 per share
   
1,126,496
   
11
   
59,841
   
-
   
59,852
 
Conversion of debentures payable plus accrued interest at $.02 and $.06 per share
   
50,497,133
   
505
   
1,757,123
   
-
   
1,757,628
 
Value of warrants issued
   
-
   
-
   
3,556,057
   
-
   
3,556,057
 
Net loss
   
-
   
-
   
-
   
(4,149,978
)
 
(4,149,978
)
                                 
Balance, May 31, 2004
   
171,156,363
   
1,712
   
49,990,485
   
(49,844,018
)
 
148,179
 
                                 
Issuance of common stock at $.03 and $.10 per share
   
4,625,000
   
46
   
453,204
   
-
   
453,250
 
Exercise of warrants and options at $.02 to $.06 per share
   
39,028,511
   
390
   
820,898
   
-
   
821,288
 
Issuance of common stock for services at $.05 and $.09 per share
   
796,000
   
8
   
58,792
   
-
   
58,800
 
Conversion of debentures payable plus accrued interest at $.02 and $.05 per share
   
64,886,139
   
649
   
2,169,287
   
-
   
2,169,936
 
Non-cash compensation
   
-
   
-
   
59,675
   
-
   
59,675
 
Non-cash interest and debt discount related to warrants and debentures
   
-
   
-
   
1,016,750
   
-
   
1,016,750
 
Net loss
   
-
   
-
   
-
   
(2,693,550
)
 
(2,693,550
)
                                 
Balance, May 31, 2005
   
280,492,013
 
$
2,805
 
$
54,569,091
 
$
(52,537,568
)
$
2,034,328
 

See accompanying summary of accounting policies and notes to consolidated financial statements.

F-6

 
PATRIOT SCIENTIFIC CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS 

 
Years Ended May 31,
 
2005
 
2004
 
           
Operating activities:
             
Net loss
 
$
(2,693,550
)
$
(4,149,978
)
Adjustments to reconcile net loss to net cash used in operating activities:
             
Amortization and depreciation
   
94,353
   
135,450
 
Non-cash interest expense related to convertible debentures, notes payable and warrants
   
2,679,018
   
2,293,922
 
Gain on sale of technology
   
-
   
(75,500
)
Gain on disposal of fixed assets
   
(4,012
)
 
-
 
Unrealized loss on marketable securities
   
21,180
   
45,354
 
Common stock, options and warrants issued for services
   
118,475
   
59,852
 
Changes in:
             
Prepaid and other current assets
 
 
218,865
 
 
(235,678
)
Licenses receivable
 
 
(2,000,000
)
 
-
 
Accounts payable and accrued expenses
 
 
435,645
 
 
(149,394
)
Contingency fee payable
 
 
501,700
 
 
-
 
Net cash used in operating activities
   
(628,326
)
 
(2,075,972
)
               
Investing activities:
             
Purchase of short term investments
   
(897,706
)
 
-
 
Proceeds from sale of fixed assets
   
5,000
   
-
 
Proceeds from sale of technology
   
-
   
7,500
 
Purchase of property, equipment and patents, net
   
-
   
(36,123
)
Net cash used in investing activities
   
(892,706
)
 
(28,623
)
               
Financing activities:
             
Payment of shareholder note
   
(100,000
)
 
-
 
Proceeds from line of credit
   
100,000
   
-
 
Proceeds from issuance of secured notes payable
   
-
   
12,320
 
Payments for capital lease obligations
   
(8,020
)
 
(6,405
)
Proceeds from issuance of convertible debentures
   
490,000
   
2,175,000
 
Proceeds from issuance of common stock
   
453,250
   
50,440
 
Proceeds from exercise of common stock warrants and options
   
821,288
   
175,237
 
Proceeds from sale of accounts receivable
   
-
   
21,280
 
Net cash provided by financing activities
   
1,756,518
   
2,427,872
 
               
Net increase in cash and cash equivalents
   
235,486
   
323,277
 
Cash and cash equivalents, beginning of year
   
355,940
   
32,663
 
Cash and cash equivalents, end of year
 
$
591,426
 
$
355,940
 
               
Supplemental Disclosure of Cash Flow Information:
             
               
Cash payments for interest
 
$
15,406
 
$
17,220
 
Convertible debentures, notes payable and accrued interest exchanged for common stock
 
$
2,169,936
 
$
1,757,628
 
Debt discount arising from issuance of detachable warrants
 
$
490,000
 
$
2,873,167
 

See accompanying summary of accounting policies and notes to consolidated financial statements.

F-7


PATRIOT SCIENTIFIC CORPORATION
SUMMARY OF ACCOUNTING POLICIES

Organization and Business
 
Patriot Scientific Corporation (the “Company”), a Delaware corporation incorporated in 1987, is engaged in the development, marketing, and sale of patented microprocessor technology and the sale of high-performance high-speed data communication products.
 
Basis of Consolidation
 
The consolidated financial statements include the accounts of the Company and its majority owned subsidiaries, Metacomp, Inc. (“Metacomp”) and Plasma Scientific Corporation. All material intercompany transactions and balances have been eliminated in consolidation.
 
Reclassifications
 
Certain reclassifications have been made to the 2004 financial statements in order for them to conform to the 2005 presentation. Such reclassifications have no impact on the Company’s financial position or results of operations.
 
Financial Instruments and Concentrations of Credit Risk
 
Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, short-term investments and accounts and licenses receivable.
 
At times, the Company’s balance of cash and investments in certificates of deposits maintained with its bank may exceed the FDIC insured limit of $100,000. The Company limits its exposure of loss by maintaining its cash with financially stable financial institutions. When the Company has excess cash, the Company’s cash equivalents are placed in high quality money market accounts with major financial institutions and high grade short-term commercial paper. The Company believes this investment policy limits its exposure to concentrations of credit risk. Money market accounts are federally insured; however, commercial paper is not insured. The Company has not experienced any losses in such accounts.
 
Concentrations of credit risk with respect to receivables are primarily limited due to the high credit worthiness of the Company’s customers. The Company routinely assesses the financial strength of its customers and, as a consequence, believes that its accounts receivable credit risk exposure is limited. Generally, the Company does not require collateral or other security to support customer receivables.
 
The carrying value of financial instruments, including cash, cash equivalents, short-term investments, accounts receivable, accounts payable and accrued liabilities, approximate fair value because of the immediate or short-term maturity of these instruments. The carrying value of the Company’s line of credit obligation approximates its estimated fair value due to the instrument bearing a variable rate of interest which reflects the current market rate available to the Company. The fair value of the Company’s convertible debentures at May 31, 2005 and 2004 was approximately $880,000 and $2,450,000, which exceeded the debentures carrying amount due to the discounts applied to the instruments for accounting purposes.
 
Cash Equivalents, Marketable Securities, And Short Term Investments
 
For purposes of balance sheet classification and the statements of cash flows, the Company considers all highly liquid investments acquired with a maturity of three months or less to be a cash equivalent.
 
At May 31, 2005 and 2004, the Company had investments in marketable equity securities having a carrying value of $1,466 and $22,646, respectively. Marketable equity securities are carried at their fair value, with unrealized gains or losses reflected in the statement of operations. During the years ended May 31, 2005 and 2004, the Company recognized unrealized losses related to the write down in the carrying value of the securities of approximately $21,000 and $45,000.
 

F-8

 
PATRIOT SCIENTIFIC CORPORATION
SUMMARY OF ACCOUNTING POLICIES (CONTINUED)
 
At May 31, 2005, the Company also has approximately $696,000 in certificates of deposit maintained with various financial institutions. The certificates mature at various dates in fiscal 2006, bear interest at rates ranging from 3.1% to 3.6%, and are reported at their original cost plus accrued interest.
 
Property, Equipment and Depreciation
 
Property and equipment are stated at cost. Depreciation is computed over each asset’s estimated useful life, ranging from three to five years, using the straight-line method. The Company follows the provisions of the Financial Accounting Standards Board (“FASB”) Statement of Financial Accounting Standards (“SFAS”) No. 144, Accounting for the Impairment of Long-lived Assets. Long-lived assets and certain identifiable intangibles to be held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company evaluates the recoverability of its long-lived assets based on estimated future cash flows and the estimated fair value of such long-lived assets and provides for impairment if such undiscounted cash flows are insufficient to recover the carrying amount of the long-lived asset.
 
Patents and Trademarks
 
Patents and trademarks are carried at cost less accumulated amortization and are amortized over their estimated useful lives of four years. Estimated future annual amortization expense arising from the patents is approximately $35,000, $23,000 and $9,000 in fiscal years 2006, 2007, and 2008, respectively. The carrying value of patents and trademarks is periodically reviewed and impairments, if any, are recognized when the expected future benefit to be derived from individual intangible assets is less than its carrying value determined based on the provisions of SFAS No. 144 as discussed above.
 
Revenue Recognition
 
The Company recognizes revenue from the sale of its product upon shipment to the customer, at which time title transfers and the Company has no further obligations. Amounts received under technology licensing fee arrangements are recognized at the time the arrangement is executed, at which time the rights to the Company’s technology have been transferred and no significant performance obligations remain. Fees for maintenance or support are recorded on a straight-line basis over the underlying period of performance.
 
Research and Development Costs
 
Research and development costs are expensed as incurred.
 
Advertising
 
The Company expenses advertising costs as incurred. Advertising expense was approximately $14,000 and $3,000 for the years ended May 31, 2005 and 2004.
 
Income Taxes
 
The Company accounts for income taxes under SFAS No. 109, Accounting for Income Taxes. Deferred income taxes are recognized for the tax consequences in future years of differences between the tax basis of assets and liabilities and their financial reporting amounts at each year end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Income tax expense is the combination of the tax payable for the year and the change during the year in deferred tax assets and liabilities.
 
F-9


PATRIOT SCIENTIFIC CORPORATION
SUMMARY OF ACCOUNTING POLICIES (CONTINUED)
 
Net Loss Per Share
 
The Company applies SFAS No. 128, Earnings Per Share, for the calculation of “Basic” and “Diluted” earnings (loss) per share. Basic earnings (loss) per share includes no dilution and is computed by dividing income (loss) available to common stockholders by the weighted average number of common shares outstanding for the period. Diluted earnings (loss) per share reflects the potential dilution of securities that could share in the earnings (loss) of an entity. At May 31, 2005 and 2004, potential common shares of 143,826,204 and 193,271,524 related to the Company’s outstanding convertible debentures, warrants, and options were not included in the calculation of diluted loss per share as they had an antidilutive effect.
 
Use of Estimates
 
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates underlying the Company’s financial statements include the accrual for contested fees payable. Management has made the estimate based on information currently available to it; however, given the contingent nature of the liability, it is possible that the ultimate resolution of the liability could result in a payment of an amount greater or lesser than the amount accrued. To the extent the ultimate payment, if any, related to this matter is different than the Company’s current estimate, the Company’s results of operations in future periods may be impacted.
 
Sale of Accounts Receivable
 
The Company accounts for the transfer of trade receivables under its factoring line of credit in accordance with the provisions of SFAS No. 140, Accounting for Transfers and Servicing of Financial Assets and Extinguishments of Liabilities. If the criteria established by SFAS No. 140 are met, the transfer of receivables are recorded as a sale; otherwise the transaction is reflected as a secured borrowing.
 
Stock Based Compensation
 
The Company applies Accounting Principles Board (“APB”) Opinion 25, “Accounting for Stock Issued to Employees,” and related Interpretations in accounting for all stock option plans. Under APB Opinion 25, compensation cost has been recognized for stock options granted to employees when the option price is less than the market price of the underlying common stock on the date of grant.
 
SFAS No. 123, “Accounting for Stock-Based Compensation,” and SFAS No. 148, “Accounting for Stock-Based Compensation-Transition and Disclosure,” require the Company to provide pro forma information regarding reported net loss as if compensation cost for the Company’s stock option plans had been determined in accordance with the fair value based method prescribed in SFAS No. 123. To provide the required pro forma information, the Company estimates the fair value of each stock option at the grant date by using the Black-Scholes option-pricing model. SFAS No. 148 also provides for alternative methods of transition for a voluntary change to the fair value based method of accounting for stock-based employee compensation. The Company has elected to continue to account for stock based compensation under APB No. 25.
 
The Company applies SFAS No. 123 in valuing options and warrants granted to consultants and estimates the fair value of such options using the Black-Scholes option-pricing model. The fair value is recorded as consulting expense as services are provided. Options granted to consultants for which vesting is contingent based on future performance are measured at their then current fair value at each period end, until vested.
 
F-10


PATRIOT SCIENTIFIC CORPORATION
SUMMARY OF ACCOUNTING POLICIES (CONTINUED)
 
Had the Company used the accounting provisions of SFAS No. 123, the Company’s net loss per share would have been increased by the pro forma amounts indicated below:
 
   
Year Ended May 31,
 
   
2005
 
2004
 
Net loss as reported
 
$
(2,693,550
)
$
(4,149,978
)
Pro forma Compensation expense
   
(138,883
)
 
(152,074
)
               
Net loss pro forma
 
$
(2,832,433
)
$
(4,302,052
)
               
As reported per share
             
Basic and diluted loss
 
$
(0.01
)
$
(0.03
)
               
Pro forma per share
             
Basic and diluted loss
 
$
(0.01
)
$
(0.03
)

Recent Accounting Pronouncements
 
In December 2004, the FASB issued SFAS 123R, Share Based Payment. This statement replaces SFAS No. 123 and supersedes APB Opinion 25. SFAS No. 123R requires that the cost of share-based payment transactions (including those with employees and non-employees) be recognized as compensation based on the estimated fair value of the equity instrument awarded. SFAS No. 123R applies to all share-based payment transactions in which an entity acquires goods or services by issuing (or offering to issue) its shares, options, or other equity instruments or by incurring liabilities in amounts based on the price of the entity’s shares or other equity instruments, or that require (or may require) settlement by the issuance of an entity’s shares or other equity instruments. This statement applies to all new awards granted during the fiscal year beginning after December 15, 2005 and to previous awards that are remodified or cancelled after such date. The Company has not yet fully evaluated the effect of adopting SFAS No. 123R on its financial statements.
 
In December 2004, the FASB issued SFAS No. 153, Exchange of Nonmonetary Assets, an amendment of APB Opinion No. 29, Accounting for Nonmonetary Transaction. SFAS No. 153 is based on the principle that exchanges of nonmonetary assets should be measured based on the fair market value of the assets exchanged. SFAS No. 153 eliminates the exception of nonmonetary exchanges of similar productive assets and replaces it with a general exception for exchanges of nonmonetary assets that do not have commercial substance. SFAS 153 is effective for nonmonetary asset exchanges in fiscal periods beginning after June 15, 2005. The Company does not believe that the provisions of SFAS No. 153 will have a material impact on its financial statements.
 
In May 2005, the FASB issued SFAS No. 154, Accounting Changes and Error Corrections, which replaces APB Opinion No. 20, Accounting Changes, and FASB Statement No. 3, Reporting Accounting Changes in Interim Financial Statements, and changes the requirements for the accounting for and reporting of a change in accounting principle. SFAS No. 154 requires retrospective application to prior periods’ financial statements of changes in accounting principle, unless it is impracticable to determine either the period-specific effects or the cumulative effect of the change. SFAS No. 154 is effective for accounting changes and correction of errors made in fiscal years beginning after December 15, 2005. Early adoption is permitted for accounting changes and correction of errors made in fiscal years beginning after the date SFAS No. 154 was issued. At the present time, the Company does not believe that adoption of SFAS No. 154 will have a material effect on its financial statements.
 

F-11

 
PATRIOT SCIENTIFIC CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

1.  Management’s Plan
 
Through May 31, 2005, the Company has incurred repeated net losses and has used significant amounts of cash in its operations. Historically, the Company has had to rely on obtaining financing to fund its operations; such financing often being at unfavorable terms to the Company due to its poor financial condition. Management of the Company believes that 2005 represents a turning point for the Company. During 2005, the Company was able to resolve long-standing legal disputes involving ownership and other issues related to its patented technologies. As a result, the Company has been able to enter into two significant license agreements for its technology which will result in the Company obtaining approximately $13,000,000 in the aggregate. These agreements are discussed more fully elsewhere in the notes to these financial statements. Prospectively, the Company anticipates that it may need to spend additional funds in its efforts to further develop its technologies and expand the technologies’ markets. The Company believes that the funds obtained through these agreements will be sufficient to meet the Company’s obligations as they come due for the foreseeable future. If expanded development is commenced or new generations of microprocessor technology are accelerated beyond current plans, additional expenditures may be required. At the present time, management believes that it has the funds available to it to meet the obligations of the Company as the come due for the foreseeable future. In the event that the Company cannot do so, it will be required to curtail or alter its future plans of operations.
 
2. Property and Equipment
 
Property and equipment consisted of the following at May 31, 2005 and 2004:
 
       
   
2005
 
2004
 
Computer equipment and software
 
$
857,948
 
$
1,660,707
 
Furniture and fixtures
   
213,458
   
499,274
 
Laboratory equipment
   
35,673
   
205,594
 
     
1,107,079
   
2,365,575
 
Less accumulated depreciation and amortization
   
1,085,703
   
2,297,186
 
               
Net property and equipment
 
$
21,376
 
$
68,389
 

Depreciation expense was $46,026 and $85,141 for the years ended May 31, 2005 and 2004.
 
3. License Agreements
 
In February 2005, the Company entered into two separate licensing agreements with one customer for the Company’s Ignite microprocessor technology and the patent portfolio technology. The aggregate amount of the two licenses was $3,050,000, of which $2,950,000 was for licensing fees and $100,000 was for deferred maintenance. Maintenance under the agreement is expected to be provided over a period not to exceed four years. The payment terms of the agreements require aggregate payments of $300,000 at the time of execution, three quarterly payments of $750,000 each on April 1, August 15, and November 15, 2005 and one final payment of $500,000 on February 15, 2006. Total payments received to date under the agreements include $1,050,000 in fiscal 2005 and $750,000 in fiscal 2006. The agreements also provide for the future payment of royalties to the Company based on sales of product using the licensed technology. In connection with the license agreement, the Company became obligated to the former co-inventor of the Ignite technology for $207,600, payable in quarterly installments of $51,900, of which $155,700 remains outstanding at May 31, 2005.
 

F-12

 
PATRIOT SCIENTIFIC CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
 
Also, in conjunction with entering into these license agreements, as well as the license agreement described in Note 12, the legal advisor who had previously assisted the Company in its negotiations, has asserted a claim against the Company for amounts which it believes it is entitled. The Company is contesting the matter; the outcome of which is currently unknown. Based on its current assessment of the matter, the Company has accrued an expense of $346,000 as of May 31, 2005. The Company intends to vigorously defend itself in this matter; however, it is possible that, were the Company not to prevail in the suit, the ultimate amount payable to such legal advisor could be significantly higher based on any future license agreements entered into by the Company.
 
4. Lines of Credit
 
The Company has a line of credit with a bank which provides for advances up to $180,000 and which matures in March 2006. Advances under the line, which totaled $100,000 at May 31, 2005, are secured by a $200,000 certificate of deposit. The line of credit bears an interest rate at 2.25% above the index (5.31% at May 31, 2005).
 
Additionally, the Company has a $400,000 line of credit with a financial institution, pursuant to which it may factor accounts receivable. There were no balances outstanding under the line of credit at either May 31, 2005 or 2004. During fiscal 2004, the Company sold approximately $27,000 of receivables under the agreement; no receivables were sold during fiscal 2005.
 
5. Related Party Transactions
 
Through January 2004, an affiliate advanced approximately $200,000 to the Company. In January 2004, $100,000 of the advances, plus accrued interest thereon of $8,000, was used to exercise a warrant held by the affiliate. The balance of $100,000 was converted into four $25,000 notes, each due in January 2005, having a stated interest rate of 6%, and secured by the assets of the company. The notes were fully repaid in fiscal 2005.
 
During fiscal 2004, the Company sold services totaling approximately $25,000 to an entity owned by an officer.
 
6. Accrued Liabilities
 
At May 31, 2005 and 2004, accrued liabilities consisted of the following:
 
   
2005
 
2004
 
Due to co-inventor (Note 3)
 
$
155,700
 
$
-
 
Accrued lease obligation (Note 10)
   
100,000
   
-
 
Deferred maintenance fee
   
93,750
   
-
 
Compensation and benefits
   
80,049
   
97,757
 
Interest
   
75,654
   
62,345
 
   
$
505,153
 
$
160,102
 
7. Convertible Debentures
 
Overview. From fiscal 2002 through fiscal 2005, the Company raised approximately $5,400,000 through the issuance of convertible debentures, having stated interest rates ranging from 8% to 12%, to a limited group of investors. The convertible debentures entitle the debenture holder to convert the principal, and any accrued interest thereon, into shares of the Company’s common stock for up to two years from the date of issuance. The following represents a summary of certain salient features of the convertible debentures.
 

F-13

 
PATRIOT SCIENTIFIC CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
 
Number of Shares of Common Stock Into Which the Debentures May Be Converted. The debentures were initially convertible into shares of common stock at conversion prices that ranging from approximately $0.02 to $0.10 per share. The debentures contain provisions which allow for the conversion rate to be reset on a periodic basis based on a comparison of the market price of the Company’s common stock to the conversion price of the debentures. On those measurement dates where the market price is less than the conversion rate, a new conversion rate is set based on a weighted average of the market price for the ten days prior to the reset measurement date. As of May 31, 2005, the reset conversion rate on debentures outstanding range from $0.02 to $0.04.
 
Warrants. Concurrent with the issuance of the convertible debentures, the Company issued to the debenture holders warrants to purchase shares of the Company’s common stock. These warrants are exercisable for five years from the date of issuance at either initial negotiated exercise prices or prices equal to 115% of the volume weighted average price for our common stock for the ten days previous to the debenture date. The warrant exercise price is generally subject to being reset on each six month anniversary of its issuance, however, if the warrant holder elects to have the warrant shares registered, then the exercise price is fixed at the price in effect on the date of the election.
 
Options to Purchase Additional Debentures. Subject to the price of the Company’s common stock being equal to or greater than $0.20 per share and a two year limitation, the debenture holders may purchase additional debentures equal to the value of their initial debentures. The price at which the optional additional debentures may be converted would initially equal 115% of the volume weighted average price for the Company’s common stock for the ten days previous to the date on which the optional additional debentures were closed. The optional additional debentures would carry the same warrant amounts and reset privileges as the initial debentures.
 
Shareholder Approval. The Company may currently issue more than 20% of our outstanding shares under the convertible debentures. If the Company were to become listed on the NASDAQ Small Cap Market or NASDAQ National Market, then it must get shareholder approval to issue more than 20% of our outstanding shares. Currently, shareholder approval is not required.
 
Restrictive Covenants. For a period of 18 months from the date of issuance of the debentures, the Company is prohibited from entering into certain transactions. These include the issuance of any debt or equity securities in a private transaction which are convertible or exercisable into shares of common stock at a price based on the trading price of the common stock at any time after the initial issuance of such securities; the issuance of any debt or equity securities with a fixed conversion or exercise price subject to adjustment; and any private equity line type agreements without obtaining the debenture holders’ prior written approval. Additionally, so long as the debentures remain outstanding, the Company cannot declare or pay dividends without the debenture holders’ approval.
 
Right of First Refusal. The debenture holders have a right of first refusal to purchase or participate in any equity securities offered by the Company in any private transaction which closes on or prior to the date that is two years after the issue date of each debenture.
 
Registration Rights. Except for one debenture issued on March 23, 2004, the Company is responsible for registering the resale of the shares of its common stock which will be issued on the conversion of the debentures. As of May 31, 2005, there have been six registration statements (designated A through F).
 
Security Interest.  The convertible debentures are secured by substantially all assets of the Company.
 

F-14


PATRIOT SCIENTIFIC CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
 

The following tables present the status and activity of the Company’s convertible debentures as of and through May 31, 2005:
 
           
 
 
Conversion Prices
       
 
Series
   
Dates of Issuance
   
Aggregate Principal
 
Principal Balance at May 31, 2005
 
 Initial
   
Reset
 
  Shares Converted as of May 31, 2005
   
Warrant Shares Issued
A
 
4/23/02-
 
$1,000,000
 
$-
 
$0.08616-
 
$0.04190-
 
24,099,548
 
12,859,175
   
6/10/02
         
0.10289
 
0.04457
 
 
   
               
 
 
 
   
 
 
B
 
8/23/02-
 
605,000
 
-
 
0.05126-
 
0.04381-
 
14,777,350
 
11,234,835
   
1/24/03
         
0.0727
 
0.04722
 
 
 
 
                   
 
   
 
 
C
 
3/24/02-
 
510,000
 
-
 
0.041-
 
0.041-
 
10,470,554
 
9,377,943
   
6/9/03
         
0.065
 
0.065
     
 
               
 
         
 
D
 
8/1/03-
 
547,500
 
-
 
0.0172-
 
0.0172-
 
25,178,803
 
22,455,355
   
10/21/03
         
0.048
 
0.0477
     
 
               
 
 
 
     
 
E
 
12/1/03-
 
1,527,500
 
-
 
0.0267-
 
0.0267-
 
46,794,618
 
30,395,392
   
5/11/04
         
0.10
 
0.10
     
 
               
 
 
 
       
F
 
3/23/04
 
723,168
 
723,168
 
0.09
 
0.09
 
-
 
8,035,192
                             
                           
 
G
 
9/28/04-
 
490,000
 
157,500
 
0.016710-
 
0.01670-
 
12,433,273
 
21,690,815
   
1/17/05
         
0.04
 
0.04
       
                           
 
       
$5,403,168
 
$880,668
         
133,754,146
 
116,048,707

Convertible debentures issued since April 2002
 
$
5,403,168
 
Less debentures converted to common stock
   
(4,522,500
)
     
880,668
 
Less debt discount
   
(412,879
)
         
Convertible debentures at May 31, 2005
   
467,789
 
Less current portion
   
(421,847
)
         
Long term portion
 
$
45,942
 
         
Maturity dates of outstanding convertible debentures
       
March 23, 2006
 
$
723,168
 
November 17, 2006
   
157,500
 
         
   
$
880,668
 

At May 31, 2005, the Company’s convertible debentures were convertible into approximately 27,556,000 shares of the Company’s common stock. Subsequent to May 31, 2005, holders of debentures having a principal balance of $132,500 converted their debentures, together with accrued interest thereon of approximately $6,000, into 8,295,789 shares of the Company’s common stock.
 

F-15

 
PATRIOT SCIENTIFIC CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
 
8. Stockholders’ Equity
 
During fiscal 2004, the Company’s shareholders approved an increase in the authorized number of common shares from 200,000,000 to 400,000,000. During fiscal 2005, the authorized number of common shares was increased to 500,000,000.
 
Private Stock Offerings
 
During fiscal 2005, 4,625,000 restricted shares of common stock were issued to a group of individual investors in exchange for $453,250. Additionally, the Company issued 796,000 shares of common stock, valued at $58,800, to a vendor in exchange for services.
 
During fiscal 2004, 1,800,752 restricted shares of common stock were issued to a group of individual investors for $50,440 and 1,126,496 shares of common stock were issued to a vendor in satisfaction of $59,852 of trade accounts payable.
 
Warrants
 
At May 31, 2005, the Company had warrants outstanding to purchase 109,122,581 shares of common stock at exercise prices ranging from approximately $0.02 to $0.065 per share expiring at various dates through 2012. During fiscal 2005, the Company issued warrants to purchase 29,021,363 shares of common stock at exercise prices ranging from $0.02 to $0.08 per share and issued 38,358,511 shares of common stock on the exercise of warrants at exercise prices ranging from $0.02 to $0.04 per share.
 
At May 31, 2004, the Company had warrants outstanding to purchase 121,349,420 shares of common stock at exercise prices ranging from $0.02 to $0.6 per share expiring through 2011. During fiscal 2004, the Company issued warrants to purchase 73,436,127 shares of common stock at exercise prices ranging from $0.02 to $0.10 per share and issued 11,079,175 shares of common stock on the exercise of warrants at exercise prices ranging from $0.02 to $0.04 per share.
 
The following table presents outstanding warrants at May 31, 2005 and 2004:
 
   
2005
 
2004
 
           
Issued in conjunction with
             
Convertible debentures
   
75,196,854
   
83,278,716
 
Anti-dilution agreements
   
20,813,081
   
15,398,058
 
Equity lines of credit
   
9,965,369
   
18,765,369
 
Other
   
3,147,277
   
3,907,277
 
               
Total warrants outstanding
   
109,122,581
   
121,349,420
 

1992 Incentive Stock Option Plan (“ISO”)

The Company has an ISO Plan which expired March 20, 2002. The ISO Plan provided for grants to either full or part time employees, at the discretion of the board of directors, to purchase common stock of the Company at a price not less than the fair market value of the shares on the date of grant. In the case of a significant stockholder, the option price of the share could not be less than 110 percent of the fair market value of the share on the date of grant. Any options granted under the ISO Plan must be exercised within ten years of the date they were granted (five years in the case of a significant stockholder). At May 31, 2005, there were no remaining, outstanding options to purchase shares of common stock under the ISO Plan.
 

F-16


PATRIOT SCIENTIFIC CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
 
1992 Non-Statutory Stock Option Plan (“NSO”)

The Company has an NSO Plan which expired March 20, 2002. The NSO Plan provided, at the discretion of the board of directors, for grants to either full or part time employees, directors and consultants of the Company to purchase common stock of the Company at a price not less than the fair market value of the shares on the date of grant. Any options granted under the NSO Plan must be exercised within ten years of the date they were granted. At May 31, 2005, there were no remaining, outstanding options to purchase shares of common stock under the NSO Plan.
 
1996 Stock Option Plan

Effective March 1996, as amended, the Company adopted the 1996 Stock Option Plan. Under the 1996 Stock Option Plan, which expires in March 2006, options to purchase up to 4,000,000 shares of common stock of the Company may be granted to either full or part time employees, directors and consultants of the Company at a price not less than the fair market value on the date of grant for incentive stock options or not less than 85% of the fair market value on the date of grant for non-qualified stock options. In the case of a significant stockholder, the option price of the share is not less than 110 percent of the fair market value of the shares on the date of grant. Any option granted under the 1996 Stock Option Plan must be exercised within ten years of the date they are granted (five years in the case of a significant stockholder). During the fiscal year ended May 31, 2005, the Company granted options to purchase 645,000 shares of common stock under the 1996 Stock Option Plan. No options were granted during fiscal 2004.
 
2001 Stock Option Plan

The 2001 Stock Option Plan, which expires in February 2011, provides for the granting of options to purchase up to 3,000,000 shares of the Company’s common stock to either full or part time employees, directors and consultants of the Company at a price not less than the fair market value on the date of grant for incentive stock options or not less than 85% of the fair market value on the date of grant for non-qualified stock options. In the case of a significant stockholder, the option price of the share is not less than 110 percent of the fair market value of the shares on the date of grant. Any option granted under the 2001 Stock Option Plan must be exercised within ten years of the date they are granted (five years in the case of a significant stockholder). During the fiscal year ended May 31, 2005, the Company granted options to purchase 1,150,000 shares of its common stock. During the fiscal year ended May 31, 2004, no options were granted.
 
2003 Stock Option Plan

The 2003 Stock Option Plan, which expires in 2013, provides for the granting of options to acquire up to 6,000,000 shares of the Company’s common stock to either full or part time employees, directors and consultants of the Company at a price not less than the fair market value on the date of grant for incentive stock options or not less than 85% of the fair market value on the date of grant for non-qualified stock options. In the case of a significant stockholder, the option price of the share is not less than 110 percent of the fair market value of the shares on the date of grant. Any option granted under the 2003 Stock Option Plan must be exercised within ten years of the date they are granted (five years in the case of a significant stockholder). During the fiscal years ended May 31, 2005 and 2004, the Company granted options to purchase 1,695,000 and 2,210,000 shares of the Company’s common stock at market value.
 
SFAS No. 123, “Accounting for Stock-Based Compensation,” requires the Company to provide pro forma information regarding net loss and net loss per share as if compensation costs for the Company’s stock option plans and other stock awards had been determined in accordance with the fair value based method prescribed in SFAS No. 123. The Company estimates the fair value of each stock award at the grant date by using the Black-Scholes option-pricing model with the following weighted-average assumptions used for the two years ended May 31, 2005 and 2004, respectively: dividend yield of zero percent for both years; expected volatility of 121% to 129% and 107% to 127%, risk-free interest rates of 3.4% to 4.0% and 2.1% to 3.9%; and expected lives of three to five years for both years.
 

F-17


PATRIOT SCIENTIFIC CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
 
A summary of the status of the Company’s stock option plans and warrants as of May 31, 2005 and 2004 and changes during the years ending on those dates is presented below:
 
   
Options
 
Warrants
   
Shares
 
Weighted Average Exercise Price
 
Shares
 
Weighted Average Exercise Price 
Outstanding, May 31, 2003
 
5,054,000
 
$0.28
 
58,992,468
 
$0.06
Granted
 
2,210,000
 
0.06
 
73,436,127
 
0.05
Cancelled
 
(156,000)
 
0.13
 
-
 
-
Exercised
 
(105,000)
 
0.05
 
(11,079,175)
 
0.03
                 
Outstanding, May 31, 2004
 
7,003,000
 
0.21
 
121,349,420
 
0.05
Granted
 
3,490,000
 
0.08
 
29,021,363
 
0.04
Cancelled
 
(2,675,000)
 
0.31
 
(2,889,691)
 
0.07
Exercised
 
(670,000)
 
0.05
 
(38,358,511)
 
0.03
                 
Outstanding, May 31, 2005
 
7,148,000
 
0.13
 
109,122,581
 
0.04
                 
Exercisable, May 31, 2004
 
5,904,434
 
0.24
 
120,149,420
 
0.05
                 
Exercisable, May 31, 2005
 
5,748,000
 
0.14
 
108,622,581
 
0.04
                 
Weighted average fair value of options and warrants granted during the year ended May 31, 2004
     
$0.05
     
$0.06
                 
Weighted average fair value of options and warrants granted during the year ended May 31, 2005
     
$0.04
     
$0.05
                 

Included in the above table are certain options for which vesting is contingent based on various future performance measures.
 
Subsequent to May 31, 2005, 1,201,942 warrants were exercised, through which the Company received approximately $53,000.
 

F-18


PATRIOT SCIENTIFIC CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
 
The following table summarizes information about stock options and warrants outstanding at May 31, 2005:
 
         
Outstanding  
   
Exercisable 
 
     
Range of Exercise Prices 
   
Number Outstanding 
   
Weighted Average Remaining Contractual Life (Years) 
   
Weighted Average Exercise Price 
   
Number Exercisable 
   
Weighted Average Exercise Price 
 
Options
 
$
0.04-0.05
   
1,055,000
   
3.50
 
$
0.04
   
1,055,000
 
$
0.04
 
     
0.07-0.09
   
3,135,000
   
3.64
   
0.08
   
1,985,000
   
0.08
 
     
0.10-0.13
   
2,633,000
   
3.05
   
0.11
   
2,383,000
   
0.10
 
     
0.61-1.18
   
325,000
   
0.38
   
1.09
   
325,000
   
1.09
 
 
   
$ 0.04 -1.18 
   
7,148,000
   
3.25
 
$
0.13
   
5,748,000
 
$
0.14
 
                                       
Warrants
 
$
0.02-0.039
   
42,117,446
   
5.84
 
$
0.03
   
42,117,446
 
$
0.03
 
     
0.04-0.044
   
43,162,252
   
5.39
   
0.04
   
43,162,252
   
0.04
 
     
0.045-0.049
   
9,365,058
   
3.99
   
0.05
   
9,365,058
   
0.05
 
     
0.05-0.08
   
11,030,548
   
5.65
   
0.07
   
10,530,548
   
0.07
 
     
0.10-0.65
   
3,447,277
   
2.06
   
0.12
   
3,447,277
   
0.12
 
   
$
0.02-0.65
   
109,122,581
   
5.36
 
$
0.04
   
108,622,581
 
$
0.04
 

9. Income Taxes
 
The net deferred tax asset recorded and its approximate tax effect consisted of the following at May 31, 2005 and 2004:
 
   
2005
 
2004
 
           
Net operating loss carryforwards
 
$
13,686,000
 
$
12,873,000
 
Depreciation and amortization
   
1,240,000
   
1,434,000
 
Purchased technology
   
322,000
   
371,000
 
Contingency fee payable
   
201,000
   
-
 
License receivable
   
(800,000
)
 
-
 
Lease obligation accrual
   
40,000
   
-
 
Other, net
   
1,000
   
54,000
 
     
14,690,000
   
14,732,000
 
Valuation allowance
   
(14,690,000
)
 
(14,732,000
)
               
Net deferred tax asset
 
$
-
 
$
-
 


F-19

 
PATRIOT SCIENTIFIC CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
 
A reconciliation of the income taxes at the federal statutory rate to the effective tax rate is as follows:
 
   
Year Ended May 31,
 
   
2005
 
2004
 
           
Federal income tax benefit computed at the Federal statutory rate
 
$
(916,000
)
$
(1,411,000
)
State income tax benefit, net of Federal benefit
   
(157,000
)
 
(242,000
)
Other- permanent differences, primarily nondeductible interest
   
1,115,000
   
1,212,000
 
Change in valuation allowance
   
(42,000
)
 
441,000
 
               
Income tax benefit
 
$
-
 
$
-
 
               

As of May 31, 2005 and 2004, a valuation allowance equal to the net deferred tax asset has been recorded, as management has not determined that it is more likely than not that the deferred tax asset will be realized. No current tax provision was recorded for fiscal 2005 and 2004 due to reported losses.
 
At May 31, 2005, the Company has federal net operating loss carryforwards of approximately $36,000,000 that expire through 2025 and whose annual usage is subject to certain limitations imposed under the Internal Revenue Code of 1986, as amended. As such, certain federal net operating loss carryforwards may expire unused. Additionally, at May 31, 2005, the Company has state net operating loss carryforwards of approximately $22,000,000 that expire through 2015.
 
10. Commitments and Contingencies
 
Litigation
 
The Company is involved, both as a plaintiff and as a defendant, in several patent infringement lawsuits pertaining to various issues surrounding the Company’s technology. During 2005, several of the suits were settled, the outcome of which being the license agreements described in Notes 3 and 12. The Company is also involved in a legal matter related to disputed legal services performed for the Company related to obtaining the license agreements, which is also discussed in Note 3. At various times the Company is involved in other legal matters which arise in the ordinary conduct of its business and which, at the present time, are not expected to have a material impact on the Company’s financial position, cash flow, or results of operations.
 
Profit Sharing Plan
 
The Company has a savings and profit-sharing plan that allows participants to make contributions by salary reduction pursuant to Section 401(k) of the Internal Revenue Code. At the Company’s discretion, the Company may match contributions at 20% of the employee’s contribution up to 6% of the employee’s salary. The Company contributions are vested 20% per year beginning with the first year of service. The Company made no matching contributions to the plan in fiscal 2005 or 2004.
 
Employment Contracts
 
The Company is obligated under employment contracts with certain key employees to pay severance upon termination under certain defined conditions. Generally, unless relieved of their duties for cause, the executive officers are entitled to severance pay equal to two to four months of their then current monthly salary. In the case of a change in control, generally, the executive officers are entitled to severance pay equal to twelve months of their then current monthly salary unless they continue to work for the new controlling interest in the same function as previous to the change. Subsequent to May 31, 2005, two officers covered under employment contracts were terminated. The Company is currently in negotiations with one of the individuals to finalize his severance agreement. In September 2005, the Company agreed to pay the other key employee approximately $148,700 in full settlement of all amounts owed to him under his employment contract.
 

F-20

 
PATRIOT SCIENTIFIC CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
 
Operating and Capital Leases
 
At May 31, 2005, the Company has equipment acquired through a capital lease arrangement. The equipment was recorded at an original cost of $24,995; accumulated depreciation on the equipment at May 31, 2005 and 2004 was $24,995 and $21,524. The Company’s obligation under the capital lease at May 31, 2005 was approximately $2,300, which amount is due in fiscal 2006.
 
The Company has a non-cancelable operating lease for its office and manufacturing facilities located in San Diego, California. Future minimum lease payments required under the operating lease are $141,658 in fiscal 2006 and $23,782 in fiscal 2007. Rent expense for fiscal 2005 and 2004 was $180,527 and $181,135, respectively. Through the first quarter of fiscal 2005, the Company had sublet a portion of this facility to a third-party. The third-party vacated its portion of the facility in 2005 and paid the Company approximately $47,000 in consideration for all future amounts owed the Company under the sublease agreement. This amount is reflected in other income in the 2005 statement of operations. During the fourth quarter of 2005, the Company determined that this vacated portion of the facility will not provide any future benefit to the Company, nor is it probable that the space could be subleased again. Accordingly, the Company accrued $100,000 related to its remaining contractual lease obligation related to this space.
 
11. Sales Information
 
The Company is engaged in one business segment, the development and marketing of microprocessor technology related products and licenses. During the fiscal years ended May 31, 2005 and 2004, the Company’s product sales of high technology computer products were approximately $9,000 and $14,000 and telecommunication products were $16,000 and $63,000. Substantially all of the Company’s products were sold to customers located in the United States. During the year ended May 31, 2004, three customers accounted for 33%, 23%, and 12% of the Company’s total product sales. During the year ended May 31, 2005, there were no major customers related to the Company’s product sales. Additionally, during the fiscal year ended May 31, 2005, the Company recorded license revenues as more fully described in Note 3.
 
12. Subsequent Event
 
In June 2005, the Company entered into an agreement with the co-inventor of certain of the Company’s technology pursuant to which the Company and the co-inventor resolved all legal disputes between them. As a result of the agreement, the Company formed a new joint venture with the co-inventor into which both parties contributed their rights to the technologies. Concurrently therewith, the joint venture entered into a license agreement with a third party pursuant to which it received $20,000,000. Both the Company and the venture partner agreed to establish a working capital fund for the new venture of $4,000,000, as well as to fund future working capital requirements. Net proceeds received by the Company from the license agreement transaction were approximately $6,700,000. In connection with this transaction, the Company paid amounts aggregating $170,000 to certain of its board members in consideration of their efforts in the consummation of this transaction.
 
Payments totaling approximately $960,000 were made in the first quarter of fiscal 2006 to the co-inventors of the technology. Additionally, a legal advisor who had previously provided services to the Company may assert a success fee against the Company based upon proceeds received by the Company under the license agreement. See further discussion in Note 3.
 
The Company granted a warrant to its venture partner to acquire up to 3,500,000 shares of the Company’s common stock at a per share price of $0.125. The warrant has a term of seven years. At the date of grant, the right to acquire 1,400,000 shares of common stock vested; the right to acquire the remaining 2,100,000 shares will vest in 700,000 increments only upon the Company’s per share stock price reaching $0.50, $0.75, and $1.00.
 

F-21



PATRIOT SCIENTIFIC CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
 
In order to complete the agreement, the Company was required to obtain approval from various warrant holders. The Company believes, based on consultation with its attorneys, it was not required by applicable law or other existing agreements to obtain approval from shareholders or any parties other than the various warrant holders. To obtain the approval of those warrant holders, the Company paid them approximately $1,890,000 and agreed to reset the per share exercise price of approximately 34,900,000 warrants to $0.015 for which the warrant holders conveyed warrants to acquire 12,000,000 shares back to the Company. Further, other warrant holders were paid $438,000 and issued additional warrants to acquire approximately 290,000 shares of the Company’s common stock.
 

F-22


PATRIOT SCIENTIFIC CORPORATION
CONSOLIDATED BALANCE SHEETS


   
February 28, 2006 (Unaudited)
 
May 31, 2005
 
ASSETS
             
Current Assets:
             
Cash and cash equivalents (including $7,847,962 held by a consolidated entity at February 28, 2006)
 
$
20,478,619
 
$
591,426
 
Restricted cash and cash equivalents
   
50,011
   
-
 
Marketable securities and short term investments
   
4,179,796
   
697,524
 
Restricted short term investment
   
-
   
201,648
 
Licenses receivable
   
34,100,000
   
2,000,000
 
Accounts receivable
   
27,496
   
-
 
Prepaid expenses and other current assets
   
111,383
   
121,758
 
Total current assets
   
58,947,305
   
3,612,356
 
               
PROPERTY AND EQUIPMENT, net of accumulated depreciation of $110,412 and $1,085,703
   
59,036
   
21,376
 
               
OTHER ASSETS
   
8,190
   
23,891
 
               
PATENTS AND TRADEMARKS, net of accumulated amortization of $575,681 and $549,563
   
40,293
   
66,411
 
   
$
59,054,824
 
$
3,724,034
 
LIABILITIES, MINORITY INTEREST, AND STOCKHOLDERS’ EQUITY
             
               
Current liabilities:
             
Line of credit
 
$
-
 
$
100,000
 
Current portion of convertible debentures, net of debt discount of $301,320 at May 31, 2005
   
-
   
421,847
 
Accounts payable
   
277,203
   
268,458
 
Accrued liabilities
   
558,549
   
505,153
 
Dividends payable
   
8,114,378
   
-
 
Accrued income taxes payable
   
1,880,000
   
-
 
Current portion of capital lease obligation
   
-
   
2,306
 
Accrued contested fee payable
   
346,000
   
346,000
 
Total current liabilities
   
11,176,130
   
1,643,764
 
               
CONVERTIBLE DEBENTURES, net of debt discount of $111,559 at May 31, 2005
   
-
   
45,942
 
Total liabilities
   
11,176,130
   
1,689,706
 
MINORITY INTEREST IN EQUITY OF CONSOLIDATED ENTITY
   
20,823,679
   
-
 
               
COMMITMENTS AND CONTINGENCIES
   
-
   
-
 
               
STOCKHOLDERS’ EQUITY
             
Preferred stock, $.00001 par value; 5,000,000 shares authorized: none outstanding
   
-
   
-
 
Common stock, $.00001 par value: 500,000,000 shares authorized: 349,336,560 and 280,492,013 issued and outstanding
   
3,494
   
2,805
 
Additional paid-in capital
   
59,650,374
   
54,569,091
 
Accumulated deficit
   
(32,598,853
)
 
(52,537,568
)
Total stockholders’ equity
   
27,055,015
   
2,034,328
 
   
$
59,054,824
 
$
3,724,034
 
               
See accompanying notes to unaudited consolidated financial statements.

F-23

 
PATRIOT SCIENTIFIC CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
 
     
Nine Months Ended 
 
     
February 28,  2 006 
   
February 28, 2005 
 
Revenues:
             
Licenses and royalties
 
$
70,000,000
 
$
2,973,148
 
Other
   
297,072
   
--
 
     
70,297,072
   
2,973,148
 
               
Cost of goods sold
   
103,351
   
--
 
               
Gross profit
   
70,193,721
   
2,973,148
 
               
Operating expenses:
             
Research and development
   
225,564
   
236,296
 
Selling, general and administrative
   
5,393,015
   
1,858,528
 
Settlement and license expense
   
3,855,132
   
--
 
     
9,473,711
   
2,094,824
 
Operating income
   
60,720,010
   
878,324
 
               
Other income (expense):
             
Unrealized gain (loss) on marketable securities
   
(1,201
)
 
(14,500
)
Other income
   
264,271
   
57,552
 
Interest expense
   
(1,181,635
)
 
(2,442,101
)
Loss on debt extinguishment
   
(1,260,688
)
 
--
 
     
(2,179,253
)
 
(2,399,049
)
               
Income (loss) before minority interest in income of consolidated entity and income taxes
   
58,540,757
   
(1,520,725
)
               
Minority interest in income of consolidated entity
   
(28,607,664
)
 
--
 
Income (loss) before income taxes
   
29,933,093
   
(1,520,725
)
Provision for income taxes
   
1,880,000
   
--
 
Net income (loss)
 
$
28,053,093
 
$
(1,520,725
)
               
Basic income (loss) per common share
 
$
0.09
 
$
(0.01
)
Diluted income (loss) per common share
 
$
0.07
 
$
(0.01
)
Weighted average number of common shares outstanding-basic
   
300,839,387
   
204,784,881
 
Weighted average number of common shares outstanding-diluted
   
397,730,530
   
204,784,881
 
 
See accompanying notes to unaudited consolidated financial statements.

F-24


PATRIOT SCIENTIFIC CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)

   
Nine Months Ended
 
   
February 28, 2006
 
February 28, 2005
 
OPERATING ACTIVITIES:
             
Net income (loss)
 
$
28,053,093
 
$
(1,520,725
)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
             
Amortization and depreciation
   
44,584
   
70,944
 
Non-cash compensation
   
150,013
   
59,674
 
Non-cash interest expense related to convertible debentures, notes payable and warrants
   
1,136,047
   
2,322,975
 
Loss on extinguishment of debt
   
1,260,688
   
-
 
Unrealized loss on marketable securities
   
1,201
   
14,415
 
Common stock issued for services and other
   
-
   
58,800
 
Expense related to warrant repricing and issuance
   
1,522,492
   
-
 
Accrued interest income added to investments
   
(19,469
)
 
-
 
Income of consolidated entity allocated to minority interest
   
28,607,664
   
-
 
Changes in:
             
Accounts receivable
   
(27,496
)
 
802
 
Prepaid and other assets
   
34,266
   
219,714
 
Licenses receivable
   
(32,100,000
)
 
(2,750,000
)
Accounts payable and accrued expenses
   
2,060,510
   
577,968
 
 Deferred maintenance        
100,000 
 
Net cash provided by (used in) operating activities
   
30,723,593
   
(845,433
)
INVESTING ACTIVITIES:
             
Purchase of marketable securities
   
(4,327,786
)
 
(200,000
)
Proceeds from sale of marketable securities
   
862,209
   
-
 
Purchase of property and equipment
   
(56,126
)
 
-
 
Purchase of restricted investments
   
(50,000
)
 
-
 
Payment for security deposit
   
(8,190
)
 
-
 
Proceeds from sale of restricted investments
   
203,210
   
-
 
Net cash used in investing activities
   
(3,376,683
)
 
(200,000
)
FINANCING ACTIVITIES:
             
Principal payments on secured notes payable
   
(100,000
)
 
(100,000
)
Proceeds from the issuance of convertible debentures
   
-
   
490,000
 
Proceeds from the issuance of common stock
   
-
   
453,250
 
Minority interest investment in consolidated entity
   
2,000,000
   
-
 
Payments for capital lease obligations
   
(2,306
)
 
(5,843
)
Proceeds from exercise of common stock warrants and options
   
678,994
   
706,414
 
Repurchase of warrants
   
(252,420
)
 
-
 
Distributions of joint venture partner
   
(9,783,985
)
 
-
 
Net cash provided by (used in) financing activities
   
(7,459,717
)
 
1,543,821
 
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS
   
19,887,193
   
498,388
 
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD
   
591,426
   
355,940
 
CASH AND CASH EQUIVALENTS, END OF PERIOD (1)
 
$
20,478,619
 
$
854,328
 

(1)Included in cash at February 28, 2006 is $7,847,962 held by a consolidated entity which amount can only be used for the operations of that entity.

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
         
Cash payments for interest
 
$
2,843
 
$
12,994
 
Convertible debentures and accrued interest exchanged for common stock
 
$
999,037
 
$
2,065,788
 
Dividend declared but not paid
 
$
8,114,378
 
$
--
 
Debt Discount
 
$
--
 
$
490,000
 

See accompanying notes to unaudited consolidated financial statements.

F-25


PATRIOT SCIENTIFIC CORPORATION
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

1.
Basis of Presentation

The unaudited consolidated financial statements of Patriot Scientific Corporation (the “Company”, “we” or “us”) presented herein have been prepared pursuant to the rules of the Securities and Exchange Commission for quarterly reports on Form 10-QSB and do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America. These statements should be read in conjunction with our audited consolidated financial statements and notes thereto included in Form 10-KSB for the year ended May 31, 2005.

In the opinion of management, the interim consolidated financial statements reflect all adjustments of a normal recurring nature necessary for a fair statement of the results for interim periods. Additionally, during the quarter ended August 31, 2005, the Company entered into certain nonrecurring transactions related to the PTSC/TPL Master Agreement (defined in Note 4), which are more fully described in Note 4. Operating results for the three and nine month periods ended February 28 2006 are not necessarily indicative of the results that may be expected for the year ending May 31, 2006.

Earnings (Loss) Per Share
 
We follow Statement of Financial Accounting Standards (“SFAS”) No. 128, “Earnings per Share.” Under SFAS No. 128, basic income (loss) per share is calculated as income (loss) available to common stockholders divided by the weighted average number of common shares outstanding. Diluted income (loss) per share is calculated as net income (loss) available to common stockholders divided by the diluted weighted average number of common shares outstanding. The diluted weighted average number of common shares is calculated using the treasury stock method for common stock issuable pursuant to outstanding stock options and common stock warrants and the if-converted method for convertible debentures. For the three and nine month periods ended February 28, 2006, potential common shares of 96,574,688 and 96,891,142, respectively, from our stock options, warrants and convertible debentures, were included in the determination of diluted earnings per share.

Restricted Cash and Cash Equivalents

Restricted cash and cash equivalents at February 28, 2006, consist of two savings accounts required to be held as collateral for corporate credit card accounts.

Stock Options

The Company applies Accounting Principles Board (“APB”) Opinion 25, “Accounting for Stock Issued to Employees,” and related interpretations in accounting for all stock option plans. Under APB Opinion 25, compensation cost has been recognized for stock options granted to employees when the option price is less than the market price of the underlying common stock on the date of grant.

SFAS No. 123, “Accounting for Stock-Based Compensation,” and SFAS No. 148, “Accounting for Stock-Based Compensation-Transition and Disclosure,” require the Company to provide pro forma information regarding net income (loss) as if compensation cost for the Company’s stock option plans had been determined in accordance with the fair value based method prescribed in SFAS No. 123. To provide the required pro forma information, the Company estimates the fair value of each stock option at the grant date by using the Black-Scholes option-pricing model. SFAS No. 148 also provides for alternative methods of transition for a voluntary change to the fair value based method of accounting for stock-based employee compensation. The Company has elected to continue to account for stock based compensation under APB Opinion 25. See “Recent Accounting Pronouncements”.
 
The Company applies SFAS No. 123 in valuing options granted to consultants and estimates the fair value of such options using the Black-Scholes option-pricing model. The fair value is recorded as consulting expense as services are provided. Options granted to consultants for which vesting is contingent based on future performance are measured at their then current fair value at each period end, until vested.

F-26


PATRIOT SCIENTIFIC CORPORATION
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
 
   Had the Company employed the accounting provisions for SFAS No. 123, the Company’s reported net income (loss) and basic and diluted income (loss) per share would have been changed by the pro forma amounts indicated below:
 
 
 
 
Three Months Ended 
 
Nine Months Ended 
 
   
February 28,  
 
February 28,
  February 28,     February 28,  
 
 
2006 
 
2005
 
2006
 
2005
 
 
 
 
 
 
 
 
 
 
 
Net income (loss)-as reported
 
$
24,885,735
 
$
658,867
 
$
28,053,093
 
$
(1,520,725
)
Pro forma compensation expense
   
(28,028
)
 
(102,100
)
 
(210,278
)
 
(109,020
)
 
                 
Net income (loss)-pro forma
 
$
24,857,707
 
$
556,767
 
$
27,842,815
 
$
(1,629,745
)
As reported per share:
                 
Basic
 
$
0.08
 
$
-
 
$
0.09
 
$
(0.01
)
Diluted
 
$
0.06
 
$
-
 
$
0.07
 
$
(0.01
)
Pro forma per share:
                 
Basic
 
$
0.08
 
$
-
 
$
0.09
 
$
(0.01
)
Diluted
 
$
0.06
 
$
-
 
$
0.07
 
$
(0.01
)

2.
Recent Accounting Pronouncements

In December 2004, the Financial Accounting Standards Board (“FASB”) issued SFAS 123R, “Share Based Payment”. This statement replaces SFAS No. 123 and supersedes APB Opinion 25. SFAS No. 123R requires that the cost of share-based payment transactions (including those with employees and non-employees) be recognized as compensation based on the estimated fair value of the equity instrument awarded. SFAS No. 123R applies to all share-based payment transactions in which an entity acquires goods or services by issuing (or offering to issue) its shares, options, or other equity instruments or by incurring liabilities in amounts based on the price of the entity’s shares or other equity instruments, or that require (or may require) settlement by the issuance of an entity’s shares or other equity instruments. This statement applies to all new awards granted during the fiscal year beginning after December 15, 2005 and to previous awards that are modified or cancelled after such date. The Company has not yet fully evaluated the effect of adopting SFAS No. 123R on its consolidated financial statements.

In December 2004, the FASB issued SFAS No. 153, “Exchange of Nonmonetary Assets,” an amendment of APB Opinion No. 29, “Accounting for Nonmmonetary Transaction.” SFAS No. 153 is based on the principle that exchanges of nonmonetary assets should be measured based on the fair market value of the assets exchanged. SFAS No. 153 eliminates the exception of nonmonetary exchanges of similar productive assets and replaces it with a general exception for exchanges of nonmonetary assets that do not have commercial substance. SFAS 153 is effective for nonmonetary asset exchanges in fiscal periods beginning after June 15, 2005. The Company does not believe that the provisions of SFAS No. 153 will have a material impact on its consolidated financial statements.

In May 2005, the FASB issued SFAS No. 154, “Accounting Changes and Error Corrections,” which replaces APB Opinion No. 20, “Accounting Changes,” and FASB Statement No. 3, “Reporting Accounting Changes in Interim Financial Statements,” and changes the requirements for the accounting for and reporting of a change in accounting principle. SFAS No. 154 requires retrospective application to prior periods' financial statements of changes in accounting principle, unless it is impracticable to determine either the period-specific effects or the cumulative effect of the change. SFAS No. 154 is effective for accounting changes and correction of errors made in fiscal years beginning after December 15, 2005. Early adoption is permitted for accounting changes and correction of errors made in fiscal years beginning after the date SFAS No. 154 was issued. At the present time, the Company does not believe that adoption of SFAS No. 154 will have a material effect on its consolidated financial statements.
 

F-27



PATRIOT SCIENTIFIC CORPORATION
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)


3.
License Agreements

In February 2005, the Company entered into two separate licensing agreements with one customer for the Company's patent portfolio and Ignite microprocessor technology. The aggregate amount of the two licenses was $3,050,000, of which $2,950,000 was for licensing fees and $100,000 was for maintenance services. Maintenance under the agreements is expected to be provided over a period not to exceed four years. The payment terms of the agreements required aggregate payments of $300,000 at the time of execution, three quarterly payments of $750,000 each on April 1, August 15, and November 15, 2005 and one final payment of $500,000 on February 15, 2006. The $500,000 payment due on February 15, 2006, was paid in March 2006. Total payments received in fiscal 2005 amounted to $1,050,000 and total payments received in fiscal 2006, as of February 28, 2006, amounted to $1,500,000. The agreements also provide for the future payment of royalties to the Company based on sales of product using the Ignite licensed technology. In connection with this license agreement, the Company became obligated to the former co-inventor of the patent portfolio technology for $207,600 pursuant to a July 2004 agreement under which the Company was obligated to pay a percentage of licensed proceeds to the co-inventor. The amount due was payable in four installments of $51,900; $51,900 remains outstanding at February 28, 2006, and is included in accrued liabilities. The Company has reviewed the potential obligation for future payments to the co-inventor of the patent portfolio technology in connection with entering into license agreements. The Company believes, based upon consultation with its legal counsel, that it has no further obligation to the co-inventor and has not provided an accrual for such an amount. The Company is aware of a lawsuit filed by the co-inventor of the patent portfolio technology against the Company. The Company intends to vigorously defend itself in this matter; however, it is possible that were the Company not to prevail in the suit, the ultimate amount payable to such co-inventor of the Ignite technology could be significant.

Also, in conjunction with entering into these license agreements, as well as other license agreements (See Note 4), the legal advisor who had previously assisted the Company in its intellectual property negotiations, has asserted a claim against the Company for amounts which the advisor believes it is entitled. The Company is contesting the matter; the outcome of this matter is currently unknown. Based on its current assessment of the matter, the Company has accrued a liability of $346,000 as of February 28, 2006 in connection with the February, 2005 licensing agreements. The Company intends to vigorously defend itself in this matter; however, it is possible that, were the Company not to prevail in the suit, the ultimate amount payable to such legal advisor could be significantly higher than the current accrued liability.

4.
Creation of Consolidated Limited Liability Company/License Agreement

In June 2005, the Company entered into an agreement (the “PTSC/TPL Master Agreement”) with the co-inventor of certain of the Company’s technology pursuant to which the Company and the co-inventor resolved all legal disputes between them. As a result of the agreement, the Company formed a new limited liability company (the “JV LLC”) with the co-inventor into which both parties contributed their rights to the technologies. The Company received a 50% interest in the JV LLC. The Company believes, based upon consultation with its attorneys, it was not required by applicable law or other existing agreements to obtain approval for the contribution of the license rights to the JV LLC from stockholders or any parties other than its various warrant holders. Both the Company and the JV LLC agreed to establish a working capital fund for the JV LLC of $4,000,000, of which the Company’s contribution was $2,000,000. The working capital fund increases to a maximum of $8,000,000 as license revenues are achieved. The Company and the other member of the JV LLC are obligated to fund future working capital requirements at the discretion of the JV LLC management committee, in order to maintain working capital of not more than $8,000,000. Neither the Company nor the other member of the JV LLC are required to contribute more than $2,000,000 in any fiscal year. For accounting purposes the newly formed entity is considered to be a variable interest entity, as defined in FIN 46R, for which the Company is considered to be the primary beneficiary. Accordingly, the accounts and transactions of the JV LLC have been consolidated with those of the Company and the other member of the JV LLC’s interest in the JV LLC has been presented as a minority interest in the consolidated financial statements of the Company as of and for the three and nine month periods ended February 28, 2006. The JV LLC has committed to pay a quarterly amount ranging between $500,000 and $1,000,000 (based upon a percentage of the working capital fund balance of the JV LLC) for supporting efforts to secure licensing agreements by the other member on behalf of the JV LLC. During the nine months ended February 28, 2006, the JV LLC paid $1,500,000 to the other member pursuant to this commitment. At February 28, 2006, the JV LLC’s sole asset was approximately $7,800,000 in cash. Although this amount is reported together with the Company’s cash balances in the consolidated balance sheet as of February 28, 2006, the Company does not have the ability to control the JV LLC and this cash is not available for use by the Company. The JV LLC reported net income for the three and nine month periods ended February 28, 2006 of approximately $58,600,000 and $57,200,000, respectively.

F-28



PATRIOT SCIENTIFIC CORPORATION
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

Concurrently with forming the JV LLC, the Company entered into a license agreement with a third party pursuant to which it received $10,000,000, which amount was recorded as license revenue during the quarter ended August 31, 2005. In connection with entering into the license agreement and forming the JV LLC, the Company incurred various cash and non-cash expenses. Direct, incremental cash costs incurred with the transactions included $170,000 paid to a committee of the Company’s board of directors for their efforts in consummating the transactions, approximately $1,328,000 paid to certain of the Company’s warrant holders to obtain their approval of the agreement and release of their lien and blocking rights. Additionally, $960,000 was paid to the former co-inventor of the technology. As more fully discussed in Note 3, a former legal advisor of the Company may assert a success fee against the Company based upon proceeds received by the Company under this license agreement. No amount has been accrued for this contingency as the Company believes the probability of any amount being paid to the advisor for this license agreement is remote. The Company believes, based upon consultation with its attorneys, it was not required by applicable law or other existing agreements to obtain approval for the contribution of the license rights to the JV LLC from stockholders or any parties other than its various warrant holders.

The Company also granted new warrants and agreed to reprice other outstanding warrants in order to obtain the necessary approvals from certain security interest holders as well as to obtain the release of their security interests in the Company’s intellectual property, and to finalize the limited liability company agreement. The Company granted a warrant to the other member of the JV LLC to acquire up to 3,500,000 shares of the Company’s common stock at a per share price of $0.125. The warrant has a term of seven years. At the date of grant, the right to acquire 1,400,000 common shares vested. The right to acquire the remaining 2,100,000 shares will vest in 700,000 increments only upon the Company’s common stock attaining a per share stock price of $0.50, $0.75 and $1.00. On February 21, 2006, the right to acquire 700,000 shares of the Company’s common stock pursuant to the warrant vested and on February 22, 2006, the right to acquire an additional 700,000 shares of the Company’s common stock pursuant to the warrant vested as the Company’s stock price reached $0.50 and $0.75, respectively. As additional consideration to the warrant holders for providing approval for the transaction, the Company agreed to reset the per share exercise price of approximately 35,000,000 warrants to $0.015 for which the warrant holders also conveyed other warrants to acquire 12,000,000 shares back to the Company. Further, the Company issued additional warrants to acquire approximately 290,000 shares of the Company’s common stock at a per share price of $0.03. The warrants issued and repriced were valued using the Black-Scholes method and the following assumptions: volatility of 123%, no dividends, risk free interest rates of approximately 4%, and contractual terms ranging from five to seven years. The value of the warrants issued and repriced in excess of the current value of the warrants reconveyed and the value of the warrants previously expensed was approximately $1,397,000, which amount, together with the direct, incremental cash costs previously described, is recorded as an expense and included in settlement and license expense in the nine month period ended February 28, 2006.

On January 24, 2006, the JV LLC entered into a license agreement with a third party, pursuant to which it received $26,400,000 and on February 21, 2006 and February 24, 2006, the JV LLC entered into license agreements with third parties for $2,000,000 and $31,600,000, respectively. The JV LLC recorded all of the license revenue from these agreements during the quarter ended February 28, 2006. As of February 28, 2006, the Company recorded licenses receivable of $33,600,000. The Company received a cash distribution from the joint venture of $10,115,574 in January 2006.

5.
Convertible Debentures

During the three months ended February 28, 2006, the balance of outstanding convertible debentures of $748,168 and accrued interest of $112,359, were converted into 22,523,398 shares of the Company's common stock. During the three months ended August 31, 2005, holders of debentures having a principal balance of $132,500 converted their debentures, together with accrued interest thereon of $6,040, into 8,295,789 shares of the Company's common stock. No debentures were converted during the three month period ended November 30, 2005.

F-29



PATRIOT SCIENTIFIC CORPORATION
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

As discussed in Note 6, the Company entered into reset agreements with the debenture holders to fix the conversion price of the then oustanding debentures at its current level. In connection with the reset agreement of one of the debentures, the Company recorded a debt discount of $723,168 related to a beneficial conversion feature at the date of the modification of the conversion rate feature. The Company determined that the debt modification did not result in a debt extinguishment. During the three month period ended February 28, 2006, the Company amortized the entire amount of the debt discount to interest expense upon the conversion of the related debenture into shares of the Company's common stock.

In connection with the reset agreement of the other outstanding debenture, the Company issued 7,000,000 warrants to the debenture holder as consideration of entering into the reset agreement. The Company has determined that the issuance of the warrants in connection with the reset agreement resulted in a debt extinguishment under EITF No. 96-19, "Debtor's Accounting for a Modification or Exchange of Debt Instruments", and EITF No. 05-7, "Accounting for Modifications to Conversion Options Embedded in Debt Instruments and Related Issues." Accordingly, the Company has recorded the fair value of the warrants issued of $1,260,688 as a loss of debt extinguishment in the accompanying consolidated statement of operations for the three month period ended February 28, 2006.
 
 
6.
Stockholders’ Equity

The following table summarizes equity transactions during the nine months ended February 28, 2006:
 
 
 
Common
 Shares
 
Amount
 
 
 
 
 
 
 
Balance June 1, 2005
   
280,492,013
 
$
54,571,896
 
 
         
Exercise of common stock options
   
2,636,522
   
208,337
 
Exercise of common stock warrants
   
8,728,544
   
470,657
 
Cashless exercise of common stock warrants
   
26,035,294
   
-
 
Stock issued on conversion of
debentures and accrued interest
   
30,819,187
   
999,037
 
Stock issued to co-inventor of technology
   
625,000
   
81,250
 
Effect of modifying convertible debt
   
-
   
723,168
 
Issuance of common stock warrants in connection with new
venture/license agreement
   
-
   
556,675
 
Extension of term of warrants previously issued to consultant
   
-
   
125,000
 
Effect of repricing and conveyance in connection with new
venture/license agreement
   
-
   
840,816
 
Repurchase of warrants
   
-
   
(252,420
)
Issuance of warrants in connection with revisions to warrant agreements
and waivers
   
-
   
1,260,688
 
Issuance of warrants to a consultant
   
-
   
68,764
 
Balance February 28, 2006
   
349,336,560
 
$
59,653,868
 
 
Stock Option Activity

F-30

 
PATRIOT SCIENTIFIC CORPORATION
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
 
At February 28, 2006, we had 829,478 options outstanding pursuant to our 1996 Stock Option Plan exercisable at prices ranging from $0.04 to $1.18 per share expiring through 2010; 1,070,000 options outstanding pursuant to our 2001 Stock Option Plan exercisable at prices ranging from $0.04 to $0.13 per share expiring through 2010; and 3,250,000 options outstanding pursuant to our 2003 Stock Option Plan exercisable at prices ranging from $0.04 to $0.17 per share expiring through 2011. Some of the options outstanding under these plans are not presently exercisable and are subject to vesting criteria.

During the nine months ended February 28, 2006, we issued options to acquire 1,350,000 shares of our common stock at a per share price of $0.16 and options to acquire 200,000 shares of our common stock at a per share price of $0.17 to members of our board of directors. During the nine months ended February 28, 2006, options to purchase 2,636,522 shares of our common stock, were exercised for proceeds of $208,337.

Warrants

At February 28, 2006, we had warrants outstanding exercisable into 68,943,590 common shares at exercise prices ranging from $0.015 to $0.65 per share, expiring through 2012. Some of those outstanding warrants were not exercisable as of February 28, 2006 as they are subject to meeting vesting criteria. During the nine months ended February 28, 2006, we issued warrants to purchase 12,457,049 shares of common stock, had investors exercise warrants to purchase 8,728,544 shares of common stock for proceeds of $470,657 and we had investors exercise warrants of 28,540,769 to purchase 26,035,294 shares of common stock on a cashless basis. During the nine months ended February 28, 2006, the Company cancelled warrants to purchase 13,366,727 shares of our common stock. Included in the aforementioned warrants issued during the nine months ended February 28, 2006 were warrants to purchase 200,000 shares of common stock issued to a consultant. The value of these warrants of $68,764 was recorded as an expense during the nine months ended February 28, 2006. The Company repriced other warrants to purchase approximately 35,000,000 common shares to $0.015 during the nine months ended February 28, 2006 (Note 4).

Effective January 11, 2006, the Company entered into a warrant redemption agreement with a warrant holder, whereby at the Company's option, the Company agreed to redeem certain warrants representing the right to acquire an aggregate of up to 10,000,000 shares of the Company's common stock, through April 2006. The warrants may be redeemed in quantities not to exceed 2,000,000 warrants in any one calendar month, at a price equal to the product of (a) the volume weighted average of the daily volume weighted average prices of the Company's common stock for all trading days in the applicable calendar month, minus the exercise price of the warrant, multiplied by (b) the number of shares being redeemed from that warrant. On February 3, 2006, the Company agreed to redeem 2,000,000 warrants for $252,420 and has recorded a liability for that amount at February 28, 2006. Payment for the redemption occurred in March 2006.

Effective February 9, 2006, the Company entered into “Reset Agreements” with certain warrant holders and received waivers from the warrant holders with regard to certain terms of certain warrants held by the warrant holders. Under the terms of the Reset Agreements, the Company and the warrant holders agreed to amend the terms of (i) each of the warrants of the Company held by the warrant holders such that the exercise price of the warrants is no longer subject to downward resets based on the trading price of the common stock of the Company, and (ii) each of the debentures of the Company held by the warrant holders such that the conversion price of the debentures is fixed at its current level. No additional expense was required for the modification of the exercise price of the warrants since the new fixed price of the warrants was equal to the original exercise price at date of issuance or was equal to the then reset price in effect for which the Company had previously recognized an expense for the modification (Note 4). The Company recognized additional interest expense of $723,168 in connection with the reset of the conversion price of the debentures (Note 5). Under the terms of the Reset Agreements, the Company and the warrant holders also agreed to amend all of the agreements entered into between the Company and the warrant holders that limit the ability of the warrant holders to be the beneficial owner of more than 4.99% of the common stock of the Company to be amended to provide that the warrant holders may not, through the exercise of warrants, the conversion of debentures, or otherwise, be the beneficial owner of more than 9.99% of the common stock of the Company.

Under the terms of the waiver agreements, the warrant holders agreed to amend their rights under the terms of certain warrants held by each of them to receive a payment in the event of a payment of a dividend by the Company. Prior to entering into the waiver agreements, if at any time after the issuance date of the subject warrants, the Company made any distributions to holders of its common stock, the warrant holders would be entitled to receive a payment equal to the amount of such distribution which would have been payable to them had they owned the shares of common stock issuable upon exercise of the subject warrants as of the record date for the distribution. Under the terms of the waiver agreement, if the market price of the Company's common stock on the record date for a distribution is greater than or equal to $0.15 per share, the payment to the warrant holders would be reduced to the amount which would be payable to the warrant holders had they engaged in a cashless exercise of the subject warrants as of the record date for the distribution. In consideration for entering into the agreements, the Company issued warrants for the right to acquire 7,000,000 shares of the Company’s common stock to one warrant holder and recognized a loss on debt extinguishment of $1,260,688 (Note 5).

F-31


PATRIOT SCIENTIFIC CORPORATION
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

Common Stock

On July 22, 2005, 625,000 shares of common stock valued at $0.13 per share (based on the fair value on the date of issuance) were issued to the co-inventor of certain technology. The Company recorded an expense of $81,250 in connection with the issuance of these shares.

During February 2006, the Company announced a dividend of $0.02 per share of common stock for stockholders of record and qualified warrant holders as of February 24, 2006. The dividend resulted in an accrued liability of $8,114,378 as of February 28, 2006. The Company paid such amount in March 2006. In March 2006, the Company announced a dividend of $0.04 per share of common stock for stockholders of record and qualified warrant holders as of March 31, 2006. The dividend of approximately $16,584,000 is expected to be paid in April 2006.
 
7.
Income taxes

During the nine months ended February 28, 2006, the Company recorded a $1,880,000 provision for income taxes which relates to Federal alternative minimum tax and California state tax. Deferred income taxes are provided for the difference in the treatment of certain income and expense items for financial and tax reporting purposes. Deferred tax assets consist principally of income tax benefits arising from the Company’s Federal net operating loss carry-forwards and the excess of the tax basis of fixed and intangible assets over the book basis. During the nine months ended February 28, 2006, the Company utilized approximately $33,400,000 of its available Federal net operating loss carry-forwards to offset its taxable income arising during the nine month period ended February 28, 2006. At February 28, 2006 and May 31, 2005 a valuation allowance of approximately $2,100,000 and $14,700,000, respectively, which amounts are equal to the Company’s net deferred tax assets at those dates, has been recorded, as management has not determined that it is more likely than not that the benefit from the deferred tax asset will be realized.

At February 28, 2006, the Company has Federal net operating loss carry-forwards of approximately $900,000 that expire through 2025. Annual usage of these net operating loss carryforwards may be limited in the future due to changes in our stockholders.
 
 
8.
Commitments and Contingencies

During the quarter ended August 31, 2005, the Company terminated two of its officers, each of whom had an employment contract with the Company. One of the officers agreed to accept as severance approximately $150,000 and to have the maturity date of options held by him extended for one year. Approximately $27,300 remains outstanding to him at February 28, 2006. Further, the Company agreed to accelerate the vesting of all outstanding options held by the officer and to extend their term to September 2006. The Company recorded an expense of approximately $125,000 related to this option modification in the quarter ended August 31, 2005.

The Company has not reached an agreement with the other officer; however, it accrued approximately $50,000 during the three month period ended August 31, 2005 for amounts which it believes may be due to this individual. The former officer has filed a complaint against the Company seeking arbitration and claiming he is owed approximately $1,500,000. The Company believes the claim is without merit and intends to vigorously defend itself.

The Company is aware of a lawsuit filed by the co-inventor of the patent porfolio technology against the Company for potential obligations for future payments to the co-inventor of the patent portolio technology in connection with entering into licensing agreements. The Company intends to vigorously defend itself in this matter; however, it is possible that were the Company not to prevail in the suit, the ultimate amount payable to such co-inventor of the patent porfolio technology could be significant.

F-32


PATRIOT SCIENTIFIC CORPORATION
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

Also, in conjunction with entering into these license agreements, as well as other license agreements (See Note 4), the legal advisor who had previously assisted the Company in its negotiations, has asserted a claim against the Company for amounts which the advisor believes it is entitled. The Company is contesting the matter; the outcome of this matter is currently unknown. Based on its current assessment of the matter, the Company has accrued a liability of $346,000 as of February 28, 2006. The Company intends to vigorously defend itself in this matter; however, it is possible that, were the Company not to prevail in the suit, the ultimate amount payable to such legal advisor could be significantly higher than the current accrued liability.

Guarantees and Indemnities - The Company has made certain guarantees and indemnities, under which it may be required to make payments to a guaranteed or indemnified party. The Company indemnifies its directors, officers, employees and agents to the maximum extent permitted under the laws of the State of Delaware. In connection with its facility leases, the Company has indemnified its lessors for certain claims arising from the use of the facilities. The duration of the guarantees and indemnities varies, and in many cases is indefinite. These guarantees and indemnities do not provide for any limitation of the maximum potential future payments the Company could be obligated to make. Historically, the Company has not been obligated to make any payments for these obligations and no liabilities have been recorded for these guarantees and indemnities in the accompanying consolidated balance sheets.
 

F-33

 
Until the completion of the resale of the common stock included in this Prospectus, all dealers that effect transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to the dealers’ obligation to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions.
Table of Contents

Prospectus Summary
    1  
Risk Factors
    1  
Plan of Distribution
    4  
Selling Shareholders
    5  
Our Company
    6  
Available Information
    6  
Business
    7  
Use of Proceeds
    15  
Legal Proceedings
    15  
Management’s Discussion and Analysis of
Financial Condition and Results of Operations
    16  
Selected Financial Information
    23  
Management
    25  
Executive Compensation
    28  
Security Ownership of Certain Beneficial Owners
and Management
    30  
Market for Common Equity and Related
Stockholder Matters
    30  
Description of Securities
    33  
Changes in and Disagareements with Accounts
on Accounting and Financial Disclosure
    33  
Legal Opinion
    34  
Experts
    35  
Index to Financial Statements
    F-1  

The Resale of
23,684,442 Shares
of
Common Stock
Offered by
Shareholders
 


PATRIOT SCIENTIFIC CORPORATION



PROSPECTUS



Subject to Completion, June 26, 2006




 
PART II

INFORMATION NOT REQUIRED IN PROSPECTUS

ITEM 24. INDEMNIFICATION OF OFFICERS AND DIRECTORS.
 
Pursuant to the Company’s Certificate of Incorporation, and as permitted by Section 145 of the General Corporation Law of Delaware, the Company may indemnify its directors and officers under certain circumstances against reasonable expenses (including court costs and attorney’s fees), judgments, penalties, fines, and amounts paid in settlement actually and reasonably incurred in connection with any action, suit or proceeding, whether civil, criminal, administrative or investigative, to which any of them is a party by reason of his being a director, officer, employee, or agent of the Company if it is determined that he acted in accordance with the applicable standard of conduct set forth in such statutory provisions. Thus, the indemnification provisions will protect officers and directors from liability only if the officer or director meets the applicable standard of conduct and the Company has the financial ability to honor the indemnity.
 
ITEM 25. OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION.
 
Expenses payable in connection with the registration and distribution of the securities being registered hereunder, all of which will be borne by the Registrant, are as follows:
 
Registration Fee - Securities and Exchange Commission
 
$
2,128.76
 
Printing and Engraving
   
1,000
*
Legal Fees and Expenses
   
15,000
*
Accounting Fees
   
15,000
*
Blue Sky Fees and Expenses
   
1,000
*
         
Total
 
$
34,128.76
*

* Estimated

ITEM 26. RECENT SALES OF UNREGISTERED SECURITIES
 
We offered and sold the following common stock, either for cash or in consideration of services rendered as indicated below, and common stock warrants without registration under the Securities Act of 1933, as amended, and exemption for such sales from registration under the Act is claimed in reliance upon the exemption provided by Section 4(2) thereof on the basis that such offers and sales were transactions not involving any public offering. Appropriate precautions against transfer have been taken, including the placing of a restrictive legend on all certificates evidencing such securities. All such sales were effected without the aid of underwriters, and no sales commissions were paid.
 
Common Stock
 
 
Name
 
 
Date of Sale
 
Number of
Shares
 
Aggregate
Purchase Price
 
Purchase Price Per
Share
 
                           
John Laws
   
January 21, 2003
   
98,039
   
5,000
   
0.05 Cash
 
REC Music Foundation
   
February 3, 2003
   
400,000
   
12,000
   
0.03 Cash
 
John Castellano
   
February 3, 2003
   
138,889
   
5,000
   
0.04 Cash
 
Lyle Armstrong
   
February 7, 2003
   
125,000
   
4,500
   
0.04 Cash
 
Lyle Armstrong
   
February 13, 2003
   
88,889
   
3,000
   
0.03 Cash
 
Red Oak Inc.
   
February 13, 2003
   
59,259
   
2,000
   
0.03 Cash
 
Orrin Noling
   
February 24, 2003
   
162,338
   
5,000
   
0.03 Cash
 
Michael Korbiak
   
March 3, 2003
   
155,807
   
5,500
   
0.04 Cash
 
Lyle Armstrong
   
August 1, 2003
   
44,118
   
1,500
   
0.03 Cash
 
Red Oak Inc.
   
August 1, 2003
   
44,118
   
1,500
   
0.03 Cash
 
 
35


Name
 
Date of Sale
 
Number of Shares
 
Aggregate
Purchase Price
 
Purchase Price Per
Share
 
                           
Red Oak Inc.
   
August 20, 2003
   
100,000
   
3,000
   
0.03 Cash
 
REC Music Foundation
   
August 26, 2003
   
1,000,000
   
25,000
   
0.03 Cash
 
Red Oak Inc.
   
September 16, 2003
   
64,516
   
2,000
   
0.03 Cash
 
Dean Gullick
   
September 23, 2003
   
181,333
   
5,440
   
0.03 Cash
 
Lydon Inc.
   
September 30, 2003
   
67,667
   
2,000
   
0.03 Cash
 
Red Oak Inc.
   
October 31, 2003
   
100,000
   
3,300
   
0.03 Cash
 
Red Oak Inc.
   
November 25, 2003
   
100,000
   
3,300
   
0.03 Cash
 
Red Oak Inc.
   
January 27, 2004
   
100,000
   
3,400
   
0.03 Cash
 
Hawk Associates, Inc.
   
January 5, 2004
   
700,000
   
30,252
   
0.04 Services
 
Hawk Associates, Inc.
   
February 3, 2004
   
300,000
   
14,800
   
0.05 Services
 
Hawk Associates, Inc.
   
April 21, 2004
   
126,496
   
14,800
   
0.12 Services
 
Hawk and Associates
   
August 2, 2004
   
296,000
   
14,800
   
0.05 Services
 
Red Oak Inc.
   
October 20, 2004
   
125,000
   
3,250
   
0.03 Cash
 
Hawk and Associates
   
January 10, 2005
   
500,000
   
44,000
   
0.09 Services
 
AMD Corporation
   
February 4, 2005
   
4,500,000
   
430000
   
0.10 Cash
 

Warrants
 
 
Name
 
 
Date of Issuance
 
Number of
Shares
 
Initial Exercise
Price Per Share
 
 
Expiration Date
 
                           
Swartz Private Equity
   
January 1, 2003
   
2,804,719
   
0.05400
   
April 1, 2011
 
Lincoln Ventures
   
January 24, 2003
   
3,000,000
   
0.05444
   
April 1, 2011
 
Lincoln Ventures
   
March 24, 2002
   
3,963,414
   
0.04100
   
April 1, 2011
 
Swartz Private Equity
   
April 1, 2003
   
621,512
   
0.04080
   
April 1, 2011
 
Lincoln Ventures
   
April 15, 2003
   
222,222
   
0.04500
   
April 1, 2011
 
Lincoln Ventures
   
May 20, 2003
   
2,884,615
   
0.06500
   
April 1, 2011
 
Lincoln Ventures
   
June 9, 2003
   
2,307,692
   
0.06500
   
April 1, 2011
 
Hawk Associates
   
June 16, 2003
   
200,000
   
0.06000
   
June 16, 2008
 
Hawk Associates
   
February 6, 2006
   
100,000
   
0.20000
   
February 6, 2011
 
Hawk Associates
   
February 21, 2006
   
100,000
   
0.50000
   
February 21, 2011
 
Hawk Associates
   
March 1, 2006
   
100,000
   
1.00000
   
March 1, 2011
 
Swartz Private Equity
   
July 1, 2003
   
193,333
   
0.05720
   
April 1, 2011
 
James Zolin
   
August 1, 2003
   
520,833
   
0.04800
   
August 1, 2008
 
Victor Gabourel
   
August 1, 2003
   
520,833
   
0.04800
   
August 1, 2008
 
Richard Daniels
   
August 1, 2003
   
520,833
   
0.04800
   
August 1, 2008
 
Lincoln Ventures
   
October 21, 2003
   
2,142,857
   
0.03500
   
April 1, 2011
 
Charles Merk
   
December 1, 2003
   
641,026
   
0.03900
   
December 1, 2008
 
Stan Caplan
   
February 2, 2004
   
375,000
   
0.04000
   
February 2, 2009
 
Wayne Opperman
   
February 2, 2004
   
1,250,000
   
0.04000
   
February 2, 2009
 
James Gamble
   
February 2, 2004
   
125,000
   
0.04000
   
February 2, 2009
 
Steven Pratt
   
February 2, 2004
   
250,000
   
0.04000
   
February 2, 2009
 
Donald Opperman
   
February 2, 2004
   
250,000
   
0.04000
   
February 2, 2009
 
Gary Leikam
   
February 2, 2004
   
125,000
   
0.04000
   
February 2, 2009
 
Adnan Aladray
   
February 2, 2004
   
250,000
   
0.04000
   
February 2, 2009
 
Nazeah Aladray
   
February 2, 2004
   
125,000
   
0.04000
   
February 2, 2009
 
LaRiccia Trust
   
February 2, 2004
   
250,000
   
0.04000
   
February 2, 2009
 
James & Josephine Zolin
   
February 2, 2004
   
750,000
   
0.04000
   
February 2, 2009
 
James Zolin
   
February 2, 2004
   
125,000
   
0.04000
   
February 2, 2009
 
Victor Gabourel
   
February 2, 2004
   
625,000
   
0.04000
   
February 2, 2009
 
Ed Kashou
   
February 2, 2004
   
500,000
   
0.04000
   
February 2, 2009
 
Ed Kashou
   
February 2, 2004
   
1,000,000
   
0.04000
   
February 2, 2009
 
Dan Vincent
   
February 2, 2004
   
125,000
   
0.04000
   
February 2, 2009
 
Richard Daniels
   
February 2, 2004
   
750,000
   
0.04000
   
February 2, 2009
 
 
36


 
Name
 
 
Date of Issuance
 
Number of
Shares
 
Initial Exercise
Price Per Share
 
 
Expiration Date
 
                           
Stan Caplan
   
February 2, 2004
   
750,000
   
0.04000
   
February 2, 2009
 
Barbara Opperman
   
February 2, 2004
   
250,000
   
0.04000
   
February 2, 2009
 
Leo Correia
   
February 2, 2004
   
250,000
   
0.04000
   
February 2, 2009
 
Mt. Savage Productions
   
April 26, 2004
   
1,000,000
   
0.10000
   
April 26, 2009
 
Wayne Opperman
   
September 28, 2004
   
1,250,000
   
0.04000
   
September 28, 2009
 
Wayne Opperman
   
November 16, 2004
   
1,600,000
   
0.02500
   
November 16, 2011
 
James & Josephine Zolin
   
November 16, 2004
   
1,600,000
   
0.02500
   
November 16, 2011
 
Victor Gabourel
   
November 16, 2004
   
1,600,000
   
0.02500
   
November 16, 2011
 
Richard Daniels
   
November 16, 2004
   
1,000,000
   
0.02500
   
November 16, 2011
 
Lincoln Ventures LLC
   
November 17, 2004
   
9,431,137
   
0.01670
   
April 1, 2011
 
Lincoln Ventures LLC
   
November 18, 2004
   
4,000,000
   
0.02500
   
April 1, 2011
 
Stan Caplan
   
December 9, 2004
   
806,452
   
0.03100
   
December 9, 2011
 
Daniel Nunes
   
January 17, 2005
   
403,226
   
0.03100
   
January 17, 2012
 
TPL
   
June 15, 2005
   
3,500,000
   
0.12500
   
June 15, 2012
 
Lincoln Ventures LLC
   
February 9, 2006
   
7,000,000
   
0.0775
   
April 1, 2011
 

Name
 
Date of Sale
 
Amount
 
Initial Conversion Price
 
                     
Lincoln Ventures
   
1/24/2003
 
$
150,000
 
$
0.05500
 
Lincoln Ventures
   
3/24/2003
   
162,500
   
0.04100
 
Stan Caplan
   
4/15/2003
   
10,000
   
0.04500
 
Lincoln Ventures
   
5/20/2003
   
187,500
   
0.06500
 
Lincoln Ventures
   
6/9/2003
   
150,000
   
0.06500
 
James Zolin
   
8/1/2003
   
25,000
   
0.04800
 
Victor Gabourel
   
8/1/2003
   
25,000
   
0.04800
 
Richard Daniels
   
8/1/2003
   
25,000
   
0.04800
 
Lincoln Ventures
   
8/5/2003
   
120,000
   
0.01720
 
Lincoln Ventures
   
9/22/2003
   
202,500
   
0.01720
 
Lincoln Ventures
   
10/21/2003
   
75,000
   
0.03500
 
Short term Convertible
                   
James Zolin
   
9/30/2003
   
15,000
   
0.04000
 
Josephine Zolin
   
9/30/2003
   
15,000
   
0.04000
 
Wayne Opperman
   
9/30/2003
   
20,000
   
0.04000
 
Richard Daniels
   
9/30/2003
   
25,000
   
0.04000
 
Charles Merk
   
12/1/2003
   
25,000
   
0.03900
 
Lincoln Ventures
   
1/23/2004
   
275,000
   
0.02667
 
Stan Caplan
   
2/2/2004
   
15,000
   
0.04000
 
Wayne Opperman
   
2/2/2004
   
50,000
   
0.04000
 
James Gamble
   
2/2/2004
   
5,000
   
0.04000
 
Steven Pratt
   
2/2/2004
   
10,000
   
0.04000
 
Donald Opperman
   
2/2/2004
   
10,000
   
0.04000
 
Gary Leikam
   
2/2/2004
   
5,000
   
0.04000
 
Adrian Aladray
   
2/2/2004
   
10,000
   
0.04000
 
Nazeah Aladray
   
2/2/2004
   
5,000
   
0.04000
 
Urban LaRiccia Trust
   
2/2/2004
   
10,000
   
0.04000
 
James & Joe Zolin
   
2/2/2004
   
30,000
   
0.04000
 
James Zolin
   
2/2/2004
   
5,000
   
0.04000
 
Vic Gabourel
   
2/2/2004
   
25,000
   
0.04000
 
Ed Kashou
   
2/2/2004
   
20,000
   
0.04000
 
Ed Kashou
   
2/2/2004
   
40,000
   
0.04000
 
Dan Vincent
   
2/2/2004
   
5,000
   
0.04000
 
Rick Daniels
   
2/2/2004
   
30,000
   
0.04000
 
Stan Caplan
   
2/2/2004
   
30,000
   
0.04000
 
Barbara Opperman
   
2/2/2004
   
10,000
   
0.04000
 
 
37


Name
 
Date of Sale
 
Amount
 
Initial Conversion Price
 
Leo Correia
   
2/2/2004
   
10,000
   
0.04000
 
Lincoln Ventures
   
3/24/2004
   
315,900
   
0.09383
 
Mt. Savage Productions
   
4/26/2004
   
100,000
   
0.10000
 
Lincoln Ventures
   
5/11/2004
   
486,600
   
0.07000
 
Wayne Opperman
   
9/28/2004
   
50,000
   
0.04000
 
Wayne Opperman
   
11/16/2004
   
40,000
   
0.02500
 
James & Joe Zolin
   
11/16/2004
   
40,000
   
0.02500
 
Victor Gabourel
   
11/16/2004
   
40,000
   
0.02500
 
Richard Daniels
   
11/16/2004
   
25,000
   
0.02500
 
Lincoln Ventures
   
11/17/2004
   
157,500
   
0.01670
 
Lincoln Ventures
   
11/18/2004
   
100,000
   
0.02500
 
Stan Caplan
   
12/9/2004
   
25,000
   
0.03100
 
Daniel Nunes
   
1/17/2005
   
12,500
   
0.03100
 

ITEM 27. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES.
 
The Exhibits and Financial Statement Schedules to this Registration Statement are listed in the Exhibit Index commencing at page EX-1 hereof.
 
ITEM 28. UNDERTAKINGS.
 
The undersigned Registrant hereby undertakes the following:
 
(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:
 
(i) to include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;
 
(ii) to reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information in this Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and
 
(iii) to include any additional or changed material information on the plan of distribution.
 
(2) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
 
(3) To remove from registration by means of a post-effective amendment to this Registration Statement any of the securities being registered which remain unsold at the termination of this offering.
 
Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers or persons controlling the Registrant pursuant to the General Corporation Law of Delaware, the Certificate of Incorporation, or otherwise, the Registrant has been advised that, in the opinion of the Securities and Exchange Commission, such indemnification is against public policy as expressed in such Act, and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or person controlling the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or person controlling the Registrant in connection with any securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in such Act and will be governed by the final adjudication of such issue.
 
38

 
The undersigned registrant hereby undertakes that, for purposes of determining liability under the Securities Act of 1933, to any purchaser, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use.
 
The undersigned registrant hereby undertakes that, for purposes of determining liability under the Securities Act of 1933, each filing of the registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
 
39


SIGNATURES

In accordance with the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements of filing on Form SB-2 and authorized this Registration Statement to be signed on its behalf by the undersigned, in the City of Carlsbad, State of California, on June 26, 2006.
 
     
  PATRIOT SCIENTIFIC CORPORATION
 
 
 
 
 
 
  By:   /s/ DAVID H. POHL
 
David H. Pohl
  President, Chief Executive Officer and Director
 
40


In accordance with the requirements of the Securities Act of 1933, this Registration Statement was signed by the following persons in the capacities and on the dates stated:
 
Signature
 
Title
 
Date
         
/s/ DAVID H. POHL 
 
President, Chief Executive Officer and Secretary
 
June 26, 2006
David Pohl        
         
 
 
Chief Financial Officer, Principal Financial Officer,
 
June 26, 2006
Thomas J. Sweeney   and Principal Accounting Officer    
         
/s/ CARLTON JOHNSON
 
Director
 
June 26, 2006
Carlton Johnson
       
         
/s/ HELMUT FALK JR.
 
Director
 
June 26, 2006
Helmut Falk Jr.
       
         
/s/ GLORIA H. FELCYN
 
Director
 
June 26, 2006
Gloria H. Felcyn
       
         
/s/ JAMES TURLEY
 
Director
 
June 26, 2006
James Turley
       
         
 
41

 
EXHIBITS

(a) Exhibits
 
The following exhibits are included as part of this Registration Statement, except those exhibits marked (1), which have previously been filed with the Securities and Exchange Commission and are incorporated by reference to another registration statement, report or document. References to the “Company” in this Exhibit Index mean PATRIOT SCIENTIFIC CORPORATION, a Delaware corporation.
 
Exhibit No.
 
Document
     
2.1
 
Agreement to Exchange Technology for Stock in Patriot Scientific Corporation, (1) incorporated by reference to Exhibit 2.1 to Form 8-K dated August 10, 1989
     
2.2
 
Assets Purchase Agreement and Plan of Reorganization dated June 22, 1994, among (1) the Company, nanoTronics Corporation and Helmut Falk, incorporated by reference to Exhibit 10.4 to Form 8-K dated July 6, 1994
     
2.2.1
 
Amendment to Development Agreement dated April 23, 1996 between the Company and (1) Sierra Systems, incorporated by reference to Exhibit 2.2.1 to Pre-Effective Amendment No. 1 to Registration Statement on Form SB-2 dated April 29, 1996
     
2.3
 
Form of Exchange Offer dated December 4, 1996 between the Company and certain (1) shareholders of Metacomp, Inc. incorporated by reference to Exhibit 2.3 to Form 8-K dated January 9, 1997
     
2.4
 
Letter of Transmittal to Accompany Shares of Common Stock of Metacomp, Inc. (1) Tendered Pursuant to the Exchange Offer Dated December 4, 1996 incorporated by reference to Exhibit 2.4 to Form 8-K dated January 9, 1997
     
3.1
 
Original Articles of Incorporation of the Company’s predecessor, Patriot Financial (1) Corporation, incorporated by reference to Exhibit 3.1 to Registration Statement on Form S-18, file no. 33-23143-FW
     
3.2
 
Articles of Amendment of Patriot Financial Corporation, as filed with the Colorado (1) Secretary of State on July 21, 1988, incorporated by reference to Exhibit 3.2 to Registration Statement on Form S-18, File No. 33-23143-FW
     
3.3
 
Certificate of Incorporation of the Company, as filed with the Delaware Secretary (1) of State on March 24, 1992, incorporated by reference to Exhibit 3.3 to Form 8-K dated May 12, 1992
     
3.3.1
 
Certificate of Amendment to the Certificate of Incorporation of the Company, as (1) filed with the Delaware Secretary of State on April 18, 1995, incorporated by reference to Exhibit 3.3.1 to Form 10-KSB for the fiscal year ended May 31, 1995
     
3.3.2
 
Certificate of Amendment to the Certificate of Incorporation of the Company, as (1) filed with the Delaware Secretary of State on June 19,1997, incorporated by reference to Exhibit 3.3.2 to Form 10-KSB for the fiscal year ended May 31, 1997
     
3.3.3
 
Certificate of Amendment to the Certificate of Incorporation of the Company, as (1) filed with the Delaware Secretary of State on April 28, 2000, incorporated by reference to Exhibit 3.3.3 to Registration Statement on Form S-3 dated May 5, 2000
     
3.3.4
 
Certificate of Amendment to the Certificate of Incorporation of the Company, as (1) filed with the Delaware Secretary of State on May 6, 2002, incorporated by reference to Exhibit 3.3.4 to Registration Statement on Form S-3 dated June 27, 2002
 
42


Exhibit No.
 
Document
     
3.3.5
 
Certificate of Amendment to the Certificate of Incorporation of the Company, as (1) filed with the Delaware Secretary of State on October 16, 2003, incorporated by reference to Exhibit 3.3.5 to Registration Statement on Form SB-2 dated May 21, 2004
     
3.4
 
Articles and Certificate of Merger of Patriot Financial Corporation into the (1) Company dated May 1, 1992, with Agreement and Plan of Merger attached thereto as Exhibit A, incorporated by reference to Exhibit 3.4 to Form 8-K dated May 12, 1992
     
3.5
 
Certificate of Merger issued by the Delaware Secretary of State on May 8, 1992 (1) incorporated by reference to Exhibit 3.5 to Form 8-K dated May 12, 1992
     
3.6
 
Certificate of Merger issued by the Colorado Secretary of State on May 12, 1992 (1) incorporated by reference to Exhibit 3.6 to Form 8-K dated May 12, 1992
     
3.7
 
Bylaws of the Company, incorporated by reference to Exhibit 3.7 to Form 8-K dated (1) May 12, 1992
     
4.1
 
Specimen common stock certificate, incorporated by reference to Exhibit 4.1 Form (1) 8-K dated May 12, 1992
     
4.2
 
Form of Stock Purchase Warrant (Labway Corporation) dated February 29, 1996 (1) exercisable to purchase 253,166 common shares at $1.58 per share until August 31, 1996, granted to investors in connection with an offering of securities made in reliance upon Regulation S, incorporated by reference to Exhibit 4.2 to Form 10-QSB for fiscal quarter ended February 29, 1996
     
4.3
 
Form of 6% Convertible Subordinated Promissory Note due September 30, 1998 (1) aggregating $1,500,000 to six investors incorporated by reference to Exhibit 4.3 to Form 10-QSB for fiscal quarter ended August 31, 1996
     
4.4
 
Form of 5% Convertible Term Debenture (CC Investments, LDC) due June 2, 1999 (1) aggregating $2,000,000 to two investors incorporated by reference to Exhibit 4.4 to Form 8-K dated June 16, 1997
     
4.5
 
Form of Stock Purchase Warrant (CC Investments, LDC) dated June 2, 1997 (1) exercisable to purchase an aggregate of 400,000 common shares at $1.69125 per share until June 2, 2002, granted to two investors in connection with the offering of securities in Exhibit 4.4 incorporated by reference to Exhibit 4.5 to Form 8-K dated June 16, 1997
     
4.6
 
Registration Rights Agreement dated June 2, 1997 by and among the Company and CC (1) Investments, LDC and the Matthew Fund, N.V. related to the registration of the common stock related to Exhibits 4.4 and 4.5 incorporated by reference to Exhibit 4.6 to Form 8-K dated June 16, 1997
     
4.7
 
Form of Warrant to Purchase Common Stock (Swartz Family Partnership, L.P.) dated (1) June 2, 1997 exercisable to purchase an aggregate of 211,733 common shares at $1.69125 per share until June 2, 2002, granted to a group of investors in connection with the offering of securities in Exhibit 4.4 incorporated by reference to Exhibit 4.7 to Form 8-K dated June 16, 1997
     
4.8
 
Registration Rights Agreement dated June 2, 1997 by and among the Company and (1) Swartz Investments, LLC related to the registration of the common stock related to Exhibit 4.7 incorporated by reference to Exhibit 4.8 to Form 8-K dated June 16, 1997
 
43


Exhibit No.
 
Document
     
4.9
 
Form of 5% Convertible Term Debenture (CC Investments, LDC) due June 2, 1999 (1) aggregating $1,000,000 to two investors incorporated by reference to Exhibit 4.9 to Form 10-KSB for the fiscal year ended May 31, 1998
     
4.10
 
Form of Stock Purchase Warrant (CC Investments, LDC) dated November 24, 1997 (1) exercisable to purchase an aggregate of 200,000 common shares at $1.50 per share until June 2, 2002, granted to two investors in connection with the offering of securities described in Exhibit 4.9 incorporated by reference to Exhibit 4.10 to Form 10-KSB for the year ended May 31, 1998
     
4.11
 
Form of Warrant to Purchase Common Stock (Swartz Family Partnership, L.P.) dated (1) November 24, 1997 exercisable to purchase an aggregate of 105,867 common shares at $1.50 per share until June 2, 2002, granted to a group of investors in connection with the offering of securities described in Exhibit 4.9 incorporated by reference to Exhibit 4.11 to Form 10-KSB for the year ended May 31, 1998
     
4.12
 
Form of Warrant to Purchase Common Stock (Investor Communications Group, Inc.) (1) dated June 16, 1997 exercisable to purchase an aggregate of 130,000 common shares at prices ranging from $2.50 to $7.50 per share until June 15, 1999 incorporated by reference to Exhibit 4.12 to Form 10-KSB for the year ended May 31, 1998
     
4.13
 
Warrant to Purchase Common Stock issued to Spellcaster Telecommunications, Inc. (1) dated April 28, 1998 exercisable to purchase an aggregate of 100,000 common shares at $1.25 per share until April 28, 2000 incorporated by reference to Exhibit 4.13 to Form 10-KSB for the year ended May 31, 1998
     
4.14
 
Investment agreement dated February 24, 1999 by and between the Company and Swartz (1) Private Equity, LLC for a maximum aggregate amount of $5,000,000 incorporated by reference to Exhibit 4.14 to Form 10-QSB/A for the fiscal quarter ended November 30, 1998
     
4.15
 
Registration Rights Agreement dated February 24, 1999 by and between the Company (1) and Swartz Private Equity, LLC related to the registration of the common stock related to Exhibit 4.14 incorporated by reference to Exhibit 4.15 to Form 10-QSB/A for the fiscal quarter ended November 30, 1998
     
4.16
 
Form of Warrant to Purchase Common Stock (Swartz Private Equity, LLC) dated (1) February 24, 1999 exercisable to purchase common shares in connection with the offering of securities in Exhibit 4.14 incorporated by reference to Exhibit 4.16 to Form 10-QSB/A for the fiscal quarter ended November 30, 1998
     
4.17
 
Amended and Restated Investment Agreement dated July 12, 1999 by and between the (1) Company and Swartz Private Equity, LLC for a maximum aggregate amount of $5,000,000 incorporated by reference to Exhibit 4.17 to Pre-Effective Amendment No. 2 to Registration Statement on Form SB-2 dated July 14, 1999
     
4.18
 
Investment Agreement dated April 28, 2000 by and between the Company and Swartz (1) Private Equity, LLC for a maximum aggregate amount of $30,000,000 incorporated by reference to Exhibit 4.18 to Registration Statement on Form S-3 dated May 5, 2000
     
4.18.1
 
Waiver and Agreement dated September 24, 2001 amending the Investment Agreement (1) dated April 28, 2000 by and between the Company and Swartz Private Equity, LLC for a maximum aggregate amount of $30,000,000 incorporated by reference to Exhibit 4.18.1 to Registration Statement on Form S-1 dated October 11, 2001
 
44

 
Exhibit No.
 
Document
     
4.19
 
2001 Stock Option Plan of the Company dated February 21, 2001 incorporated by (1) reference to Exhibit 4.19 to Registration Statement on Form S-8 dated March 26, 2001
     
4.20
 
Investment agreement dated September 17, 2001 by and between the Company and (1) Swartz Private Equity, LLC for a maximum aggregate amount of $25,000,000 incorporated by reference to Exhibit 4.20 to Registration Statement on Form S-1 dated October 11, 2001
     
4.21
 
Registration Rights Agreement dated September 17, 2001 by and between the Company (1) and Swartz Private Equity, LLC related to the registration of the common stock related to Exhibit 4.20 incorporated by reference to Exhibit 4.21 to Registration Statement on Form S-1 dated October 11, 2001
     
4.22
 
Warrant to Purchase Common Stock dated September 17, 2001 exercisable to purchase (1) common shares in connection with the Offering of securities in Exhibit 4.20 incorporated by reference to Exhibit 4.22 to Registration Statement on Form S-1 dated October 11, 2001
     
4.23
 
Financial Consulting Services Agreement between the Company and M. Blaine Riley, (1) Randall Letcavage and Rosemary Nguyen incorporated by reference to Exhibit 4.23 to Registration Statement on Form S-8 dated January 22, 2002
     
4.24
 
Form of 8% Convertible Debenture (Lincoln Ventures, LLC) due June 10, 2004 (1) aggregating $1,000,000 to six investors incorporated by reference to Exhibit 4.24 to Registration Statement on Form S-3 dated June 27, 2002
     
4.25
 
Form of Stock Purchase Warrant (Lincoln Ventures, LLC) dated June 10, 2002 (1) exercisable to purchase an aggregate of 12,859,175 common shares at initial exercise prices ranging form $0.08616 to $0.10289 per share until June 10, 2007, granted to six investors in connection with the offering of securities described in Exhibit 4.24 incorporated by reference to Exhibit 4.25 to Registration Statement on Form S-3 dated June 27, 2002
     
4.26
 
Form of Registration Rights Agreement (Lincoln Ventures, LLC) dated June 10, 2002 (1) by and among the Company and six investors related to the registration of the common stock related to Exhibit 4.24 incorporated by reference to Exhibit 4.26 to Registration Statement on Form S-3 dated June 27, 2002
     
4.27
 
2003 Stock Option Plan of the Company dated July 2, 2003 incorporated by reference (1) to Exhibit 4.27 to Registration Statement on Form S-8 dated September 4, 2003
     
4.28
 
Form of 8% Convertible Debenture, Stock Purchase Warrant, Registration Rights (2) Agreement and Securities Purchase Agreement for financings entered into between September 28, 2004 and January 17, 2005
     
4.29
 
Non-Qualified Stock Option Agreement by and between Patriot Scientific Corporation and David H. Pohl, entered into as of June 5, 2006 incorporated by reference (1) to Exhibit 10.2 to Form 8-K dated June 5, 2006
     
5.1
 
Opinion of Luce, Forward, Hamilton & Scripps LLP(3)
     
10.1
 
1992 Incentive Stock Option Plan of the Company, incorporated by reference to (1) Exhibit 10.1 to Form 8-K dated May 12, 1992
     
10.1.1
 
Amendment to 1992 Incentive Stock Option Plan dated January 11, 1995, incorporated (1) by reference to Exhibit 10.1.1 to Form S-8 dated July 17, 1996
     
10.2
 
1992 Non-Statutory Stock Option Plan of the Company, incorporated by reference to (1) Exhibit 10.2 to Form 8-K dated May 12, 1992
 
45

 
Exhibit No.
 
Document
     
10.2.1
 
Amendment to 1992 Non-Statutory Stock Option Plan dated January 11, 1995 (1) incorporated by reference to Exhibit 10.2.1 to Form 10-KSB for fiscal year ended May 31, 1996
     
10.3
 
Lease Agreement between the Company’s subsidiary Metacomp, Inc. and Clar-O-Wood (1) Partnership, a California limited partnership dated April 11, 1991 as amended November 11, 1992 and November 2, 1995 incorporated by reference to Exhibit 10.3 to Form 10-KSB for fiscal year ended May 31, 1997
     
10.4
 
Stock Purchase Agreement dated November 29 and 30, 1995, between the Company and (1) SEA, Ltd., incorporated by reference to Exhibit 10.4 to Form 8-K dated December 11, 1995
     
10.4.1
 
Letter Amendment to Stock Purchase Agreement dated February 21, 1996, between the (1) Company and SEA, Ltd., incorporated by reference to Exhibit 10.4.1 to Form 10-QSB for fiscal quarter ended 2/29/96
     
10.5
 
1995 Employee Stock Compensation Plan of the Company, incorporated by reference to (1) Exhibit 10.5 to Form 10-QSB for fiscal quarter ended 11/30/95
     
10.6
 
Letter Stock and Warrant Agreement dated January 10, 1996 between the Company and (1) Robert E. Crawford, Jr., incorporated by reference to Exhibit 10.6 to Form 10-QSB for fiscal quarter ended February 29, 1996
     
10.7
 
Non-Exclusive Manufacturing and Line of Credit Agreement dated February 28, 1996, (1) between the Company and Labway Corporation, incorporated by reference to Exhibit 10.7 to Form 10-QSB for fiscal quarter ended February 29, 1996
     
10.8
 
Distribution and Representation Agreement dated February 28, 1996, between the (1) Company and Innoware, Inc., incorporated by reference to Exhibit 10.8 to Form 10-QSB for fiscal quarter ended February 29, 1996
     
10.9
 
Employment Agreement dated November 20, 1995 between the Company and Elwood G. (1) Norris, incorporated by reference to Exhibit 10.9 to Registration Statement on Form SB-2 dated March 18, 1996
     
10.9.1
 
First Amendment to Employment Agreement dated May 17, 1996 between the Company and (1) Elwood G. Norris, incorporated by reference to Exhibit 10.9.1 to Pre-Effective Amendment No. 2 to Registration Statement on Form SB-2 dated May 23, 1996
     
10.10
 
Employment Agreement dated November 20, 1995 between the Company and Robert (1) Putnam, incorporated by reference to Exhibit 10.10 to Registration Statement on Form SB-2 dated March 18, 1996
     
10.11
 
Sales Contractual Agreement dated March 19, 1996 between the Company and Evolve (1) Software, Inc., incorporated by reference to Exhibit 10.11 to Pre-Effective Amendment No. 1 to Registration Statement on Form SB-2 dated April 29, 1996
     
10.11.1
 
Two Year Stock Purchase Warrant dated March 19, 1996 Granted to Evolve Software, (1) Inc. Providing for the Purchase of up to 50,000 Common Shares at $2.85, incorporated by reference to Exhibit 10.11.1 to Pre-Effective Amendment No. 1 to Registration Statement on Form SB-2 dated April 29, 1996


46



Exhibit No.
 
Document
     
10.12
 
Employment Agreement dated as of May 8, 1996 between the Company and Michael A. (1) Carenzo, including Schedule A - Stock Option Agreement, incorporated by reference to Exhibit 10.12 to Pre-Effective Amendment No. 2 to Registration Statement on Form SB-2 dated May 23, 1996
     
10.12.1
 
First Amendment to Employment Agreement dated as of May 8, 1996 between the (1) Company and Michael A. Carenzo dated September 23, 1996, incorporated by reference to Exhibit 10.12.1 to Form 10-KSB for the fiscal year ended May 31, 1997
     
10.13
 
1996 Stock Option Plan of the Company dated March 25, 1996 and approved by the (1) Shareholders on May 17, 1996, incorporated by reference to Exhibit 10.13 to Pre-Effective Amendment No. 2 to Registration Statement on Form SB-2 dated May 23, 1996
     
10.14
 
Sales Contractual Agreement dated June 20, 1996 between the Company and (1) Compunetics Incorporated incorporated by reference to Exhibit 10.14 to Form 10-KSB for fiscal year ended May 31, 1996
     
10.15
 
Sales Contractual Agreement dated July 31, 1996 between the Company and Premier (1) Technical Sales, Inc. incorporated by reference to Exhibit 10.15 to Form 10-KSB for fiscal year ended May 31, 1996
     
10.16
 
Employment Agreement dated January 1, 1997 between the Company and Norman J. (1) Dawson incorporated by reference to Exhibit 10.16 to Form 10-KSB for fiscal year ended May 31, 1997
     
10.17
 
Employment Agreement dated January 1, 1997 between the Company and Jayanta K. (1) Maitra incorporated by reference to Exhibit 10.17 to Form 10-KSB for fiscal year ended May 31, 1997
     
10.18
 
Technology License and Distribution Agreement dated June 23, 1997 between the (1) Company and Sun Microsystems, Inc. incorporated by reference to Exhibit 10.18 to Form 10-KSB for the fiscal year ended May 31, 1997
     
10.19
 
Employment Agreement dated March 23, 1998 between the Company and James T. Lunney (1) incorporated by reference to Exhibit 10.19 to Form 10-KSB for the fiscal year ended May 31, 1998
     
10.20
 
Employment Agreement dated July 28, 1997 between the Company and Phillip Morettini (1) incorporated by reference to Exhibit 10.20 to Form 10-KSB for the fiscal year ended May 31, 1998
     
10.21
 
Employment Agreement dated July 23, 1998 between the Company and Lowell W. (1) Giffhorn incorporated by reference to Exhibit 10.21 to Form 10-KSB for the fiscal year ended May 31, 1998
     
10.22
 
Secured Promissory Note dated June 12, 2000 between the Company and James T. (1) Lunney incorporated by reference to Exhibit 10.22 to Form 10-KSB for the fiscal year ended May 31, 2000
     
10.23
 
Purchase Agreement dated June 29, 2000 between the Company and 4S 37/38, LLC (1) incorporated by reference to Exhibit 10.23 to Form 10-KSB for the fiscal year ended May 31, 2000
     
10.24
 
Employment Agreement dated October 2, 2000 between the Company and Miklos B. (1) Korodi incorporated by reference to Exhibit 10.24 to Form 10-QSB for the fiscal quarter ended November 30, 2000
 
47


Exhibit No.
 
Document
     
10.25
 
Employment Agreement dated December 1, 2000 between the Company and Richard G. (1) Blum incorporated by reference to Exhibit 10.25 to Form 10-QSB for the fiscal quarter ended November 30, 2000
     
10.26
 
Employment Agreement dated January 29, 2001 between the Company and Serge J. (1) Miller incorporated by reference to Exhibit 10.26 to Form 10-KSB for the fiscal year ended May 31, 2001
     
10.27
 
Lease Agreement dated February 23, 2001 between the Company and Arden Realty (1) Finance IV, LLC incorporated by reference to Exhibit 10.27 to Form 10-KSB for the fiscal year ended May 31, 2001
     
10.28
 
Employment Agreement dated January 1, 2001 between the Company and David H. Pohl (1) incorporated by reference to Exhibit 10.28 to Form 10-KSB for the fiscal year ended May 31, 2001
     
10.29
 
Employment Agreement dated April 26, 2001 between the Company and David H. Pohl (1) incorporated by reference to Exhibit 10.29 to Form 10-KSB for the fiscal year ended May 31, 2001
     
10.30
 
Employment Agreement dated November 17, 2001 between the Company and Lowell W. (1) Giffhorn incorporated by reference to Exhibit 10.30 to Registration Statement on Form S-3 dated June 27, 2002
     
10.31
 
Employment Agreement dated December 20, 2001 between the Company and Jayanta (1) Maitra incorporated by reference to Exhibit 10.31 to Registration Statement on Form S-3 dated June 27, 2002
     
10.32
 
Consulting Agreement dated March 7, 2002 between the Company and SDMC, Inc. (1) incorporated by reference to Exhibit 10.32 to Registration Statement on Form S-3 dated June 27, 2002
     
10.33
 
Employment Agreement dated January 2, 2004 between the Company and Jayanta Maitra (1) incorporated by reference to Exhibit 10.33 to Registration Statement on Form SB-2 dated May 21, 2004
     
10.34
 
Consulting Agreement dated March 18, 2004 between the Company and SDMC, Inc. (1) incorporated by reference to Exhibit 10.34 to Registration Statement on Form SB-2 dated May 21, 2004
     
10.35
 
Employment Agreement dated June 1, 2004 between the Company and Patrick Nunally (1) incorporated by reference to Exhibit 10.35 to Form 10-K for the fiscal year ended May 31, 2004
     
10.36
 
Amendment No. 1 to Employment Agreement dated July 12, 2004 between the Company (1) and Patrick Nunally
     
10.37
 
Employment Agreement dated September 1, 2004 between the Company and Lowell W. (2) Giffhorn
     
10.38
 
IGNITE License Agreement with Advanced Micro Devices, Inc., dated February 21, 2005, (1) incorporated by reference to Exhibit 10.38 to Form 8-K filed February 28, 2005
     
10.39
 
Patent Portfolio License Agreement with Advanced Micro Devices, Inc., dated February 21, 2005, (1) incorporated by reference to Exhibit 10.39 to Form 8-K filed February 28, 2005


48


Exhibit No.
 
Document
     
10.40***
 
Master Agreement, dated as of June 7, 2005, by and among the Company, Technology Properties Limited, a California corporation and Charles H. Moore, an individual, (3)
     
10.41***
 
Commercialization Agreement dated as of June 7, 2005 by and among PNEWCO LLC, Technology Properties Limited, a California corporation, and the Company (3)
     
10.42***
 
Limited Liability Company Operating Agreement of PNEWCO LLC, a Delaware limited liability company, dated as of June 7, 2005 (3)
     
10.43
 
Agreement for Part-Time Employment dated August 3, 2005 between the Company and Thomas J. Sweeney, (1) incorporated by reference to Exhibit 99.3 to Form 8-K filed August 9, 2005
     
10.44
 
Agreement dated July 27, 2004 among Patriot, Russell H. Fish, III and the Fish Family Trust regarding assistance with certain litigation.
     
10.45
 
Antidilution Agreement and Addendum to Warrants dated March 19, 2003, between the Company and Swartz Private Equity, LLC
     
14.1
 
Code of Ethics for Senior Financial Officers incorporated by reference to Exhibit  (1) 14.1 to Form 10-K for the fiscal year ended May 31, 2003
     
21.1
 
Subsidiaries of the small business issuer incorporated by reference to Exhibit  (1) 21.1 to Form 10-K for the fiscal year ended May 31, 2004
     
23.1
 
Consent of Luce, Forward, Hamilton & Scripps LLP (included in Exhibit 5.1)
     
23.2
 
Consent of Mayer Hoffman McCann P.C. independent registered certified (3) public accounting firm
     
23.3
 
Consent of Nation Smith Hermes Diamond independent registered certified (3) public accounting firm
     
99.1
 
Form of ISO Plan Option (Gaspar) dated May 29, 1992, incorporated by reference to (1) Exhibit 28.2 to Registration Statement on Form SB-2, file no. 33-57858
     
99.2
 
Form of NSO Plan Option (Berlin) dated May 29, 1992, incorporated by reference to (1) Exhibit 28.3 to Registration Statement on Form SB-2, file no. 33-57858
     
99.3
 
Form of Incentive Stock Option Agreement to the Company’s 1996 Stock Option Plan (1) (individual agreements differ as to number of shares, dates, prices and vesting), incorporated by reference to Pre-Effective Amendment No. 2 to Registration Statement on Form SB-2 dated May 23, 1996
     
99.4
 
Form of NonQualified Stock Option Agreement to the Company’s 1996 Stock Option (1) Plan (individual agreement differ as to number of shares, date, prices and vesting), incorporated by reference to Pre-Effective Amendment No. 2 to Registration Statement on Form SB-2 dated May 23, 1996
     
99.5
 
Press Release of the Company dated November 4, 1996 incorporated by reference to (1) Exhibit 99.5 to Form 8-K dated January 9, 1997
     
99.6
 
Form of Incentive Stock Option Agreement to the Company’s 2001 Stock Option Plan (1) incorporated by reference to Exhibit 99.6 to Registration Statement on Form S-8 filed March 26, 2001
 
49

 
Exhibit No.
 
Document
     
99.7
 
Form of Non-Qualified Stock Option Agreement to the Company’s 2001 Stock Option (1) Plan incorporated by reference to Exhibit 99.7 to Registration Statement on Form S-8 filed March 26, 2001
     
99.8
 
Form of Incentive Stock Option Agreement to the Company’s 2003 Stock Option Plan (1) incorporated by reference to Exhibit 99.8 to Registration Statement on Form S-8 filed September 4, 2003
     
99.9
 
Form of Non-Qualified Stock Option Agreement to the Company’s 2003 Stock Option (1) Plan incorporated by reference to Exhibit 99.9 to Registration Statement on Form S-8 filed September 4, 2003
_________________________

(1)
Previously filed in indicated registration statement or report.

(2)
Exhibit filed with this Registration Statement on Form SB-2, as originally filed.
 
(3)
Exhibit filed herewith this Amended Registration Statement on Form SB-2.

(b)
Reports on Form 8-K - A report on Form 8-K was filed on December 22, 2004, related to the resignation of a director and chairman of the board.
 
*** Portions of these exhibits have been omitted pursuant to a request for confidential treatment. That material has been filed separately with the Commission.

All other schedules have been omitted because the information required to be set forth therein is not applicable or is shown in the Consolidated Financial Statements or the Notes thereto.
 
50

EX-5.1 2 v046258_ex5-1.htm
EXHIBIT 5.1
 
 
600 West Broadway
Suite 2600
San Diego, CA 92101-3372
619.236.1414
619.232.8311 fax

www.luce.com
   
June 26, 2006
 

Board of Directors
PATRIOT SCIENTIFIC CORPORATION
6183 Paseo Del Norte, Suite 180
Carlsbad, California 92011

Re:
First Amendment to the Registration Statement to Form SB-2
 
Ladies and Gentlemen:
 
We have acted as your counsel in connection with the preparation of the First Amendment to the Registration Statement to Form SB-2 (the “Registration Statement”) to be filed with the Securities and Exchange Commission to register 23,684,442 shares of common stock, no par value per share (the “Common Stock”), of Patriot Scientific Corporation, a Delaware corporation (the “Company”), to be resold by the selling shareholders set forth in the registration statement.
 

For purposes of rendering this opinion, we have made such legal and factual examinations as we have deemed necessary under the circumstances and, as part of such examination, we have examined, among other things, originals and copies, certified or otherwise, identified to our satisfaction, of such documents, corporate records and other instruments as we have deemed necessary or appropriate. For the purposes of such examination, we have assumed the genuineness of all signatures on original documents and the conformity to original documents of all copies submitted to us.

On the basis of and in reliance upon the foregoing examination and assumptions, we are of the opinion that assuming the Registration Statement shall have become effective pursuant to the provisions of the Securities Act of 1933, as amended, the shares of Common Stock being offered under the Plan, when issued in accordance with the Registration Statement and the provisions of the Plan, will be validly issued, fully paid and non-assessable.

We hereby consent to the filing of this opinion as an exhibit to the Registration Statement
 
Very truly yours,

/s/ Luce, Forward, Hamilton & Scripps LLP

LUCE, FORWARD, HAMILTON & SCRIPPS llp
 
 
 

 

GRAPHIC 3 logo.jpg GRAPHIC begin 644 logo.jpg M_]C_X``02D9)1@`!`@$`2`!(``#_X0MK17AI9@``34T`*@````@`!P$2``,` M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q M``(````;````<@$R``(````4````C8=I``0````!````I````-````!(```` M`0```$@````!061O8F4@4&AO=&]S:&]P($-3(%=I;F1O=W,`,C`P-CHP-CHR M-R`P,CHQ,3HQ-0```````Z`!``,````!``$``*`"``0````!````>*`#``0` M```!````)0`````````&`0,``P````$`!@```1H`!0````$```$>`1L`!0`` M``$```$F`2@``P````$``@```@$`!`````$```$N`@(`!`````$```HU```` M`````$@````!````2`````'_V/_@`!!*1DE&``$"`0!(`$@``/_M``Q!9&]B M95]#30`!_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)#!$+"@L1%0\, M#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P, M#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,#!$,#`P,#`P, M#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`)0!X`P$B``(1`0,1`?_=``0` M"/_$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$``04!`0$!`0$` M`````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!``(1`P0A$C$% M05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D M1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F M]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#(3$2!$%187$B M$P4R@9$4H;%"(\%2T?`S)&+A7U5F9VAI:FML;6YO8G-T=7 M9W>'EZ>WQ__:``P#`0`"$0,1`#\`ZWZO8N,SZT=;V5-;Z+JA5`'L#VN-GI_N M;_Y*UKNH9;.NT=.:VOT+J7W%YW;QL+6.9SM]WJ+#Z/U7I]'UDZU;=G]6?->!;7D8KG]9JXYQ$*!`_62NOW?=;V9UJS`MSGY89]EQ&5FH,G MU'NMW-95J=GTV;446==`ILL9CP]S1;2P/+JVNTW"[=MM]+_"?HJUD]:P[^K8 MF=DX`]8,LQWT;>+?L^Y]OI?O?SNQG_"5K6;U_IEE-5E5H>^YS6BF8L;)_2>K M6??5Z#=S[=ZCE`<,3&-ROAF/W?1'_%_37B7J(E*AO'^MZI?^@M7I?5>KYU9N M]/'#&9+L:Q@+@XACMEEE9<=OT?TFQ;?.A7']!OZ537=F77.&35FY#ZJ0YWZ0 M6%U=7IXY/IN]3U?99L78$@"3H!RAS$1&9`%#7I2<$C*-DV?.WB>F5?5]F3UU MG4A0UE>2]M3'[0X,]WMQV_3_`*OIK?QE=.1D7`NEY;^CJ9 M76ZOW;&[[7^HLGZNLZ=G9_7*;@RS[3DO=5N`W.K.X>I2YP_Z3%=Z>6=(ZYU- MF:\559[VY&-<\[6.@;;JO4=[?4K_`'%/FUE,:F48QE&,OENL?RQ_QV+%I&)T M$92E$R&_Z?S'_$5D?6/*IZ;G6^C6W/Z98UF322XL(>1Z=M3Q[MEK7[V[E#J' MUAZIA69>,<>JS(Q*6Y8[>P-VOP76_ M1]OTZFH>WC$>+A$JU,?*.&4X_P"!Q95<>0RX>(QO3B_PLL82_P`/AQI[.N9X MS/LE3:'NR&56]/=#XM98Z+G.U]GV>O\`2N_D)=0Z]F8&-E93ZJ[:ZK130&[@ M7;0'95K]7;64_IO^VEBBOJ>`VJUE;K#]7;SCL'>^G((#8/YOI568ZU#@C,L? MTQN2&?8\9S,EP#7;[,F3DG])/T=O_@Z!QXXF)(!C^E]/[O[\?:_\-4)Y""+( ME^C]?[W[OZS_`,*=#JW4-(?4_VO]S7?G+,9GUYO3.@5W7&N^G)%5Y:=KV^FRVGU MMWYK7_H_TG\M0RK#B?5SJ_1\L1GUN+O5(]V2VQX>S)'^ELV^RS]Q.C@B.&,H MW(2`/]WW."4O[JI9I'BD#0,21Y^WQ"/]YZ"_J^;T\8]W4:ZW8F0YK'7TEP-3 MG_0]6JS=NJ<[V^HQ_P#825+K%U?6.F8_2^G.^T6Y#J38]FK:JV%MEEMS_HL^ MAM]/^<24?MQ]N^'];Q5P?ZO_`#G!_P`Q=QRXZXOU=7Q_U_W.)__0]+9F.L=M MK:TP\LU=V@EKM!_)CW;^\CM]&);M@';(C0MENW^RF_ M0[A]'<"=O$S^="2FLWJ,5M>:X:9[\0&EO(_>?L4QDD-?::_:UQ9(F3!+/W?W MD1[\2M[:K"QK[-&,,`NB!HW_`#5("G7:&^[W&(U_E):J8UWN+WML`9L$\S(_ M./"A3E/N`_EM1HJ&YQ#1(]QTU'\I.WTY]L2.8B=?]R2D- MF6VND6N`$N+8GP)#C_FMW)AE-?=Z!9+I@SQIN_[[L=_UQ$!QMQ:-F[7<-)TC M?/\`GJ45-,^T$=]/+_S%)2C:T6BJ#N+2X&#$#3Z2#9DO;:ZMK`=NT`F>7G:W M\W:CFQ@,%P!B8)[)%M;I!`,_2^7BDIK#-EI(9K$\]PUS_#^0D,Z8(9[>':Z@ MRVN./WG(OJ8@J]?=7Z0$>IIMCZ.W"':?G<&?Y:-%5A`,UXK98Z ML0\%Q$D':-O[S?=])$NO=63#0Z-NWF?<=O$*6W''9@VZCC2--RD6U/)D-<[2 M>"8Y""FO]KLV.>UC2UK6NT)_.&Z/HI*P:ZR(+1',1\DDE/\`_]'O;&L]$[K' M>G]JMV`,$@S=ZS7?I/,7T&^Z_TOL]D^UD M^GO]V[W^IO\`Z/L_D>FK/2Q2,D?9G$G8-PH_TOH;?_!$G#%^ MT6>H^SUO2&_I_4_0I\`4>KE?9W7;O1,RUL[H'T/=_/;/27S M@D@;X3\W_-I(KB'R_P#.M^CL-M7[&L!L<<;>/1<]D`-EFSTF,M-KF;_YK])] MJW_\*@WMQOLI^T/MG?7O]C/6W>GIZOZ3Z"^=TD1?$=_F.W!:C5#;Y?ZS]%7# MINYWJNL+X=MVM`'\_?OV^[^O]/\`,_X16:!B>CF_9G.](TMG:W4#T_;&]^Y] MGI[?]&OFQ)`W7Z7_`#:W4*O]'_G7L_2EPJ%S/M+WN'VD0&M@>IZ8_EO=Z7]5 M)?-:2&M==OZO"NTOIO\`UN)__]G_[1`F4&AO=&]S:&]P(#,N,``X0DE-!"4` M`````!``````````````````````.$))30/M```````0`$@````!``$`2``` M``$``3A"24T$)@``````#@`````````````_@```.$))300-```````$```` M>#A"24T$&0``````!````!XX0DE-`_,```````D```````````$`.$))300* M```````!```X0DE-)Q````````H``0`````````".$))30/U``````!(`"]F M9@`!`&QF9@`&```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````& M```````!`#4````!`"T````&```````!.$))30/X``````!P``#_________ M____________________`^@`````_____________________________P/H M`````/____________________________\#Z`````#_________________ M____________`^@``#A"24T$`````````@`!.$))300"```````$`````#A" M24T$"```````$`````$```)````"0``````X0DE-!!X```````0`````.$)) M300:``````-)````!@``````````````)0```'@````*`%4`;@!T`&D`=`!L M`&4`9``M`#$````!``````````````````````````$``````````````'@` M```E``````````````````````$`````````````````````````$`````$` M``````!N=6QL`````@````9B;W5N9'-/8FIC`````0```````%)C=#$````$ M`````%1O<"!L;VYG``````````!,969T;&]N9P``````````0G1O;6QO;F<` M```E`````%)G:'1L;VYG````>`````9S;&EC97-6;$QS`````4]B:F,````! M```````%7!E96YU;0````I%4VQI8V54>7!E`````$EM9R`` M```&8F]U;F1S3V)J8P````$```````!28W0Q````!`````!4;W`@;&]N9P`` M````````3&5F=&QO;F<``````````$)T;VUL;VYG````)0````!29VAT;&]N M9P```'@````#=7)L5$585`````$```````!N=6QL5$585`````$```````!- M'1415A4`````0``````"6AOD%L:6=N````!V1E9F%U;'0````)=F5R=$%L M:6=N96YU;0````]%4VQI8V5697)T06QI9VX````'9&5F875L=`````MB9T-O M;&]R5'EP965N=6T````115-L:6-E0D=#;VQO)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6U MQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$``@(!`@0$`P0%!@<'!@4U M`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?56 M9G:&EJ:VQM;F]B7I[?'_]H`#`,!``(1`Q$`/P#K?J]BXS/K1UO9 M4UOHNJ%4`>P/:XV>G^YO_DK6NZAELZ[1TYK:_0NI?<7G=O&PM8YG.WW>HL/H M_5>GT?63K5MUS657NJ--AG:[8TM?L?\`1]JLV]4QW=9Z?U9\UX%M>1BMR'`A MH(>ST['D_P`VR_TG^GO5S)"4LEF)(]J-7^_[-Z?UFKCG$0H$#]9*Z_=]UO9G M6K,"W.?EAGV7$96:@R?4>ZW)>HB4J&\ M?ZWJE_Z"U>E]5ZOG5F[T\<,9DNQK&`N#B&.V665EQV_1_2;%M\Z%GCD^F[U/5]EFQ=@2`).@'*',1$9D`4->E)P2 M,HV39\[>)Z95]7V9/76=2%#65Y+VU,?M#@SW>W';]/\`J^FM_%RLAUIZ5TYS M".FU5UY&1<"Z7EOZ.IE=;J_=L;OM?ZBR?JZSIV=G];9[M[`W:_!=;]'V_3J:A[>,1XN$2K4Q\HX93C_`('%E5QY#+AXC&]. M+_"RQA+_``^'&GLZYGC,^R5-H>[(95;T]T/BUECHN<[7V?9Z_P!*[^0EU#KV M9@8V5E/JKMKJM%-`;N!=M`=E6OU=M93^F_[:6**^IX#:K65NL/U=O..P=[Z< M@@-@_F^E59CK4.",RQ_3&Y(9]CQG,R7`-=OLR9.2?TD_1V_^#H''CB8D@&/Z M7T_N_OQ]K_PU0GD((LB7Z/U_O?N_K/\`PIT.K=1R\6W!9BBIS*0-`Q)'G[?$(_WGH+^KYO3Q MCW=1KK=B9#FL=?27`U.?]#U:K-VZISO;ZC'_`-A)4NL75]8Z9C]+Z<[[1;D. MI-CV:MJK86V66W/^BSZ&WT_YQ)1^W'V[X?UO%7!_J_\`.<'_`#%W'+CKB_5U M?'_7_HQ6UYKAIGOQ`:6\C]Y^Q3&2 M0U]IK]K7%DB9,$L_=_>1'OQ*WMJL+&OLT8PP"Z(&C?\`-4@*==H;[O<8C7^4 MEJIC7>XO>VP!FP3S,C\X\*%.4^YS-K6[7AQ/NDC:1X#^6U&BH;G$-$CW'34? MRD[?3GVQ(YB)U_W)*0V9;:Z1:X`2XMB?`D./^:WI14TS[01WT\O_,4E*-K1:*H.XM+@8,0-/I(- MF2]MKJVL!V[0"9Y>=K?S=J.;&`P7`&)@GLD6UND$`S]+Y>*2FL,V6DAFL3SW M#7/\/Y"0SI@AGMX=KJ#+:XX_>-AX(=I M^=P9_EHT56$`S7BMECJQ#P7$20=HV_O-]WTD2Z]U9,-#HV[>9]QV\0I;<<=F M#;J.-(TW*1;4\F0USM)X)CD(*:_VNS8Y[6-+6M:[0G\X;H^BDK!KK(@M$]L:ST3NL=Z?VJW8`P2#-WK-=^D]S?I^F]-0VG[52:GCU9O],.8 M.99N; M)^AXQ?0;[K_2^SV3[63Z>_W;O?ZF_P#H^S^1Z:L]+%(R1]F<2=@W!S0"&;:) MW[7N=O\`H>G_`.A*^;TD3='YNN_#2!5C;IMQ6_166,'[3F;G7;XL]<-:-NS] M4]79ZC_2^AM_\$2<,7[19ZC[/6](;]S6Q.RC?/Z3^?4VRQLAOVAD[]UGO9ZG]3]"GP!1ZN5]G==N M]$S+6SN@?0]W\]L])?."2!OA/S?\VDBN(?+_`,ZWZ.PVU?L:P&QQQMX]%SV0 M`V6;/28RTVN9O_FOTGVK?_PJ#>W&^RG[0^V=]>_V,];=Z>GJ_I/H+YW21%\1 MW^8[<%J-4-OE_K/T5<.F[G>JZPOAVW:T`?S]^_;[OZ_T_P`S_A%9H&)Z.;]F M<[TC2V=K=0/3]L;W[GV>GM_T:^;$D#=?I?\`-K=0J_T?^=>S]*7"H7,^TO>X M?:1`:V!ZGIC^6]WI?U4E\UI(:UUV_J\*[2^F_P#6XG__V0`X0DE-!"$````` M`%,````!`0````\`00!D`&\`8@!E`"``4`!H`&\`=`!O`',`:`!O`'`````2 M`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P`"``0P!3`````0`X0DE- M!`8```````<``P````$!`/_A%_EH='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q M+C`O`#P_>'!A8VME="!B96=I;CTG[[N_)R!I9#TG5S5-,$UP0V5H:4AZDY48WIK8SED)S\^"CQX.GAM<&UE=&$@>&UL;G,Z>#TG861O8F4Z;G,Z;65T M82\G('@Z>&UP=&L])UA-4"!T;V]L:VET(#,N,"TR."P@9G)A;65W;W)K(#$N M-B<^"CQR9&8Z4D1&('AM;&YS.G)D9CTG:'1T<#HO+W=W=RYW,RYO&UL;G,Z:5@])VAT='`Z+R]N&UL;G,Z<&AO=&]S:&]P/2=H='1P.B\O;G,N861O M8F4N8V]M+W!H;W1O3X*(#PO&%P.DUE=&%D871A1&%T93X*("`\>&%P.D-R96%T;W)4 M;V]L/D%D;V)E(%!H;W1O&UL;G,Z>&%P34T])VAT='`Z+R]N&%P M+S$N,"]M;2\G/@H@(#QX87!-33I$;V-U;65N=$E$/F%D;V)E.F1O8VED.G!H M;W1O&UL;G,Z9&,])VAT='`Z+R]P=7)L M+F]R9R]D8R]E;&5M96YT&UP;65T83X*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`* M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@"CP_>'!A8VME="!E;F0])W0``9&5S8P`````` M```2D!\@'Z`@,"#`(4`AT")@(O`C@"00)+`E0"70)G`G$" M>@*$`HX"F`*B`JP"M@+!`LL"U0+@`NL"]0,``PL#%@,A`RT#.`-#`T\#6@-F M`W(#?@.*`Y8#H@.N`[H#QP/3`^`#[`/Y!`8$$P0@!"T$.P1(!%4$8P1Q!'X$ MC`2:!*@$M@3$!-,$X03P!/X%#044%]@8&!A8&)P8W!D@&609J!GL&C`:=!J\&P`;1!N,&]0<'!QD'*P<]!T\' M80=T!X8'F0>L![\'T@?E!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(^PD0 M"24).@E/"60)>0F/":0)N@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+ M"PLB"SD+40MI"X`+F`NP"\@+X0OY#!(,*@Q##%P,=0R.#*<,P`S9#/,-#0TF M#4`-6@UT#8X-J0W##=X-^`X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>#WH/ ME@^S#\\/[!`)$"800Q!A$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F M$D429!*$$J,2PQ+C$P,3(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.%/`5 M$A4T%585>!6;%;T5X!8#%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@; M&$`891B*&*\8U1CZ&2`911EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[&V,; MBANR&]H<`APJ'%(<>QRC',P<]1T>'4<=:AZ4'KX>Z1\3 M'SX?:1^4'[\?ZB`5($$@;""8(,0@\"$<(4@A=2&A(B>K)]PH#2@_*'$HHBC4*08I."EK*9TIT"H"*C4J:"J;*L\K`BLV*VDK MG2O1+`4L.2QN+*(LURT,+4$M=BVK+>$N%BY,+H(NMR[N+R0O6B^1+\<-] M1B)&9T:K1O!'-4=[1\!(!4A+2)%(UTD=26-)J4GP2C=*?4K$2PQ+4TN:2^), M*DQR3+I-`DU*39--W$XE3FY.MT\`3TE/DT_=4"=0<5"[40914%&;4>92,5)\ M4L=3$U-?4ZI3]E1"5(]4VU4H5755PE8/5EQ6J5;W5T17DE?@6"]8?5C+61I9 M:5FX6@=:5EJF6O5;15N56^5<-5R&7-9=)UUX7&EYL7KU?#U]A7[-@!6!7 M8*I@_&%/8:)A]6))8IQB\&-#8Y=CZV1`9)1DZ64]99)EYV8]9I)FZ&<]9Y-G MZ6@_:)9H[&E#:9II\6I(:I]J]VM/:Z=K_VQ7;*]M"&U@;;EN$FYK;L1O'F]X M;]%P*W"&<.!Q.G&5&YXS'DJ>8EYYWI&>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_A'_E M@$>`J($*@6N!S8(P@I*"](-7@[J$'82`A..%1X6KA@Z&I+CDTV3MI0@E(J4])5?EAMJ(FHI:C!J-VH^:D5J3' MI3BEJ:8:IHNF_:=NI^"H4JC$J3>IJ:H_R#W(O,DZR;G*.,JWRS;+MLPUS+7--$S%F+P)'*"\25#-%.2HK)C<\(U1">3H[,V%U1D M=,/2X@@F@PD*&!F$E$5&I+16TU4H&O+C\\34Y/1E=865I;7%U>7U9G:&EJ:V MQM;F]C='5V=WAY>GM\?7Y_(B8J+C(V.CX*3E)66EYB9FINGM\?7Y_(B8J+C(V.CX.4E9:7F)F:FYR=GI^2HZ M2EIJ>HJ:JKK*VNKZ_]H`#`,!``(1`Q$`/P";>6K2UC\W>8.$*+Z#0B$``!`Z ML9/3_DY_M<IYAM],58OJ\T#SESRYCTV5 M&3KQ^+U,QHXXG&9?Q1EPN09GC$>E*-[KTFG3:C)>*GU.S2)H1'7U9'F+*D6Y MX?;3CDH8>,1$?KGQ?[!C++PF5_3!763S"H@EDCMJ2.HGMT#EHU;;D)N7&7TJ M_O/W4>1K'N/4RN>WTH+2-8UK4(C/Z5L(X[MK66,%PY6-^$DD98\:\?WG#+,N M*$#7J^CC88\DY;^GZN!D)`(H>F8CDO/M)A\MQW7F./5%MUCBNI%A20J'"#E\ M-NI^/_5]/-OE.3AQ\/%]'XXW68XX[GQ0Z5J$WH1+J>E2+ M'=P,6,;*Y`CEBI>9M7L)+V MU:VAENK.!;T,A?@]N6].4\?M1RPGX_M/ZB8<>GA+A-RX9R\/_DHB>>4;%#BA M'Q/\Q7E\P:B+[ZG$MN[W,<,VF/1Z3)(U)F;?X/J\?[UO\C(C!'AXCQ>GB\7^ MA_TFR.:5T.'UQZ3JMP;>,7VD2^E<1\F,3C:CQ/\`"_Q*WV6R MT:8&<1?HS-9SD1D:]6)%SZU?Z:+:?4XHFL;ADC:Y@+`Q/)]CU8I.7*)F^'U$ M?_897'#&=B/UQ_G?QLSEE&C+Z)/_T)?HFKZ;;^:=?FGG6.&X:$P2M7@_!2K\ M'^R>)S9YL4CBQ@#Z>)U^+)$9)DGZD5+J]LVN:9K+@Q:9+'=6BW+@A`0Z>G(Y M(_=I/Z3^GSRL8CXN"S7K&XUBSU&ZTX>L$DMGM^.XF^ MK2 M=E405I*M3^\]6,_'%Z"\GEY_R9CG!,$V/I;_`!HTQKR[<:/!'/>S3L+N&_N7 MA@#N3()2T<7IVY/IMZGJ_!(J?[/,S41F2`!Z?#A^.-Q,)B+)^KCDSHD`5.P& MY.:QV+"?+,>EZAJ/F&"<1R?6KIVAY`8-6COY!##J+I=6EQ(>*-1>,T7J-\(DC/['\F4Y/WF.'#SQ^B M;;#T3EQ?Y3U02?6(N>G^9=6J1;ZBUO#9`@@R"`HKRHOVF5VY^G_D)ZF9.(U+ M'#^+%Q\?_)1Q\L?3DE_JG#P?YB::8L=GKUY:7I-S;ZO&KV-_(>9=`O%[%I?L M_#]N)?VLQ\GJQ@Q],L/]YC_Z>M\/3,@^J.7Z)_\`3M*%BU;3DAF2)I6\M7#6 ML8[W$%T0%`/[/I126^9%PG8O_&H\?_"LF+\3:*E'?_E'EP?\,AD3AM/%]*^D MK=A/J5HR73!5?G+=U-R?WE>/'C]K_B_,83X?77US]'_)+Z&_@XO3?T0_Z:_6 ME2:E%?Z3Y:BFG,5S!=+%<%6XNGIQRPB;E^RK_N_WG^7F0CCJ<3E_6(^*[660.ER.\LG'X)/Y,,1Q983C_`'?_`$Q_ MH(D>''*!^O\`Z:IOK<\6MZ3;:3IC"XFN6@,KIND,:,LDDLS_`&4^QQ6/^\RC M"/#F9R]/!Q?Y[=E(R0$8^KBX7__1ZTEZTK\8E4T->)8JU&)VY^CW7^;%5-=3I$CF*BGET.PH%*]0/VGX8JJ"Z(628Q#BK%*BO( MT)0=5'[7'%56.=C)(DBA.`!ZUJ*?$>G3%5."\>=H^*KP<,2>52.)'@*?MKBK M))/]7*`M4@UZ;%O^->#?\],55S*HF$- M&Y%2P-#QH#3[7CBJC+=.LS1J@(7@`23U<\5_9XXJL%_521'O2M*]PC/X?Y&* MN&H5HP3X>CU.X/)8Z4IV9L5:%]((DE:,4<%B*D'B./3DHY-\6*JT]P\1:BAB M`O#K6K'CT`_XCBJE]@'_`#3@2XR1@T+`&E:$ MCH.^&D6XK&W($`U^UTWIXX$J7JV0A^LA5MOVNA!_R\:6W<;84V0!?B'3:FW+!2VV4A=C4*S4%>A-.HQ2V8HB*%!3 MK2FVPIBK_]/I,JIZ)Y2-Z1NY2@$:U!K-ZRL?4^)?M^F__"9D#_>?\2XYY?YW M_%+;=8/KD!BD'K5N#$&0=:IR69DDY>K_`)3K_L,976_]%$:O;^DBKP0?74]= MI/7^J2_W8/&GP^H3Q;CR_P!]K)\&1C=;?SVCR^MZ)XE$7C_ M`'IXF`*A M]/X\1A+AL_5^/#;=;3ZS+ZKR_6/1'J$'.O[S^\X^CSR._#_`$>)35^? M_2*K2.@ M"\DX>DB2F5DY_P!U^\^M<_\`BW#/Z_Z7X_'\Q8UP?T?Q^/YZA<+:?4S]9DE) MYQ<_@3U^?I;>K23[&2C=[C<"J@#_>B?GQ^+_7^W M^Q_Q9D8\73\>B*RX>OX]GQ_WWD3=Q MO^_P#_ !V3\_ ` end EX-10.40 4 v046258_ex10-40.htm
EXHIBIT 10.40
 

 

 

MASTER AGREEMENT
 

 
by and among
 

 
PATRIOT SCIENTIFIC CORPORATION
 
and
 
TECHNOLOGY PROPERTIES LIMITED INC.
 
and
 
CHARLES H. MOORE
 

 

 
Dated as of June 7, 2005
 

 

 

 

 
***
Indicates material omitted pursuant to an application for confidential treatment and that material has been filed separately with the Commission.
 


 
TABLE OF CONTENTS
 
Page
 
ARTICLE I
DEFINITIONS
3
1.1
Definitions
3
1.2
Index of Other Defined Terms
5
     
ARTICLE II
THE TRANSACTIONS
5
2.1
Execution of Ancillary Agreements
5
2.2
Formation of Delaware Limited Liability Companies
6
2.3
Patriot License to Intel
6
2.4
Stipulated Final Judgment
6
2.5
Delivery of Intel Proceeds
6
2.6
Closing
6
2.7
Actions at Closing
6
     
ARTICLE III
REPRESENTATIONS AND WARRANTIES OF PATRIOT
7
3.1
Corporate Existence and Power
7
3.2
Authorization
7
3.3
Governmental Authorization
7
3.4
Non-Contravention
7
3.5
Absence of Certain Changes or Events.
8
3.6
Intellectual Property.
8
3.7
Litigation
8
3.8
Advisory Fees
9
3.9
Bulk Sales
9
     
ARTICLE IV
REPRESENTATIONS AND WARRANTIES OF TPL
9
4.1
Organization and Existence
9
4.2
Corporate Authorization
9
4.3
Governmental Authorization
9
4.4
Non-Contravention
9
4.5
Absence of Certain Changes or Events.
10
4.6
Intellectual Property.
10
4.7
Litigation
10
4.8
Advisory Fees
11
4.9
Bulk Sales
11
     
ARTICLE V
REPRESENTATIONS AND WARRANTIES OF MOORE
11
5.1
Authorization
11
5.2
Governmental Authorization
11
5.3
Non-Contravention
11
5.4
Absence of Certain Changes or Events.
11
5.5
Intellectual Property.
11
5.6
Litigation
12
5.7
Advisory Fees
12
 
 
-i-

 
ARTICLE VI
COVENANTS OF PATRIOT
12
6.1
Court Approval of Stipulated Final Judgment
12
6.2
Retention of Rights; No Action With Respect to the MSD Patents
12
     
ARTICLE VII
COVENANTS OF ALL PARTIES
13
7.1
Protection and Maintenance of the MSD Patents
13
7.2
Commercialization Program.
13
7.3
Further Assurances
13
7.4
Certain Filings
14
7.5
Notification
14
7.6
Public Announcements
14
7.7
No Interference
14
7.8
No Transfer
15
7.9
Litigation Cooperation
15
     
ARTICLE VIII
CONDITIONS TO CLOSING
15
8.1
Conditions to Obligations of Each Party
15
8.2
Conditions to Obligations of TPL
16
8.3
Conditions to Obligations of Patriot
16
     
ARTICLE IX
INDEMNIFICATION
17
9.1
Patriot Agreement to Indemnify
17
9.2
TPL Agreement to Indemnify
17
9.3
Moore Agreement to Indemnify
18
9.4
Survival of Representations, Warranties and Covenants
18
9.5
Claims for Indemnification
18
9.6
Defense of Claims
18
     
ARTICLE X
TERMINATION
19
10.1
Grounds for Termination
19
10.2
Effect of Termination.
21
     
ARTICLE XI
MISCELLANEOUS
21
11.1
Notices
21
11.2
Amendments; No Waivers.
23
11.3
Expenses
23
11.4
Successors and Assigns
23
11.5
Governing Law
23
11.6
Counterparts; Effectiveness
23
11.7
Entire Agreement
23
11.8
Captions
24
11.9
Severability
24
11.10
Construction
24
11.11
Cumulative Remedies
24
11.12
Specific Performance
24
11.13
Third-Party Beneficiaries
24
11.14
No Liability of Intel
24
11.15
No Punitive, Exemplary, or Consequential Damages
25
 
 
-ii-

 
EXHIBITS
 
EXHIBIT A Stipulated Final Judgment
EXHIBIT B Operating Agreement (Exhibit 10.42)
EXHIBIT C Newco License
EXHIBIT D Commercialization Agreement (Exhibit 10.41) ***
EXHIBIT E Escrow Agreement ***
EXHIBIT F-1 Consent and Release Agreement
EXHIBIT F-2 Consent and Release Agreement
EXHIBIT G Form of Merger Agreement
EXHIBIT H Patriot License to Intel ***
EXHIBIT I Form of Warrant
EXHIBIT J Form of Registration Rights Agreement
 
-iii-

 
AGREEMENT
 
This AGREEMENT (this “Agreement“), dated as of June 7, 2005, is by and among PATRIOT SCIENTIFIC CORPORATION, a Delaware corporation having its principal offices located at 10989 Via Frontera, San Diego, CA 92127 (“Patriot”), TECHNOLOGY PROPERTIES LIMITED INC., a California corporation having its principal offices located at 21730 Stevens Creek Blvd., Suite 201, Cupertino, CA 95014 (“TPL”), and Charles H. Moore, an individual whose principal residence is in Sierra County, California (“Moore”).
 
R E C I T A L S
 
WHEREAS, Patriot is engaged in the business of developing, marketing, and selling microprocessors and microprocessor technology, as well as other complementary products;
 
WHEREAS, TPL is engaged in the business of developing, managing, and commercializing intellectual property assets and proprietary product technology;
 
WHEREAS, Patriot, TPL and Moore are involved in the Inventorship Litigation (as defined below) with respect to the ownership of rights and interests in certain microprocessor science and design patents identified on Schedule 1 attached hereto (the “MSD Patents”);
 
WHEREAS, Patriot has initiated the Infringement Litigation (as defined below), which has been stayed pending the outcome of the Inventorship Litigation;
 
WHEREAS, the Patriot security holders identified on Schedule 2 attached hereto (the “Patriot Rights Holders”) have certain rights with respect to the transactions contemplated by this Agreement;
 
WHEREAS, to resolve the Inventorship Litigation and disagreements among the parties, provide funds to Patriot to finance its operations, and provide for the effective commercialization of the MSD Patents, the parties have agreed that:
 
A. Patriot, TPL and Moore will enter into this Agreement; Patriot and TPL will enter into the Operating Agreement attached hereto as Exhibit B (the “Operating Agreement”); Patriot, TPL, and P-Newco will enter into the Commercialization Agreement attached hereto as Exhibit D (the “Commercialization Agreement”); Patriot and TPL will enter into the Warrant substantially in the form attached hereto as Exhibit I (the “Warrant”), as well as the Registration Rights Agreement substantially in the form attached hereto as Exhibit J (the “Registration Rights Agreement”) ; and Patriot and TPL will open an escrow account (the “Escrow Account”) and enter into an escrow agreement substantially in the form attached hereto as Exhibit E (the “Escrow Agreement”) to facilitate the transactions contemplated by this Agreement;
 
B. Patriot has entered into a license in respect of the MSD Patents with Intel Corporation (“Intel“), attached hereto as Exhibit H (the “Patriot License to Intel”);
 
C. As soon as possible after the date hereof, Patriot, TPL and Moore will settle all litigation among them pursuant to the Stipulated Final Judgment substantially in the form attached hereto as Exhibit A (the “Stipulated Final Judgment”), and will take any and all action necessary to cause the trade secrets litigation currently pending between Patriot and TPL in Santa Clara Superior Court (the “Trade Secrets Litigation”) to be dismissed without prejudice, and the Infringement Litigation involving Intel and Patriot shall be dismissed with prejudice;
 

 
D. As soon as possible after the date hereof, TPL will request that Intel deliver all of the unpaid Milestone Payments (as defined in the Intel Patent License Agreement) pursuant to Section 3.2 of the Intel Patent License Agreement to the account set forth on Exhibit A to the Escrow Agreement, and the rights of Patriot and TPL with regard to the Milestone Payments shall thereafter be as set forth in the Escrow Agreement;
 
E. Patriot will form a wholly owned subsidiary (“P-Newco”), and Patriot and P-Newco will enter into a license with respect to certain of Patriot’s rights in the MSD Patents, substantially in the form attached hereto as Exhibit C;
 
F. TPL will form a wholly owned subsidiary (“T-Newco”), and TPL and T-Newco will enter into a license with respect to certain of TPL’s rights in the MSD Patents, substantially in the form attached hereto as Exhibit C (collectively with the license entered into between Patriot and P-Newco identified in Recital E above, the “Newco Licenses” );
 
G. Patriot, TPL, T-Newco and P-Newco will enter into an agreement and plan of merger substantially in the form attached hereto as Exhibit G (the “Merger Agreement”) pursuant to which T-Newco will merge with and into P-Newco, with P-Newco continuing as the surviving entity;
 
H. Upon the earlier of (a) the mutual agreement of Patriot, TPL, and P-Newco, or (b) three months from the date hereof, P-Newco will grant to TPL its rights in the MSD Patents (the “Grant”) in furtherance of the commercialization program contemplated by the Commercialization Agreement, in the form attached as Exhibit 1 to the Commercialization Agreement;
 
I. TPL will cause the Patriot Cash Consideration (as defined below) to be paid to Patriot at Closing from the funds in the Escrow Account pursuant to the terms of the Escrow Agreement;
 
J. TPL will cause One Million Dollars ($1,000,000) of TPL’s funds in the Escrow Account, and Patriot will cause at least One Million Dollars ($1,000,000) of Patriot’s funds in the Escrow Account, to be paid in cash at Closing, to the Patriot Rights Holders in exchange for the Patriot Rights Holders entering into a consent and release agreement substantially in one of the alternate forms attached as Exhibits F-1 or F-2 hereto (the “Consent and Release Agreement”);
 

 
K. TPL will cause Two Million Dollars ($2,000,000) of TPL’s funds in the Escrow Account to be contributed in cash at Closing to P-Newco as TPL’s first installment of the Working Capital Contribution;
 
L. Patriot will cause Two Million Dollars ($2,000,000) of Patriot’s funds in the Escrow Account to be contributed in cash at Closing to P-Newco as Patriot’s first installment of the Working Capital Contribution; and
 
M. P-Newco will allocate the proceeds generated from the commercialization program to Patriot and TPL pursuant to the terms of the Commercialization Agreement and the Operating Agreement.
 
A G R E E M E N T
 
NOW, THEREFORE, in consideration of the foregoing premises, and their respective representations, warranties, covenants and agreements hereinafter set forth, the parties hereto agree as follows.
 
ARTICLE I
DEFINITIONS
 
1.1 Definitions. The following terms, as used herein, have the following meanings:
 
“Applicable Law” means any domestic or foreign, federal, state or local statute, law, common law, ordinance, rule, administrative interpretation, regulation, order, writ, injunction, directive, judgment, decree, permit or other requirement of any Governmental Authority.
 
“Business Day” means a day other than a Saturday, Sunday or other day on which commercial banks in San Diego, California are authorized or required by law to close.
 
“Damages” means all demands, claims, actions or causes of action, assessments, losses (including reasonably foreseeable lost profits), damages, costs, expenses, liabilities, judgments, awards, fines, sanctions, penalties, charges and amounts paid in settlement (net of insurance proceeds and proceeds from related third party indemnification, contribution or similar claims actually received), including (a) interest at a rate equal to 200 basis points above the prime rate, as in effect from time to time, of Citibank, N.A., on cash disbursements in respect of any of the foregoing, compounded quarterly, from the date each such cash disbursement is made until the Person incurring the same shall have been indemnified in respect thereof, (b) reasonable costs, fees and expenses of such Person’s Representatives and (c) any reasonable costs, fees and expenses incurred in connection with investigating, defending against, or settling any such claims.
 
“Exchange Act” means the Securities Exchange Act of 1934, as amended.
 
“Governmental Authority” means any foreign, domestic, federal, territorial, state or local governmental authority, quasi-governmental authority, instrumentality, court, government or self-regulatory organization, commission, tribunal or organization or any regulatory, administrative or other agency, or any political or other subdivision, department or branch of any of the foregoing.
 

 
“Gross Cash Proceeds” means all cash proceeds received pursuant to licenses, judgments, settlements and other payments with respect to the right to make, use, sell and offer to sell products subject to the MSD Patents.
 
“Indemnifying Party” means: (a) with respect to any TPL Indemnitee asserting a claim under Section 9.1, Patriot; (b) with respect to any Patriot Indemnitee asserting a claim under Section 9.2, TPL; and (c) with respect to any Patriot/TPL Indemnitee asserting a claim under Section 9.3, Moore.
 
“Indemnitee” means: (a) the TPL Indemnitees with respect to any claim for which Patriot is an Indemnifying Party under Section 9.1; (b) the Patriot Indemnitees with respect to claims for which TPL is an Indemnifying Party under Section 9.2; and (c) the Patriot/TPL Indemnitees with respect to any claim for which Moore is an Indemnifying Party under Section 9.3.
 
“Infringement Litigation” means the lawsuits filed by Patriot against five electronics companies alleging infringement of certain U.S. Patents and assigned the following case numbers: (a) Southern District of New York, 03CV10142; (b) Northern District of California, C035787; (c) Southern District of New York, 03CV10180; (d) Eastern District of New York, CV036432; and (e) District of New Jersey, 03CV06210, including the related claims of Intel against Patriot.
 
“Intel Patent License Agreement” means that certain license agreement by and among TPL Micro Ltd., TPL, Moore and Intel, dated June 28, 2004, as may be amended from time to time.
 
“Inventorship Litigation” means the lawsuit filed by Patriot on February 13, 2004 in the United States District Court, Northern District of California against TPL, Daniel E. Leckrone and Charles H. Moore, alleging claims for declaratory judgment for determination and correction of inventorship and assigned case number C040618JF(HRL).
 
“knowledge” means the actual knowledge of a Person and its Representatives, after a reasonable investigation of the surrounding circumstances.
 
“Liability” means, with respect to any Person, any liability or obligation of such Person of any kind, character or description, whether known or unknown, absolute or contingent, accrued or unaccrued, liquidated or unliquidated, secured or unsecured, joint or several, due or to become due, vested or unvested, executory, determined, determinable or otherwise and whether or not the same is required to be accrued on the financial statements of such Person or is disclosed on any schedule to this Agreement.
 
“Lien” means, with respect to any asset, any mortgage, title defect or objection, lien, pledge, charge, security interest, hypothecation, restriction, encumbrance or charge of any kind in respect of such asset.
 
“Material Adverse Effect” means any circumstance, development, event, condition, effect or change that, individually or when taken together with all other circumstances, developments, events, conditions, effects and changes that have occurred, had or has or, with the passage of time, would be reasonably likely to have, a material adverse effect on, or a material adverse change in, (a) the MSD Patents, (b) the anticipated benefits of the transactions contemplated
 

 
by this Agreement or (c) the ability of the parties hereto to consummate the transactions contemplated hereby.
 
“Net Cash Proceeds” has the meaning set forth in Section 6.1(a)(v) of the Operating Agreement.
 
“Patriot Cash Consideration” means Ten Million Dollars ($10,000,000) minus Two Million Dollars ($2,000,000) (which amount constitutes Patriot’s first installment of the Working Capital Contribution pursuant to Section 5.3(a) of the Operating Agreement) minus Patriot’s share of the Consent and Release Consideration, which represents an allocation and sharing of proceeds to be received from Intel pursuant to Section 3.2(c) of the Intel Patent License Agreement.
 
“Patriot Common Stock” means the common stock, par value $0.00001 per share, of Patriot.
 
“Person” means an individual, corporation, partnership, limited liability company, joint venture, association, trust, estate or other entity or organization, including a Governmental Authority.
 
“Representatives” means the officers, directors, employees, attorneys, accountants, advisors, representatives and agents of a Person.
 
“SEC” means the Securities and Exchange Commission.
 
“Securities Act” means the Securities Act of 1933, as amended.
 
“Working Capital Contribution” shall have the meaning given to it in the Operating Agreement.
 
1.2 Index of Other Defined Terms. In addition to those terms defined above, the following terms shall have the respective meanings given thereto in the sections indicated below:
 
Defined Term Section
Page
”Agreement” Preamble,
3
”Closing Date” 2.6,
9
”Closing” 2.6,
8
”Commercialization Agreement” Recitals,
3
”Consent and Release Agreement” Recitals
4
”Consent and Release Consideration” 2.7(f)
9
”Escrow Account” Recitals,
3
”Escrow Agreement” Recitals,
3
”Grant” Recitals,
4
”Intel Parties” 11.13,
27
”Intel” Recitals,
4
”Merger Agreement” Recitals,
4
”Moore” Preamble,
3
”MSD Patents” Recitals,
3
”Newco Licenses” Recitals,
4
”Operating Agreement” Recitals,
3
”Patriot Indemnitees” 9.2,
20
”Patriot License to Intel” Recitals,
4
”Patriot Rights Holders” Recitals,
3
”Patriot/TPL Indemnitees” 9.3,
20
”Patriot” Preamble,
3
”P-Newco” Recitals,
4
”Proceedings” 3.7,
11
”Registration Rights Agreement” Recitals,
3
”Stipulated Final Judgment” Recitals,
4
”Termination Date” 10.1,
22
”T-Newco” Recitals,
4
”TPL Indemnitees” 9.1,
19
”TPL” Preamble,
3
”Trade Secrets Litigation” Recitals,
4
”Warrant” Recitals, 3
 
 
 


ARTICLE II
THE TRANSACTIONS
 
2.1 Execution of Ancillary Agreements. As soon as possible after the date hereof, and in any event not later than the Closing Date, Patriot, TPL, Moore and P-Newco shall enter into the following agreements, as the case may be:
 
(a) Patriot and TPL shall enter into the Operating Agreement;
 
(b) Patriot, TPL and P-Newco shall enter into the Commercialization Agreement;
 
(c) Patriot and TPL shall enter into the Warrant and the Registration Rights Agreement;
 
(d) Patriot, TPL and Premier Trust, Inc. as the Escrow Agent shall enter into the Escrow Agreement to facilitate the transactions contemplated hereby.
 
2.2 Formation of Delaware Limited Liability Companies. As soon as possible, and to effect the transactions contemplated hereby:
 
(a) Patriot will form P-Newco, a wholly owned Delaware limited liability company, and
 
(b) TPL will form T-Newco, a wholly owned Delaware limited liability company.
 
2.3 Patriot License to Intel. Patriot has entered into the Patriot License to Intel.
 
2.4 Stipulated Final Judgment. As soon as possible after the date hereof, Patriot, TPL and Moore shall enter into the Stipulated Final Judgment and file it promptly thereafter with the court.
 
2.5 Delivery of Intel Proceeds. As soon as possible after the date hereof, TPL shall request that Intel deliver all of the unpaid Milestone Payments (as defined in the Intel Patent License Agreement) pursuant to Section 3.2 of the Intel Patent License Agreement to the account set forth on Exhibit A to the Escrow Agreement, and the rights of Patriot and TPL with regard to the Milestone Payments shall thereafter be as set forth in the Escrow Agreement.
 

 
2.6 Closing. The closing (the “Closing”) of the transactions contemplated by this Agreement shall take place at the offices of Gibson, Dunn & Crutcher LLP, 333 South Grand Avenue, Los Angeles, California 90071, on June 14, 2005 or, if the conditions to Closing set forth in Article VIII (other than conditions that by their terms can only be satisfied on the Closing Date) have not been satisfied or waived by such date, then on the second Business Day after the last of the conditions to Closing set forth in Article VIII (other than conditions that by their terms can only be satisfied on the Closing Date) have been satisfied or waived by the party entitled to waive the same or on any such other date as to which TPL and Patriot may mutually agree in writing (the “Closing Date”).
 
2.7 Actions at Closing. At Closing:
 
(a) Each of Patriot and TPL shall deliver to the other party executed copies of this Agreement, the Escrow Agreement, the Operating Agreement, the Commercialization Agreement, the Newco Licenses, the Merger Agreement, and the Grant attached as Exhibit 1 to the Commercialization Agreement;
 
(b) The Certificate of Merger shall be filed with the Secretary of State of the State of Delaware;
 
(c) The officer’s certificates contemplated by Sections 8.2(a)(iii) and 8.3(a)(iii) shall be delivered by Patriot and TPL, respectively;
 
(d) Patriot shall deliver to TPL the Consent and Release Agreements executed by all of the Patriot Rights Holders;
 
(e) TPL will cause One Million Dollars ($1,000,000) of TPL’s funds in the Escrow Account, and Patriot will cause at least One Million Dollars ($1,000,000) of Patriot’s funds in the Escrow Account, to be paid in cash at Closing to the Patriot Rights Holders set forth on Schedule 2 pursuant to the terms of the Escrow Agreement (the “Consent and Release Consideration”);
 
(f) TPL will cause Two Million Dollars ($2,000,000) of TPL’s funds in the Escrow Account to be contributed in cash at Closing to P-Newco as TPL’s first installment of the Working Capital Contribution;
 
(g) Patriot will cause Two Million Dollars ($2,000,000) of Patriot’s funds in the Escrow Account to be contributed in cash at Closing to P-Newco as Patriot’s first installment of the Working Capital Contribution; and
 
(h) TPL shall cause all Net Cash Proceeds generated pursuant to Section 7.2(b), if any, to be paid to P-Newco.
 

 
ARTICLE III
REPRESENTATIONS AND WARRANTIES OF PATRIOT
 
As an inducement to TPL to enter into this Agreement and to consummate the transactions contemplated herein, Patriot hereby represents and warrants to TPL that:
 
3.1 Corporate Existence and Power. Patriot is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware and has all corporate power to enter into this Agreement and consummate the transactions contemplated hereby.
 
3.2 Authorization. The execution, delivery and performance by Patriot of this Agreement and the consummation by Patriot of the transactions contemplated hereby are within the corporate powers of Patriot and have been duly authorized by all necessary corporate action on the part of Patriot. This Agreement has been duly and validly executed by Patriot and constitutes the legal, valid and binding agreement of Patriot, enforceable against Patriot in accordance with its terms, except as may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ rights generally and subject to general principles of equity.
 
3.3 Governmental Authorization. The execution, delivery and performance by Patriot of this Agreement require no action by, consent or approval of, or filing with, any Governmental Authority other than any actions, consents, approvals or filings otherwise expressly referred to in this Agreement.
 
3.4 Non-Contravention. The execution, delivery and performance by Patriot of this Agreement does not (a) contravene or conflict with the certificate of incorporation or bylaws of Patriot, a true and correct copy of each of which has been delivered to TPL; (b) contravene or constitute a default or breach under any material agreement to which Patriot is a party; (c) contravene or conflict with or constitute a violation of any provision of any Applicable Law binding upon or applicable to Patriot; or (d) result in the creation or imposition of any Lien on the MSD Patents.
 
3.5 Absence of Certain Changes or Events.
 
(a) Except as set forth on Schedule 3.5(a), as of the date hereof there has not been any change, circumstance, event or proceedings against Patriot that could reasonably be expected to result in a Material Adverse Effect.
 
(b) Except as set forth on Schedule 3.5(b), and except as otherwise contemplated by or disclosed in this Agreement, Patriot has not entered into any contract or agreement in respect of the MSD Patents.
 
3.6 Intellectual Property.
 

 
(a) Except as set forth on Schedule 3.6(a), Patriot owns exclusively all right, title and interest in and to the MSD Patents, free and clear of any and all Liens, encumbrances or other adverse ownership claims, and Patriot has not received any notice or claim challenging Patriot’s ownership of the MSD Patents or suggesting that any Person, other than TPL and Moore, has any claim of legal or beneficial ownership with respect thereto, nor, to Patriot’s knowledge, is there a reasonable basis for any claim that Patriot does not have such good and valid title to the MSD Patents.
 
(b) To the knowledge of Patriot, the MSD Patents are valid, enforceable and subsisting. Except as disclosed in Schedule 3.6(b), Patriot has not received any notice or claim challenging or questioning the validity or enforceability of the MSD Patents or indicating an intention on the part of any Person to bring a claim that the MSD Patents are invalid or unenforceable or have been misused, and to Patriot’s knowledge no reasonable basis exists for any such claim.
 
(c) To the knowledge of Patriot (i) Patriot has not taken any action or failed to take any action (including the manner in which it has conducted its business, or used or enforced, or failed to use or enforce, the MSD Patents) that would result in the abandonment, cancellation, forfeiture, relinquishment, invalidation or unenforceability of the MSD Patents and (ii) subsequent to the acquisition of its interest therein, Patriot has timely paid all filing, examination, issuance, post registration and maintenance fees, annuities and the like associated with or required with respect to the MSD Patents.
 
(d) To the knowledge of Patriot, none of the activities or operations of Patriot with respect to the MSD Patents infringes upon, misappropriates, violates, dilutes or constitutes the unauthorized use of any rights, interests, or property of any third party. Patriot has not received any notice or claim asserting or suggesting that any such infringement, misappropriation, violation, dilution or unauthorized use is or may be occurring or has or may have occurred, nor, to Patriot’s knowledge, is there any reasonable basis therefor. The MSD Patents are not subject to any outstanding order, judgment, decree or stipulation restricting the use, sale, transfer, assignment or licensing thereof by Patriot to any Person.
 
3.7 Litigation. Except as disclosed in Schedule 3.7 (i) there are no actions, suits, claims, hearings, arbitrations, proceedings (public or private) or governmental investigations that have been brought by or against any Governmental Authority or any other Person (collectively, “Proceedings”) pending or, to the knowledge of Patriot, threatened, against or by Patriot or the MSD Patents or which seek to enjoin or rescind the transactions contemplated by this Agreement, nor, to the knowledge of Patriot, is there any valid basis for any such Proceedings; and (ii) there are no existing orders, judgments or decrees of any Governmental Authority naming Patriot as an affected party or otherwise affecting the MSD Patents or the performance by Patriot of the transactions contemplated by this Agreement, nor, to the knowledge of Patriot, is there any valid basis for any such order, judgment or decree.
 
3.8 Advisory Fees. Except as set forth in Schedule 3.8, there is no investment banker, broker, finder or other intermediary or advisor that has been retained by or is authorized to act on behalf of Patriot who is entitled to any fee, commission or reimbursement of expenses from Patriot, TPL or any of their respective Representatives upon consummation of the transactions contemplated by this Agreement or otherwise.
 

 
3.9 Bulk Sales. There are no bulk sales statutes or laws applicable to Patriot or the MSD Patents in connection with the consummation of the transactions contemplated by this Agreement.
 
ARTICLE IV
REPRESENTATIONS AND WARRANTIES OF TPL
 
As an inducement to Patriot to enter into this Agreement and to consummate the transactions contemplated herein, TPL hereby represents and warrants to Patriot that:
 
4.1 Organization and Existence. TPL is a corporation duly incorporated, validly existing and in good standing under the laws of the State of California and has all corporate power to enter into this Agreement and consummate the transactions contemplated hereby.
 
4.2 Corporate Authorization. The execution, delivery and performance by TPL of this Agreement and the consummation by TPL of the transactions contemplated hereby are within the corporate powers of TPL and have been duly authorized by all necessary corporate action on the part of TPL. This Agreement has been duly and validly executed by TPL and constitutes the legal, valid and binding agreement of TPL, enforceable in accordance with its terms, except as may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ rights generally and subject to general principles of equity.
 
4.3 Governmental Authorization. The execution, delivery and performance by TPL of this Agreement require no action by, consent or approval of, or filing with, any Governmental Authority other than any actions, consents, approvals or filings otherwise expressly referred to in this Agreement.
 
4.4 Non-Contravention. The execution, delivery and performance by TPL of this Agreement does not (a) contravene or conflict with the certificate of incorporation or bylaws of TPL, a true and correct copy of each of which has been delivered to Patriot; (b) contravene or constitute a default or breach under any material agreement to which TPL is a party; (c) contravene or conflict with or constitute a violation of any provision of any Applicable Law binding upon or applicable to TPL; or (d) result in the creation or imposition of any Lien on the MSD Patents.
 

 
4.5 Absence of Certain Changes or Events.
 
(a) Except as set forth on Schedule 4.5(a), as of the date hereof there has not been any change, circumstance, event or proceedings against TPL that could reasonably be expected to result in a Material Adverse Effect.
 
(b) Except as set forth on Schedule 4.5(b), and except as otherwise contemplated by or disclosed in this Agreement, TPL has not entered into any contract or agreement in respect of the MSD Patents.
 
4.6 Intellectual Property.
 
(a) TPL has a valid and subsisting license to the MSD Patents from Moore. Except as disclosed on Schedule 4.6(a), TPL has not received any notice or claim challenging TPL’s rights with respect to the MSD Patents or suggesting that any Person, other than Patriot and Moore, has any claim of legal or beneficial ownership with respect thereto, nor, to TPL’s knowledge, is there a reasonable basis for any such claim.
 
(b) To the knowledge of TPL, the MSD Patents are valid, enforceable and subsisting. Except as disclosed on Schedule 4.6(b), TPL has not received any notice or claim challenging or questioning the validity or enforceability of the MSD Patents or indicating an intention on the part of any Person to bring a claim that the MSD Patents are invalid or unenforceable or have been misused, and to TPL’s knowledge no reasonable basis exists for any such claim.
 
(c) To the knowledge of TPL, TPL has not taken any action or failed to take any action (including the manner in which it has conducted its business, or used or enforced, or failed to use or enforce, the MSD Patents) that would result in the abandonment, cancellation, forfeiture, relinquishment, invalidation or unenforceability of the MSD Patents.
 
(d) To the knowledge of TPL, none of the activities or operations of TPL with respect to the MSD Patents infringes upon, misappropriates, violates, dilutes or constitutes the unauthorized use of any rights, interests, or property of any third party. TPL has not received any notice or claim asserting or suggesting that any such infringement, misappropriation, violation, dilution or unauthorized use is or may be occurring or has or may have occurred, nor, to TPL’s knowledge, is there any reasonable basis therefor. To the knowledge of TPL, the MSD Patents are not subject to any outstanding order, judgment, decree or stipulation restricting the use, sale, transfer, assignment or licensing thereof by TPL to any Person.
 
4.7 Litigation. Except as disclosed on Schedule 4.7 (i) there are no Proceedings pending or, to the knowledge of TPL, threatened, against or by TPL or the MSD Patents or which seek to enjoin or rescind the transactions contemplated by this Agreement, nor, to the knowledge of TPL, is there any valid basis for any such Proceedings; and (ii) there are no existing orders, judgments or decrees of any Governmental Authority naming TPL as an affected party or otherwise affecting the MSD Patents or the performance by TPL of the transactions contemplated by this Agreement, nor, to the knowledge of TPL, is there any valid basis for any such order, judgment or decree.
 

 
4.8 Advisory Fees. Except as set forth on Schedule 4.8, there is no investment banker, broker, finder or other intermediary or advisor that has been retained by or is authorized to act on behalf of TPL who is entitled to any fee, commission or reimbursement of expenses from TPL, Patriot or any of their respective Representatives upon consummation of the transactions contemplated by this Agreement or otherwise.
 
4.9 Bulk Sales. There are no bulk sales statutes or laws applicable to TPL or the MSD Patents in connection with the consummation of the transactions contemplated by this Agreement.
 
ARTICLE V
REPRESENTATIONS AND WARRANTIES OF MOORE
 
5.1 Authorization. This Agreement has been duly and validly executed by Moore and constitutes the legal, valid and binding agreement of Moore, enforceable against Moore in accordance with its terms, except as may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ rights generally and subject to general principles of equity.
 
5.2 Governmental Authorization. The execution, delivery and performance by Moore of this Agreement require no action by, consent or approval of, or filing with, any Governmental Authority other than any actions, consents, approvals or filings otherwise expressly referred to in this Agreement.
 
5.3 Non-Contravention. The execution, delivery and performance by Moore of this Agreement does not: (a) contravene or constitute a default or breach under any material agreement to which Moore is a party; (b) contravene or conflict with or constitute a violation of any provision of any Applicable Law binding upon or applicable to Moore; or (c) result in the creation or imposition of any Lien on the MSD Patents.
 
5.4 Absence of Certain Changes or Events.
 
(a) Except as set forth on Schedule 5.4(a), as of the date hereof there has not been any change, circumstance, event or proceedings against Moore that could reasonably be expected to result in a Material Adverse Effect.
 
(b) Except as set forth on Schedule 5.4(b), and except as otherwise contemplated by or disclosed in this Agreement, Moore has not entered into any contract or agreement in respect of the MSD Patents.
 
 


5.5 Intellectual Property.
 
(a) Except as set forth on Schedule 5.5(a), Moore owns exclusively all right, title and interest in and to the MSD Patents, free and clear of any and all Liens, encumbrances or other adverse ownership claims, and Moore has not received any notice or claim challenging Moore’s ownership of the MSD Patents or suggesting that any Person, other than TPL and Moore, has any claim of legal or beneficial ownership with respect thereto, nor, to Moore’s knowledge, is there a reasonable basis for any claim that Moore does not have such good and valid title to the MSD Patents.
 
(b) To the knowledge of Moore, the MSD Patents are valid, enforceable and subsisting. Except as disclosed on Schedule 5.5(b), Moore has not received any notice or claim challenging or questioning the validity or enforceability of the MSD Patents or indicating an intention on the part of any Person to bring a claim that the MSD Patents are invalid or unenforceable or have been misused, and to Moore’s knowledge no reasonable basis exists for any such claim.
 
(c) To the knowledge of Moore (i) Moore has not taken any action or failed to take any action (including the manner in which it has conducted his business, or used or enforced, or failed to use or enforce, the MSD Patents) that would result in the abandonment, cancellation, forfeiture, relinquishment, invalidation or unenforceability of the MSD Patents and (ii) Moore has timely paid all filing, examination, issuance, post registration and maintenance fees, annuities and the like associated with or required with respect to the MSD Patents.
 
(d) To the knowledge of Moore, none of the activities or operations of Moore with respect to the MSD Patents infringes upon, misappropriates, violates, dilutes or constitutes the unauthorized use of any rights, interests, or property of any third party. Moore has not received any notice or claim asserting or suggesting that any such infringement, misappropriation, violation, dilution or unauthorized use is or may be occurring or has or may have occurred, nor, to Moore’s knowledge, is there any reasonable basis therefor. The MSD Patents are not subject to any outstanding order, judgment, decree or stipulation restricting the use, sale, transfer, assignment or licensing thereof by Moore to any Person.
 
5.6 Litigation. Except as disclosed on Schedule 5.6 (i) there are no Proceedings pending or, to the knowledge of Moore, threatened, against or by Moore or the MSD Patents or which seek to enjoin or rescind the transactions contemplated by this Agreement, nor, to the knowledge of Moore, is there any valid basis for any such Proceedings; and (ii) there are no existing orders, judgments or decrees of any Governmental Authority naming Moore as an affected party or otherwise affecting the MSD Patents or the performance by Moore of the transactions contemplated by this Agreement, nor, to the knowledge of Moore, is there any valid basis for any such order, judgment or decree.
 
5.7 Advisory Fees. Except as set forth on Schedule 5.7, there is no investment banker, broker, finder or other intermediary or advisor that has been retained by or is authorized to act on behalf of Moore who is entitled to any fee, commission or reimbursement of expenses from Patriot, TPL or any of their
 

 
respective Representatives upon consummation of the transactions contemplated by this Agreement or otherwise.
 
ARTICLE VI
COVENANTS OF PATRIOT
 
6.1 Court Approval of Stipulated Final Judgment. Patriot shall use its reasonable best efforts to obtain court approval of the Stipulated Final Judgment as soon as possible after the date hereof.
 
6.2 Retention of Rights; No Action With Respect to the MSD Patents. Patriot and TPL shall retain all of their respective rights with respect to the MSD Patents, except those rights to the MSD Patents transferred by Patriot and TPL to P-Newco pursuant to the Newco Licenses and the Merger Agreement. From the date hereof until the termination of the Commercialization Agreement, neither Patriot nor any of its Representatives shall take any action with respect to those matters concerning which TPL is authorized to act on behalf of the parties pursuant to the Commercialization Agreement and the Grant referred to therein, including, but not limited to, contacting, pursuing litigation against, or entering into discussions or negotiations with potential infringers, entering into license agreements, settlement agreements, or other similar agreements with respect to the MSD Patents, or selling or otherwise transferring any interest in the MSD Patents. Notwithstanding the foregoing, subject to Section 7.7, Patriot shall be entitled to take all actions contemplated by Section 7.1 of this Agreement. From the termination of the Commercialization Agreement until one year from the date thereof, Patriot shall not contact or enter into discussions or negotiations with, or enter into license agreements, settlement agreements, or other similar agreements with respect to the MSD Patents, or pursue any litigation or other dispute resolution involving claims related to the MSD Patents with regard to any potential licensee with whom TPL is engaged in active negotiations at the time of the termination of the Commercialization Agreement and identified in writing by TPL within five (5) days after such termination.
 
ARTICLE VII
COVENANTS OF ALL PARTIES
 
7.1 Protection and Maintenance of the MSD Patents. Subject to Section 7.7, Patriot, TPL and Moore, as well as each of Patriot’s and TPL’s appointees to P-Newco’s Management Committee, shall use their respective best efforts to protect and maintain the MSD Patents, including taking all actions necessary to maintain the effectiveness of the MSD Patents.
 
7.2 Commercialization Program.
 
(a) From the date hereof, TPL shall use its commercially reasonable best efforts to pursue the commercialization program on behalf of P-Newco, substantially in the manner contemplated by the Commercialization Agreement, with all proceeds therefrom to be allocated among the parties consistent with the terms of the Commercialization Agreement and the Operating Agreement, and Patriot and Moore shall provide all reasonable assistance and cooperation with respect thereto.
 

 
(b) Upon receipt of any proceeds in connection with TPL’s commercialization efforts pursuant to Section 7.2(a) between the date hereof and the earlier of (i) the Termination Date and (ii) the Closing, TPL shall cause all Net Cash Proceeds generated as a result thereof to be paid to P-Newco at the Closing to be retained and/or distributed by P-Newco pursuant to the terms of the Operating Agreement.
 
(c) From the date hereof until the earlier of (i) the Termination Date and (ii) the Closing, TPL agrees to provide Patriot prompt notice upon (A) execution of any agreements relating to the MSD Patents, and (B) receipt by P-Newco of any funds therefrom.
 
7.3 Further Assurances. TPL, Patriot and Moore agree to execute and deliver such other documents, certificates, agreements and other writings and to take such other actions as may be reasonably necessary or desirable in order to consummate or implement expeditiously the transactions contemplated by this Agreement.
 
7.4 Certain Filings. TPL and Patriot shall cooperate with one another in determining whether any action by or in respect of, or filing with, any Governmental Authority is required or reasonably appropriate, or any action, consent, approval or waiver from any party to any contract is required or reasonably appropriate, in connection with the consummation of the transactions contemplated by this Agreement. Subject to the terms and conditions of this Agreement, in taking such actions or making any such filings, the parties hereto shall furnish information required in connection therewith and seek timely to obtain any such actions, consents, approvals or waivers.
 
7.5 Notification. Patriot, TPL and Moore will promptly:
 
(a) notify the other parties in writing if it or he becomes aware of any action, event, condition or circumstance, or group of actions, events, conditions or circumstances, that results in, or could reasonably be expected to result in, a Material Adverse Effect;
 
(b) notify the other parties in writing of the commencement of any Proceeding by or against it or him, or of becoming aware of any claim, action, suit, inquiry, proceeding, notice of violation, demand letter, subpoena, government audit or disallowance that could be expected to result in a Proceeding by or against it or him; and
 
(c) notify the other parties in writing of the occurrence of any breach by it or him of any representation or warranty, or any covenant or agreement, contained in this Agreement.
 
7.6 Public Announcements. From the date hereof until the earlier of the Termination Date or the termination of the Commercialization Agreement, TPL and Patriot agree to consult with each other before (a) issuing any press release, (b) making any public statement with respect to this Agreement or the transactions contemplated hereby (including, without limitation, with respect to the consideration to be paid
 

 
pursuant to this Agreement or any license agreement pursuant to the Commercialization Agreement), or (c) making any SEC filing, and, except as may be required by Applicable Law, will not issue any such press release or public statement without the prior consent of the other party hereto. In the event a party determines that a public statement is required by Applicable Law, prior to making such statement or filing it shall provide to the other party a copy of such proposed statement or filing at least two Business Days prior to making such statement or filing and shall make such changes as may be reasonably requested by the other party. With respect to any SEC filing pursuant to Patriot’s obligations under the Exchange Act or otherwise, Patriot shall give TPL at least five Business Days advance notice of such filing (except to the extent compliance with applicable law shall require a shorter period of advance notice), and shall provide TPL a copy of the proposed filing for TPL’s review and comment, including all exhibits thereto, for purposes of determining whether to make a confidential treatment request with respect to any exhibit related to the transactions contemplated by this Agreement. Patriot agrees to make all requests for confidential treatment reasonably requested by TPL and consult with TPL regarding the requirement to make such a filing. Notwithstanding the foregoing, the parties may, on a confidential basis, advise and release information regarding the existence and content of this Agreement or the transactions contemplated hereby to their Representatives in connection with or related to the transactions contemplated by this Agreement.
 
7.7 No Interference. From the date hereof through the earlier of the Termination Date or the termination of the Commercialization Agreement, Patriot, Moore and P-Newco shall each avoid and refrain from any and all activity of any kind or nature which may impede, impair, frustrate or otherwise interfere with the activities of TPL in the execution of the commercialization program contemplated by the Commercialization Agreement, and shall:
 
(a) Exert their respective reasonable best efforts to impose the covenants of this Agreement, the Commercialization Agreement, and the transactions contemplated hereby and thereby on their respective affiliates or Representatives; and
 
(b) Be responsible hereunder for each and every failure in the good and faithful performance of this Agreement and the Commercialization Agreement by themselves and/or their respective affiliates or Representatives (other than TPL).
 
7.8 No Transfer. From the date hereof until one year after the termination of the Commercialization Agreement, with the exception of the agreements and transactions entered into pursuant to the commercialization program contemplated by the Commercialization Agreement, Patriot, P-Newco, TPL and Moore shall not transfer, assign, license, or otherwise convey any interest in, or grant any security interest with respect to, any portion of their interest in the MSD Patents without the written consent of all parties hereto, other than to entities which (a) are owned and controlled by the transferring Person and (b) agree to be bound by this Section 7.8, or (c) in the case of Moore, pursuant to a living trust, will or other estate planning device, or via intestate succession, provided however that any transferee of Moore’s interest in the MSD Patents under this Section 7.8(c) shall agree to be bound by this Section 7.8. Any transfer pursuant to this Section 7.8 shall be subject to existing licenses in respect of the MSD Patents.
 

 
7.9 Litigation Cooperation. Patriot, P-Newco and Moore agree to cooperate in any litigation with respect to the MSD Patents, including providing any reasonable assistance in connection with such litigation or joining as a party thereto, as requested by TPL.
 
ARTICLE VIII
CONDITIONS TO CLOSING
 
8.1 Conditions to Obligations of Each Party. The obligations of each of TPL and Patriot to consummate the Closing are subject to the satisfaction of each of the following conditions:
 
(a) The transactions contemplated by this Agreement and the consummation of the Closing shall not violate any Applicable Law. No temporary restraining order, preliminary or permanent injunction, cease and desist order or other order issued by any court of competent jurisdiction or any competent Governmental Authority or any other legal restraint or prohibition preventing the transactions contemplated by this Agreement, or imposing Damages in respect thereto, shall be in effect, and there shall be no pending or threatened actions or proceedings by any Governmental Authority (or determinations by any Governmental Authority).
 
(b) Patriot, TPL and Moore shall have agreed on and selected the Independent Manager (as defined in the Operating Agreement) for P-Newco, and the first Annual Business Plan for P-Newco shall have been approved.
 
(c) Intel shall have disbursed to the Escrow Account all unpaid Milestone Payments (as defined in the Intel Patent License Agreement) set forth in Section 3.2 of the Intel Patent License Agreement.
 
8.2 Conditions to Obligations of TPL. The obligations of TPL to consummate the Closing are subject to the satisfaction of each of the following conditions:
 
(a) (i) Patriot shall have complied with, performed and satisfied each of its agreements and covenants contained herein and required to be performed and satisfied by it on or prior to the Closing, (ii) each of the representations and warranties of Patriot contained in this Agreement, or in any certificate or document delivered to TPL pursuant hereto, shall have been true and correct in all material respects when made and shall contain no misstatement or omission that would make any such representation or warranty materially misleading when made and shall be true and correct in all material respects on, and contain no misstatement or omissions that would make any such representation or warranty materially misleading at and as of the Closing with the same force and effect as if made as of the Closing except for those representations and warranties which address matters only as of a particular date (which shall remain true and correct as of such particular date), and (iii) TPL shall have received certificates signed by a duly authorized executive officer of Patriot to the foregoing effect and to the effect that the conditions specified within this Section 8.2 have been satisfied.
 

 
(b) This Agreement, the Escrow Agreement, the Merger Agreement, the Operating Agreement, the Commercialization Agreement, the Warrant, the Registration Rights Agreement, and the Stipulated Final Judgment shall have been executed and delivered by Patriot, Moore and P-Newco, as applicable.
 
(c) The Stipulated Final Judgment shall have been executed by Patriot and delivered to TPL, with such changes as may be requested by the court.
 
(d) The Trade Secrets Litigation shall have been dismissed without prejudice.
 
8.3 Conditions to Obligations of Patriot. The obligations of Patriot to consummate the Closing are subject to the satisfaction of each of the following conditions:
 
(a) (i) TPL shall have complied with, performed and satisfied each of its agreements and covenants contained herein and required to be performed and satisfied by it on or prior to the Closing, (ii) each of the representations and warranties of TPL contained in this Agreement, or in any certificate or document delivered to Patriot pursuant hereto, shall have been true and correct in all material respects when made and shall contain no misstatement or omission that would make any such representation or warranty materially misleading when made and shall be true and correct in all material respects on, and contain no misstatement or omissions that would make any such representation or warranty materially misleading at and as of the Closing with the same force and effect as if made as of the Closing except for those representations and warranties which address matters only as of a particular date (which shall remain true and correct as of such particular date), and (iii) Patriot shall have received certificates signed by a duly authorized executive officer of TPL to the foregoing effect and to the effect that the conditions specified within this Section 8.3 have been satisfied.
 
(b) This Agreement, the Escrow Agreement, the Merger Agreement, the Operating Agreement, the Commercialization Agreement, and the Stipulated Final Judgment shall have been executed and delivered by TPL, Moore and P-Newco, as applicable.
 
(c) The Infringement Litigation involving Intel and Patriot shall have been dismissed with prejudice.
 
ARTICLE IX
INDEMNIFICATION
 
9.1 Patriot Agreement to Indemnify. Patriot shall indemnify and hold harmless TPL and Moore and their respective affiliates and Representatives (collectively, the “TPL Indemnitees”) in respect of any and all Damages which any of the TPL Indemnitees may incur or sustain, or to which any of the TPL Indemnitees may be subjected, as a result of:
 
(a) any inaccuracy or misrepresentation in or breach of any representation or warranty contained in this Agreement;
 

 
(b) any breach by Patriot of any covenant or agreement to be performed by Patriot;
 
(c) any Proceeding brought by any Person, based upon or arising from actions of Patriot prior or subsequent to the date hereof, including without limitation: (i) any public disclosure made by Patriot, or any omission by Patriot to disclose, in any filing with the SEC, press release, prospectus or any oral or written communication; (ii) any alleged breach by Patriot or any of Patriot’s officers, directors, employees or agents of any duty to holders of Patriot Common Stock or any other Patriot securities, or right or agreement to purchase Patriot Common Stock or any other Patriot securities; or (iii) any actions of Patriot or any predecessor in interest to Patriot with respect to the MSD Patents (or any actual or alleged agreement pertaining thereto); provided, however, that this Section 9.1(c) shall not apply to Proceedings related to actions taken by Patriot in good faith pursuant to this Agreement and the agreements contemplated hereby;
 
(d) any Proceeding brought by any current or former affiliate, Representative, stockholder, creditor or stakeholder of Patriot based upon or arising from the negotiation or consummation of the transactions contemplated by this Agreement, including without limitation any action brought by Russell Fish, the law firm of Beatie & Osborn LLP or any of its partners, members, associates, or employees, Russell H. Beatie, Daniel A. Osborn, John E. Lynch or Willis E. Higgins; or
 
(e) any Taxes of Patriot.
 
9.2 TPL Agreement to Indemnify. TPL shall indemnify and hold harmless Patriot and its Representatives (collectively, the “Patriot Indemnitees“) in respect of any and all Damages which any of the Patriot Indemnitees may incur or sustain, or to which any of the Patriot Indemnitees may be subjected, as a result of:
 
(a) any inaccuracy or misrepresentation in or breach of any representation or warranty contained in this Agreement;
 
(b) any breach by TPL of any covenant or agreement to be performed by TPL;
 
(c) any Damages in connection with any Proceeding brought by any Person, other than Patriot’s current or former Representatives, based upon or arising from actions of TPL prior or subsequent to the date hereof, including without limitation, any actions of TPL or any predecessor in interest to TPL with respect to the MSD Patents (or any actual or alleged agreement pertaining thereto); provided, however, that this Section 9.2(c) shall not apply to Proceedings related to actions taken by TPL in good faith pursuant to this Agreement and the agreements contemplated hereby; or
 
(d) any Taxes of TPL.
 
9.3 Moore Agreement to Indemnify. Moore shall indemnify and hold harmless Patriot and TPL and their respective affiliates or Representatives (collectively, the “Patriot/TPL Indemnitees”) in respect of any and all Damages which any of the Patriot/TPL Indemnitees may incur or sustain, or to which any of the Patriot/TPL Indemnitees may be subjected, as a result of:
 
(a) any inaccuracy or misrepresentation in or breach of any representation or warranty contained in Article V of this Agreement; or
 

 
(b) any breach by Moore of any covenant or agreement to be performed by Moore.
 
9.4 Survival of Representations, Warranties and Covenants. All representations, warranties, covenants, agreements and obligations of each Indemnifying Party contained in this Agreement and all claims of any TPL Indemnitee or Patriot Indemnitee in respect of any breach of any representation, warranty, covenant, agreement or obligation of any Indemnifying Party contained in this Agreement, shall survive the Closing and all due diligence performed by the respective parties.
 
9.5 Claims for Indemnification. If any Indemnitee shall believe that such Indemnitee is entitled to indemnification pursuant to this Article IX in respect of any Damages, such Indemnitee shall give the appropriate Indemnifying Party prompt written notice thereof. Any such notice shall set forth in reasonable detail and to the extent then known the basis for such claim for indemnification. The failure of such Indemnitee to give notice of any claim for indemnification promptly shall not adversely affect such Indemnitee’s right to indemnity hereunder except to the extent that such failure adversely affects the right of the Indemnifying Party to assert all reasonable defenses to such claim. Each such claim for indemnity shall expressly state that the Indemnifying Party shall have only the thirty (30) calendar day period referred to in the next sentence to dispute or deny such claim. The Indemnifying Party shall have thirty (30) calendar days following its receipt of such notice either (a) to acquiesce in such claim and the responsibility to indemnify the Indemnitee in respect thereof in accordance with the terms of this Article IX by giving such Indemnitee written notice of such acquiescence or (b) to object to the claim by giving such Indemnitee written notice of the objection. If the Indemnifying Party does not object thereto within such thirty (30) calendar day period, the Indemnifying Party shall be deemed to have acquiesced in such claim and the responsibility to indemnify the Indemnitee in respect thereof in accordance with the terms of this Article IX.
 
9.6 Defense of Claims. In connection with any claim which may give rise to indemnity under this Article IX resulting from or arising out of any claim or Proceeding against an Indemnitee by a Person that is not a party hereto, the Indemnifying Party may (unless such Indemnitee elects not to seek indemnity hereunder for such claim), upon written notice sent at any time to the relevant Indemnitee, assume the defense of any such claim or Proceeding if the Indemnifying Party with respect to such claim or Proceeding acknowledges to the Indemnitee the Indemnitee’s right to indemnity pursuant hereto in respect of the entirety of such claim (as such claim may have been modified through written agreement of the parties or arbitration hereunder) and provide assurances, reasonably satisfactory to such Indemnitee, that the Indemnifying Party will be financially able to satisfy such claim in full if such claim or Proceeding is decided adversely. The Indemnifying Party shall select counsel reasonably acceptable to such Indemnitee to conduct the defense of such claim or Proceeding, shall take all steps
 

 
reasonably necessary in the defense or settlement thereof and shall at all times diligently and promptly pursue the resolution thereof. If the Indemnifying Party shall have assumed the defense of any claim or Proceeding in accordance with this Section 9.6, the Indemnifying Party shall not (without the written consent of each Indemnitee) consent to a settlement of, or the entry of any judgment arising from, any such claim or Proceeding, unless such settlement or order shall provide for the unconditional release of all Indemnitees. If the Indemnifying Party has so elected to assume the defense, each Indemnitee shall be entitled to participate in (but not control) the defense of any such action, with its own counsel and at its own expense. Each Indemnitee shall, and shall cause each of its Representatives to, cooperate fully with the Indemnifying Party in the defense of any claim or Proceeding being defended by the Indemnifying Party pursuant to this Section 9.6. If the Indemnifying Party does not assume the defense of any claim or Proceeding resulting therefrom in accordance with the terms of this Section 9.6, such Indemnitee may defend against such claim or Proceeding in such manner as it may deem appropriate, provided that the Indemnitee may not settle such claim or Proceeding without the written consent of the Indemnifying Party (which consent shall not be unreasonably withheld or delayed), and provided further that the Indemnifying Party shall be obligated to pay Indemnitee’s attorneys’ fees and costs promptly as they are incurred in the defense of such claim or Proceeding.
 
ARTICLE X
TERMINATION
 
10.1 Grounds for Termination. This Agreement may be terminated (except as set forth in Section 10.2) and the transactions contemplated hereby abandoned at any time prior to the Closing (the “Termination Date”):
 
(a) by mutual written agreement of TPL and Patriot;
 
(b) by TPL upon written notice to Patriot of any one or more inaccuracies or misrepresentations in or breaches of the representations or warranties made by Patriot contained herein which have had or, if not cured prior to the Closing Date could be reasonably expected to have, a Material Adverse Effect when taken into account with all other uncured inaccuracies or misrepresentations in or breaches of such representations or warranties; provided, however, that a termination pursuant to this clause (b) shall become effective upon the earlier to occur of (i) fifteen (15) days after such notice with respect to such a misrepresentation or breach that is not capable of being cured on or prior to the Closing Date, or (ii) immediately prior to the Closing with respect to such a misrepresentation or breach that is capable of being cured, but is not cured, on or prior to the Closing Date;
 
(c) by TPL at any time upon written notice to Patriot of the failure by Patriot to perform and satisfy in all material respects any of its obligations under this Agreement required to be performed and satisfied on or prior to the Closing Date; provided, however, that a termination pursuant to this clause (c) shall become effective upon the earlier to occur of (i) three (3) days after such notice with respect to such a failure that is not capable of being cured on or prior to the Closing Date, (ii) fifteen (15) days after such notice with respect to such a failure that is capable of being cured on or prior to the Closing Date, but is not cured, on or prior to such fifteenth (15th) day, or
 

 
(iii) immediately prior to the Closing with respect to such a failure that is capable of being cured, but is not cured, on or prior to the Closing Date;
 
(d) by Patriot at any time upon written notice to TPL of any one or more inaccuracies or misrepresentations in or breaches of the representations or warranties made by TPL or Moore contained herein which have had or, if not cured prior to the Closing Date could be reasonably expected to have, a Material Adverse Effect when taken into account with all other uncured inaccuracies or misrepresentations in or breaches of such representations or warranties; provided, however, that a termination pursuant to this clause (d) shall become effective upon the earlier to occur of (i) fifteen (15) days after such notice with respect to such a misrepresentation or breach that is not capable of being cured on or prior to the Closing Date, or (ii) immediately prior to the Closing with respect to such a misrepresentation or breach that is capable of being cured, but is not cured, on or prior to the Closing Date;
 
(e) by Patriot at any time upon written notice to TPL of TPL’s failure to perform and satisfy in all material respects any of its obligations under this Agreement required to be performed and satisfied on or prior to the Closing Date; provided, however, that a termination pursuant to this clause (e) shall become effective upon the earlier to occur of (i) three (3) days after such notice with respect to such a failure that is not capable of being cured on or prior to the Closing Date, (ii) fifteen (15) days after such notice with respect to such a failure that is capable of being cured on or prior to the Closing Date, but is not cured, on or prior to such fifteenth (15th) day, or (iii) immediately prior to the Closing with respect to such a failure that is capable of being cured, but is not cured, on or prior to the Closing Date;
 
(f) by Patriot or TPL if the Closing shall not have been consummated by November 30, 2005; provided, however, that Patriot or TPL may not terminate this Agreement pursuant to this clause (f) if the Closing shall not have been consummated within such time period by reason of the failure of that party or any of its Representatives to perform in all material respects any of its or their respective covenants or agreements contained in this Agreement;
 
(g) by Patriot if TPL has caused a Material Adverse Effect other than any Material Adverse Effect caused by any proceeding brought by any current or former affiliate, Representative, stockholder, creditor or stakeholder of Patriot relating to any effect of the public announcement of this Agreement, the transactions contemplated hereby or the consummation of such transactions;
 
(h) by TPL if Patriot has caused a Material Adverse Effect; and
 
(i) by any party hereto if any federal, state or foreign law or regulation thereunder shall hereafter be enacted or become applicable that makes the transactions contemplated hereby or the consummation of the Closing illegal or otherwise prohibited, or if any judgment, injunction, order or decree enjoining either party hereto from consummating the transactions contemplated hereby is entered, and such judgment, injunction, order or decree shall become final and nonappealable.
 
The party desiring to terminate this Agreement pursuant to clauses (b) through (i) shall give written notice of such termination to the other party pursuant to Section 11.1.
 
10.2 Effect of Termination.
 

 
(a) If this Agreement is terminated as permitted by Section 10.1, such termination shall be without liability of any party to any other party to this Agreement except as hereinafter expressly provided in this Section 10.2.
 
(b) If such termination shall result from the willful failure of Patriot to fulfill a condition to the performance of the obligations of TPL, the willful failure of Patriot to perform a covenant contained in this Agreement or a willful breach by Patriot of its representations and warranties contained in this Agreement, Patriot shall be fully responsible for all Damages incurred by TPL as a result of such failure or breach by Patriot.
 
(c) If such termination shall result from the willful failure of TPL to fulfill a condition to the performance of the obligations of Patriot, the willful failure of TPL to perform a covenant contained in this Agreement or a willful breach by TPL of its representations and warranties contained in this Agreement, TPL shall be fully responsible for all Damages incurred by Patriot as a result of such failure or breach by TPL.
 
(d) If such termination shall result for any reason other than (i) the willful failure of Patriot to fulfill a condition to the performance of the obligations of TPL; (ii) the willful failure of Patriot to perform a covenant contained in this Agreement; or (iii) the willful breach by Patriot of its representations and warranties contained in this Agreement, Patriot shall be entitled to one-half of the Net Cash Proceeds generated by TPL from the period beginning from the date hereof and ending on the date this Agreement is terminated. It is expressly agreed and understood that Patriot shall not be entitled to any of the Milestone Payments (as such term is defined in the Intel Patent License Agreement), which shall only be distributed pursuant to the terms of the Escrow Agreement. TPL shall pay Patriot, by wire transfer in immediately available funds, to the account set forth on Exhibit E of the Escrow Agreement, such funds within the later of (A) five (5) days after the termination of this Agreement and (B) sixty (60) days of receipt thereof by TPL.
 
(e) The provisions of Article IX, as well as Sections 7.6, 11.1, 11.5, 11.9, 11.13 and 11.14 and this Section 10.2 shall survive any termination of this Agreement pursuant to this Article X, and each party hereto shall be fully responsible for any breach of any such provision, whether or not such breach occurs prior to the termination of this Agreement. In addition, the parties expressly agree that the Stipulated Final Judgment is severable and has significance independent of this Agreement and any other agreements and transactions contemplated hereby and thereby, and as such shall not be affected or disturbed by the Termination of this Agreement.
 
ARTICLE XI
MISCELLANEOUS
 
11.1 Notices. All notices, requests, demands, claims and other communications hereunder shall be in writing. Any notice, request, demand, claim, or other communication hereunder shall be deemed duly given (a) if personally delivered, when so delivered, (b) if mailed, two Business Days after having been sent by registered or certified mail, return receipt requested, postage prepaid and addressed to the intended recipient as set forth below, (c) if given by fax, once such notice or other communication is transmitted to the fax number specified below and the appropriate answer back or telephonic confirmation is received, provided that a copy of such notice or other communication is promptly
 

 
thereafter mailed in accordance with the provisions of clause (b) above or (d) of this Section 11.1, or (d) if sent through an overnight delivery service in circumstances to which such service guarantees next day delivery, the day following being so sent:
 
If to Patriot:

Patriot Scientific Corporation
10989 Via Frontera
San Diego, CA 92127
Attn: President
Fax: (858) 674-5004

with a copy to:

Luce, Forward, Hamilton & Scripps LLP
600 West Broadway, Suite 2600
San Diego, CA 92101
Attn: Otto E. Sorensen, Esq.
Fax: (619) 232-8311

If to TPL:

Technology Properties Limited Inc.
P.O. Box 20250
San Jose, CA 95160
Attn: Daniel E. Leckrone, Chairman
Fax: (408) 296-6637

with a copy to:

Gibson, Dunn & Crutcher LLP
333 S. Grand Avenue
Los Angeles, California 90071
Attn: Andrew E. Bogen, Esq.
Fax: (213) 229-6159

If to Moore:

Charles H. Moore
40 Cedar Lane
P.O. Box 127
Sierra City, CA 96125
Fax: (413) 714-5590

Any party may give any notice, request, demand, claim or other communication hereunder using any other means (including ordinary mail or electronic mail), but no such notice, request, demand, claim or other communication shall be deemed to have been duly given unless and until it actually is received by the individual for whom it is intended. Any party may change the address to which
 

 
notices, requests, demands, claims and other communications hereunder are to be delivered by giving the other parties notice in the manner herein set forth.
 
11.2 Amendments; No Waivers.
 
(a) Any provision of this Agreement may be amended or waived if, and only if, such amendment or waiver is in writing and signed, in the case of an amendment, by all parties hereto, or in the case of a waiver, by the party against whom the waiver is to be effective; provided, however, that any amendment or waiver to Section 11.9, Section 11.13, Section 11.14 or this Section 11.12(a) or any other amendment or waiver with respect to this Agreement of the agreements referenced herein that adversely affects Intel shall be effective only if such written amendment or waiver also has been executed and delivered by Intel.
 
(b) No waiver by a party of any default, misrepresentation or breach of warranty or covenant hereunder, whether intentional or not, shall be deemed to extend to any prior or subsequent default, misrepresentation or breach of warranty or covenant hereunder or affect in any way any rights arising by virtue of any prior or subsequent occurrence. No failure or delay by a party in exercising any right, power or privilege hereunder shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right, power or privilege. The rights and remedies herein provided shall be cumulative and not exclusive of any rights or remedies provided by law.
 
11.3 Expenses. All costs and expenses incurred in connection with this Agreement and in closing and carrying out the transactions contemplated hereby shall be paid by the party incurring such cost or expense.
 
11.4 Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and permitted assigns. No party hereto may assign either this Agreement or any of its rights, interests or obligations hereunder without the prior written approval of the other party.
 
11.5 Governing Law. This Agreement shall be construed in accordance with and governed by the internal laws (without reference to choice or conflict of laws) of the State of California.
 
11.6 Counterparts; Effectiveness. This Agreement may be signed in any number of counterparts and the signatures delivered by fax or other similar means, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. This Agreement shall become effective when each party hereto shall have received a counterpart hereof signed by the other parties hereto.
 
11.7 Entire Agreement. This Agreement (including the Schedules and Exhibits referred to herein which are hereby incorporated by reference and the other agreements executed simultaneously herewith) constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior agreements, understandings and negotiations, both written and oral, between the parties with respect to the subject matter of this Agreement.
 
11.8 Captions. The captions herein are included for convenience of reference only and shall be ignored in the construction or interpretation hereof. All references to an Article or Section include all subparts thereof.
 

 
11.9 Severability. The failure of any provision of this Agreement by virtue of its being construed as invalid or otherwise unenforceable shall render the entire Agreement cancelable at the option of the party asserting the enforceability of the said provision. Notwithstanding the foregoing, the parties expressly agree that the Stipulated Final Judgment, Section 11.2(a), Section 11.13 and Section 11.14 are severable and have significance independent of this Agreement and any other agreements and transactions contemplated hereby and thereby, and as such shall not be affected or disturbed by the invalidity, illegality or unenforceability of any such provision or provisions or of the entirety of any such agreements.
 
11.10 Construction. The parties hereto intend that each representation, warranty and covenant contained herein shall have independent significance. If any party has beached any representation, warranty or covenant contained herein in any respect, the fact that there exists another representation, warranty or covenant relating to the same subject matter (regardless of the relative levels of specificity) that the party has not breached shall not detract from or mitigate the fact that the party is in breach of the first representation, warranty or covenant.
 
11.11 Cumulative Remedies. The rights, remedies, powers and privileges herein provided are cumulative and not exclusive of any rights, remedies, powers and privileges provided by law.
 
11.12 Specific Performance. The parties hereby acknowledge and agree that the failure of any party to perform its agreements and covenants hereunder, including its failure to take all actions as are necessary on its part to consummate the agreements contemplated hereby, will cause irreparable injury to the other party, for which damages, even if available, will not be an adequate remedy. Accordingly, each party hereby consents to the issuance of injunctive relief without bond by any court of competent jurisdiction to compel performance of such party’s obligations and to the granting by any court of the remedy of specific performance of its obligations hereunder.
 
11.13 Third-Party Beneficiaries. Except as specifically provided in (a) Article IX with respect to indemnification provided to the Indemnitees identified therein, and (b) Section 11.14, no provision of this Agreement shall create any third-party beneficiary rights in any Person, including any employee or former employee of Patriot or any Representative thereof (including any beneficiary or dependent thereof). Each of Intel and its present, former and future direct and indirect distributors of Intel Licensed Products (collectively, the “Intel Parties”) shall be an express, intended third-party beneficiary of Section 11.2(a), Section 11.9 and Section 11.14.
 
11.14 No Liability of Intel. Upon payment by Intel of all of the unpaid Milestone Payments provided for at Section 3.2 of the Intel Patent License Agreement to the account designated at Exhibit A to the Escrow Agreement attached hereto as Exhibit E, each of Intel and the Intel Parties shall be forthwith and without further or other action of any kind by anyone, released from all potential liability with respect to Intel Licensed Products and based upon the rights of Patriot in and to the Core Patents (as described in the Intel Patent License Agreement). It is the intention of the parties to this Agreement in executing this Agreement that the same shall be effective as a bar to each and every claim, demand and cause of action hereinabove specified in this Section 11.14. In furtherance of this intention, each of the parties to this Agreement hereby expressly waives any and all rights and benefits conferred upon him by the provisions of Section 1542 of the California Civil Code (or any similar provision of any other applicable law) and expressly consents that this Agreement shall be given full force and effect according to each and all of its express terms and provisions, including those related to unknown and unsuspected claims, demands and causes of action, if any, as well as those related to any other claims, demands and causes of action hereinabove specified. Section 1542 of the California Civil Code provides:
 

 
“A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM OR HER MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR.”
 
Each of the parties to this Agreement acknowledges that it or he may hereafter discover claims or facts in addition to or different from those which it or he now knows or believes to exist with respect to the subject matter of this Agreement and which, if known or suspected at the time of executing this Agreement, may have materially affected this release. Nevertheless, each of the parties to this Agreement hereby waives any right, claim, or cause of action that might arise as a result of such different or additional claims or facts. Each of the parties to this Agreement acknowledges that it or he understands the significance and consequence of the release set forth in this Section 11.14 and such specific waiver of Section 1542 (and any other similar provisions of any other applicable laws).
 
For the avoidance of doubt, the releases provided for in this Section 11.14 shall extend solely to the use and practice of the Core Patents with respect to Intel Licensed Products.
 
11.15 No Punitive, Exemplary, or Consequential Damages. Except as expressly set forth herein, the parties hereto understand and agree that under no circumstances shall punitive, exemplary or consequential damages be available to any party for breach of this Agreement.
 
[signature page follows]
 



IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed by their respective authorized officers as of the day and year first above written.
 
PATRIOT SCIENTIFIC CORPORATION, a
Delaware corporation

By:_____________________________________________
Name:___________________________________________
Title:____________________________________________


TECHNOLOGY PROPERTIES LIMITED INC., a
California corporation

By:_____________________________________________
Name:___________________________________________
Title:____________________________________________


CHARLES H. MOORE, an individual

___________________________________________

 


EXHIBIT A
 
TOWNSEND AND TOWNSEND AND CREW LLP
ROGER L. COOK (State Bar No. 55208)
ERIC P. JACOBS (State Bar No. 88413)
IRIS SOCKEL MITRAKOS (State Bar No. 190162)
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111
Telephone: (415) 576-0200
Facsimile: (415) 576-0300
 
Attorneys for Defendants Technology Properties, Ltd.
 
 
and Daniel E. Leckrone
 
HENNEMAN & SAUNDERS
F. ERIC SAUNDERS (State Bar No. 87686)
3081 Ponderosa Road
P.O.Box 2215
Arnold, CA 95223
Telephone: (209) 795-6650
Facsimile: (209) 795-6659
 
Attorney for Defendant Charles H. Moore
 
UNITED STATES DISTRICT COURT
FOR THE NORTHERN DISTRICT OF CALIFORNIA
SAN JOSE DIVISION

PATRIOT SCIENTIFIC CORPORATION,
 
Plaintiff,
 
v.
 
CHARLES H. MOORE, TECHNOLOGY PROPERTIES LTD., and DANIEL E. LECKRONE,
Defendants.
 
Case No. C 04 0618 JF (HRL)
E-FILING CASE
 
STIPULATED FINAL JUDGMENT
 
 

 


IT IS HEREBY ORDERED, ADJUDGED, and DECREED as follows:
 
Plaintiff Patriot Scientific Corporation ("Patriot"), on one hand, and Defendants Charles H. Moore ("Moore"), Technology Properties, Ltd. ("TPL") and Daniel E. Leckrone ("Leckrone"), on the other hand, hereby stipulate and agree as follows:
 
1. Patriot, Moore, and TPL, among others, have entered into a series of negotiated agreements, pursuant to which Patriot, Moore, and TPL have agreed to settle all litigation among them on the terms and conditions contained in that certain Master Agreement by and among Patriot, TPL and Moore, dated as of June 1, 2005.
 
2. Pursuant to the terms of the Master Agreement referred to above, the settlement of the litigation among Patriot, Moore, and TPL, as well as the transactions contemplated by the Master Agreement, will not become effective unless and until this Stipulated Final Judgment is executed by all of the parties hereto and filed with the Court.
 
3. Patriot, Moore, and TPL desire to settle all litigation among them through this Stipulated Final Judgment and the negotiated agreements, and have all right, power, and authority to do so, as well as to enter into the Master Agreement and related documents and effectuate the transactions contemplated thereby in furtherance of the terms of this Stipulated Final Judgment and the negotiated agreements.
 
4. In connection therewith, Patriot's Third Amended Complaint seeking a declaration as to inventorship and ownership of United States Patent Number 5,809,336 (the "'336 Patent") shall be and hereby is dismissed with prejudice.
 
5. Final judgment shall be and hereby is entered in favor of Defendants Moore, TPL and Leckrone on Defendants' Counterclaims for a declaration that Moore is at least a co-inventor and TPL is at least a co-owner of the '336 Patent and U.S. Patent Nos. 6,598,148 ("'148 Patent"), 5,440,749 ("749 Patent"), 5,530,890 ("'890 Patent"), 5,604,915 ("'915 Patent"), 5,659,703 ("'703 Patent") and 5,784,584 ("'584 Patent").
 
6. Patriot waives any and all right to appeal from this Stipulated Final Judgment.
 


7. Each party shall bear its own attorneys' fees and costs in connection with this action.
 
8. This Court shall retain jurisdiction over this action for the purposes of enforcing, construing, clarifying, and modifying this Stipulated Final Judgment.
 
9. The Clerk of the Court is directed to give notice of entry of this Stipulated Final Judgment pursuant to Rule 77(d) of the Federal Rules of Civil Procedure.
 

[remainder of page intentionally blank]
 


DATED: June __, 2005
TOWNSEND and TOWNSEND and CREW LLP
 

By:__________________________________________
Roger L. Cook
Attorneys for Defendants
Technology Properties Ltd. and Daniel E. Leckrone
DATED: June __, 2005
HENNEMANN & SAUNDERS
 
 
By:__________________________________________
F. Eric Saunders
Attorney for Defendant Charles H. Moore
 
DATED: June __, 2005
 
By:__________________________________________
Carlton Johnson
Attorney for Plaintiff
Patriot Scientific Corporation


IT IS SO ORDERED

DATED: June __, 2005          
__________________________________________
UNITED STATES DISTRICT COURT JUDGE

 

 
EXHIBIT B
 

 

 

LIMITED LIABILITY COMPANY
 
OPERATING AGREEMENT
 
OF
 
[P-NEWCO],
 
A DELAWARE LIMITED LIABILITY COMPANY
 

 
TABLE OF CONTENTS
 
Page
     
ARTICLE 1
DEFINITIONS
1
     
ARTICLE 2
FORMATION OF LIMITED LIABILITY COMPANY
7
2.1
Formation
7
2.2
Name; Principal Place of Business
7
2.3
Registered Office and Registered Agent
7
2.4
Agreement; Effect of Inconsistencies With the Act or the Code
7
2.5
Business
8
2.6
Term
8
2.7
Qualification
8
     
ARTICLE 3
MEMBERSHIP
8
3.1
Members
8
3.2
Representations and Warranties
9
3.3
Incorporation of Representations and Warranties
9
3.4
Resignation or Withdrawal of a Member.
10
3.5
Effect of Certain Events on Membership.
10
3.6
Restrictions on Transfers of Interests
10
3.7
No Authority as Agent
11
     
ARTICLE 4
MANAGEMENT
11
4.1
Management of the Company by Management Committee
11
4.2
Appointment of Management Committee.
11
4.3
Responsibilities of the Management Committee
13
4.4
Officers
13
4.5
Liability of Committee Members and Officers
14
4.6
Records, Audits and Reports
14
 
   
ARTICLE 5
CAPITAL CONTRIBUTIONS
15
5.1
Initial Capital Contributions
15
5.2
Percentage Interests
15
5.3
Working Capital Contributions.
15
5.4
Failure to Make Contributions
15
5.5
Capital Accounts
16
 
   
ARTICLE 6
DISTRIBUTIONS, ALLOCATIONS AND TAX MATTERS
17
6.1
Application of Gross Cash Proceeds.
17
6.2
Allocation of Net Profits
18
6.3
Allocation of Net Losses
18
6.4
General Rules for Allocations
18
6.5
Special Allocations to Capital Accounts.
18
6.6
Tax Allocations; Section 704(c) of the Code.
19
6.7
Tax Matters Member.
20
6.8
Section 754 Election
20
6.9
Returns and Other Elections
20
6.10
Partnership Tax Treatment
21
 
 

 
 
 
   
ARTICLE 7
INDEMNIFICATION AND LIMITATION OF LIABILITY
21
7.1
Indemnification.
21
7.2
Limitation of Liability
22
7.3
Savings Clause
22
 
   
ARTICLE 8
DISSOLUTION AND WINDING UP
23
8.1
Dissolution
23
8.2
Winding Up
23
8.3
Reversion of Rights
23
8.4
Order of Payment Upon Liquidation
23
8.5
Antecedent Activities.
23
8.6
Limitations on Payments Made in Dissolution
24
8.7
Certificate of Cancellation
24
8.8
Effect of Filing Certificate of Cancellation
24
 
   
ARTICLE 9
MISCELLANEOUS
24
9.1
Amendment
24
9.2
Governing Law and Severability
25
9.3
Counterparts
25
9.4
Titles and Subtitles
25
9.5
Notices
25
9.6
Entire Agreement
25
9.7
Power of Attorney
26
9.8
Related Party Transactions
26
9.9
Dispute Resolution
26
9.10
No Partition
26
9.11
Bankruptcy
26

SCHEDULE 1 - INITIAL CAPITAL CONTRIBUTIONS
 
SCHEDULE 2 - PERCENTAGE INTERESTS
 
EXHIBIT A - CONSENT OF CHARLES H. MOORE TO LIMITED LIABILITY OPERATING AGREEMENT OF P-NEWCO, A DELAWARE LIMITED LIABILITY COMPANY
 

 
LIMITED LIABILITY COMPANY
OPERATING AGREEMENT FOR
[P-NEWCO],
A DELAWARE LIMITED LIABILITY COMPANY
 
This Limited Liability Company Operating Agreement (this “Operating Agreement”) of [P-Newco], a Delaware limited liability company (the “Company”), is made as of June 7, 2005, by and between PATRIOT SCIENTIFIC CORPORATION, a Delaware corporation (“Patriot”), and TECHNOLOGY PROPERTIES LIMITED INC., a California corporation (“TPL”) (collectively, the “Members”).
 
RECITALS
 
WHEREAS, Patriot has formed the Company as a limited liability company under the Delaware Limited Liability Company Act, 6 Del. C. § 18-101, et seq., as amended (the “Act”), for the purposes of effecting the transactions contemplated by the Master Agreement (as defined below);
 
WHEREAS, prior to the capital contributions and the issuance of the Percentage Interests described in Article 5 hereof, Patriot has been the sole member of the Company;
 
WHEREAS, the Members wish to enter into this Operating Agreement to provide for the structure, governance and operation of the Company.
 
AGREEMENT
 
NOW THEREFORE, in consideration of the respective covenants and promises contained herein and for other good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, the parties hereto agree as follows:
 
ARTICLE 1
DEFINITIONS
 
The following terms shall have the meanings set forth below for purposes of this Operating Agreement:
 
Act” means the Delaware Limited Liability Company Act.
 
Active Potential Licensees” has the meaning set forth in Section 6.2 of the Master Agreement.
 
Adjusted Capital Account Deficit” means, with respect to any Member for any taxable year or other period, the deficit balance, if any, in such Member’s Capital Account as of the end of such year or other period, after giving effect to the following adjustments: (a) credit to such Capital Account any amounts that such Member is obligated to restore or is deemed obligated to restore as described in the penultimate sentence of Treasury Regulation Section 1.704-2(g)(1) and in Treasury Regulation Section 1.704-2(i); and (b) debit to such Capital Account the items described in Treasury Regulation Sections 1.704-1(b)(2)(ii)(d)(4), (5) and (6).
 

 
Adjusted Gross Cash Proceeds” means Gross Cash Proceeds minus TPL Direct Reimbursable Expenses.
 
Affiliate”, with respect to any Person, means any other Person directly or indirectly controlling, controlled by or under common control with, such Person. For purposes of this Operating Agreement, “control” (including with correlative meanings, the terms “controlling”, “controlled by” or “under common control with”) as used with respect to any Person, shall mean the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of such Person, whether through the ownership of voting securities or by contract or otherwise.
 
Annual Business Plan” means, for any Fiscal Year, the Company’s annual financial and operating plan and budget for such Fiscal Year as formally approved by the Management Committee, as such financial and operating plan and budget may be amended from time to time by the Management Committee.
 
Antecedent Activities” means active negotiations with parties identified as Active Potential Licensees pursuant to Section 6.2 of the Master Agreement..
 
Applicable Law” means any domestic or foreign, federal, state or local statute, law, common law, ordinance, rule, administrative interpretation, regulation, order, writ, injunction, directive, judgment, decree, permit or other requirement of any Governmental Authority.
 
Book Value” means, with respect to any asset, the asset’s adjusted basis for federal income tax purposes, except as follows:
 
(a)The initial Book Value of any asset contributed by a Member to the Company shall be the gross fair market value of such asset (not reduced by any associated liabilities), as agreed to by the contributing Member and the Management Committee;
 
(b)The Book Value of the property of the Company shall be adjusted to equal its gross fair market value, as determined by the Management Committee, as of the following times: (i) the acquisition of an additional Interest by any new or existing Member in exchange for more than a de minimis Capital Contribution; (ii) the distribution by the Company to a Member of more than a de minimis amount of property as consideration for an Interest; (iii) the liquidation of the Company within the meaning of Treasury Regulations Section 1.704-1 (b)(2)(ii)(g); and (iv) any other instance in which such adjustment is permitted under Treasury Regulation Section 1.704-1(b)(2)(iv); provided, however, that adjustments pursuant to clauses (i), (ii), and (iv) above shall be made only if the Management Committee reasonably determines that such adjustments are necessary or appropriate to reflect the relative economic interests of the Members in the Company; and
 
(c)The Book Value of any property distributed to a Member shall be adjusted to equal the gross fair market value of such asset on the date of distribution as determined by the Management Committee.
 
The Book Value of any property which has been established or adjusted to reflect gross fair market value hereunder shall thereafter be adjusted by depreciation as provided in Treasury Regulation
 

 
Section 1.704-1(b)(2)(iv)(g) and any other adjustment to the value of such property other than depreciation or amortization.
 
Capital Account” means, with respect to any Member, the capital account maintained by the Company for such Member in accordance with Section 5.5.
 
Change of Control” means (a) the merger or consolidation of Patriot with or into another corporation in which Patriot is not the surviving entity, or a reverse triangular merger, or similar transaction, in which Patriot is the surviving entity but the shares of Patriot’s capital stock outstanding immediately prior to the merger are converted into other property, whether in the form of securities, cash, or otherwise, and as a result of which the outstanding capital stock of Patriot prior to such transaction represents less than a majority of the outstanding capital stock of Patriot or the acquirer or successor following such transaction, (b) any sale or transfer of all or substantially all of Patriot’s assets to any other Person, or (c) the sale or transfer of shares of Patriot’s capital stock, warrants, options or instruments convertible into capital stock of Patriot and as a result of which the outstanding capital stock of Patriot on a fully diluted basis assuming conversion of all outstanding instruments convertible into shares of Patriot’s capital stock prior to such transaction represents less than a majority of the outstanding capital stock of Patriot or the acquirer or successor following such transaction.
 
Certificate of Formation” means the Certificate of Formation of the Company as filed with the Secretary of State of the State of Delaware on June [__], 2005, as the same may be amended or restated from time to time.
 
Code” means the Internal Revenue Code of 1986, as amended from time to time, or any successor federal tax statute enacted after the date of this Operating Agreement.
 
Commercialization Agreement” means that certain Commercialization Agreement, dated as of the date hereof, by and among Patriot, TPL and the Company.
 
Company” has the meaning set forth in the Preamble.
 
Company Expenses” means any direct operating expenses of the Company as may be approved by the Management Committee, including any fees or other compensation payable to the Managers or for expenses related to the preparation of Company financial statements, tax reporting and the maintenance of a bank account in the name of the Company, and other similar administrative expenses.
 
Company Minimum Gain” means “partnership minimum gain” as defined in Treasury Regulation Section 1.704-2(d).
 
Damages” means all demands, claims, actions or causes of action, assessments, losses (including reasonably foreseeable lost profits), damages, costs, expenses, liabilities, judgments, awards, fines, sanctions, penalties, charges and amounts paid in settlement (net of insurance proceeds and proceeds from related third party indemnification, contribution or similar claims actually received), including (a) interest at a rate equal to 200 basis points above the prime rate, as in effect from time to time, of Citibank, N.A., on cash disbursements in respect of any of the foregoing, compounded quarterly, from the date each such cash disbursement is made until the Person incurring the same shall have been indemnified in respect thereof, (b) reasonable costs, fees and expenses of
 

 
such Person’s Representatives and (c) any reasonable costs, fees and expenses incurred in connection with investigating, defending against, or settling any such claims.
 
Exchange Act” means the Securities Exchange Act of 1934, as amended.
 
Fair Market Value” shall mean, with respect to the Initial Capital Contributions, the fair market value of such asset as determined by the Members.
 
Fiscal Year” means (i) any twelve (12) month period commencing on June 1 and ending on May 31, or (ii) any portion of the period described in clause (i) of this sentence for which the Company is required to allocate Net Profits, Net Losses and other items of Company income, gain, loss or deduction pursuant to Article VI, as the case may be.
 
Governmental Approval” means an authorization, consent, approval, permit or license issued by, or a registration or filing with, any Governmental Authority.
 
Governmental Authority” means any foreign, domestic, federal, territorial, state or local governmental authority, quasi-governmental authority, instrumentality, court, government or self-regulatory organization, commission, tribunal or organization or any regulatory, administrative or other agency, or any political or other subdivision, department or branch of any of the foregoing.
 
Gross Cash Proceeds” means all cash proceeds received pursuant to licenses, judgments, settlements and other payments with respect to the right to make, have made, use, sell, and import products utilizing the MSD Patents.
 
Indemnitees” means the Members, Managers, officers and employees of the Company, as well as their respective Representatives, entitled to indemnification by the Company pursuant to Article VII.
 
Independent Manager” has the meaning set forth in Section 4.2(c).
 
Initial Capital Contributions” has the meaning set forth in Section 5.1.
 
Initial Working Capital Contribution” means the Two Million Dollars ($2,000,000) payable by each of Patriot and TPL, in the aggregate amount of Four Million Dollars ($4,000,000), due upon the execution of this Operating Agreement.
 
JAMS” has the meaning set forth in Section 4.2(c).
 
Liabilities” means, with respect to any Person, any liability or obligation of such Person of any kind, character or description, whether known or unknown, absolute or contingent, accrued or unaccrued, liquidated or unliquidated, secured or unsecured, joint or several, due or to become due, vested or unvested, executory, determined, determinable or otherwise and whether or not the same is required to be accrued on the financial statements of such Person or is disclosed on any schedule to the Master Agreement or this Operating Agreement.
 
Lien” means, with respect to any asset, any mortgage, title defect or objection, lien, pledge, charge, security interest, hypothecation, restriction, encumbrance or charge of any kind in respect of such asset.
 

 
Liquidator” has the meaning set forth in Section 8.2.
 
Management Committee” has the meaning set forth in Section 4.1.
 
Manager” means a member of the Management Committee.
 
Master Agreement” means that certain agreement, dated as of May [27], 2005, by and between Patriot and TPL.
 
Member Minimum Gain” means the Company’s “partner nonrecourse debt minimum gain” as defined in Treasury Regulation Section 1.704-2(i)(2).
 
Member Nonrecourse Debt” means “partner nonrecourse debt” as defined in Treasury Regulation Section 1.704-2(b)(4).
 
Member Nonrecourse Deductions” means “partner nonrecourse deductions” as defined in Treasury Regulation Section 1.704-2(i)(2).
 
Members” has the meaning set forth in the Preamble.
 
MSD Patents” means those microprocessor science and design patents identified on Schedule 1 to the Master Agreement.
 
Net Cash Proceeds” has the meaning set forth in Section 6.1(a)(v).
 
Net Profit” or “Net Loss” means, for any Accounting Period, the amount, computed as of the last day thereof, of the net income or loss of the Company determined in accordance with federal income tax principles (but without requiring any items to be stated separately pursuant to Code Section 703), with the following adjustments:
 
(a) Any income of the Company that is exempt from federal income tax shall be included in the computation of Net Profit or Net Loss;
 
(b) Any expenditures of the Company described in Code Section 705(a)(2)(B) or treated as Code Section 705(a)(2)(B) expenditures pursuant to Treasury Regulations Section 1.704-l(b)(2)(iv)(i) shall be included in the computation of Net Profit or Net Loss;
 
(c) Any adjustment in the Book Value of property in accordance with this Agreement and pursuant to Treasury Regulation Section 1.704-1(b)(2)(iv)(f) or (g) shall be taken into account as gain or loss from the disposition of such asset for purposes of computing Net Profit or Net Loss (to the extent such adjustment is not already reflected in the Capital Accounts of the Members);
 
(d) In any situation in which an item of income, gain, loss or deduction is affected by the adjusted tax basis of property, the Book Value of the property shall be used in lieu of adjusted basis (notwithstanding that the adjusted tax basis of such property may differ from its Book Value), and in lieu of depreciation, amortization and other cost recovery deductions taken into account in computing taxable income or loss, there will be taken into account
 

 
depreciation for the taxable year or other period as determined in accordance with Treasury Regulation Section 1.704-1(b)(2)(iv)(g); and
 
(e) Any items of income, gain, deduction and loss specially allocated pursuant to Section 6.6 of this Agreement shall not be considered in determining Net Profit or Net Loss.
 
Newco Licenses” means the P-Newco License and the T-Newco License.
 
Nonrecourse Deductions” has the meaning set forth in Treasury Regulation Section 1.704-2(b)(1).
 
Operating Agreement” has the meaning set forth in the Preamble.
 
Patriot” has the meaning set forth in the Preamble.
 
Patriot Appointee” has the meaning set forth in Section 4.2(a).
 
Percentage Interest” means a Member’s percentage interest in the Company, as such Percentage Interest may be adjusted from time to time pursuant to the terms of this Operating Agreement.
 
Person” means an individual, corporation, partnership, limited liability company, joint venture, association, trust, estate or other entity or organization, including a Governmental Authority.
 
P-Newco License” means that certain license agreement entered into between Patriot and the Company.
 
Proceedings” means any actions, suits, claims, hearings, arbitrations, proceedings (public or private) or governmental investigations that have been brought by or against any Governmental Authority or any other Person.
 
Recovery Event” means the moment at which payment is actually received by Patriot, TPL, or the Company as a result of or in connection with any Antecedent Activities.
 
Regulatory Allocations” are those allocations contained in Section 6.5.
 
Representatives” means the officers, directors, employees, attorneys, accountants, advisors, representatives and agents of a Person.
 
Securities Act” means the Securities Act of 1933, as amended.
 
Tax Matters Member” means that Member appointed by the Management Committee with the power to manage and control, on behalf of the Company, any administrative proceeding at the Company level with the Internal Revenue Service relating to the determination of any item of Company income, gain, loss, deduction or credit for federal income tax purposes.
 
T-Newco” means a newly formed Delaware limited liability company, wholly owned by TPL.
 

 
T-Newco License” means that certain license agreement entered into between TPL and T-Newco.
 
TPL” has the meaning set forth in the Preamble.
 
TPL Appointee” has the meaning set forth in Section 4.2(b).
 
TPL Direct Reimbursable Expenses” has the meaning set forth in Section 4.2 of the Commercialization Agreement.
 
Transfer” has the meaning set forth in Section 3.6.
 
Treasury Regulations” means the proposed, temporary and final regulations promulgated under the Code in effect as of the date of filing the Certificate of Formation and the corresponding sections of any regulations subsequently issued that amend or supersede those regulations.
 
Working Capital Contribution” means the amount payable to the Company each Fiscal Year by each of the Members for the Company’s working capital requirements pursuant to Section 5.3.
 
Working Capital Fund” means the fund containing the Company’s working capital to be maintained pursuant to Section 5.3(b).
 
ARTICLE 2
FORMATION OF LIMITED LIABILITY COMPANY
 
2.1 Formation. Patriot caused the Certificate of Formation of the Company to be filed with the Delaware Secretary of State on June [__], 2005.
 
2.2 Name; Principal Place of Business. Unless and until amended in accordance with this Operating Agreement and the Act, the name of the Company is “[__________]”. The principal place of business of the Company shall be such place or places as the Management Committee from time to time determines.
 
2.3 Registered Office and Registered Agent. The Company’s initial registered office shall be at the office of its registered agent at 160 Greentree Drive, Suite 101, Dover, Delaware 19904, and the name of its initial registered agent at such address shall be National Registered Agents, Inc. The registered agent may be changed from time to time by filing the address of the new registered office and/or the name of the new registered agent with the Secretary of State of the State of Delaware pursuant to the Act.
 
2.4 Agreement; Effect of Inconsistencies With the Act or the Code. It is the express intention of the Members that this Operating Agreement, together with the Exhibits and Schedules, shall be the sole source of agreement of the parties with respect to the structure, governance and the operation of the Company and, except to the extent a provision of this Operating Agreement expressly incorporates federal income tax rules by reference to sections of the
 

 
Code or Treasury Regulations or is expressly prohibited or ineffective under the Act, this Operating Agreement shall govern the structure and operation of the Company, even when inconsistent with, or different than, the provisions of the Act or any other law or rule. To the extent that any provision of this Operating Agreement is prohibited or ineffective under the Act, this Operating Agreement shall be deemed to be amended to the smallest degree possible in order to make this Operating Agreement effective under the Act in accordance with the intent of the parties. In the event the Act is subsequently amended or interpreted in such a way to make any provision of this Operating Agreement that was formerly invalid valid, such provision shall be considered to be valid from the effective date of such interpretation or amendment. Each of the Members shall be entitled to rely on the provisions of this Operating Agreement, and none of the Members shall be liable to the Company or to any of the other Members for any action or refusal to act taken in good faith reliance on the terms of this Operating Agreement. The Members hereby agree that the duties and obligations imposed on the Members as such shall be those set forth in this Operating Agreement, which is intended to govern the relationship among and between the Company and the Members, notwithstanding any provision of the Act or common law to the contrary.
 
2.5 Business. The purpose of the Company is to engage in any activity for which a limited liability company may be organized under the Act.
 
2.6 Term. The term of the Company commenced upon the filing of the Certificate of Formation with the Delaware Secretary of State on June [__], 2005 and shall continue until the Company’s dissolution in accordance with Article VIII of this Operating Agreement.
 
2.7 Qualification. The Management Committee shall cause the Company to be qualified or registered, if and to the extent required, under the applicable laws of any jurisdiction in which such registration may be required, and shall be authorized to execute, deliver and file any certificates and documents necessary to effect such qualification or registration.
 
ARTICLE 3
MEMBERSHIP
 
3.1 Members. The names and addresses of the Members are as follows:
 
Patriot Scientific Corporation
10989 Via Frontera
San Diego, California 92127
Technology Properties Limited Inc.
21730 Stevens Creek Boulevard, Suite 201
Cupertino, California 95014
 

 


3.2 Representations and Warranties. Each Member hereby represents and warrants to the Company and the other Member as follows:
 
(a) Such Member is either an individual or a corporation duly organized, validly existing and in good standing under the laws of its state of incorporation with all requisite corporate power and authority to own, lease and operate its properties and assets and to carry on its business as now conducted;
 
(b) Such Member has all requisite power and authority to execute and deliver this Operating Agreement and to perform its obligations hereunder. The execution and delivery by such corporate Member of this Operating Agreement and the consummation of the transactions contemplated hereby have been duly authorized by all necessary corporate action on its part. This Operating Agreement has been duly executed and delivered by such Member and constitutes the legal, valid and binding obligations of such Member, enforceable against it in accordance with its terms, except as enforcement may be limited by equitable principles and by bankruptcy, insolvency, reorganization, moratorium or similar laws relating to creditors’ rights generally;
 
(c) The execution, delivery and performance by such Member of this Operating Agreement and the consummation of the transactions contemplated hereby do not and will not (i) violate the certificate of incorporation or bylaws of such Member, in each case as amended through the date hereof, (ii) conflict with, result in a breach of or constitute (or, with the giving of notice or lapse of time, or both, constitute) a default under, or require the approval or consent of any Person pursuant to, any material agreement, instrument or other document to which such Member is a party or by which it or its properties or assets is bound, or (iii) violate any material provision of any statute, rule or regulation applicable to such Member or binding on it or any of its assets, or (iv) except as set forth in the Newco Licenses, result in the creation or imposition of any Lien on the MSD Patents.
 
(d) Such Member is acquiring its Percentage Interest for investment purposes and not with a view to the resale or distribution thereof;
 
(e) Such Member understands and acknowledges that such Member’s Percentage Interest has not been registered under the Securities Act or any state securities or blue sky laws and may not be sold unless registered under the Securities Act and qualified under applicable state securities or blue sky laws or such sale is made pursuant to an exemption from such registration and qualification requirements;
 
(f) The limitations on Transfer contained in Section 3.6 create an economic risk that such Member is capable of bearing; and
 
(g) Such Member is a “United States person” within the meaning of Section 7701(a)(30) of the Code.
 
3.3 Incorporation of Representations and Warranties. Each of Patriot and TPL hereby reaffirms the representations and warranties made by such Member in the Master Agreement as if such representations and warranties were set forth fully herein.
 

 
3.4 Resignation or Withdrawal of a Member.
 
(a) No Member shall resign from membership in the Company or withdraw their interest in the capital of the Company, except (i) in connection with the dissolution of the Company pursuant to the provisions of Article VIII, or (ii) with the prior written consent of all of the other Members.
 
(b) The resignation of a Member shall not (i) relieve such Member of any of its covenants, agreements, duties, obligations or liabilities under this Operating Agreement whether arising prior to, on, or after the date of such resignation (including, without limitation, any contingent obligations based on acts or omissions occurring, or liabilities or obligations incurred, prior to, on or after the date of such resignation), or (ii) directly or indirectly result in the termination of, or relieve such Member (or any Affiliate thereof) of, or otherwise affect, any of the covenants, agreements, duties, obligations or liabilities of such Member (or any Affiliate thereof) under any other agreement to which such Member is a party.
 
3.5 Effect of Certain Events on Membership.
 
(a) Bankruptcy, Foreclosure, or Other Similar Event. In the event of a Member’s bankruptcy, or the foreclosure upon or other similar proceeding with respect to that Member’s interest in the MSD Patents or that Member’s Percentage Interest:
 
 
(i)
any and all rights that Member may have under Section 4.2 of this Operating Agreement shall automatically terminate; and
 
 
(ii)
any and all rights that Member may have under Sections 2.2.1 and 2.2.2 of the P-Newco License or T-Newco License, as the case may be, shall automatically and without further action by any of the parties thereto be irrevocably transferred to the Company.
 
(b) Change of Control. In the event of a Change of Control of Patriot or TPL:
 
 
(i)
any and all rights Patriot or TPL may have under Section 4.2 of this Operating Agreement, as the case may be, shall automatically terminate; and
 
 
(ii)
Patriot or TPL’s rights under Sections 2.2.1 and 2.2.2 of the P-Newco License or T-Newco License, as the case may be, shall automatically and without further action by any of the parties thereto be irrevocably transferred to the Company.
 
3.6 Restrictions on Transfers of Interests. Except as provided in Section 5.4, no Member shall sell, assign, pledge, mortgage or otherwise dispose of or transfer (a “Transfer”) its Percentage Interest in the Company, whether in whole or in part, without the consent of the Management Committee, which consent may be withheld for any or for no reason.
 

 
3.7 No Authority as Agent. Except as may be authorized by the Management Committee, or as set forth in the Commercialization Agreement, no Member shall have the authority in its or his capacity as a Member to enter into any transaction on behalf of the Company or to otherwise bind the Company.
 
ARTICLE 4
MANAGEMENT
 
4.1 Management of the Company by Management Committee. The business and affairs of the Company shall be managed by a management committee (the “Management Committee”) consisting of three (3) Managers, which number may not be changed without the written consent of the Members holding at least seventy-five percent (75%) of the Percentage Interests.
 
4.2 Appointment of Management Committee.
 
(a) Patriot Appointment. Patriot shall have the right to appoint one (1) Manager to the Management Committee (the “Patriot Appointee”).
 
(b) TPL Appointment. TPL shall have the right to appoint one (1) Manager to the Management Committee (the “TPL Appointee”).
 
(c) Independent Manager. The Patriot Appointee and the TPL Appointee shall work together in good faith to appoint a mutually acceptable third Manager (the “Independent Manager”). In the event that the Patriot Appointee and the TPL Appointee are unable to appoint a mutually acceptable Manager within 10 days of the resignation or removal of the Independent Manager, either party may apply to the Judicial Arbitration and Mediation Service (“JAMS”) in Santa Clara County, or the nearest county thereto, if necessary, for the appointment of the Independent Manager, and JAMS shall select the Independent Manager from a list of no more than three persons submitted by each party. All costs associated with the selection of the Independent Manager by JAMS pursuant to this Section 4.2(c) shall be paid by the Company.
 
(d) Term of Service. Each Manager (other than the Independent Manager) will serve until his or her death or resignation from the Management Committee, or until his or her removal from the Management Committee by the Member who appointed him or her. The Independent Manager shall serve a five (5) year term (subject to earlier removal as provided below).
 
(e) Initial Managers.  The initial Managers are as follows:
 
Patriot Appointee
David H. Pohl
TPL Appointee
Daniel E. Leckrone
Independent Manager
Robert K. Neilson

 


(f) Meetings; Place of Meetings; Telephonic Participation. Meetings of the Management Committee may be held at such times and places within or without the State of Delaware as the Management Committee may from time to time designate or as shall be designated by the Manager or Managers calling the meeting in the notice or waiver of notice of any such meeting. Regular meetings of the Management Committee shall be held not less than once during every calendar quarter. Special meetings of the Management Committee shall be held whenever called by one or more Managers. Notice of the time, place and purpose of each such special meeting shall be sent by facsimile transmission or electronic mail or be delivered personally or mailed to and received by each Manager not less than seventy-two (72) hours before the time at which the meeting is to be held. Notice of any meeting of the Management Committee shall not be required to be given to any Manager who waives such notice in writing or who is present at such meeting, except a Manager who shall attend such meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. At the request of any Manager, any or all Managers may participate telephonically in any meeting of the Management Committee so long as all persons participating in the meeting can hear each other, and such participation shall constitute presence in person at such meeting. Any action required or permitted to be taken at any meeting of the Management Committee may be taken without a meeting, without prior notice and without a vote, if a consent in writing (including by electronic transmission as permitted by Section 18-302 of the Act), setting forth the action so taken, shall be signed or delivered by all Managers. Such written (or electronically transmitted) consent shall be filed with the minutes of proceedings of the Management Committee.
 
(g) Quorum. Two (2) Managers must be present at a meeting of the Management Committee to establish a quorum for the transaction of business.
 
(h) Majority Vote. All actions to be taken by the Management Committee shall require the affirmative vote of at least two (2) of the three (3) Managers.
 
(i) Resignation; Removal; Vacancies; Compensation.
 
 
(i)
Resignation. A Manager may resign at any time by giving written notice to the Members. The resignation of a Manager shall take effect upon receipt of such notice or at such later time as shall be specified in the notice. Unless otherwise specified in the notice, the acceptance of the resignation shall not be necessary to make it effective.
 
 
(ii)
Removal. The Patriot Appointee to the Management Committee may be removed only by Patriot, with or without cause. The TPL Appointee to the Management Committee may be removed only by TPL, with or without cause. The Independent Manager may be removed at any time, with or without cause, by written consent of the Members holding at least seventy-five percent (75%) of the Percentage Interests.
 
 
(iii)
Vacancies. Vacancies on the Management Committee shall be filled by the Member who originally appointed the vacating Manager, or, in the case of the Independent Manager, pursuant to Section 4.2(c) of this Operating Agreement.
 
 


 
(iv)
Compensation. No Manager other than the Independent Manager (in the Members’ discretion) shall be eligible to receive separate compensation from the Company for his or her services on the Management Committee; provided, however, that the Managers shall be reimbursed by the Company for the reasonable and actual costs incurred in attending and participating in any meetings of the Management Committee and other costs and expenses reasonably related to fulfilling the duties and obligations of a Manager hereunder.
 
4.3 Responsibilities of the Management Committee. The Management Committee shall have the responsibility, on behalf of the Company:
 
(a) To approve the Annual Business Plan, as well as any modifications thereto.
 
(b) To make any distributions to Members pursuant to Article VI.
 
(c) To make any filings with any Governmental Authority on behalf of the Company.
 
(d) To purchase liability and other insurance to protect the Company’s properties and business and to purchase liability insurance to indemnify or otherwise protect the Members, Managers, officers and employees of the Company.
 
(e) To make certain decisions regarding tax matters pursuant to the terms of this Operating Agreement.
 
(f) To approve the execution by TPL pursuant to the Commercialization Agreement of any license agreement, infringement claim settlement or other agreement with respect to the MSD Patents, the proposed terms of which do not fall within the guidelines for allowable license agreements and infringement claim settlements set forth in Exhibit C to the Commercialization Agreement.
 
(g) To approve any modifications, amendments or waivers of the Commercialization Agreement, and any of the license or other agreements referred to therein to which the Company is a party.
 
(h) To take or authorize such other actions on behalf of the Company as are consistent with Applicable Law and the fiduciary duties of the Managers and the Members.
 
4.4 Officers. The Company shall have a President and Treasurer and such other officers as the Management Committee may determine. Any officer except the President and the Treasurer may hold more than one office concurrently. Except as set forth herein, the officers shall serve at the pleasure of the Management Committee. The Management Committee may determine a reasonable compensation to be paid to each officer so appointed. The officers shall exercise such powers as shall be determined or delegated from time to time by the Management Committee.
 

 
(a) President. The Company shall have a President with primary responsibility for and active charge of the management and supervision of the Company’s business and affairs. The President may execute in the name of the Company license agreements, settlement agreements, checks and other similar documents and instruments to the extent that such execution is consistent with and in furtherance of the Annual Business Plan, as well as such other documents and instruments otherwise authorized for execution by the Management Committee. For as long as the Commercialization Agreement is in effect, Robert K. Neilson shall be President of the Company.
 
(b) Treasurer. The Company shall have a Treasurer as the principal financial officer and principal accounting officer of the Company who shall keep full and accurate accounts of receipts and disbursements in books belonging to the Company. The initial treasurer shall be [__________].
 
4.5 Liability of Committee Members and Officers. The Managers and the officers shall not be liable to the Company or to any Member for any Damages suffered or sustained by the Company or any Member, as the case may be, unless the Damage results from the fraud, deceit, gross negligence, willful misconduct, breach of fiduciary duty, a knowing violation of law by a specific Manager or officer or a material breach of such Manager’s or officer’s obligations under this Operating Agreement, in which event only the Manager or officer who engaged in such conduct or behavior (and no other Manager or officer) shall be liable for the full extent of Damages suffered or sustained to the full extent permitted pursuant to this Agreement or provided by Applicable Law.
 
4.6 Records, Audits and Reports. At the expense of the Company, proper and complete records and books of account shall be kept or shall be caused to be kept by the Management Committee (or a designee thereof) in which shall be entered fully and accurately all transactions and other matters relating to the Company’s business in the detail and completeness customary and usual for businesses of the type engaged in by the Company. The books and records shall at all times be maintained at the principal executive offices of the Company and shall be open to the inspection and examination of the Members or their duly authorized agents during business hours. At a minimum, the Company shall keep at its principal place of business:
 
(a) A current list of the full name and last known business, residence or mailing address of each Member and Manager;
 
(b) A copy of the Certificate of Formation and all amendments thereto, together with executed copies of any powers of attorney pursuant to which any amendment has been executed;
 
(c) Copies of the Company’s federal, state and local income tax returns and reports, if any, for the four most recent years;
 
(d) A copy of this Operating Agreement, as amended to date, any correspondence relating to any Member’s obligation to contribute cash, property or services, and copies of any financial statements of the Company for the three most recent years; and
 

 
(e) Minutes of every meeting of the Management Committee, or any written consents of the Managers obtained in lieu of a meeting.
 
The Management Committee shall maintain and preserve, during the term of the Company and for a period of five years thereafter, all accounts, books and other relevant Company documents.
 
ARTICLE 5
CAPITAL CONTRIBUTIONS
 
5.1 Initial Capital Contributions. Concurrently with the execution hereof, Patriot and TPL shall enter into the P-Newco License, TPL and T-Newco shall enter into the T-Newco License, T-Newco shall merge with and into the Company and each of the Members shall make the capital contributions set forth on Schedule 1 hereto (collectively, the “Initial Capital Contributions”). The Initial Capital Contributions to the Company of each Member shall be deemed to have a Fair Market Value as set forth opposite such Member’s name on Schedule 1 hereto.
 
5.2 Percentage Interests. Upon making its Initial Capital Contribution, and as a result of the merger contemplated by the Merger Agreement (as defined in the Master Agreement), TPL shall be issued Percentage Interests in the Company such that Patriot will no longer be the sole Member of the Company and the Members shall have the Percentage Interests set forth on Schedule 2 hereto. Percentage Interests shall for all purposes be personal property. A Member has no interest in specific property of the Company.
 
5.3 Working Capital Contributions.
 
(a) Initial Working Capital Contribution. On the date hereof, Patriot and TPL shall each make an Initial Working Capital Contribution to the Company of Two Million Dollars ($2,000,000), for an aggregate Initial Working Capital Contribution of Four Million Dollars ($4,000,000).
 
(b) Future Working Capital Contributions. At any time during the Fiscal Year at the discretion of the Management Committee, Patriot and TPL shall be obligated to make Working Capital Contributions in equal amounts in order to maintain a Working Capital Fund of not more than Eight Million Dollars ($8,000,000), and then only to the extent necessary to bring the balance of the Working Capital Fund to Eight Million Dollars ($8,000,000), provided, however, that neither TPL nor Patriot shall be required to contribute more than Two Million Dollars ($2,000,000) in any Fiscal Year.
 
Except as provided in this Section 5.3, no Member shall be obligated to make any contribution of capital to the Company.
 
5.4 Failure to Make Contributions. The failure of Patriot or TPL to make Working Capital Contributions when due pursuant to Section 5.3 shall result in the following adjustments to that Member’s Percentage Interest:
 

 
(a) For each One Dollar ($1) that is not contributed by Patriot or TPL when due pursuant to Section 5.3, one hundred thousandth of a percent (0.00001%) of the outstanding Percentage Interests of the Company shall be deducted from that Member’s Percentage Interest and transferred to the other Member. As an example, if a Member failed to contribute One Million Dollars ($1,000,000) when due pursuant to Section 5.3, ten percent (10%) of the outstanding Percentage Interests of the Company would be deducted from that Member’s Percentage Interest and transferred to the other Member.
 
(b) In the event that Patriot’s Percentage Interest falls below twenty-five percent (25%), Patriot shall lose the right to appoint the Patriot Appointee pursuant to Section 4.2(a), and TPL shall have the right to appoint the Patriot Appointee, such that TPL shall have the right to appoint two (2) of the three (3) Managers. In the event that TPL’s Percentage Interest falls below twenty-five percent (25%), TPL shall lose the right to appoint the TPL Appointee pursuant to Section 4.2(b), and Patriot shall have the right to appoint the TPL Appointee, such that Patriot shall have the right to appoint two (2) of the three (3) Managers.
 
5.5 Capital Accounts. A separate Capital Account shall be established and maintained for each Member.
 
(a) Each Member’s Capital Account will be increased by:
 
 
(i)
The Initial Capital Contribution by the Member to the Company pursuant to Section 5.1;
 
 
(ii)
The Working Capital Contributions by the Member to the Company pursuant to Section 5.3; and
 
 
(iii)
Each Member’s pro rata allocation of the Company’s and each Member’s contributions to the Working Capital Fund.
 
(b) Each Member’s Capital Account will be decreased by:
 
 
(i)
The amount of Net Cash Proceeds distributed to the Member by the Company;
 
 
(ii)
The Fair Market Value of property distributed to the Member by the Company; and
 
 
(iii)
Allocations to the Member of Net Losses.
 
(c) The manner in which Capital Accounts are to be maintained pursuant to this Section 5.5 is intended to comply with the requirements of Section 704(b) of the Code and the Treasury Regulations promulgated thereunder. If, in the opinion of the Management Committee after consultation with the Company’s accountants, the manner in which Capital Accounts are to be maintained pursuant to the preceding provisions of this Section 5.5 should be modified to comply with Section 704(b) of the Code and the Treasury Regulations thereunder, then, notwithstanding anything to the contrary contained in the preceding provisions of this Section 5.5, the method in which Capital Accounts are maintained shall be
 

 
so modified without any approval of the Management Committee; provided, however, that any change in the manner of maintaining Capital Accounts shall not materially alter the economic agreement between the Members.
 
(d) No Member shall have any liability to restore all or any portion of a deficit balance in the Member’s Capital Account.
 
ARTICLE  6
DISTRIBUTIONS, ALLOCATIONS AND TAX MATTERS
 
6.1 Application of Gross Cash Proceeds.
 
(a) Application of Gross Cash Proceeds. Within sixty (60) days after the close of each of the Company’s fiscal quarters, the Company shall apply and distribute Gross Cash Proceeds in accordance with the following schedule of priorities:
 
 
(i)
First, for the payment to TPL (or, in the case of any payment to satisfy the obligations of the Company under Section 4.2 of the Commercialization Agreement, directly to the Person identified by TPL) in satisfaction of the Company’s payment obligations under Sections 4.2 and 4.3 of the Commercialization Agreement;
 
 
(ii)
Next, to the payment of any Company Expenses;
 
 
(iii)
Next, for the Working Capital Fund until the Working Capital Fund equals Eight Million Dollars ($8,000,000);
 
 
(iv)
Next,
 
 
(1)
for payment to Patriot of an amount equal to ten percent (10%) of the Gross Cash Proceeds until Patriot shall have received Twenty Million Dollars ($20,000,000); and
 
 
(2)
for payment to TPL of an amount equal to fifteen percent (15%) of the Adjusted Gross Cash Proceeds minus any amounts previously advanced to TPL (and not previously credited against payments to TPL hereunder) pursuant to Section 4.3 of the Commercialization Agreement; and
 
 
(v)
Finally, the remaining Gross Cash Proceeds (such remaining amount, the “Net Cash Proceeds”) to the Members according to their respective Percentage Interests.
 
In the event that funds sufficient to satisfy the payments required to be made pursuant to subsections (iv)(a) and (iv)(b) above are unavailable, such payment obligations shall be pari passu, and any unpaid amounts thereof shall be paid from Gross Cash Proceeds subsequently received by the Company.
 

 
(b) Distribution of Company Property. Company property shall be distributed only pursuant to Article VIII.
 
(c) Withholdings. All amounts withheld pursuant to the Code or any provisions of state or local tax law with respect to any payment or distribution to the Members from the Company shall be treated as amounts distributed to the relevant Members pursuant to this Section 6.1.
 
6.2 Allocation of Net Profits. Subject to the provisions of Sections 6.4 and 6.5, Net Profits for any Fiscal Year or other period shall be allocated to the Members according to their Percentage Interests.
 
6.3 Allocation of Net Losses. Subject to the provisions of Sections 6.4 and 6.5, Net Losses for any Fiscal Year or other period shall be allocated to the Members according to their Percentage Interests.
 
6.4 General Rules for Allocations. The rules of this Section 6.4 shall govern all allocations under this Article:
 
(a) Except as otherwise provided in this Operating Agreement, an allocation of Net Profits or Net Losses shall be treated as an allocation between the Members of the same share of each item of income, gain, loss and deduction that is taken into account in computing such Net Profits or Net Losses, as the case may be.
 
(b) If any Member is deemed to have received imputed income with respect to any property licensed or otherwise made available to the Company pursuant to this Operating Agreement, the corresponding imputed expenses to the Company arising out of such arrangement shall be specially allocated to such Member.
 
(c) For purposes of determining the Net Profits or Net Losses allocable to any period, the Net Profits and Net Losses shall be determined on a daily, monthly or other basis, as determined by the Management Committee using any permissible method under Section 706 of the Code and the Treasury Regulations promulgated thereunder.
 
6.5 Special Allocations to Capital Accounts.
 
(a) Notwithstanding anything to the contrary contained in this Article 6, if there is a net decrease in Company Minimum Gain or in any Member Minimum Gain during any taxable year or other period, prior to any other allocation pursuant hereto, such Member shall be specially allocated items of income and gain for such year (and, if necessary, subsequent years) in an amount and manner required by Treasury Regulation Sections 1.704-2(f) or 1.704-2(i)(4). The items to be so allocated shall be determined in accordance with Treasury Regulation Section 1.704-2.
 

 
(b) Nonrecourse Deductions for any taxable year or other period shall be allocated (as nearly as possible) under Treasury Regulation Section 1.704-2 to the Members, pro rata in proportion to their respective Percentage Interests.
 
(c) Any Member Nonrecourse Deductions for any taxable year or other period shall be allocated to the Member that made, or guaranteed or is otherwise liable with respect to the loan to which such Member Nonrecourse Deductions are attributable in accordance with principles under Treasury Regulation Section 1.704-2(i).
 
(d) Any Member who unexpectedly receives an adjustment, allocation or distribution described in Treasury Regulation Section 1.704-1(b)(2)(ii)(d)(4), (5) or (6) which causes or increases a negative balance in his or its Capital Account shall be allocated items of income and gain sufficient to eliminate such increase or negative balance caused thereby, as quickly as possible, to the extent required by such Treasury Regulation.
 
(e) No allocation or loss or deduction shall be made to any Member if, as a result of such allocation, such Member would have an Adjusted Capital Account Deficit. Any such disallowed allocation shall be made to the Members entitled to receive such allocation under Treasury Regulation Section 1.704 in proportion to their respective Percentage Interests. If losses or deductions are reallocated under this subsection 6.5(e), subsequent allocations of income and losses (and items thereof) shall be made so that, to the extent possible, the net amount allocated under this subsection 6.5(e) equals the amount that would have been allocated to each Member if no reallocation had occurred under this subsection 6.5(e).
 
(f) For purposes of Section 752 of the Code and the Treasury Regulations thereunder, excess nonrecourse liabilities (within the meaning of Treasury Regulations Section 1.752-3(a)(3)) shall be allocated to the Members pro rata in proportion to their respective Percentage Interests.
 
(g) The allocations contained in Sections 6.5(a), 6.5(c), 6.5(d) and 6.5(e) (the “Regulatory Allocations”) are intended to comply with certain requirements of Treasury Regulation Sections 1.704-1 and 1.704-2. The Regulatory Allocations shall be taken into account in allocating Net Profit and Net Loss and other items of income, gain, loss and deduction among the Members so that to the extent possible, the allocations contained in this Agreement other than the Regulatory Allocations and the Regulatory Allocations made to each Member shall equal the net amount that would have been allocated to each Member had the Regulatory Allocations not occurred. The Management Committee shall take account of the fact that certain of the Regulatory Allocations will occur at a period in the future for purposes of applying this Section 6.5(g).
 
6.6 Tax Allocations; Section 704(c) of the Code.
 
(a) Except as otherwise provided in this Section 6.6, for income tax purposes, each item of income, gain, loss, and deduction of the Company shall be allocated among the Members in accordance with the manner in which the equivalent items of Net Profits and Net Losses were allocated under the preceding sections of this Article VI.
 
(b) In the event the Book Value of a Company asset differs from its adjusted federal income tax basis, then all allocations of income, gain, loss and deduction with respect
 

 
to such asset shall take into account any variation between the adjusted tax basis of such asset and its Book Value. Such allocations shall be made under the principles of Sections 704(b) and 704(c) of the Code and the Treasury Regulations thereunder and are intended to eliminate, to the extent possible, disparities that otherwise exist between the balances of the Members’ Capital Accounts, as maintained by the Company, and such balances had the Capital Accounts been maintained in accordance with tax accounting principles. It is intended, for example, that any taxable gain recognized by the Company upon the disposition of property contributed by a Member to the Company shall be allocated to the contributing Member to the extent that the property’s initial Book Value exceeded its adjusted income tax basis on the date of the contribution, with any excess taxable gain being allocated to the Members (including the contributing Member) in a manner that coincides with the corresponding allocation of “book” gain. Any elections, accounting conventions or other decisions relating to such allocations shall be made by the Management Committee in a manner that (i) reasonably reflects the purposes and intention of this Operating Agreement, and (ii) complies with Sections 704(b) and 704(c) of the Code and the Treasury Regulations thereunder. The Management Committee shall determine the method set forth in Treasury Regulation Section 1.704-3c to be used for allocating such terms.
 
6.7 Tax Matters Member.
 
(a) At such time as it deems necessary, the Management Committee shall elect the “Tax Matters Member” of the Company for purposes of Section 6231(a)(7) of the Code. The Tax Matters Member shall have the power to manage and control, on behalf of the Company, any administrative proceeding at the Company level with the Internal Revenue Service relating to the determination of any item of Company income, gain, loss, deduction or credit for federal income tax purposes.
 
(b) The Tax Matters Member shall, within ten (10) days of the receipt of any notice from the Internal Revenue Service in any administrative proceeding at the Company level relating to the determination of any Company item of income, gain, loss, deduction or credit, mail a copy of such notice to the other Members.
 
6.8 Section 754 Election. The Tax Matters Member may, in its discretion, make, on behalf of the Company, an election in accordance with Section 754 of the Code so as to adjust the basis of Company property in the case of a distribution of property within the meaning of Section 734 of the Code, and in the case of a transfer of a Member’s Percentage Interest within the meaning of Section 743 of the Code. Each Member shall, upon the request of the Tax Matters Member, furnish such information as the Tax Matters Member shall deem necessary or appropriate to give effect to such election.
 
6.9 Returns and Other Elections. The Chief Financial Officer shall cause the preparation and timely filing all tax returns required to be filed by the Company pursuant to the Code and all other tax returns deemed necessary and required in each jurisdiction in which the Company does business. Copies of those returns, or pertinent information from the returns, shall be furnished to the Members within a reasonable time after the end of the Company’s fiscal year. All elections permitted to be made by the Company
 

 
under federal or state laws shall be made by the Chief Financial Officer, provided that the Management Committee may direct the Chief Financial Officer to make or refrain from making any tax election.
 
6.10 Partnership Tax Treatment. The Members expect and intend that the Company shall be treated as a partnership for all federal and state income tax purposes, and the Members agree that they will not: (a) take a position on any federal, state, local or other tax return, or otherwise assert a position, inconsistent with such expectation and intent; or (b) elect for the Company to be treated as an association for tax purposes or do any other act or thing which could cause the Company to be treated as other than a partnership for federal income tax purposes.
 
ARTICLE 7
INDEMNIFICATION AND LIMITATION OF LIABILITY
 
7.1 Indemnification.
 
(a) To the fullest extent permitted by the Act and by law, the Members, Managers, officers and employees of the Company, as well as their respective Representatives (collectively, “Indemnitees”) shall, in accordance with this Section 7.1, be indemnified, protected, held harmless and defended by the Company from and against any and all Damages and Liabilities by reason of their management of, or involvement in, the affairs of the Company, or rendering of advice or consultation with respect thereto, or which relate to the Company, its properties, business or affairs, if such Indemnitee acted in good faith and in a manner such Indemnitee reasonably believed to be in, or not opposed to, the best interests of the Company.
 
(b) If any Indemnitee shall believe that such Indemnitee is entitled to indemnification pursuant to this Article 7 in respect of any Damages or Liabilities, such Indemnitee shall give the Company prompt written notice thereof. Any such notice shall set forth in reasonable detail and to the extent then known the basis for such claim for indemnification. The failure of such Indemnitee to give notice of any claim for indemnification promptly shall not adversely affect such Indemnitee’s right to indemnity hereunder except to the extent that such failure adversely affects the right of the Company to assert all reasonable defenses to such claim. Each such claim for indemnity shall expressly state that the Company shall have only the thirty (30) calendar day period referred to in the next sentence to dispute or deny such claim. The Company shall have thirty (30) calendar days following its receipt of such notice either (y) to acquiesce in such claim and the responsibility to indemnify the Indemnitee in respect thereof in accordance with the terms of this Article 7 by giving such Indemnitee written notice of such acquiescence or (z) to object to the claim by giving such Indemnitee written notice of the objection. If the Company does not object thereto within such thirty (30) calendar day period, the Company shall be deemed to have acquiesced in such claim and the responsibility to indemnify the Indemnitee in respect thereof in accordance with the terms of this Article 7.
 
(c) In connection with any claim which may give rise to indemnity under this Article 7 resulting from or arising out of any claim or Proceeding against an Indemnitee by a
 

 
Person that is not a party hereto, the Company may (unless such Indemnitee elects not to seek indemnity hereunder for such claim), upon written notice sent at any time to the relevant Indemnitee, assume the defense of any such claim or Proceeding if the Company with respect to such claim or Proceeding acknowledges to the Indemnitee the Indemnitee’s right to indemnity pursuant hereto in respect of the entirety of such claim (as such claim may have been modified through written agreement of the parties or arbitration hereunder) and provide assurances, reasonably satisfactory to such Indemnitee, that the Company will be financially able to satisfy such claim in full if such claim or Proceeding is decided adversely. The Company shall select counsel reasonably acceptable to such Indemnitee to conduct the defense of such claim or Proceeding, shall take all steps reasonably necessary in the defense or settlement thereof and shall at all times diligently and promptly pursue the resolution thereof. If the Company shall have assumed the defense of any claim or Proceeding in accordance with this Section 7, the Company shall not (without the written consent of each Indemnitee) consent to a settlement of, or the entry of any judgment arising from, any such claim or Proceeding, unless such settlement or order shall provide for the unconditional release of all Indemnitees. If the Company has so elected to assume the defense, each Indemnitee shall be entitled to participate in (but not control) the defense of any such action, with its own counsel and at its own expense. Each Indemnitee shall, and shall cause each of its Representatives to, cooperate fully with the Company in the defense of any claim or Proceeding being defended by the Company pursuant to this Section 7. If the Company does not assume the defense of any claim or Proceeding resulting therefrom in accordance with the terms of this Section 7, such Indemnitee may defend against such claim or Proceeding in such manner as it may deem appropriate, provided that the Indemnitee may not settle such claim or Proceeding without the written consent of the Company (which consent shall not be unreasonably withheld or delayed), and provided further that the Company shall be obligated to pay Indemnitee’s attorneys’ fees and costs promptly as they are incurred in the defense of such claim or Proceeding.
 
(d) The indemnification provided by this Section 7.1 shall not be deemed to be exclusive of any other rights to which any Person may be entitled under any agreement, or as a matter of law, or otherwise, both as to action in a Person’s official capacity and to action in another capacity.
 
(e) The Management Committee shall have power to purchase and maintain insurance on behalf of the Company, the Managers, the Members, officers, employees or agents of the Company and any other Indemnitees at the expense of the Company, against any liability asserted against or incurred by them in any such capacity whether or not the Company would have the power to indemnify such Persons against such liability under the provisions of this Operating Agreement.
 
7.2 Limitation of Liability. The debts, obligations and liabilities of the Company shall be solely the debts, obligations and liabilities of the Company; and, except as provided under the Act, no Manager or Member shall be obligated personally for any such debt, obligation or liability of the Company solely by reason of being a Manager or Member of the Company.
 
7.3 Savings Clause. If this Article 7 or any portion hereof shall be invalidated on any ground by any court of competent jurisdiction, the Company shall nevertheless indemnify and hold harmless each Indemnitee or any other person indemnified pursuant to this Article 7 as to costs, charges and expenses (including, without limitation, reasonable attorneys’ fees), judgments, fines and amounts paid in settlement with respect to any action, suit or proceeding, whether civil, criminal, administrative or investigative, to the full extent permitted by any applicable portion of this Article 7 that shall not have been invalidated and to the fullest extent permitted by applicable law.
 

 
ARTICLE 8
DISSOLUTION AND WINDING UP
 
8.1 Dissolution. The Company shall be dissolved, its assets shall be disposed of, and its affairs wound up on the first to occur of the following:
 
(a) The written agreement of Members holding at least seventy-five percent (75%) of the Percentage Interests to dissolve the Company; or
 
(b) The entry of a decree of judicial dissolution under Section 18-802 of the Act.
 
Except for the foregoing, the Company shall not dissolve on the occurrence of any other event.
 
8.2 Winding Up. Upon the occurrence of any event specified in Section 8.1, the Management Committee promptly shall notify each of the Members, and the Company shall continue solely for the purpose of, and immediately begin the process of, winding up its affairs in an orderly manner, liquidating its assets, and satisfying the claims of its creditors. The Management Committee shall promptly appoint a Person to act as the liquidator of the Company (the “Liquidator”) who shall be responsible for overseeing the winding up and liquidation of the Company pursuant to the terms of this Operating Agreement. The Liquidator shall give written notice of the commencement of winding up by mail to all known creditors and claimants whose addresses appear on the records of the Company.
 
8.3 Reversion of Rights. Upon the occurrence of any event specified in Section 8.1, or upon the valid termination of the Commercialization Agreement by the Company, all of the rights granted by each of Patriot and TPL to the Company pursuant to the P-Newco License and T-Newco License, respectively, shall immediately and without further action by any of the parties thereto revert in their entirety to each of Patriot and TPL, respectively.
 
8.4 Order of Payment Upon Liquidation. Immediately after the reversion of rights contemplated by Section 8.3 above, payment shall be made in the manner contemplated by Section 6.1.
 
8.5 Antecedent Activities.
 
 


(a) The occurrence of any Recovery Event within twelve (12) months of a Termination Event, as defined in Section 6.2 of the Commercialization Agreement, shall entitle each of the Members to payment of the proceeds of such Recovery Event in accordance with Section 6.1.
 
(b) The entitlements set forth in Section 8.5(a) shall vest in the Members without further action. All proceeds and incidents of any such Recovery Event shall be transferred by the Member receiving such proceeds within three (3) Business Days (as defined in the Master Agreement) after receipt of such proceeds directly into an independent escrow account approved by Patriot and TPL for distribution pursuant to the terms of this Operating Agreement and the joint instructions of Patriot and TPL.
 
8.6 Limitations on Payments Made in Dissolution. Each Member shall only be entitled to look to the assets of the Company for the return of its Initial Capital Contribution, Working Capital Contribution and positive Capital Account balance and shall have no recourse for its Initial Capital Contribution, Working Capital Contribution, positive Capital Account balance and/or share of Gross Cash Proceeds (upon dissolution or otherwise) against the Management Committee or any other Member in the event the assets of the Company remaining after payment of or due provision for all debts, liabilities and obligations of the Company are insufficient to return such Member’s Initial Capital Contribution and positive Capital Account balance.
 
8.7 Certificate of Cancellation. When all debts, liabilities and obligations have been paid and discharged or adequate provisions have been made therefor and all of the remaining property and assets have been distributed to the Members, a certificate of cancellation shall be executed in duplicate and verified by all three (3) Managers, which certificate shall set forth the information required by the Act. Duplicate originals of the certificate of cancellation shall be delivered to the Secretary of State of the State of Delaware.
 
8.8 Effect of Filing Certificate of Cancellation. Upon the issuance of the certificate of cancellation, the existence of the Company shall cease. The Management Committee shall have the authority to distribute any Company property discovered after dissolution and take such other action as may be necessary on behalf of and in the name of the Company.
 
ARTICLE 9
MISCELLANEOUS
 
9.1 Amendment. The Management Committee shall have the duty and authority to amend the Certificate of Formation as and to the extent necessary to reflect any and all changes or corrections necessary or appropriate as a result of any action taken by the Members in accordance with the terms of this Operating Agreement. Members holding at least seventy-five percent (75%) of the Percentage Interests shall have the authority to amend this Operating Agreement. Notwithstanding anything to the contrary set forth herein, neither the Management Committee nor the Members may amend the Certificate of Formation or this Operating Agreement to decrease the Percentage Interest of a
 

 
Member, increase the Working Capital Contributions of a Member or the liability of a Member with respect to the Company without the consent of each Member affected thereby.
 
9.2 Governing Law and Severability. This Operating Agreement shall, in all respects, be construed in accordance with and governed by the laws of the State of Delaware as applied to agreements among Delaware residents entered into and to be performed entirely within Delaware. If any provision of this Operating Agreement becomes or is deemed invalid, illegal or unenforceable in any jurisdiction by reason of the scope, extent or duration of its coverage, then such provision shall be deemed amended to the extent necessary to conform to applicable law so as to be valid and enforceable or, if such provision cannot be so amended without materially altering the intention of the parties, then such provision shall be stricken and the remainder of this Operating Agreement shall continue in full force and effect. Should there ever occur any conflict between any provision contained in this Operating Agreement and any present or future statute, law, ordinance or regulation contrary to which the parties have no legal right to contract, the latter shall prevail, but the provision of this Operating Agreement affected thereby shall be curtailed and limited only to the extent necessary to bring it into compliance with the law. All the other terms and provisions of this Operating Agreement shall continue in full force and effect without impairment or limitation.
 
9.3 Counterparts. This Operating Agreement may be executed simultaneously in multiple counterparts and by facsimile, each of which shall be deemed an original, but all of which taken together shall constitute one and the same instrument.
 
9.4 Titles and Subtitles. The headings of this Operating Agreement are inserted for convenience only and shall not constitute a part of this Operating Agreement in construing or interpreting any provision hereof.
 
9.5 Notices. All notices and other communications required or permitted under this Operating Agreement shall be delivered to the parties at the address appearing on the books of Company, or at such other address that they designate by notice to all other parties in accordance with this section. All notices and communications shall be deemed to have been received unless otherwise set forth herein: (a) in the case of personal delivery, on the date of such delivery; (b) in the case of facsimile transmission, on the date on which the sender receives confirmation by facsimile transmission that such notice was received by the addressee, provided that a copy of such transmission is additionally sent by mail as set forth in (d) below; (c) in the case of overnight air courier, on the second business day following the day sent, with receipt confirmed by the courier; and (d) in the case of mailing by first class certified or registered mail, postage prepaid, return receipt requested, on the fifth business day following such mailing.
 
9.6 Entire Agreement. This Operating Agreement, as well as the Stipulated Final Judgment, Master Agreement, Commercialization Agreement and Newco Licenses, constitutes the entire agreement and
 

 
understanding of the parties with respect to the terms and conditions of the transactions referred to herein and therein and supersede all prior and contemporaneous agreements and understandings, oral or written, between the parties relating to such subject matter, other than as provided herein and therein.
 
9.7 Power of Attorney. By signing this Operating Agreement, each Member designates and appoints the Management Committee as their true and lawful attorney, in his name, place and stead, to make, execute, sign and file such instruments, documents or certificates which may from time to time be required by the laws of the United States of America and the State of Delaware and any political subdivision thereof or any other state or political subdivision in which the Company shall do business to carry out the purposes of this Operating Agreement, except where such action requires the express approval of a Member hereunder. The Management Committee shall provide to the Members copies of all documents executed pursuant to the power of attorney contained in this Section 9.7.
 
9.8 Related Party Transactions. The Company shall not, without the approval of the Management Committee, engage in any loans, leases, contracts or other transactions with any Manager, officer or key employee of the Company, any member of any such person’s immediate family, including the parents, spouse, children and other relatives of any such person, or any Person controlled by such person, with the exception of the payments to be made to TPL pursuant to Article IV of the Commercialization Agreement.
 
9.9 Dispute Resolution. All rights and obligations under this Operating Agreement shall be resolved as if all persons and all transactions related to this Operating Agreement had their legal residence, situs, and employment in Santa Clara County, California. Within fifteen (15) days after written notice of the dispute, members of the most senior management of the parties shall meet and exercise their best efforts to resolve any dispute under this Operating Agreement. If the dispute is not resolved to the mutual satisfaction of the parties within thirty (30) days after such notice, the Company, Patriot and TPL shall submit such dispute to expedited binding arbitration before a single arbitrator. The arbitration shall be administered by JAMS pursuant to its Comprehensive Arbitration Rules and Procedures. Judgment on the award, including without limitation injunctive relief, may be entered in any court having jurisdiction. All costs related to such arbitration shall be paid in advance by the Company, including the cost of translating into English all discoverable materials, and of providing contemporaneous translation of all live testimony. All performances due hereunder by the Company, Patriot and TPL shall continue unabated throughout the entire process and a final adjudication in accordance with the terms hereof has been made from which no appeal or review can be undertaken. This clause shall not preclude the parties from seeking provisional remedies in aid of arbitration, including without limitation a temporary or preliminary injunctive relief, from a court of appropriate jurisdiction. The arbitrator may, in the award, allocate all or part of the costs of the arbitration, including the fees of the arbitrator and the reasonable attorneys’ fees of the prevailing party.
 
9.10 No Partition. No Member nor any legal successor of a Member shall have the right to partition the property of the Company or any part thereof or interest therein, or to file a complaint or institute any proceeding at law or in equity to partition the property of the Company or any part thereof or interest therein. Each Member, for such Member and such Member’s legal successor, hereby waives any such rights. The Members intend that, during the term of this Operating Agreement, the rights of the Members and their successors in interest, as among themselves, shall be governed solely by the terms of this Operating Agreement and by the Act.
 
9.11 Bankruptcy. Neither the Management Committee, nor any Manager or Member of the Company, shall be permitted to file a bankruptcy petition on behalf of the Company unless the filing of the bankruptcy petition shall first have been approved in writing by Members holding at least seventy-five percent (75%) of the Percentage Interests of the Company.
 
[signature page follows]
 

 
IN WITNESS WHEREOF, the parties hereto have executed this Operating Agreement as of the day and year first above written.
 
PATRIOT SCIENTIFIC CORPORATION,
a Delaware corporation
 
By:________________________________________
Its:________________________________________
 
 
TECHNOLOGY PROPERTIES LIMITED INC.,
a California corporation
 
By:________________________________________
Daniel E. Leckron
Its:  Chairman
 

 

 
SCHEDULE 1
 
INITIAL CAPITAL CONTRIBUTIONS
 
 
MEMBER
 
CONTRIBUTIONS
 
AGGREGATE FAIR MARKET VALUE OF CONTRIBUTIONS
Patriot Scientific Corporation
 
· P-Newco License
· $2,000,000
   
Technology Properties Limited Inc.
 
· T-Newco License
· $2,000,000
   

 


SCHEDULE 2
 
PERCENTAGE INTERESTS
 

 
MEMBER
 
PERCENTAGE INTEREST
Patriot Scientific Corporation
 
50%
Technology Properties Limited Inc.
 
50%
 

 

 
EXHIBIT A
 
 
CONSENT OF CHARLES H. MOORE
TO
LIMITED LIABILITY OPERATING AGREEMENT
OF
P-NEWCO
A DELAWARE LIMITED LIABILITY COMPANY

 
Charles H. Moore (“Moore”) does hereby affirm and acknowledge that:
 
(a) Moore has read and reviewed the accompanying Limited Liability Company Operating Agreement (the “P-Newco Operating Agreement”) for P-Newco, a Delaware Limited Liability Company (“P-Newco”) and is familiar with the contents thereof;
 
(b) Technology Properties Limited Inc., a California Corporation, has full power and authority to enter into the P-Newco Operating Agreement insofar as it affects the interests of Moore in the microprocessor science and design patents set forth on Schedule 1 to the Master Agreement, to which Moore is a party; and
 
(c) Moore consents to the P-Newco Operating Agreement.
 
IN WITNESS WHEREOF, Moore has executed this Consent as of the [__] day of [__________], 2005.
 
CHARLES H. MOORE
 
________________________________________
 


EXHIBIT C
 
NEWCO LICENSE

This License ("License") is entered into by and between ______________ (“___”) as the Licensor on the one hand, and NewCo as the Licensee ("NewCo") on the other hand, as a part of that certain _________ ("__Ag”) entered into between the parties contemporaneously herewith.

NOW THEREFORE, for and in consideration of the mutual cove-nants herein contained as well as of other good and valuable consideration the receipt and sufficiency of which is hereby acknowledged, it is covenanted and agreed by and between the parties hereto that:

1. Subject Matter.

1.1. The patents described in the Schedule of Patents at Attachment I hereof, sometimes collectively referred to as the “Licensed Patents”.

2. Grant of License.

2.1. ____ hereby grants unto NewCo an exclusive, personal, and non-transferable, worldwide right and license:

2.1.1. To grant sublicenses to make, have made, use, sell, and import products utilizing the Licensed Patents; and,

2.1.2. To sue either in its own name or jointly with Licensor if required by law, and to pursue for the use and benefit of NewCo: (i) all remedies of whatsoever kind or nature with respect to the protection, use, and enforcement of the Licensed Patents; (ii) the collection of all claims for damages, profits, and awards relating to the past, present, or future use or ownership of the Licensed Patents; and (iii) all equitable relief available in connection therewith.

2.2. Provided, however, that ___ shall for all purposes be deemed to have retained a non-exclusive, worldwide, irrevocable right and license:

2.2.1 To utilize the Licensed Patents on a royalty-free basis to make, have made, use, sell and/or import products that are designed, manufactured, and sold by ___ under brand names currently owned or subsequently originated and owned by ___; and,


2.2.2. To utilize the Licensed Patents on a royalty-bearing basis to make, have made, use, sell and/or import products that are not designed, manufactured, and sold by ___under brand names currently owned or subsequently originated and owned by ___.

3. Royalty.

3.1. ___ shall be entitled to receive as a royalty under this License that certain portion of the Net Recovery realized from the commercialization of the Licensed Patents which is provided for and payable under the terms of the __ Ag entered into contemporaneously herewith.

3.2. _____ shall pay to NewCo a royalty for all products described in section 2.2.2. which is fair, reasonable, non-discriminatory, and within the terms of NewCo's standard licensing programs then in effect.

4. Dispute Resolution

4.1. All rights and obligations under this Agreement shall be resolved as if all persons and all transactions related to this Agreement had their legal residence, situs, and employment in Santa Clara County, California. Within 15 days after written notice of the dispute, members of the most senior management of the parties shall meet and exercise their best efforts to resolve any dispute under the Agreement. If the dispute is not resolved to the mutual satisfaction of the parties within 30 days after such notice, NewCo shall as requested by ____, either:

4.1.1. Submit such dispute to expedited binding arbitration under the rules of the American Arbitration Association with discovery in general accordance with the Federal Rules of Civil Procedure. All costs related to such Arbitration shall be paid in advance by NewCo, including the cost of translating into English all discoverable materials, and of providing contemporaneous translation of all live testimony; or,

4.1.2. Submit such dispute to the Superior Court of Santa Clara County, California, for resolution by Summary Judgment and/or trial by jury as directed by the said Court.

4.2. At ______'s option, NewCo shall submit any issue of validity to the issuing patent office in a Petition for Reexamination or comparable proceeding. The outcome shall be binding on the parties unless appealed by _______.


4.3. In either case, all performances due hereunder by NewCo shall continue unabated throughout the entire process and a final adjudication in accordance with the terms hereof has been made from which no appeal or review can be undertaken.

5. General.

5.1. In no event shall any right, duty, or privilege arising hereunder be assigned by either party to an entity which it does not own and control, without the prior written consent of the other party. Any attempted or purported assignment without such consent shall be voidable at the option of the non-consenting party.

5.2. Any covenant requiring a party to perform or provide an act or service shall be construed to impose upon such party the burden of the cost thereof unless otherwise provided for herein.

5.3. Section titles are intended only to aid and assist the reader as an index device and are not intended to be descriptive of the contents of the section or to be used for construction or interpretation.

5.4. The failure of any provision of this Agreement by virtue of its being construed as invalid or otherwise unenforceable shall render the entire Agreement cancelable at the option of the party asserting the enforceability of the said provision.

5.5. All notices shall be in writing and effective upon delivery or upon posting by certified mail, return receipt requested, addressed as follows (or such other address as may be hereafter designated):

If to ______:
If to NewCo:
______________________
______________________
(address)
(address)

5.5. This Agreement together with its exhibits and attachments contains the entire agreement between the parties and supersedes any and all other agreements between them relating to the subject matter hereof.

6. Attachments.

6.1. Attachment I: Schedule of Patents



IN WITNESS WHEREOF, the parties have hereunto set their hands and seals as of the date of the execution hereof by the last signatory hereto.
 
____________________________
NEWCO
   
   
by ____________________________
by ____________________________
  ___________________________
  __________________________
   
   
   
date: _________________________
date: _______________________
 


ATTACHMENT I (For ___Ag)
SCHEDULE OF PATENTS
 
 

 
EXHIBIT D
 

 
COMMERCIALIZATION AGREEMENT
 
by and among
 
P-NEWCO
 
and
 
TECHNOLOGY PROPERTIES LIMITED
 
and
 
PATRIOT SCIENTIFIC CORPORATION
 

 

 

 

 
***
Indicates material omitted pursuant to an application for confidential treatment and that material has been filed separately with the Commission.
 


 
TABLE OF CONTENTS
 
Page
   
ARTICLE 1 GRANT
1
ARTICLE 2 COMMERCIALIZATION
2
ARTICLE 3 COVENANTS
3
ARTICLE 4 PAYMENT ***
4
ARTICLE 5 TERM
5
ARTICLE 6 TERMINATION
5
ARTICLE 7 REPRESENTATIONS AND WARRANTIES
6
ARTICLE 8 GENERAL
7
 
EXHIBIT A
GRANT & SCHEDULE OF PATENTS
SCHEDULE 1
SCHEDULE OF PATENTS
SCHEDULE 2
PROJECT DESCRIPTION ***
SCHEDULE 3
SCHEDULE OF OUTSTANDING ACTIVITIES/RIGHTS/CLAIMS
 

 
COMMERCIALIZATION AGREEMENT

This Commercialization Agreement (“Commercialization Agreement”) is entered into by and among [P-Newco], a Delaware limited liability corporation (“P-Newco”), Patriot Scientific Corporation, a Delaware corporation (“Patriot”), having its principal place of business at 10989 Via Frontera, San Diego, California 92127, and Technology Properties Limited Inc., a California Corporation (“TPL”), having its principal place of business at 21730 Stevens Creek Boulevard, Ste. 201, Cupertino, California 95014. Capitalized terms used but not defined herein shall have the meanings given to such terms in that certain agreement dated as of June 7, 2005 (the “Master Agreement”).
 
WHEREAS, Patriot, TPL and Charles H. Moore (“Moore”) collectively hold all rights with respect to certain microprocessor implementation and architecture patents set forth on Schedule 1 (the “MSD Patents”);
 
WHEREAS, Moore has transferred complete authority for the management of Moore’s rights to the MSD Patents to TPL;
 
WHEREAS, Patriot, TPL and Moore have entered into the Master Agreement, pursuant to which Patriot and TPL are entering into licenses with P-Newco and T-Newco, respectively, with respect to certain of their rights in the MSD Patents (collectively, the “Newco Licenses”);
 
WHEREAS, Patriot, TPL, P-Newco and T-Newco have entered into a Merger Agreement, pursuant to which T-Newco merged with and into P-Newco, with P-Newco continuing as the surviving entity and holding all of the rights with respect to the MSD Patents formerly held by P-Newco and T-Newco;
 
WHEREAS, pursuant to the Master Agreement, P-Newco, Patriot and TPL are entering into this Commercialization Agreement providing for the commercialization of P-Newco’s interests in the MSD Patents by TPL in return for the commitment of TPL to diligently pursue the commercialization; and
 
WHEREAS, concurrently herewith Patriot and TPL are entering into that certain Limited Liability Company Operating Agreement of P-Newco (the “Operating Agreement”), governing the rights and obligations of Patriot and TPL with respect to their membership interests in P-Newco and the distribution of the proceeds received from the commercialization program contemplated by this Commercialization Agreement.
 
NOW THEREFORE, for and in consideration of the mutual covenants herein contained as well as other good and valuable consideration the receipt and sufficiency of which is hereby acknowledged, the parties hereto covenant and agree that:
 
ARTICLE I
GRANT
 
1.1 Pursuant to the Master Agreement, P-Newco and TPL shall enter into the grant attached hereto as Exhibit A (the “Grant”).
 

 
ARTICLE II
COMMERCIALIZATION
 
2.1 TPL shall exert reasonable best efforts to implement the activities (the “Commercialization”) described at Schedule 2 and to conduct the project described therein (“Project”) in accordance with the project description (the “Project Description”) including the Business Plan then in effect.
 
(a) The first Business Plan is made a part of the Project Description as Attachment I to Schedule 2, and shall remain in full force and effect until replaced by agreement of P-Newco and TPL.
 
(b) TPL shall have no obligation to pursue or fund any effort to prosecute, maintain, enforce or defend any element of the MSD Patents other than as specifically provided for in Schedule 2.
 
2.2 By these presents, P-Newco appoints, authorizes, and directs TPL to take any and all action for the term of this Commercialization Agreement, with respect to all matters that are related to P-Newco’s rights to the MSD Patents, including without limitation:
 
(a) entering into settlement and/or license agreements related to the MSD Patents which meet the Commercialization guidelines set forth in Section II of Schedule 2;
 
(b) with the prior written consent of the P-Newco Management Committee, entering into any settlement and license agreements related to the MSD Patents which do not meet the guidelines set forth in Section II of Schedule 2;
 
(c) to sue in the name of TPL, Moore, Patriot and/or P-Newco and to pursue for the use and benefit of the parties hereto as their respective interests appear: (i) all remedies of whatsoever kind or nature with respect to the protection, use, and enforcement of the MSD Patents; (ii) the collection of all claims for damages, profits, and awards relating to the past, present, or future use or ownership of the MSD Patents; and (iii) all equitable relief available in connection therewith; and
 
(d) to otherwise manage and control by license, sublicense, or other agreement the practice and/or use of the MSD Patents by third parties.
 
2.3. TPL may utilize the services of its various licensing personnel who may be lawyers to implement the Commercialization of the MSD Patents. Such services shall for no purpose be deemed to be legal services or to give rise to a lawyer-client relationship between TPL and/or TPL affiliates or Representatives on the one hand, and P-Newco and/or Patriot or any of their respective affiliates or Representatives on the other hand. Without limiting the foregoing, neither TPL nor any TPL Representative shall for any purpose be deemed to have:
 
 
(i)
Provided legal services or advice to;
 
 
(ii)
Undertaken the representation of; or
 
 


 
(iii)
Entered into a lawyer-client relationship with,
 
P-Newco, Patriot or any of P-Newco’s or Patriot’s respective affiliates or Representatives.
 
ARTICLE III
COVENANTS
 
3.1 Within sixty (60) days after the close of each calendar quarter TPL shall deliver to P-Newco: (i) an operating statement reflecting the Project’s financial activity over the past quarter; (ii) a calculation of the Gross Cash Proceeds (as defined in the Operating Agreement) resulting from the Project; and (iii) an itemization of all TPL Direct Reimbursable Expenses (as defined below).
 
(a) Within thirty (30) days after P-Newco’s receipt thereof, Patriot shall deliver to TPL written notice detailing all objections to such materials and calculations on an individual item-by-item basis. Any objection not so noticed shall be deemed to be waived.
 
(b) Costs related to verifying reported time and expense charges and/or auditing reports or activities shall be paid in advance by the entity (either Patriot or TPL) supporting such request for verification or audit.
 
3.2 As requested by TPL, Patriot and P-Newco shall have a continuing obligation to exert their respective reasonable best efforts to support the Project, cooperate with TPL in the execution of its obligations, and to provide such support in the manner described herein and in the Master Agreement.
 
3.3 Upon reasonable request, P-Newco and Patriot shall promptly execute and deliver all documents, instruments, and things necessary or useful in the conduct of TPL’s activities hereunder, and Patriot and P-Newco agree to cooperate in any litigation with respect to the MSD Patents, including providing any reasonable assistance in connection with such litigation or joining as a party thereto, as requested by TPL, provided that neither Patriot nor P-Newco shall be required to provide financial support except as otherwise provided in the Commercialization Agreement.
 
3.4 Patriot and P-Newco shall each avoid and refrain from any and all activity of any kind or nature which may impede, impair, frustrate or otherwise interfere with the activities of TPL in the execution the Project, and shall:
 
(a) Exert their respective reasonable best efforts to impose the covenants of this Commercialization Agreement, the Master Agreement and the transactions contemplated hereby and thereby on their respective directors, officers, employees, consultants, attorneys, agents and other affiliates or Representatives; and
 
(b) Be responsible hereunder for each and every failure in the good and faithful performance of this Commercialization Agreement and transaction by themselves and/or their respective directors, officers, employees, consultants, attorneys, agents and other affiliates or Representatives (other than TPL).
 
3.5 With the exception of the agreements and transactions entered into pursuant to the Project, P-Newco, Patriot and TPL shall not transfer, assign, license, or otherwise convey any
 

 
interest in, or grant any security interest with respect to, any portion of their interest in the MSD Patents during the term of this Commercialization Agreement without the written consent of all parties hereto, other than to entities which are owned and controlled by the transferring Person and who assume and agree to pay and perform all of the transferor’s obligations hereunder.
 
3.6 Upon the termination of this Commercialization Agreement, Patriot shall be entitled to receive a copy of third party “DeCaps” (as such term is commonly understood to mean in the industry) related to the Commercialization and third party expert analyses thereof; and TPL does hereby consent to the deliveries thereof by such third party experts. In the event any of the foregoing are not provided by such third parties, TPL will provide Patriot with copies of such documents in its possession. In addition, a Patriot Representative shall be entitled to view such “DeCaps” on a quarterly basis, but shall not be entitled to make copies thereof. With the exception of TPL’s obligations pursuant to Section 3.1 and this Section 3.6, TPL shall not be obligated to share any other materials related to the Commercialization, including without limitation any attorney work product generated during the term of this Commercialization Agreement or thereafter, which for all intents and purposes shall be deemed to be privileged, proprietary and exclusive to TPL.
 
3.7. P-Newco and Patriot shall on a continuing basis provide TPL all leads, information, and materials which Patriot encounters or discovers which may relate to the rights to the MSD Patents transferred by Patriot and TPL to P-Newco pursuant to the Newco Licenses, shall exert their respective reasonable best efforts to support the Commercialization activities of TPL hereunder, and shall refrain from all contact with third parties regarding the MSD Patents except as is specifically approved and/or requested in writing by TPL. The foregoing shall not affect the exercise of the retained rights of Patriot or TPL under the Newco Licenses.
 
ARTICLE IV
PAYMENT
 
4.1 TPL shall cause all Gross Cash Proceeds generated from the Commercialization efforts to be paid directly to P-Newco.
 
4.2 Upon the submission of customary and appropriate invoices and other supporting documentation, P-Newco shall reimburse TPL for the payment of all legal and third-party expert fees and other related third-party costs and expenses, including without limitation those incurred in connection with patent maintenance and prosecution and third party “DeCaps” and third party expert analysis relating thereto (the “TPL Direct Reimbursable Expenses”) incurred by TPL in connection with the Project and in conformity with the applicable Business Plan, as well as all TPL Direct Reimbursable Expenses not in conformity with the applicable Business Plan, to the extent approved by the P-Newco Management Committee. All such reimbursement shall be made prior to the due date indicated on the invoice.
 
4.3 P-Newco shall make payment to TPL of $500,000 no later than three (3) days prior to the start of each fiscal quarter from the Working Capital Fund to cover indirect and other expenses related to the Project which do not constitute TPL Direct Reimbursable Expenses (“TPL Other Project Expenses”). Advances to TPL made pursuant to this Section 4.3 shall be nonaccountable and nonrecoupable, but shall offset the amounts owed TPL pursuant to Section 6.1(a)(iv)(b) of the Operating Agreement in the manner contemplated by such Section 6.1(a)(iv)(b). At such time as the
 

 
Working Capital Fund exceeds [***] after the first [***] has been generated pursuant to the Commercialization, such quarterly payment shall be increased (but not decreased) to one-eighth of the amount of the Working Capital Fund.
 
4.4 To the extent that P-Newco does not have sufficient funds from the Working Capital Fund at the time any payment is due pursuant to this Article IV, TPL shall refrain from enforcing any collection rights against P-Newco for such payments until the earlier of (a) such time as funds become available in the Working Capital Fund, or (b) termination of this Commercialization Agreement.
 
ARTICLE V
TERM
 
5.1 This Commercialization Agreement shall continue for the useful life of the MSD Patents, which shall be deemed to be the greater of the period of time during which any of the MSD Patents is either (i) susceptible to legal protection, or (ii) reasonably perceived to have commercial value.
 
5.2 In the event that facts or events are discovered or occur which materially reduce TPL’s evaluation of the useful life or commercial value of the MSD Patents, or the viability of the Project, TPL may reduce the term of this Commercialization Agreement accordingly by providing P-Newco with ninety (90) days written notice, provided that TPL shall not reduce the term of this Commercialization Agreement to less than six (6) months.
 
5.3 After the expiration of the term provided for above, neither party shall have any further obligation hereunder other than the administration of all outstanding transactions as under Article VI below, and the obligations of confidentiality undertaken by the parties.
 
ARTICLE VI
TERMINATION
 
6.1 TPL may terminate this Commercialization Agreement upon the failure of Patriot or P-Newco to substantially perform any of their material obligations to be performed hereunder, including without limitation the payment obligations pursuant to Article IV of this Commercialization Agreement.
 
6.2 P-Newco may terminate this Commercialization Agreement if:
 
(a) TPL has failed to close transactions in accordance with the Performance Milestones set forth in Section IV of Schedule 2, and
 
 
(i)
there has been no material breach by Patriot or P-Newco of this Commercialization Agreement, the Master Agreement, the Newco Licenses or the Operating Agreement; and
 
 
(ii)
there has been no event or occurrence which negatively and materially impacts the viability or value of the MSD Patents; and
 
 


 
(iii)
the failure of TPL is not reasonably attributable to the conduct of P-Newco, Patriot and/or their respective affiliates or Representatives (other than TPL); or
 
(b) TPL enters into a liquidation under Chapter 7 of the United States Bankruptcy Code; or
 
(c) TPL enters into a reorganization under Chapter 11 of the United States Bankruptcy Code, and TPL ceases to be a debtor in possession during the pendency of such bankruptcy proceeding.
 
Each of the events referred to in Sections 6.1 and 6.2 shall be referred to as a “Termination Event.” In no event shall the conduct of Moore be deemed to constitute a Termination Event.
 
6.3 Upon termination pursuant to this Article VI:
 
(a) All rights to the MSD Patents arising under the Grant or this Commercialization Agreement shall be transferred to P-Newco subject to all outstanding rights under licenses, agreements, or awards theretofore made and entered into by or with TPL prior to such expiration or termination which, for all purposes, shall continue and be administered by TPL under TPL’s then current reasonable hourly fee schedule as if this Commercialization Agreement were still in full force and effect.
 
(b) All amounts due to TPL with respect to TPL Direct Project Expenses and TPL Other Project Expenses shall be paid from Gross Cash Proceeds as such funds are received.
 
(c) At the option of Patriot, TPL, or P-Newco, all of the rights and privileges of whatsoever kind or nature granted by it shall immediately and without further action whatsoever revert in their entirety to each of Patriot, TPL, or P-Newco, as the case may be, and all licenses granting such rights and privileges shall be deemed to be for all purposes cancelled.
 
(d) In the event of a termination by P-Newco or Patriot, all claims for loss and/or damages shall be deemed to be liquidated and discharged with respect to each party upon its completion of the dissolution, distributions and the documentation and transfers contemplated by Article 8 of the Operating Agreement, provided, however, that claims based on conduct which is intentional, willful, or grossly negligent shall survive.
 
ARTICLE VII
REPRESENTATIONS AND WARRANTIES
 
7.1 P-Newco and Patriot acknowledge, represent, and warrant to TPL that:
 
(a) TPL and its Representatives have prepared this Commercialization Agreement at the request of P-Newco and Patriot and such preparation by TPL shall not be used as basis for construing the terms hereof against TPL or otherwise;
 

 
(b) Neither TPL nor its Representatives have for any purpose undertaken the representation of or entered into a lawyer/client relationship with Patriot or P-Newco or any of their Representatives;
 
(c) P-Newco and Patriot release, acquit, and agree to hold TPL and its Representatives harmless with respect to all claims of whatsoever kind or nature by or on behalf of P-Newco and Patriot and related to the preparation, execution, and delivery of this Commercialization Agreement; and,
 
(d) P-Newco and Patriot have sought and received the advice of independent counsel and are in no way relying on any advice or representations of TPL or its Representatives.
 
7.2 Patriot and TPL each represent and warrant to one another that:
 
(a) It is the sole owner of all right, title and interest in and to its portion of the MSD Patents, excepting only the rights reflected at the Schedule of Outstanding Activities/Rights/Claims attached as Schedule 3; and
 
(b) There are no outstanding agreements, rights or interests which are inconsistent with the provisions of this Commercialization Agreement or which could give rise to such rights or interests.
 
7.3 P-Newco represents and warrants to TPL that:
 
(a) It is the sole owner, and for the term of this Commercialization Agreement will remain the sole owner, of all right, title, and interest in and to those certain rights to the MSD Patents transferred by Patriot and TPL to P-Newco pursuant to the P-Newco License and T-Newco License; and
 
(b) There are no outstanding agreements, rights or interests which are inconsistent with the provisions of this Commercialization Agreement or which could give rise to such rights or interests.
 
ARTICLE VIII
GENERAL
 
8.1 In no event shall any right, duty or privilege arising hereunder be assigned by either party to an entity which it does not own and control without the prior written consent of the other parties. Any attempted or purported assignment without such consent shall be voidable at the option of the non-consenting party.
 
8.2 Any covenant requiring a party to perform or provide an act or service shall be construed to impose upon such party the burden of the cost thereof unless otherwise provided for herein.
 
8.3 Section titles are intended only to aid and assist the reader and are not intended to be descriptive of the contents of the section or to be used for construction or interpretation.
 

 
8.4 The failure of any provision of this Commercialization Agreement by virtue of its being construed as invalid or otherwise unenforceable shall render the entire Commercialization Agreement cancelable at the option of the party asserting the enforceability of the said provision.
 
8.5 All notices shall be in writing and effective upon delivery or upon posting by certified mail, return receipt requested, addressed as follows (or such other address as may be hereafter designated):
 
If to Patriot:

Patriot Scientific Corporation
10989 Via Frontera
San Diego, CA 92127
Attn: President
Fax: (858) 674-5005

with a copy to:

Luce, Forward, Hamilton & Scripps LLP
600 West Broadway, Suite 2600
San Diego, CA 92101
Attn: Otto E. Sorensen, Esq.
Fax: (619) 232-8311

If to TPL:

Technology Properties Limited
21730 Stevens Creek Blvd., Suite 201A
Cupertino, CA 95014
Attn: Daniel E. Leckrone, Chairman
Fax: (408) 296-6637

with a copy to:

Gibson, Dunn & Crutcher LLP
333 S. Grand Avenue
Los Angeles, California 90071
Attn: Andrew E. Bogen, Esq.
Fax: (213) 229-6159

If to P-Newco:
 
8.6 This Commercialization Agreement together with its exhibits and attachments, the Stipulated Final Judgment, the Master Agreement, the Newco Licenses, the Operating Agreement
 

 
and the Escrow Agreement contains the entire agreement between the parties and supersedes any and all other agreements between them relating to the subject matter hereof.
 
8.7 With the exception of the Grant attached hereto as Exhibit A and the obligation to share certain materials pursuant to Section 3.6, this Commercialization Agreement shall create no rights or licenses to any intellectual property between or among the parties, nor shall it create any obligation to share technology, trade secrets, know-how, show-how and other proprietary developments and discoveries conceived or reduced to practice during the course of the Project.
 
8.8 Any provision of this Commercialization Agreement may be amended or waived if, and only if, such amendment or waiver is in writing and signed, in the case of an amendment, by all parties hereto, or in the case of a waiver, by the party against whom the waiver is to be effective.
 

 
IN WITNESS WHEREOF, the parties have hereunto set their hands and seal as of the date of the execution hereof by the last signatory hereto.
 
PATRIOT SCIENTIFIC CORPORATION, a
Delaware corporation

__________________________________________
By:
Its:


TECHNOLOGY PROPERTIES LIMITED, a California corporation

 
__________________________________________
By: Daniel E. Leckrone
Its: Chairman


P-NEWCO, a Delaware limited liability company

 
__________________________________________
By:
Its: Patriot Member

 
__________________________________________
By:
Its: TPL Member
 


EXHIBIT A
GRANT
(NEWCO TO TPL)


This Grant (“Grant”) is entered into by and between Newco (sometimes “Newco”) on the one hand, and Technology Properties Limited (“TPL”), on the other hand, and is made and entered into for the purpose of implementing that certain Commercialization Agreement (“ComAg”) entered into between the parties contemporaneously herewith.
 
NOW THEREFORE, for and in consideration of the mutual cove-nants herein contained as well as of other good and valuable consideration the receipt and sufficiency of which is hereby acknowledged, it is covenanted and agreed by and between the parties hereto that:
 
1. Subject Matter.
 
1.1 The patents described in the Schedule of Patents at Attachment I hereof, sometimes collectively referred to as the “Project Patents.”
 
2. Grant.
 
2.1 Pursuant to the provisions of section 2.1 of the Licenses made a part hereof as Attachment I (PTSC to Newco) and Attachment II (TPL to Newco), Newco hereby grants unto Technology Properties Limited the exclusive, personal and non-transferable, worldwide right to:
 
2.1.1 To grant licenses and sub-licenses to make, have made, use, sell, and import products and/or services utilizing the Project Patents, for all fields of use and for all applications;
 
2.1.2 To sue in the name of Technology Properties Limited or jointly with Patriot Scientific Corporation, Charles H. Moore and/or Newco if required by law, and to pursue for the use and benefit of Technology Properties Limited: (i) all remedies of whatsoever kind or nature with respect to the protection, use, and enforcement of the Project Patents; (ii) the collection of all claims for damages, profits, and awards relating to the past, present, or future use or ownership of the Project Patents; and (iii) all equitable relief available in connection therewith; and,
 
2.1.3 To otherwise manage and control by license, sublicense, or other agreement the practice and/or use of the Project Patents by third parties.
 
Accordingly, Newco divests itself of all rights with respect to the activities and/or rights described at 2.1.1., 2.1.2., and 2.1.3. above, and Newco retains no such right.
 
2.2 The grant at Section 2.1 above shall be subject to (a) the terms and conditions of the Patent License Agreement between Patriot and Intel Corporation, dated as of June 1, 2005, and (b) the rights retained by PTSC and TPL under the provisions of section 2.2 of the said Attachments I and II, respectively.
 

 
3. General.
 
3.1 In no event shall any right, duty, or privilege arising hereunder be assigned by either party to an entity which it does not own and control, without the prior written consent of the other party. Any attempted or purported assignment without such consent shall be voidable at the option of the non-consenting party.
 
3.2 Any covenant requiring a party to perform or provide an act or service shall be construed to impose upon such party the burden of the cost thereof unless otherwise provided for herein or in the ComAg.
 
3.3 Section titles are intended only to aid and assist the reader and are not intended to be descriptive of the contents of the section or to be used for construction or interpretation.
 
3.4 The failure of any provision of this Agreement by virtue of its being construed as invalid or otherwise unenforceable shall render the entire Agreement cancelable at the option of the party asserting the enforceability of the said provision.
 
3.5 All notices shall be in writing and effective upon delivery or upon posting by certified mail, return receipt requested, addressed as follows (or such other address as may be hereafter designated):
 

 
If to TPL:

Daniel E Leckrone, Chm
21730 Stevens Creek Blvd
Cupertino, CA 95014
Telephone: 408-446-4222
Facsimile: 408-446-5444

If to Newco:

Daniel E Leckrone, Chm
21730 Stevens Creek Blvd
Cupertino, CA 95014
Telephone: 408-446-4222
Facsimile: 408-446-5444

AND

Patriot Scientific Corporation
10989 Via Frontera
San Diego, CA 92127
Attn: President
Fax: (858) 674-5005

AND

Robert K. Neilson
Relational Advisors LLC
11975 El Camino Real, Suite 300
San Diego, California 92130
Fax: (858) 704-3341

3.6 This Agreement together with its exhibits and attachments contains the entire agreement between the parties and supersedes any and all other agreements between them relating to the subject matter hereof.
 
3.7 This Agreement shall be construed in accordance with and governed by the internal laws (without reference to choice or conflict of laws) of the State of California.
 

 
IN WITNESS WHEREOF, the parties have hereunto set their hands and seals as of the date of the execution hereof by the last signatory hereto.
 
NEWCO
 
 
By:__________________________________________
Robert K. Neilson
 
Date:__________________________________________
TECHNOLOGY PROPERTIES LTD.
 
 
By:__________________________________________
Daniel E. Leckrone, Chairman
 
Date:__________________________________________

 
Attachment I - Schedule of Patents
 
(See next page)
 

 
EXHIBIT A
SCHEDULE OF PATENTS

A. PROJECT PATENTS - US
                   
NUMBER
 
NAME
 
FILED
 
ISSUED
 
EXPIRY
US
5,440,749
 
Hi Perf, Lo cost Micro Arch
 
3 AUG 89
 
8 AUG 95
 
8 AUG 12
US
5,530,890
 
Hi Perf, Lo cost Micro Arch
 
7 JUN 95
 
25 JUN 96
 
25 JUN 13
US
5,659,703
 
Micro Sys with Hierarchical stack
 
7 JUN 95
 
19 AUG 97
 
19 AUG 14
US
5,784,584
 
Multiple Instructions within Groups
 
7 JUN 95
 
21 JUL 98
 
21 JUL 15
US
5,809,336
 
Hi Perf Variable Speed Sys Clock
 
7 JUN 95
 
15 SEP 98
 
15 SEP 15
US
5,604,915
 
Load Dependent Bus Timing
 
7 JUN 95
 
18 FEB 97
 
18 FEB 14
US
6,598,148
 
Hi Perf Microprocessor
 
29 JUL 98
 
22 JUL 03
 
3 AUG 09
     
Having Variable Speed Sys Clock
           
                   
B. PROJECT PATENT APPLICATIONS PENDING - US
                   
SN 09/051,263     RISC Microprocessor Architecture   8 AUG 98   _ _ _ _   3 AUG 09
 
 C. PROJECT PATENTS - NON US (Preliminary)
 
DE
69033568.7
 
Hi Perf, Lo Cost Micro
 
2 AUG 90
 
14 JUN 00
 
2 AUG 10
DE
69033568T2
 
Preisguenstiger Hochleistungsmikro
 
2 AUG 90
 
1 MAR 01
 
- - - -
DE
69033568C0
 
Preisguenstiger Hochleistungsmikro
 
2 AUG 90
 
20 JUL 00
 
- - - -
EP
0786730
 
Hi Perf, Lo Cost Micro
 
2 AUG 90
 
14 JUN 00
 
2 AUG 10
EP
786730A1
 
Hi Perf, Lo Cost Micro
 
2 AUG 90
 
30 JUL 97
 
- - - -
EP
497772A4
 
Hi Perf, Lo Cost Micro
 
2 AUG 90
 
4 AUG 93
 
- - - -
EP
497772A1
 
Hi Perf, Lo Cost Micro
 
2 AUG 90
 
12 AUG 92
 
- - - -
EP
0870226
 
RISC Microprocessor Architecture
 
_ _ _ _
 
_ _ _ _
 
- - - -
FR
0786730
 
Hi Perf, Lo Cost Micro
 
2 AUG 90
 
14 JUL 00
 
- - - -
WO
9715001
 
RISC Microprocessor Arch
 
_ _ _ _
 
_ _ _ _
 
- - - -
WO
9102311A3
 
Hi Perf, Lo Cost Micro
 
2 AUG 90
 
21 MAR 91
 
- - - -
WO
9102311A1
 
Hi Perf, Lo Cost Micro
 
2 AUG 90
 
1 FEB 91
 
- - - -
JP
5502125T2
 
_ _ _ _ _ _
 
2 AUG 90
 
15 APR 93
 
- - - -
JP
2966085B2
 
Hi Perf, Lo Cost Micro
 
2 AUG 90
 
13 AUG 99
 
2 AUG 10
AU
6067290A1
 
Hi Perf, Lo Cost Micro
 
2 AUG 90
 
11 MAR 91
 
- - - -

The schedule of Patents shall include the items listed above, as well as all progenitors and progeny thereof, and all additions, changes, amendments, modifications, actions, counterparts, continuations, continuations-in-part, extensions, reissues, divisionals and/or renewals of such items, progenitors, and/or progeny.
 

 
SCHEDULE 1
SCHEDULE OF PATENTS

A. MSD PATENTS - US
 
Number     Name   Filed   Issued   Expiry
US
5,440,749
 
Hi Perf, Lo cost Micro Arch
 
3 AUG 89
 
8 AUG 95
 
8 AUG 12
US
5,530,890
 
Hi Perf, Lo cost Micro Arch
 
7 JUN 95
 
25 JUN 96
 
25 JUN 13
US
5,659,703
 
Micro Sys with Hierarchical stack
 
7 JUN 95
 
19 AUG 97
 
19 AUG 14
US
5,784,584
 
Multiple Instructions within Groups
 
7 JUN 95
 
21 JUL 98
 
21 JUL 15
US
5,809,336
 
Hi Perf Variable Speed Sys Clock
 
7 JUN 95
 
15 SEP 98
 
15 SEP 15
US
5,604,915
 
Load Dependent Bus Timing
 
7 JUN 95
 
18 FEB 97
 
18 FEB 14
US
6,598,148
 
Hi Perf Microprocessor
Having Variable Speed Sys Clock
 
29 JUL 98
 
22 JUL 03
 
3 AUG 09

B. PROJECT PATENT APPLICATIONS PENDING - US
 
Number
Name
Filed
Issued
Expiry
SN
09/051,263
RISC Microprocessor Architecture
8 AUG 98
- - - -
3 AUG 09

C. MSD PATENTS - NON US (Preliminary)
 
Number   Name Filed Issued Expiry
DE
69033568.7
Hi Perf, Lo Cost Micro
2 AUG 90
14 JUN 00
2 AUG 10
DE
69033568T2
Preisguenstiger Hochleistungsmikro
2 AUG 90
1 MAR 01
- - - -
DE
69033568C0
Preisguenstiger Hochleistungsmikro
2 AUG 90
20 JUL 00
- - - -
EP
0786730
Hi Perf, Lo Cost Micro
2 AUG 90
14 JUN 00
2 AUG 10
EP
786730A1
Hi Perf, Lo Cost Micro
2 AUG 90
30 JUL 97
- - - -
EP
497772A4
Hi Perf, Lo Cost Micro
2 AUG 90
4 AUG 93
- - - -
EP
497772A1
Hi Perf, Lo Cost Micro
2 AUG 90
12 AUG 92
- - - -
EP
0870226
RISC Microprocessor Architecture
- - - -
- - - -
- - - -
FR
0786730
Hi Perf, Lo Cost Micro
2 AUG 90
14 JUL 00
- - - -
WO
9715001
RISC Microprocessor Arch
- - - -
- - - -
- - - -
WO
9102311A3
Hi Perf, Lo Cost Micro
2 AUG 90
21 MAR 91
- - - -
WO
9102311A1
Hi Perf, Lo Cost Micro
2 AUG 90
1 FEB 91
- - - -
JP
5502125T2
_ _ _ _ _ _
2 AUG 90
15 APR 93
- - - -
JP
2966085B2
Hi Perf, Lo Cost Micro
2 AUG 90
13 AUG 99
2 AUG 10
AU
6067290A1
Hi Perf, Lo Cost Micro
2 AUG 90
11 MAR 91
- - - -

The schedule of Patents shall include the items listed above, as well as all progenitors and progeny thereof, and all additions, changes, amendments, modifications, actions, counterparts, continuations, continuations-in-part, extensions, reissues, divisionals and/or renewals of such items, progenitors, and/or progeny.
 

 
SCHEDULE 2
PROJECT DESCRIPTION

I. OBJECTIVES & ACTIVITIES
 
 
A.)
Develop and execute a commercialization program for the rights to the MSD Patents transferred by Patriot and TPL to P-Newco pursuant to the Newco Licenses which:
 
 
i.)
Establishes the MSD Patents as an income-producing, commercially valuable asset; and
 
 
ii.)
Builds long-term Project value; and
 
 
iii.)
Minimizes risks to Project assets.
 
 
B.)
Promote the commercialization program by encouraging the implementation and use of the MSD Patents through licenses, and various relationships.
 
 
C.)
Transform selected unauthorized use of the MSD Patents into strategically and commercially valuable authorized use.
 
 
D.)
Pursue licensing discussions with multiple simultaneous identified prospects.
 
 
E.)
Pursue parallel litigation on a selective strategic basis.
 
 
F.)
Negotiate and document agreements relating to the Project and the MSD Patents.
 
 
G.)
***
 
 
H.)
***
 
 
I.)
***
 
II. COMMERCIALIZATION GUIDELINES
 
 
A.)
***
 
 

 
III. ADDITIONAL ACTIONS
 
 
A.)
***
 
 
B.)
***
 
 
C.)
***
 
IV. ***
 
***
 
V. BUSINESS PLAN
 
 
A.)
A Business Plan detailing the implementation of the Project is attached hereto as Attachment I and will remain in full force and effect until duly amended or replaced.
 
 


ATTACHMENT 1 TO SCHEDULE 2

BUSINESS PLAN

 
I. ***
 
 

 
SCHEDULE 3
SCHEDULE OF OUTSTANDING ACTIVITIES/RIGHTS/CLAIMS
 

AGREEMENT
DATE
TPL
 
1. Moore - TPL Commercialization Agreement
22 OCT 02
2. P-Newco - TPL - PTSC Commercialization Agreement
25 MAY 05
3. TPL - Intel License Agree ment
28 JUN 04
   
PTSC
 
1. PTSC - AMD License Agreement
_________
2. P-Newco - TPL - PTSC Commercialization Agreement
25 MAY 05
3. ________________________
 
 
 

 
EXHIBIT E

***
Indicates material omitted pursuant to an application for confidential treatment and that material has been filed separately with the Commission.

ESCROW AGREEMENT

This Escrow Agreement (this “Agreement”), dated as of June 7, 2005, is by and among Patriot Scientific Corporation, a Delaware corporation (“Patriot”), Technology Properties Limited Inc., a California corporation (“TPL”), and Premier Trust, Inc., a Nevada corporation (the “Escrow Agent”).

RECITALS

WHEREAS, concurrently herewith Patriot, TPL and Charles H Moore have executed delivered that certain agreement dated as of June 7, 2005 (the “Master Agreement”);

WHEREAS, the parties hereto desire to enter into this Agreement to facilitate the transaction contemplated by the Master Agreement; and
 
WHEREAS, the Escrow Agent is willing to act as escrow agent pursuant to the terms and conditions of this Agreement.

AGREEMENT

NOW, THEREFORE, in consideration of the premises and intending to be legally bound hereby, the parties agree as follows:
 
1. Delivery of Escrowed Cash. As soon as practicable, Patriot and TPL shall direct Intel Corporation to deliver by wire transfer in immediately available funds to the account set forth on Exhibit A hereto all of the unpaid Milestone payments (as defined in the Intel Patent License Agreement) pursuant to Section 3.2 of the Intel Patent License Agreement (the “Escrowed Cash”). The Escrow Agent agrees to hold and safeguard the Escrowed Cash during the Escrow Period in accordance with this Agreement, separate and apart from the Escrow Agent’s assets.
 
2. Investment of Escrowed Cash. During the Escrow Period, the Escrow Agent will hold and maintain the Escrowed Cash in an interest bearing deposit account at Torrey Pines Bank. Upon any distribution to Patriot or TPL pursuant to Section 4 below, Patriot or TPL, as the case may be, shall be entitled to receive interest earned on such amount to the date of disbursement. All other interest earned by the investment of the Escrowed Cash shall be the joint property of TPL and Patriot in equal parts, payable by the Escrow Agent to TPL and Patriot in equal parts upon the expiration of the Escrow Period (as defined below).
 
3. Escrow Period. The period of Escrow (the “Escrow Period”) shall begin on the date hereof and end at the earliest of (a) the Closing; or (b) the Termination Date.
 
4. Escrow Disbursements. The Escrow Agent shall deliver the Escrowed Cash as follows:

 
1

 
 
(a) Immediately upon receipt of the Escrowed Cash, $*** to TPL in immediately available funds to the account set forth on Exhibit B hereto.
 
(b) Immediately after the disbursement pursuant to subsection (a) above, $*** to Relational Advisors in immediately available funds to the account set forth on Exhibit C hereto.
 
(c) Immediately after the disbursement pursuant to subsection (a) above, $*** to Gibson, Dunn & Crutcher LLP in immediately available funds to the account set forth on exhibit D hereto.
 
(d) Upon the execution and delivery by Patriot of the Stipulated Final Judgment, $*** to Patriot by wire transfer in immediately available funds, to the account set forth on Exhibit E hereto.
 
(e) At the Closing, $*** to the Patriot Rights Holders set forth on Exhibit F hereto, by wire or check, as indicated, in the amounts and to the addresses or accounts appearing next to their names.
 
(f) At the Closing, $4,000,000 to P-Newco in immediately available funds to the account set forth on Exhibit G hereto, or, in the event that the advance to TPL pursuant to Section 4(g) has been disbursed, then $2,000,000 to P-Newco in immediately available funds to the account set forth on Exhibit E hereto.
 
(g) If the Closing has not already occurred, then sixty (60) days after the execution hereof, $2,000,000 to TPL by wire transfer in immediately available funds to the account set forth on Exhibit B hereto, as an advance of the working capital amounts contemplated by Section 4.3 of the Commercialization Agreement.
 
(h) Upon the Termination Date:
 
(1) $***, plus all interest earned on such amount to date, to TPL immediately available funds to the account set forth on Exhibit B hereto;
 
(2) $***, plus all interest earned on such amount to date, to Patriot in immediately available funds to the account set forth on Exhibit E hereto;
 
(3) $2,000,000, plus all interest earned on such amount to date, to TPL in immediately available funds to the account set forth on Exhibit B hereto or, in the event that advance to TPL pursuant to Section 4(g) has been disbursed, then $***, plus all interest earned on such amount to date, to TPL in immediately available funds to the account set forth on Exhibit B hereto;
 
(4) $2,000,000, plus all interest earned on such amount to date, to Patriot in immediately available funds to the account set forth on Exhibit E hereto or, in the event that the advance to TPL pursuant to Section 4(g) has been disbursed, then $***, plus all interest earned on such amount to date, to Patriot in immediately available funds to the account set forth on Exhibit E hereto.
 
5. Fees and Expenses of Escrow Agent. The Escrow Agent’s fee shall be $***, plus $25 per disbursement pursuant to Section 5, plus actual costs incurred by the Escrow Agent in the performance of its obligations hereunder, including without limitation the costs associated wiring the funds and other administrative costs (the “Escrow Fee”). Each of Patriot and TPL agree to pay the Escrow Agent one-half of the Escrow Fee.

 
2

 
 
6. Liabilities and Duties of Escrow Agent.

(a) The duties and obligations of the Escrow Agent shall be determined solely by the express provisions of this Agreement and the Escrow Agent shall have no implied duties and shall not be liable except for the performance of such duties and obligations as are specifically set forth in this Agreement.
 
(b) Patriot and TPL will indemnify the Escrow Agent for, arid hold it harmless against, any loss, liability or expense, including but not limited to, reasonable attorneys’ fees, occurred without gross negligence, bad faith, or willful misconduct on the part of the Escrow Agent arising out of or in connection with its acceptance of, or the performance of its duties and obligations under, this Agreement.
 
(c) The Escrow Agent shall be fully protected in acting and relying upon any written notice, direction, request, waiver, consent, receipt or other paper or document which the Escrow Agent in good faith believes to be genuine and duly authorized and to have been signed or presented by the proper party.
 
(d) The Escrow Agent is hereby expressly authorized to disregard any and all warnings given by any of the parties hereto or by any other person, excepting only orders or process of a court of law of competent jurisdiction. In the event the Escrow Agent obeys or complies with any such order, judgment, or decree of any court, the Escrow Agent shall not be liable to any of the parties hereto or to any other person by reason of such compliance, notwithstanding any such order, judgment, or decree being subsequently reversed, modified, annulled, set aside, aside, vacated, or found to have been entered without jurisdiction or proper authority.
 
(e) The Escrow Agent shall not be liable for the expiration of any rights under the statute of limitations with respect to this Agreement.
 
(f) If any dispute or controversy arises between the parties to this Agreement the matters set forth in this Agreement, the Escrow Agent shall not be required to determine or decide the dispute or controversy or to take any action regarding the same. The Escrow Agent may in such event hold the Escrowed Cash in the Escrow Account and may wait for the settlement of any such dispute or controversy through appropriate final legal proceedings. Furthermore, the Escrow Agent may, in its good faith discretion after seeking advice of counsel, file an action of interpleader requiring the parties to answer and litigate any claims or rights among themselves. In connection with the interpleader proceeding, the Escrow Agent is authorized to deposit with the clerk or other authorized agent of the court the Escrowed Cash. Upon initiating the interpleader proceeding, the Escrow Agent shall be fully released and discharged from any obligations with respect to the documents, cash or other matters subject or relating to the dispute or controversy.
 
(g) The Escrow Agent may resign at any time upon at least 30 days written of notice to each Patriot and TPL; provided, however, that no such resignation shall become effective until a successor escrow agent has been appointed by the Escrow Agent, subject to the approval of each of Patriot and TPL, which approval shall not be unreasonably withheld. The escrow agent shall execute and deliver an instrument accepting such appointment and it shall thereupon be deemed the Escrow Agent hereunder and without further acts shall be vested with all the Escrowed Cash, as well as all the rights, powers, and duties of the predecessor Escrow Agent as if originally named as Escrow Agent. Thereafter (and upon the delivery of all of the Escrow Cash to the successor escrow agent), the predecessor Escrow Agent shall be discharged any further duties and liabilities under this Agreement.

 
3

 
 
7. Notices. All notices and other communications hereunder shall be in writing. Any notice or other communication hereunder shall be deemed duly given (i) if personally delivered, when so delivered, (ii) if mailed, two Business Days after having been sent by registered or certified mail, return receipt requested, postage prepaid and addressed to the intended recipient as set forth below, (iii) if given by fax, once such notice or other communication is transmitted to the fax number specified below and the appropriate answer back or telephonic confirmation is received, provided that a copy of such notice or other Communication is promptly thereafter mailed in accordance with the provisions of clause (ii) above or (iv) of this Section 7, or (iv) if sent through an overnight delivery service in circumstances to which such service guarantees next day delivery, the day following being so sent:
 
If to Patriot:

Patriot Scientific Corporation
10989 Via Frontera
San Diego, CA 92127
Attn: President
Fax: (858) 674-5004

with a copy to:

Otto E. Sorensen, Esq.
Luce, Forward, Hamilton & Scripps LLP
600 West Broadway, Suite 2600
San Diego, CA 92101
Attn: Otto E. Sorensen, Esq.
Fax: (619) 232-8311

If to TPL:

Technology Properties Limited Inc.
P.O. Box 20250
San Jose, CA 95160
Atm: Daniel E. Leckrone, Chairman
Fax: (408) 296-6637

with a copy to:

Gibson, Dunn & Crutcher LLP
333 S. Grand Avenue
Los Angeles, California 90071
Attn: Andrew E. Bogen, Esq.
Fax: (213) 229-6159

 
4

 
 
Any party may give any notice, request, demand, claim or other communication hereunder using any other means (including ordinary mail or electronic mail), but no such notice, request, demand, claim or other communication shall be deemed to have been duly given unless and until it actually is received by the individual for whom it is intended.
 
8. Amendments; No Waivers.
 
(a) Any provision of this Agreement may be amended or waived if, and only if such amendment or waiver is in writing and signed, in the case of an amendment, by all parties hereto, or in the case of a waiver, by the party against whom the waiver is to be effective.
 
(b) No waiver by a party of any default, misrepresentation or breach of warranty or covenant hereunder, whether intentional or not, shall be deemed to extend to any prior or subsequent default, misrepresentation or breach of warranty or covenant hereunder or affect in any way any rights arising by virtue of any prior or subsequent occurrence. No failure or delay by a party in exercising any right, power or privilege hereunder shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right, power or privilege. The rights and remedies herein provided shall be cumulative and not exclusive of any rights or remedies provided by law.
 
9. Expense. Except as provided herein, all costs and expenses incurred in connection with this Agreement shall be paid by the party incurring such cost or expense.
 
10. Successors and Assign. This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and permitted assigns. No party hereto may assign either this Agreement or any of its rights, interests or obligations hereunder lout the prior written approval of each other party.
 
11. Governing Law. This Agreement shall be construed in accordance with and governed by the internal laws (without reference to choice or conflict of laws) of the State of Delaware.
 
12. Counterparts; Effectiveness. This Agreement may be signed in any number of counterparts and the signatures delivered by fax, each of which shall be an original, with the effect as if the signatures thereto and hereto were upon the same instrument. This Agreement shall become effective when each party hereto shall have received a counterpart hereof signed by the other parties hereto.
 
13. Entire Agreement. This Agreement (including the other agreements executed simultaneously herewith arid all Schedules and Exhibits thereto and hereto) constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior agreements, understandings and negotiations, both written and oral, between the parties with respect to the subject matter of this Agreement. Neither this Agreement nor any provision hereof is intended to confer upon any Person other than the parties hereto any rights or remedies hereunder.
 
14. Captions The captions herein are included for convenience of reference only and shall be ignored in the construction or interpretation hereof. All references to a Section include all subparts thereof.

 
5

 
 
15. Third-Party Beneficiaries. No provision of this Agreement shall create any third-party beneficiary rights in any Person (as defined in the Master Agreement).
 
16. No Punitive, Exemplary, or Consequential Damages. The parties hereto expressly understand and agree that under no circumstances shall punitive, exemplary, or consequential damages be available to any party for breach of this Agreement.

 
[signature page follows]

 
6

 

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed by their respective authorized officers as of the day and year first above written.
 
 
 
PATRIOT SCIENTIFIC CORPORATION,
a Delaware corporation


By: _______________________________
Name: _____________________________
Title: ______________________________



TECHNOLOGY PROPERTIES LIMITED INC.,
a California corporation


By: _______________________________
Name: _____________________________
Title: ______________________________



PREMIER TRUST, INC.,
a Nevada corporation


By: _______________________________
Name: _____________________________
Title: ______________________________

 
 
7

 
 
Exhibit A
 
Escrow Agent’s Wire Transfer Information

Torrey Pines Bank
12220 El Camino Real
San Diego, CA 92130
ABA/Routing Number: 122243635
Beneficiary Account Name: ***
Beneficiary Account Number: ***

 
8

 

Exhibit B
 
TPL’s Wire Transfer Information

Acct Name: ***
Acct No: ***
Bank Name:           San Jose National Bank
1 North Market Street
San Jose, CA 95113
ABA No: 121139216
Contact: Lisa Valles, Manager
Wire Transfer Dept
408-496-4880

 
9

 
 
Exhibit C
 
Relational Advisors’ Wire Transfer Information

Wells Fargo Bank for the benefit of:
***
Account # ***
ABA #: 121-000-248
Attn: Michael Morgan

 
10

 
 
Exhibit D
 
Gibson, Dunn & Crutcher’s Wire Transfer Information

Wells Fargo Bank
333 South Grand Avenue
Los Angeles, CA. 90071-1515
Name of account: ***
Account No: ***
ABA No: 121000248
Attn: Julie Saavedra
Telephone: (213) 253-6146
Fax: (213)628-1415

 
11

 
 
Exhibit E
 
Patriot’s Wire Transfer Information

Silicon Valley Bank, San Jose
Routing #: 121140399
For credit of: ***
Credit Account #: ***

 
12

 
 
Exhibit F
 
Patriot Rights Holders

***
Chase Manhattan Bank NYC
***
ABA 021 000 021
 
FBO: Salomon Smith Barney
 
a/c: ***
***
 
***
 
   
***
Chase Manhattan Bank NYC
***
ABA 021 000 021
 
FBO: Salomon Smith Barney
 
a/c: ***
***
 
***
 
   
***
***
***
***
***
 
   
***
***
***
***
***
 
   
***
***
***
***
***
 
   
***
***
***
***
***
 
   
***
***
***
***
***
 
   
***
***
***
***
***
 

 
13

 
 
Exhibit G
 
P-Newco’s Wire Transfer Information
 
14

 
EXHIBIT F-1
 
WAIVER, CONSENT AND RELEASE AGREEMENT
 
This WAIVER, CONSENT AND RELEASE AGREEMENT (this “Agreement”) is made and entered into as of ______________, 2006, by and between PATRIOT SCIENTIFIC CORPORATION, a Delaware corporation (the “COMPANY”), and ____________________, an _______ limited liability company (the “Rights Holder”).
 
RECITALS
 
A. WHEREAS, the Rights Holder holds warrants to purchase shares of the common stock, $_________ par value per share, of the COMPANY (the “Warrants”), as well as a debenture convertible into shares of the common stock of the COMPANY (the “Debenture”) purchased pursuant to certain Securities Purchase Agreements, by and between the COMPANY and the RIGHTS HOLDER (collectively, the “Securities Purchase Agreements”).
 
B. WHEREAS, the COMPANY desires to enter into the transactions contemplated by that certain Master Agreement dated as of the date hereof, by and among the COMPANY, ______________, a California corporation (“_____”) and ______________ (such transactions referred to herein as the “Proposed Transactions”).
 
C. WHEREAS, the Proposed Transactions will result in the creation of an entity (“________”) which will hold and manage the subject intellectual property of the COMPANY. As a part of the Proposed Transactions, the COMPANY will receive stock of ______ (the “_________ Stock”) and will be entitled to receive an income stream from _________ (the “_________ Income”) as specified in the Master Agreement.
 
D. WHEREAS, the Securities Purchase Agreements, the Warrants and the Debenture include provisions which may be implicated by the Proposed Transactions, and which may give the Rights Holder certain rights with respect to the Proposed Transactions.
 
E. WHEREAS, the Proposed Transactions and any and all actions taken before, as of, or after the date hereof by the COMPANY (and any person acting for or on behalf of the COMPANY) or _________ that are specifically authorized by the Master Agreement shall be referred to herein as the “Approved Actions.”
 
F. WHEREAS, the COMPANY and the Rights Holder desire to facilitate the Proposed Transactions by entering into this Agreement.
 
NOW, THEREFORE, in consideration of the respective promises, representations, warranties, covenants and conditions contained in this Agreement, the parties hereby agree as follows:
 
1. Consent. Effective upon the receipt by the Rights Holder of the consideration described in Section 2 of this Agreement, the Rights Holder hereby consents to, approves and ratifies the Proposed Transactions and the Approved Actions, each subject to Section 9 below.
 



2. Conveyance of Warrants. Effective upon the receipt by the Rights Holder of the consideration described in Section 7 of this Agreement, the Rights Holder hereby sells, transfers and conveys to the COMPANY, free and clear of any and all liens or other adverse claims thereto, __________ (____________) Warrants described on Exhibit A hereto. The Rights Holder agrees to execute any documents and take any other action that may be required to effect and memorialize such transfer of the Warrants to the COMPANY pursuant to this Section 2.
 
3. Warrant Price Reset. Effective upon receipt by the Rights Holder of the consideration pursuant to Section 7 of this Agreement, the exercise price of the ____________ (____________) Warrants described on Exhibit B herein will be reset to ____________ dollars per share.
 
4. Waiver of Right of First Refusal, Limitation of Sale or Disposition of Intellectual Property and Redemption Upon Major Transaction. Effective upon the receipt by the Rights Holder of the consideration described in Section 7 of this Agreement, the Rights Holder hereby waives any right of first refusal or any right to limit the sale or disposition of the COMPANY’s intellectual property, including but not limited to those rights set forth in Sections 4(l) and 4(m) of the Securities Purchase Agreements, and waives its right to redemption upon a Major Transaction as set forth in Section 4(o) of the Securities Purchase Agreements, in each case to the extent necessary to allow the Proposed Transactions and the Approved Actions to occur, or any future transaction in which the Company may engage, all subject to Section 9 below.
 
5. Waiver of Redemption Right. Effective upon the receipt by the Rights Holder of the consideration pursuant to Section 7 of this Agreement, the Rights Holder waives any right to require any warrant redemption as a consequence of the Proposed Transactions or any future transaction in which the Company may engage, subject to Section 9 below.
 
6. Release of Lien. Effective upon the receipt by the Rights Holder of the consideration pursuant to Section 7 of this Agreement, the Rights Holder barely releases its liens with regard to the COMPANY’s intellectual property portfolio, including without limitation ________, and agrees to take any and all action necessary to cause all UCC financing statements, USPTO filings and other filings or documents evidencing such lien to be terminated, provided that the debts underlying such liens shall remain intact.
 
7. Payment to Rights Holder. In consideration of the covenants, promises, and agreements set forth in this Agreement, the Rights Holder shall be paid $____________ pursuant to the Escrow Agreement upon the closing of the Proposed Transactions. The Rights Holder hereby acknowledges that such consideration constitutes good, valid and sufficient consideration in exchange for the covenants, promises, and agreements of the Rights Holder set forth in this Agreement.
 
8. Amendment of Securities Purchase Agreements. Effective as of the receipt of consideration pursuant to Section 7 of this Agreement, the Securities Purchase Agreements shall be amended to remove Sections 4(l), 4(m) and 4(o) in their entirety, and such sections shall be of no further force or affect, all subject to Section 9 below. The COMPANY and the Rights Holder hereby acknowledge and agree that this Agreement meets all of the requirements for amendment of the Securities Purchase Agreements provided in Section 8(e) thereof.
 



9. Redemption. Notwithstanding anything to the contrary herein, in the event that any one or more of the following occur (each, a “Redemption Trigger”), the Rights Holder, at its option, may require the COMPANY to effect a Warrant Redemption (as defined below) of any or all (at the Rights Holders’ option) of the Rights Holders’ Warrants (as defined below):
 
A. The COMPANY merges into or is bought out by another company, or becomes a private company that does not have publicly traded common stock, or sells all or substantially all of the COMPANY’s assets, or
B. Common stock of the COMPANY is tendered, purchased or exchanged pursuant to a tender offer, purchase offer or exchange offer, or
C. There is a Change of Control (as defined below) of the COMPANY’s boards of directors, and one or more of the following occurs:
(1) COMPANY sells, conveys, disposes of, spins off or assigns any or all of the NEWCO Stock, or any or all of its rights to receive the ____________ Income, to any third party, in each case without the Rights Holder’s written consent.
(2) The COMPANY issues or sells, or agrees to issue or sell Variable Equity Securities (as defined below), for cash in private capital raising transactions or any securities of the Company pursuant to an equity line structure or format without obtaining the prior written approval of the Rights Holder, with the exception of any such agreements, transactions or equity lines existing as of the date hereof. For purposes hereof, the following shall be collectively referred to herein as, the “Variable Equity Securities”; any debt or equity securities (or securities pursuant to an equity line structure or similar structure) which are convertible into, exercisable or exchangeable for, or carry the right to receive additional shares of Common Stock either (i) at any conversion, exercise or exchange rate or other price that is based upon and/or varies with the trading prices of or quotations for Common Stock at any time after the initial issuance of such debt or equity security, or (ii) with a fixed conversion, exercise or exchange price that greater than a ____ (__%) discount to the then prevailing market or is subject to being reset at some future date at any time after the initial issuance of such debt or equity security due to a change in the market price of the Company’s Common Stock since date of initial issuance.

If a Redemption Trigger has occurred and the Rights Holder elects a redemption, then any of the Rights Holders’ Warrants selected by the Rights Holder for such redemption shall be redeemed (“Warrant Redemption”) by the Company as of the record date for such Redemption Trigger at a price per share (that is, per share of common stock represented by the warrants) for each Rights Holder Warrant equal to the “Redemption Price,” which shall be defined as the greater of (A) $0.__ per share, less the Exercise Price per share in effect for that Rights Holder Warrant on the trading day immediately preceding the record date of the Redemption Trigger (each subject to adjustment to account for any forward or reverse stock splits), or (B) the applicable Warrant Redemption market Value (as defined below). For purposes hereof, the “Warrant Redemption Market Value” shall equal the aggregate of the highest Warrant Market Values (as defined below) for all of the Right Holders’ Warrants being so redeemed calculated
 



on any date during the thirty (30) business day period ending on the record date for the Redemption Trigger.
 
For purposes hereof,
 
“Change in Control” shall mean any change in the makeup of the COMPANY’s board of directors such that the remaining board members from the following group do not constitute a majority of the board: ____________, ____________, ____________, and ____________.
 
“Rights Holders’ Warrants” shall mean all warrants to purchase common stock that have been issued from the Company to the Rights Holder for any reason at any time in the past up through the date hereof.
 
“Warrant Market Value” shall equal the number of shares that would be issuable in a “cashless exercise” on the date in question, under the terms of the warrant (without regard to any contractual, legal, or regulatory restrictions on such exercise and issuance, if any, and without regard to whether or not a sufficient number of shares are authorized and reserved to effect any such exercise and issuance), multiplied by the Closing Price of the Company’s common stock for the preceding trading day.
 
“Closing Price” shall mean the closing price on the O.T.C. Bulletin Board, Nasdaq Small Cap Market, the National Market System (“NMS”), the New York Stock Exchange, or if no longer traded on the Nasdaq Small Cap Market, the National Market System (“NMS”), the New York Stock Exchange, or the O.T.C. Bulletin Board, the “Closing Bid Price” shall equal the closing price on the principal national securities exchange or the over-the-counter system on which the Common Stock is so traded and, if not available, the mean of the high and low prices on the principal national securities exchange or other market on which the Common Stock is so traded.
 
10. Representations and Warrants of Rights Holder. In order to induce the COMPANY to enter into this Agreement, the Rights Holder represents and warrants to the COMPANY as follows:
 
10.1 Full Knowledge. The Rights Holder acknowledges and agrees that it is fully aware of all of the terms and conditions of the Proposed Transactions, and that its representatives have had an opportunity to discuss such terms and conditions with COMPANY representatives, and to ask any questions the Rights Holder has deemed necessary.

10.2 Compliance with Law. The execution, delivery and performance by the Rights Holder of this Agreement and the consummation of the transactions contemplated hereby, will not cause the Rights Holder to violate or contravene (i) any provision of law, (ii) any rule or regulation of any agency or government, or (iii) any order, writ, judgment, injunction, decree, determination or award, to which he is subject.



10.3 Authorization. When executed and delivered by the Rights Holder, this Agreement will constitute a valid and legally binding obligation of the Rights Holder enforceable in accordance with its terms, except as may be limited by (i) judicial principles respecting election of remedies or limiting the availability of specific performance, injunctive relief and other equitable remedies, (ii) judicial principles with respect to provisions contrary to public safety, and (iii) bankruptcy, insolvency, reorganization, moratorium or other similar laws, now or hereafter in effect, generally relating to creditors’ rights.

11. Representations and Warranties of COMPANY. In order to induce the Rights Holder to enter into this Agreement, COMPANY represents and warrants to the Rights Holder as follows:

11.1 Compliance with Law. The execution, delivery and performance by COMPANY of this Agreement and the consummation of the transactions contemplated hereby, will not cause COMPANY to violate or contravene (i) any provision of law, (ii) any rule or regulation of any agency or government, or (iii) any order, writ, judgment, injunction, decree, determination or award, to which it is subject.

11.2 Authorization. When executed and delivered by COMPANY, this Agreement will constitute a valid and legally binding obligation of COMPANY enforceable in accordance with its terms, except as may be limited by (i) judicial principles respecting election of remedies or limiting the availability of specific performance, injunctive relief and other equitable remedies, (ii) judicial principles with respect to provisions contrary to public policy, and (iii) bankruptcy, insolvency, reorganization, moratorium or other similar laws, now or hereafter in effect, generally relating to creditors’ rights.

12. Taxes. Each party shall be responsible for all taxes incurred by it as a result of any transaction contemplated by this Agreement.

13. Cooperation. COMPANY and Rights Holder acknowledge that it may be necessary to execute documents other than those specifically referred to herein in order to consummate the transactions contemplated herein. COMPANY and Rights Holder agree to cooperate with each other by executing such other documents and taking such other action as may be reasonably necessary to complete the transactions in accordance with the intent of the parties as evidenced in this Agreement.

14.
General Provisions.

14.1 Survival of Representations and Warranties. All representations and warranties of the parties made in, pursuant to or in connection with this Agreement shall survive the execution and delivery of this Agreement.


 
14.2 Entire Agreement. With reference to the subject matter hereof, this Agreement is the complete and exclusive statement of all terms of the agreement between the parties and supersedes and cancels all prior and contemporaneous negotiations, agreements and representations, and constitutes the entire agreement between the parties. There are no representations, inducements, promises or agreements, oral or otherwise, with reference to the subject matter hereof, other than as expressly set forth herein. No modification, alteration, amendment or waiver of any provision hereof shall be effective unless in writing and signed by both parties.

14.3 Successors Bound; Limited Assignment. This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and permissible assigns, except that neither party shall, without prior written consent of the other, delegate, assign, transfer, encumber or otherwise dispose of any of its rights, duties or interests under this Agreement or any part thereof.

14.4 Headings. The headings of the sections and paragraphs of this Agreement have been inserted for convenience of reference only and do not constitute a part of this Agreement.

14.5 Governing Law. It is the intention of the parties that the laws of California, including such jurisdiction’s principles of conflict of law, shall govern the validity of this Agreement, the construction of its terms and the interpretation of the rights and duties of the parties, as such laws are applied to agreements between California residents entered into and to be performed entirely within California.

14.6 Forum; Expenses. In the event that any cause of action, lawsuit or other proceeding is brought by any party of this Agreement because of an alleged dispute, breach or misrepresentation in connection with or arising under this Agreement, any court of competent jurisdiction in San Diego County shall be the sole and exclusive forum for such cause of action, lawsuit or proceeding, and the prevailing party in any such action, lawsuit or proceeding shall be entitled to recover, in addition to any remedy at law or equity available to any prevailing party, all reasonable costs and expenses incurred or sustained by such prevailing party in connection with such action, lawsuit or proceeding, including, without limitation, attorneys’ fees and court costs.

14.7 Counterparts. This Agreement may be executed in two or more counterparts and by the different parties hereto in separate counterparts with the same effect as if all parties had signed the same document. All



such counterparts shall be deemed an original, shall be construed together and shall constitute one and the same instrument.

IN WITNESS WHEREOF, the parties have caused this Agreement to be executed on the day and year first written above.
 
PATRIOT SCIENTIFIC CORPORATION    
     
By: /s/ David H. Pohl    By: /s/___________________________
David H. Pohl   _____________________________(Name),
President & CEO
  _____________________________(Title)
 


 
EXHIBIT A
Warrants Proposed to be Conveyed to Patriot Scientific
Corporation by _______________

Warrants Held in
Name of
Warrant Description
Issue Date
Warrants Held
Number of Warrants to be conveyed back to PTSC
Current Exercise Price as of ______
_____
____________
______
______
______
$______
     
TOTAL:
______
 


Initials of _________________: ____________
 
Initials of Patriot Scientific Corporation: ______


 
EXHIBIT B
Warrants of ______________
Proposed to Be Reset to $______

Warrant Description
Issue Date
Number of Warrants Held
Number of Warrants being Reset to $0.___
Current Exercise Price as of _______
Debenture Warrant #
     
$______
Debenture Warrant #
     
$______
Debenture Warrant #
     
$______
Debenture Warrant #
     
$______
Debenture Warrant #
     
$______
Debenture Warrant #
     
$______


Initials of ________________: ____________
 
Initials of Patriot Scientific Corporation: ______
 
 

 
EXHIBIT F-2
 
WAIVER, CONSENT AND RELEASE AGREEMENT
 
This WAIVER, CONSENT AND RELEASE AGREEMENT (this “Agreement”) is made and entered into as of __________, 2006, by and between PATRIOT SCIENTIFIC CORPORATION, a Delaware corporation, (the “COMPANY”), and __________, an individual residing in __________ County, State of __________ (the “Rights Holder”).
 
RECITALS
 
A. WHEREAS, the Rights Holder holds warrants to purchase shares of the common stock, $__________ par value per share, of the COMPANY (the “Warrants”), purchased pursuant to that certain Securities Purchase Agreement, dated as of __________, 200__, by and among the COMPANY and the RIGHTS HOLDER (the “Securities Purchase Agreement”).
 
B. WHEREAS, the COMPANY desires to enter into the transactions contemplated by that certain Master Agreement dated as of the date hereof, by and among the COMPANY, __________, a __________ corporation (“__________”) and __________ (such transactions referred to herein as the “Proposed Transactions”).
 
C. WHEREAS, the Securities Purchase Agreement and the Warrants include provisions which may be implicated by the Proposed Transactions, and which may give the Rights Holder certain rights with respect to the Proposed Transactions.
 
D. WHEREAS, the COMPANY and the Rights Holder desire to facilitate the Proposed Transactions by entering into this Agreement.
 
NOW, THEREFORE, in consideration of the respective promises, representations, warranties, covenants and conditions contained in this Agreement, the parties hereby agree as follows:
 
1.  Consent. Effective upon the receipt by the Rights Holder of the consideration pursuant to Section 2 of this Agreement, the Rights Holder hereby consents to, approves and ratifies the Proposed Transactions and any and all actions taken before, as of, or after the date hereof by the COMPANY (and any person acting for or on behalf of the COMPANY) in connection with the Proposed Transactions.
 
2.  Payment to Rights Holder. In consideration of his covenants, promises, and agreements set forth in this Agreement, the Rights Holder shall be paid $__________ by check to the address below upon the closing of the Proposed Transactions. The Rights Holder hereby acknowledges that such consideration constitutes good, valid and sufficient consideration in exchange for the covenants, promises, and agreements of the Rights Holder set forth in this Agreement.
 
3.  Amendment of Securities Purchase Agreement. Effective as of the receipt of consideration pursuant to Section 2 of this Agreement, the Securities Purchase Agreement shall be amended to remove Section 4(1) in its entirety, and such section shall be of no further force or
 

 
4.  effect. The COMPANY and the Rights Holder hereby acknowledge and agree that this Agreement meets all of the requirements for amendment of the Securities Purchase Agreement provided in Section 8(e) thereof.
 
5.  Representations and Warranties of Rights Holder. In order to induce the COMPANY to enter into this Agreement, the Rights Holder represents and warrants to the COMPANY as follows:
 
5.1.  Full Knowledge. The Rights Holder acknowledges and agrees that he is fully aware of all of the terms and conditions of the Proposed Transactions, and that he has had an opportunity to discuss such terms and conditions with COMPANY representatives, and to ask any questions he has deemed necessary.
 
5.2.  Compliance with Law. The execution, delivery and performance by the Rights Holder of this Agreement and the consummation of the transactions contemplated hereby, will not cause the Rights Holder to violate or contravene (i) any provision of law, (ii) any rule or regulation of any agency or government, or (iii) any order, writ, judgment, injunction, decree, determination or award, to which he is subject.
 
5.3.  Authorization. When executed and delivered by the Rights Holder, this Agreement will constitute a valid and legally binding obligation of the Rights Holder enforceable in accordance with its terms, except as may be limited by (i) judicial principles respecting election of remedies or limiting the availability of specific performance, injunctive relief and other equitable remedies, (ii) judicial principles with respect to provisions contrary to public policy, and (iii) bankruptcy, insolvency, reorganization, moratorium or other similar laws, now or hereafter in effect, generally relating to creditors’ rights.
 
6.  Representations and Warranties of COMPANY. In order to induce the Rights Holder to enter into this Agreement, COMPANY represents and warrants to the Rights Holder as follows:
 
6.1.  Compliance with Law. The execution, delivery and performance by COMPANY of this Agreement and the consummation of the transactions contemplated hereby, will not cause COMPANY to violate or contravene (i) any provision of law, (ii) any rule or regulation of any agency or government, or (iii) any order, writ, judgment, injunction, decree, determination or award, to which it is subject.
 
6.2.  Authorization. When executed and delivered by COMPANY, this Agreement will constitute a valid and legally binding obligation of COMPANY enforceable in accordance with its terms, except as may be limited by (i) judicial principles respecting election of remedies or limiting the availability of specific performance, injunctive relief and other equitable remedies, (ii) judicial principles with respect to provisions contrary to public policy, and (iii) bankruptcy, insolvency, reorganization, moratorium or other similar laws, now or hereafter in effect, generally relating to creditors’ rights.
 
7.  Taxes. Each party shall be responsible for all taxes incurred by it as a result of any transaction contemplated by this Agreement.
 

 
8.  Cooperation. COMPANY and Rights Holder acknowledge that it may be necessary to execute documents other than those specifically referred to herein in order to consummate the transactions contemplated herein. COMPANY and Rights Holder agree to cooperate with each other by executing such other documents and taking such other action as may be reasonably necessary to complete the transactions in accordance with the intent of the parties as evidenced in this Agreement.
 
9.  General Provisions.
 
9.1.  Survival of Representations and Warranties. All representations and warranties of the parties made in, pursuant to or in connection with this Agreement shall survive the execution and delivery of this Agreement.
 
9.2.  Severability. Should any one or more of the provisions of this Agreement or of any agreement entered into pursuant to this Agreement be determined to be illegal or unenforceable, then such illegal or unenforceable provision shall be modified by the proper court only to the extent necessary and possible to make such provision enforceable, and such modified provision and all other provisions of this Agreement and of each other agreement entered into pursuant to this Agreement shall be given effect separately from the provision or portion thereof determined to be illegal or unenforceable and shall not be affected thereby.
 
9.3.  Entire Agreement. With reference to the subject matter hereof, this Agreement is the complete and exclusive statement of all terms of the agreement between the parties and supersedes and cancels all prior and contemporaneous negotiations, agreements and representations, and constitutes the entire agreement between the parties. There are no representations, inducements, promises or agreements, oral or otherwise, with reference to the subject matter hereof, other than as expressly set forth herein. No modification, alteration, amendment or waiver of any provision hereof shall be effective unless in writing and signed by both parties.
 
9.4.  Successors Bound; Limited Assignment. This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and permissible assigns, except that neither party shall, without prior written consent of the other, delegate, assign, transfer, encumber or otherwise dispose of any of its rights, duties or interests under this Agreement or any part thereof.
 
9.5.  Headings. The headings of the sections and paragraphs of this Agreement have been inserted for convenience of reference only and do not constitute a part of this Agreement.
 
9.6.  Governing Law. It is the intention of the parties that the laws of California, including such jurisdiction’s principles of conflict of law, shall govern the validity of this Agreement, the construction of its terms and the interpretation of the rights and duties of the parties, as such laws are applied to agreements between California residents entered into and to be performed entirely within California.
 
9.7.  Forum; Expenses. In the event that any cause of action, lawsuit or other proceeding is brought by any party of this Agreement because of an alleged dispute, breach or
 

 
9.8.  misrepresentation in connection with or arising under this Agreement, any court of competent jurisdiction in San Diego County shall be the sole and exclusive forum for such cause of action, lawsuit or proceeding, and the prevailing party in any such action, lawsuit or proceeding shall be entitled to recover, in addition to any remedy at law or equity available to any prevailing party, all reasonable costs and expenses incurred or sustained by such prevailing party in connection with such action, lawsuit or proceeding, including, without limitation, attorneys’ fees and court costs.
 
9.9.  Counterparts. This Agreement may be executed in two or more counterparts and by the different parties hereto in separate counterparts with the same effect as if all parties had signed the same document. All such counterparts shall be deemed an original, shall be construed together and shall constitute one and the same instrument.
 

 
IN WITNESS WHEREOF, the parties have caused this Agreement to be executed on the day and year first written above.
 
PATRIOT SCIENTIFIC CORPORATION   RIGHTS HOLDER
     
By: /s/ David H. Pohl    By: /s/___________________________
David H. Pohl   _____________________________(Name)
President & CEO
 
 
 

 
EXHIBIT G
 
AGREEMENT AND PLAN OF MERGER
BY AND AMONG
PATRIOT SCIENTIFIC CORPORATION,
P-NEWCO LLC
TECHNOLOGY PROPERTIES LIMITED INC.
AND
TPL NEWCO, LLC
 
 
This Agreement and Plan of Merger (this “Merger Agreement”) is made as of June 15, 2005, by and among PATRIOT SCIENTIFIC CORPORATION, a Delaware corporation (“Patriot”), P-NEWCO LLC, a Delaware limited liability company wholly owned by Patriot (“P-Newco"), TECHNOLOGY PROPERTIES LIMITED INC., a California corporation (“TPL”), and TPL NEWCO, LLC, a Delaware limited liability company wholly owned by TPL (“T-Newco”). Capitalized terms used but not defined herein shall have the meanings given to such terms in that certain agreement dated as of June 7, 2005 by and among Patriot, TPL and Charles H. Moore (“Moore”) (the “Master Agreement”).
 
WHEREAS, Patriot, TPL and Moore have entered into the Master Agreement which provides for, among other things, the creation by Patriot and TPL of P-Newco and T-Newco, respectively, the respective licensing to P-Newco and T-Newco of certain of Patriot and TPL’s rights with respect to the MSD Patents, and the merger of T-Newco with and into P-Newco, with P-Newco continuing as the surviving entity (the “Surviving Entity”), in furtherance of the transactions contemplated by the Master Agreement;
 
WHEREAS, pursuant to the Delaware Limited Liability Company Act, the board of directors of Patriot and TPL, the sole members of P-Newco and T-Newco, respectively, have adopted and recommended this Merger Agreement and determined that it is advisable and in the best interests of P-Newco and T-Newco that T-Newco merge with and into P-Newco upon the terms and conditions provided herein (the “Merger”).
 
NOW, THEREFORE, in consideration of the foregoing recitals and the mutual agreements herein contained and of the mutual benefits provided hereby, the parties hereto agree as follows:
 
1. Merger. The effective date of the Merger shall be June 15, 2005 (the “Effective Date”). On the Effective Date, T-Newco shall be merged with and into P-Newco and the separate existence of T-Newco shall thereupon cease. P-Newco shall continue its existence in the State of Delaware as the Surviving Entity.
 
2. Certificate of Formation. The Certificate of Formation of P-Newco, as in effect immediately prior to the Effective Date, shall continue to be the Certificate of Formation of the Surviving Entity until duly amended in accordance with the provisions of the laws of the State of Delaware.
 
3. Conversion of Membership Interests. Upon the Effective Date, by virtue of the Merger and without any action on the part of TPL, TPL's membership interests in T-Newco
 

 
outstanding immediately prior to the Merger shall automatically be cancelled, and a fifty percent membership interests in the Surviving Entity shall be issued to TPL in exchange therefor.
 
4. Subsequent Action. If at any time after the Effective Date it shall be necessary or desirable to take any action or execute, deliver or file any instrument or document in order to vest, perfect or confirm of record in the Surviving Entity the title to any property or any rights of T-Newco, or otherwise to carry out the provisions of this Merger Agreement, the managers of the Surviving Entity are hereby authorized and empowered on behalf of T-Newco and in its name to take such action and execute, deliver and file such instruments and documents.
 
5. Rights and Duties of Surviving Entity. On the Effective Date, the Surviving Entity shall thereupon and thereafter possess all rights, privileges, immunities, licenses, and permits (whether of a public or private nature) of T-Newco; and all property (real, personal and mixed), all debts due on whatever account, all choses in action, and all and every other interest of or belonging to or due to T-Newco shall continue and be taken and deemed to be transferred to and vested in the Surviving Entity, without further act or deed, and the Surviving Entity shall thenceforth be responsible and liable for all the liabilities and obligations of T-Newco.
 
6. Representations and Warranties.
 
(a) Incorporation of Representations and Warranties. Patriot and TPL hereby reaffirm the representations and warranties made in the Master Agreement as if such representations and warranties were set forth fully herein.
 
(b) Existence and Power. Each of Patriot and TPL represents and warrants that P-Newco and T-Newco, respectively, is a Delaware limited liability company, duly formed and validly existing under the laws of the State of Delaware, and has all power and authority necessary to enter into this Merger Agreement and consummate the Merger.
 
(c) Authorization. Each of Patriot and TPL represents and warrants that the execution, delivery and performance by P-Newco and T-Newco, respectively, of this Merger Agreement and the Merger contemplated hereby has been duly and validly authorized by each of Patriot and P-Newco, on the one hand, and each of TPL and T-Newco, on the other hand, under Applicable Law, and no other corporate proceedings on the part of Patriot and P-Newco, on the one hand, and TPL and T-Newco, on the other hand, are necessary to authorize or consummate this Merger Agreement or the Merger contemplated hereby (other than the filing and recordation of the appropriate documents with respect to the Merger in accordance with the laws of the State of Delaware).
 
(d) Capitalization. Each of Patriot and TPL represents and warrants that it is the sole shareholder of P-Newco and T-Newco, respectively.
 
(e) Valid and Existing License; Sole Asset. Patriot and P-Newco, on the one hand, and TPL and T-Newco, on the other hand, represent and warrant that the Newco Licenses, the form of which is attached as Exhibit C to the Master Agreement, have been validly executed and delivered pursuant to the terms of the Master Agreement, and that each of P-Newco and T-Newco has good and valid title to all rights with respect to the MSD Patents granted by Patriot and TPL to P-Newco and T-Newco, respectively, pursuant to the Newco Licenses. Patriot and
 


P-Newco, on the one hand, and TPL and T-Newco, on the other hand, further represent and warrant that the Newco Licenses are the sole assets of P-Newco and T-Newco.
 
(f) Purpose; Absence of Changes. Each of Patriot and TPL represents and warrants that P-Newco and T-Newco, respectively, were formed and have been utilized from the date of formation until the date hereof solely to effect the transactions contemplated by this Merger Agreement and the Master Agreement, and that P-Newco and T-Newco have not engaged in any other activity whatsoever except entering into the Newco Licenses referred to in subsection (e) above, and taking any action necessary to facilitate the Merger in a manner consistent with the terms of this Merger Agreement and the Master Agreement.
 
(g) No Liabilities. Patriot and P-Newco, on the one hand, and TPL and T-Newco, on the other hand, represent and warrant that P-Newco and T-Newco do not now have, not have they ever had, any liabilities whatsoever, including but not limited to any tax liabilities or current or prospective litigation.
 

 
IN WITNESS WHEREOF, the parties hereto have caused this Merger Agreement to be duly executed by their respective authorized officers as of the day and year first above written.
   
 
PATRIOT SCIENTIFIC CORPORATION,
a Delaware corporation
 
By:______________________________________
Name:____________________________________
Title:_____________________________________
   
 
P-NEWCO LLC, a Delaware limited liability company
 
By:______________________________________
Name:____________________________________
Title:_____________________________________
   
 
TECHNOLOGY PROPERTIES LIMITED INC.,
a California corporation
 
By:______________________________________
Name:____________________________________
Title:_____________________________________
   
 
TPL NEWCO, LLC, a Delaware limited liability company
 
By:______________________________________
Name:____________________________________
Title:_____________________________________
   

 

 
EXHIBIT H
 
***
Indicates material omitted pursuant to an application for confidential treatment and that material has been filed separately with the Commission.
 

PATENT LICENSE AGREEMENT


This PATENT LICENSE AGREEMENT (“Agreement”) is entered into by and between PATRIOT SCIENTIFIC CORPORATION, a Delaware corporation (“Licensor”) having its principal place of business at 10989 Via Frontera, San Diego, California 92127, and INTEL CORPORATION, a Delaware corporation, located at 2200 Mission College Blvd., Santa Clara, CA 95052 (“Intel”).
 
RECITALS

WHEREAS, ***
 
***
 
***
 
***
 
NOW, THEREFORE, in consideration of the promises and the mutual promises and covenants contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:
 
DEFINITIONS

Capitalized terms used in this Agreement that are not otherwise defined herein shall have the meaning assigned to them in the Intel PLA. For the avoidance of doubt, the term “License” in this Agreement shall refer to Patriot Scientific Corporation.
 
Article 1. License Grant
 
1.1 Subject to the terms and conditions of this Agreement, Licensor hereby grants to Licensee ***
 
1.2 Right to License. In the event Licensor does not have the right to grant a license under any particular patent right of the scope set forth herein, then the license granted herein under such patent right shall be of the broadest scope which Licensor has the right to grant. If Licensor
 
(a) owns any rights in any Patent; or
(b) has the right to enforce or control the enforcement of any rights in any Patent; or
 


(c) can exercise any significant influence over the enforcement of any rights in any Patent but Licenser does not have the right to license those rights as broadly as set forth in Section 1.1 to Licensee hereunder (“Restricted Patent Rights”), then, if and to the extent that such Restricted Patent Rights would have been licensed to the Licensee if Licensor had the right to license such Patents;
(d) Licenser grants to the Licensee for Intel Licensed Products an immunity from suit for infringement of such Restricted Patent Rights of a scope identical to the rights that would have been granted hereunder if Licensor has the right to license such Restricted Patent Rights;
(e) Licensor shall not give their assent irrespective of whether that assent is required to allow a third party entity to assert the Restricted Patent Rights against the Licensed Products of the Licensee; and
(f) Licensor agrees to indemnify arid hold harmless Licensee against any monetary compensation, including those for damages and/or royalties, paid or to be paid by Licensee as a result of actual or threatened assertion of rights by the holder of the Restricted Patent Rights against Intel Licensed Products to the extent attributable to such Restricted Patent Rights, but only to the extent that such damage and/or royalty, directly or indirectly, benefits Licenser.

1.3 Further Assurances. To the extent Licenser does not have the right to grant any or all of the license rights granted in Section 1 of this Agreement or to the extent this Agreement does not grant such license rights, Licenser hereby grants such licenses to the fullest extent of their rights under the Patents and to the fullest extent possible under the law, and shall execute whatever documents are necessary to effectuate such license grant.
 
1.4 “Patents” shall mean all of the patents and patent applications listed on Appendix 1, and any patent, patent application or patent right throughout the Territory including, without limitation, any provisional, divisional, continuation, continuation-in-part, substitute, renewal, reissue, extension, confirmation, reexamination or registration thereof and any patent issuing therefrom including any substitute, renewal, reissue, extension, confirmation, reexamination or registration thereof
 
Article 2. Effective Date of License Grants.
 
2.1. The effective date of the license grant to each individual Patent licensed to Intel hereunder shall be the filing date of such Patent.
 
Article 3. Consideration.
 
3.1 As full consideration for the rights granted by Licensor to Licensee in Article I hereunder, and notwithstanding any rights Intel may have *** shall become immediately due and payable upon the execution of this Agreement by both parties. Licensor hereby acknowledges the adequacy of this consideration paid by Licensee to Licensor in consideration for the rights granted by Licensor in Article 1 hereunder, including without limitation ***.
 
3.2 The payment of the *** receives Notice of the triggering event by wire transfer to:
 

 
Torrey Pines Bank
 
12220 El Camino Real
San Diego, CA 92130
ABA/Routing Number: 122243635
Beneficiary Account Name: ***
Beneficiary Account Number: ***

Article 4. Other Intel PLA Provisions
 
4.1 All provisions of Articles 4 through Article 9 are hereby incorporated herein by this reference, provided only that
 
(a) Patriot Scientific Corporation shall be substituted, mutatis mutandis for the terms “***” and “Licensor” found throughout each of those provisions of the Intel PLA;
 
(b) Notices to Licensor shall be delivered to the following address or facsimile:
 
Patriot Scientific Corporation
10989 Via Frontera
San Diego, CA 92127
Attn: President
Fax: 858-674-5005

(c) Section 4.3 shall be deleted in its entirety and replaced with the following:
 
***
 
; and
 
(d) Section 9.18 shall be deleted in its entirety and replaced with the following:
 
***
 
Article 5. ***
 
***
 

 
IN WITNESS WHEREOF, the parties hereto have executed and delivered this Agreement as of the date first above written.
 
INTEL CORPORATION
 


By:__________________________________
Name:
Title:
Date: May 27, 2005


PATRIOT SCIENTIFIC CORPORATION


By:__________________________________
Name:
Title:
Date: May 27, 2005


***

***


By:__________________________________
Name: ***
Title: ***
Date: May 25, 2005


***


By:__________________________________
Name: ***
Title: ***
Date: May 25, 2005

CHARLES H. MOORE


By:__________________________________
Name: Charles H. Moore
Date: May 25, 2005
 

 
EXHIBIT I

THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAW, AND MAY NOT BE SOLD, TRANSFERRED, ASSIGNED, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF OR EXERCISED UNLESS (i) A REGISTRATION STATEMENT UNDER THE SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS SHALL HAVE BECOME EFFECTIVE WITH REGARD THERETO, OR (ii) AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS IS AVAILABLE IN CONNECTION WITH SUCH OFFER, SALE OR TRANSFER.

AN INVESTMENT IN THESE SECURITIES INVOLVES A HIGH DEGREE OF RISK. HOLDERS MUST RELY ON THEIR OWN ANALYSIS OF THE INVESTMENT AND ASSESSMENT OF THE RISKS INVOLVED.

Warrant to Purchase
Warrant Number _____
_______________ shares
 

Warrant Agreement
and
Warrant to Purchase Common Stock
of
PATRIOT SCIENTIFIC CORP.
 
THIS WARRANT AGREEMENT AND WARRANT TO PURCHASE COMMON STOCK (this “Warrant” or this “Agreement”) CERTIFIES that _____________ or any subsequent holder hereof (“Holder”) has the right to purchase from Patriot Scientific Corp., a Delaware corporation (the “Company”), up to ___________ fully paid and non-assessable shares, of the Company's common stock, $___________ par value per share (“Common Stock”), subject to adjustment as provided herein, at a price equal to the Exercise Price as defined in Section 3 below, and in the amounts provided in Section 2 below, at any time beginning on the Date of Issuance (defined below) and ending at 5:00 p.m., New York, New York time, on the date that is seven (7) years after the Date of Issuance (the “Exercise Period”).
 
Holder agrees with the Company that this Warrant is issued and all rights hereunder shall be held subject to all of the conditions, limitations and provisions set forth herein.
 
1. Date of Issuance and Term.
 
This Warrant shall be deemed to be issued on ___________, 200_ (“Date of Issuance”). The term of this Warrant is seven (7) years from the Date of Issuance.
 
2. Exercise.
 

 
(a) Amount of Exercise. The Holder hereof shall be entitled to exercise this Warrant at any time and from time to time in accordance with the following schedule:
 
(1) Upon the Closing (as defined herein), the Holder shall be entitled to exercise this Warrant to purchase ___________ shares of Common Stock.
 
(2) Upon the Trigger Price (as defined herein) reaching $_________, the Holder shall be entitled to exercise this Warrant to purchase an additional ___________ shares of Common Stock.
 
(3) Upon the Trigger Price reaching $_________, the Holder shall be entitled to exercise this Warrant to purchase an additional ___________ shares of Common Stock.
 
(4) Upon the Trigger Price reaching $________, the Holder shall be entitled to exercise this Warrant to purchase an additional ___________ shares of Common Stock.
 
“Closing” shall have the meaning given that term in the Master Agreement by and among Patriot, ___________, and ___________, dated as of ___________, 200_ (the “Master Agreement”).
 
“Trading Day” shall mean any day on which the Common Stock of the Company is traded for any period on the OTC-BB (as defined below), or on the principal securities exchange or other securities market on which the Common Stock is then being traded.
 
“Trigger Price” shall mean the closing price of the Company’s Common Stock on any Trading Day as reported by, or based upon data reported by, Bloomberg Financial Markets or an equivalent reliable reporting service.
 
(b) Manner of Exercise. During the Exercise Period, this Warrant may be exercised as to all or any lesser number of full shares of Common Stock covered hereby in accordance with the provisions of this Section 2 (the “Warrant Shares”) upon surrender of this Warrant, with the Exercise Form attached hereto as Exhibit A (the “Exercise Form”) duly completed and executed, together with the full Exercise Price (as defined below) for each share of Common Stock as to which this Warrant is exercised, at the office of the Company, Patriot Scientific Corporation, Attn: David H. Pohl, CEO; 10989 Via Frontera, San Diego, CA 92127; Telephone: (858) 674-5000, Facsimile: (858) 674-5005 or at such other office or agency as the Company may designate in writing, by overnight mail, with an advance copy of the Exercise Form sent to the Company and its Transfer Agent by facsimile (such surrender and payment of the Exercise Price hereinafter called the “Exercise of this Warrant”).
 
(c) Date of Exercise. The “Date of Exercise” of the Warrant shall be defined as the date that the advance copy of the completed and executed Exercise Form is sent by facsimile to the Company, provided that the original Warrant and Exercise Form are received by the Company as soon as practicable thereafter. Alternatively, the Date of Exercise shall be defined as the date the original Exercise Form is received by the Company, if Holder has not sent
 

 
advance notice by facsimile. The Company shall not be required to deliver the shares of Common Stock to the Holder until the requirements of Section 2(b) above are satisfied.
 
(d) Cancellation of Warrant. This Warrant shall be canceled upon the Exercise in full of this Warrant, and, as soon as practical after the Date of Exercise, Holder shall be entitled to receive Common Stock for the number of shares purchased upon such Exercise of this Warrant, and if this Warrant is not exercised in full, Holder shall be entitled to receive a new Warrant (containing terms identical to this Warrant) representing any unexercised portion of this Warrant in addition to such Common Stock.
 
(e) Holder of Record. Each person in whose name any Warrant for shares of Common Stock is issued shall, for all purposes, be deemed to be the Holder of record of such shares on the Date of Exercise of this Warrant, irrespective of the date of delivery of the Common Stock purchased upon the Exercise of this Warrant. Nothing in this Warrant shall be construed as conferring upon Holder any rights as a stockholder of the Company.
 
3. Payment of Warrant Exercise Price.
 
The Exercise Price (“Exercise Price”) shall equal $___________ per share.
 
Payment of the Exercise Price may be made by either of the following, or a combination thereof, at the election of Holder:
 
(i) Cash Exercise: cash, bank or cashiers check or wire transfer; or
 
 
(ii)
Cashless Exercise: surrender of this Warrant at the principal office of the Company together with notice of cashless election, in which event the Company shall issue Holder a number of shares of Common Stock computed using the following formula:
 
X=Y (A-B)/A
 
where: X = the number of shares of Common Stock to be issued to Holder.
 
Y = the number of shares of Common Stock for which this Warrant is being exercised.
 
A = the Market Price of one (1) share of Common Stock (for purposes of this Section 3 (ii), where “MARKET PRICE,” as of any date, means the Volume Weighted Average Price (as defined herein) of the Company's Common Stock during the ten (10) consecutive trading day period immediately preceding the date in question.
 
As used herein, the “VOLUME WEIGHTED AVERAGE PRICE” for any security as of any date means the volume weighted average sale price on the Over the Counter Electronic Bulletin Board (the
 

 
“OTC-BB”) as reported by, or based upon data reported by, Bloomberg Financial Markets or' an equivalent, reliable reporting service mutually acceptable to and hereafter designated by holders of a majority in interest of the Warrants and the Company (“BLOOMBERG”) or, if the OTC-BB is not the principal trading market for such security, the volume weighted average sale price of such security on the principal securities exchange or trading market where such security is listed or traded as reported by Bloomberg, or, if no volume weighted average sale price is reported for such security, then the last closing trade price of such security as reported by Bloomberg, or, if no last closing trade price is reported for such security by Bloomberg, the average of the bid prices of any market makers for such security that are listed in the “pink sheets” by the National Quotation Bureau, Inc. If the Volume Weighted Average Price cannot be calculated for such security on such date in the manner provided above, the volume weighted average price shall be the fair market value as mutually determined by the Company and the holders of a majority in interest of the Warrants being exercised for which the calculation of the volume weighted average price is required in order to determine the Exercise Price of such Warrants. “TRADING DAY” shall mean any day on which the Common Sock is traded for any period on the OTC-BB, or on the principal securities exchange or other securities market on which the Common Stock is then being traded.
 
B = the Exercise Price.
 
For purposes of Rule 144 and sub-section (d)(3)(ii) thereof, it is intended, understood and acknowledged that the Common Stock issuable upon exercise of this Warrant in a cashless exercise transaction shall be deemed to have been acquired at the time this Warrant was issued. Moreover, it is intended, understood and acknowledged that the holding period for the Common Stock issuable upon exercise of this Warrant in a cashless exercise transaction shall be deemed to have commenced on the date this Warrant was issued.
 
4. Holder’s Representations and Warranties.
 
Holder represents and warrants to the Company that:
 
(a) Incorporation of Representations and Warranties. The representations and warranties of the Holder contained in the Master Agreement are hereby incorporated by reference as if fully set forth herein.
 
(b) Investment Purpose. As of the date hereof, Holder is purchasing the Warrants and the Warrant Shares (collectively, the “Securities”) for its own account and not with a present view towards the public sale or distribution thereof, except pursuant to sales registered or exempted from registration under the 1933 Act; PROVIDED, HOWEVER, that by making the
 

 
representations herein, Holder does not agree to hold the Securities for any minimum or other specific term and reserves the right to dispose of the Securities at any time in accordance with or pursuant to a registration statement or an exemption under the 1933 Act and applicable state securities laws.
 
(c) Reliance On Exemptions. Holder understands that the Securities are being offered and sold to it in reliance upon specific exemptions from the registration requirements of United States federal and state securities laws and that the Company is relying upon the truth and accuracy of, and Holder's compliance with, the representations, warranties, agreements, acknowledgments and understandings of Holder set forth herein in order to determine the availability of such exemptions and the eligibility of Holder to acquire the Securities.
 
(d) Governmental Review. Holder understands that no United States federal or state agency or any other government or governmental agency has passed upon or made any recommendation or endorsement of the Securities.
 
(e) Transfer or Re-sale. Holder understands that (i) except as provided in the Registration Rights Agreement, the sale or re-sale of the Securities has not been and is not being registered under the 1933 Act or any applicable state securities laws, and the Securities may not be transferred or resold unless (a) the Securities are sold pursuant to an effective registration statement under the 1933 Act, (b) Holder shall have delivered to the Company an opinion of counsel (which opinion shall be in form, substance and scope reasonably satisfactory to counsel to the Company) to the effect that the Securities to be sold or transferred may be sold or transferred pursuant to an exemption from such registration, (c) the Securities are sold or transferred to an “affiliate” (as defined in Rule 144 promulgated under the 1933 Act (or a successor rule) (“RULE 144”) of the Holder who agrees to sell or otherwise transfer the Securities only in accordance with this Section 2(f) and who is an Accredited Investor, or (d) the Securities are sold pursuant to Rule 144; and (ii) any sale of such Securities made in reliance on Rule 144 may be made only in accordance with the terms of said Rule and further, if said Rule is not applicable, any re-sale of such Securities under circumstances in which the seller (or the person through whom the sale is made) may be deemed to be an underwriter (as that term is defined in the 1933 Act) may require compliance with some other exemption under the 1933 Act or the rules and regulations of the SEC thereunder. Notwithstanding the foregoing or anything else contained herein to the contrary, the Securities may be pledged as collateral in connection with a bona fide margin account or other lending arrangement.
 
(f) Legends. Holder understands that the Warrants and, until such time as the Warrant Shares have been registered under the 1933 Act as contemplated by the Registration Rights Agreement or otherwise may be sold pursuant to Rule 144 without any restriction as to the number of securities as of a particular date that can then be immediately sold, the Warrant Shares, may bear a restrictive legend in substantially the following form (and a stop-transfer order may be placed against transfer of the certificates for such Securities):
 
The securities represented by this certificate have not been registered under the Securities Act of 1933, as amended, or applicable state securities laws. The securities may not be sold, transferred or assigned in the absence of an effective registration
 

 
statement for the securities under said Act, or an opinion of counsel, in form, substance and scope reasonably satisfactory to counsel to the Company, that registration is not required under said Act or unless sold pursuant to Rule 144 under said Act.
 
Upon the request of any holder and the surrender of certificates, the legend set forth above shall be removed and the Company shall issue a certificate without such legend to the holder of any Security upon which it is stamped, if (a) such Security is registered for sale under an effective registration statement filed under the 1933 Act or otherwise may be sold pursuant to Rule 144 without any restriction as to the number of securities as of a particular date that can then be immediately sold, or (b) such holder provides the Company with an opinion of counsel, in form, substance and scope reasonably satisfactory to counsel to the Company, to the effect that a public sale or transfer of such Security may be made without registration under the 1933 Act and such sale or transfer is effected or (c) such holder provides the Company with reasonable assurances that such Security can be sold pursuant to Rule 144. Holder agrees to sell all Securities, including those represented by a certificate(s) from which the legend has been removed, in compliance with applicable prospectus delivery requirements, if any.
 
(g) Knowledge and Experience. Holder has such knowledge and experience in financial and business matters that it is capable of evaluating the merits and risks of the investment in the Securities.
 
5. Company’s Representations and Warranties.
 
 
The Company represents and warrants to Holder that, except as set forth on the Company's disclosure schedules to the Master Agreement:
 
(a) Incorporation of Representations and Warranties. The representations and warranties of the Company contained in the Master Agreement are hereby incorporated by reference as if fully set forth herein.
 
(b) Issuance of Shares. Upon issuance upon exercise of the Warrants in accordance with their terms, the Warrant Shares will be validly issued, fully paid and non-assessable, and free from all taxes, liens, claims and encumbrances and shall not be subject to preemptive rights or other similar rights of stockholders of the Company and will not impose personal liability upon the holder thereof.
 
(c) No Integrated Offering. Neither the Company, nor any of its affiliates, nor any person acting on its or their behalf, has directly or indirectly made any offers or sales of any security or solicited any offers to buy any security under circumstances that would require registration under the 1933 Act of the issuance of the Securities to Holder. The issuance of the Securities to Holder will not be integrated with any other issuance of the Company's securities (past, current or future) for purposes of any stockholder approval provisions applicable to the Company or its securities.
 
(d) Insurance. The Company and each of its subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in such amounts
 

 
as management of the Company believes to be prudent and customary in the businesses in which the Company and its subsidiaries are engaged. Neither the Company nor any such subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business at a cost that would not have a Material Adverse Effect (as defined in the Master Agreement).
 
(e) Solvency. The Company (both before and after giving effect to the transactions contemplated by this Agreement) is solvent (i.e., its assets have a fair market value in excess of the amount required to pay its probable liabilities on its existing debts as they become absolute and matured) and currently the Company has no information that would lead it to reasonably conclude that the Company would not have the ability to, nor does it intend to take any action that would impair its ability to, pay its debts from time to time incurred in connection therewith as such debts mature. The Company did not receive a qualified opinion from its auditors with respect to its most recent fiscal year end and does not anticipate or know of any basis upon which its auditors might issue a qualified opinion in respect of its current fiscal year.
 
(f) No Investment Company. The Company is not, and upon the issuance and sale of the Securities as contemplated by this Agreement will not be an "investment company" required to be registered under the Investment Company Act of 1940 (an “INVESTMENT COMPANY”). The Company is not controlled by an Investment Company.
 
6. Covenants.
 
(a) Form D; Blue Sky Laws. The Company agrees to file a Form D with respect to the Securities as required under Regulation D and to provide a copy thereof to Holder promptly after such filing. The Company shall, on or before the Closing Date, take such action as the Company shall reasonably determine is necessary to qualify the Securities for sale to Holder at the Closing pursuant to this Agreement under applicable securities or "blue sky" laws of the states of the United States (or to obtain an exemption from such qualification), and shall provide evidence of any such action so taken to Holder on or prior to the Closing Date.
 
(b) Reservation of Shares. The Company represents that it has at least 500,000,000 authorized shares and covenants that it will initially reserve (the “INITIAL SHARE RESERVATION”) from its authorized and unissued Common Stock a number of shares of Common Stock equal to at least 100% of the Warrant Shares, to provide for the issuance of Common Stock upon the exercise of the Warrants. The Company further covenants that, beginning on the date hereof, and continuing throughout the period the conversion right exists, the Company shall at all times have authorized, and reserved (the “ONGOING SHARE RESERVATION REQUIREMENT”) for the purpose of issuance, a sufficient number of shares of Common Stock to provide for the full exercise of the Warrants and issuance of the Warrant Shares in connection therewith. The Company shall not reduce the number of shares of Common Stock reserved for issuance upon exercise of or otherwise pursuant to the Warrants without the consent of Holder. The Company shall use its best efforts at all times to maintain the number of shares of Common Stock so reserved for issuance at no less than 100% of the number that is then actually issuable upon full exercise of the Warrants. If at any time the number of shares of Common Stock authorized and reserved for issuance is below the number of Warrant
 

 
Shares issued or issuable upon exercise of or otherwise pursuant to the Warrants, the Company will promptly take all corporate action necessary to authorize and reserve a sufficient number of shares, including, without limitation, calling a special meeting of stockholders to authorize additional shares to meet the Company's obligations under this Section 6(b), in the case of an insufficient number of authorized shares, and using its best efforts to obtain stockholder approval of an increase in such authorized number of shares.
 
(c) Listing. The Company shall use its best efforts to promptly secure the listing of the Warrant Shares upon each national securities exchange or automated quotation system, if any, upon which shares of Common Stock are then listed (subject to official notice of issuance) and, so long as Holder owns any of the Securities, shall maintain, so long as any other shares of Common Stock shall be so listed, such listing of all Warrant Shares from time to time issuable upon exercise of or otherwise pursuant to the Warrants. The Company will use its best efforts to obtain and, so long as Holder owns any of the Securities, maintain the listing and trading of its Common Stock on the OTC-BB, the Nasdaq National Market (the “NNM”), the Nasdaq SmallCap Market (the “NASDAQ SMALLCAP”), the New York Stock Exchange (“NYSE”), or the American Stock Exchange (“AMEX”) and will comply in all respects with the Company's reporting, filing and other obligations under the bylaws or rules of the National Association of Securities Dealers (“NASD”) and such exchanges, as applicable. The Company shall promptly provide to Holder copies of any notices it receives from the OTC-BB and any other exchanges or quotation systems on which the Common Stock is then listed regarding the continued eligibility of the Common Stock for listing on such exchanges and quotation systems.
 
(d) Corporate Existence. So long as Holder beneficially owns any Warrants, the Company shall maintain its corporate existence and shall not merge, consolidate or sell all or substantially all of the Company's assets, except in the event of a merger or consolidation or sale of all or substantially all of the Company's assets, where the successor or acquiring entity assumes the Company's obligations under this Agreement.
 
(e) No Integration. The Company shall not make any offers or sales of any security (other than the Securities) under circumstances that would require registration of the Securities being offered or sold hereunder under the 1933 Act or cause the offering of the Securities to be integrated with any other offering of securities by the Company for the purpose of any stockholder approval provision applicable to the Company or its securities.
 
(f) Irrevocable Transfer Agent Instructions. Within ten (10) business days after the Closing Date, the Company agrees to deliver to Holder the Irrevocable Transfer Agent Instructions (as defined below), in form and substance satisfactory to Holder, which instructions shall be acknowledged in writing by the Company's Transfer Agent.
 
(g) Confidentiality. The Company agrees to keep all information disclosed to the Company by Holder or its representatives pursuant to or in connection with this Agreement, the Registration Rights Agreement entered into as of the date hereof, or the transactions contemplated hereby and thereby, confidential, and shall not disclose any such information without first obtaining the written consent of Holder, except as required by applicable law.
 
7. Transfer Agent Instructions.
 

 
The Company shall issue irrevocable instructions to its transfer agent to issue certificates, registered in the name of Holder or its nominee for the Warrant Shares in such amounts as specified from time to time by Holder to the Company upon exercise of the Warrants in accordance with their terms (the “IRREVOCABLE TRANSFER AGENT INSTRUCTIONS”). Prior to registration of the Warrant Shares under the 1933 Act or the date on which the Warrant Shares may be sold pursuant to Rule 144 without any restriction as to the number of securities as of a particular date that can then be immediately sold, all such certificates shall bear the restrictive legend specified in Section 4(h) of this Agreement. The Company warrants that no instruction other than the Irrevocable Transfer Agent Instructions referred to in this Section 7, and stop transfer instructions to give effect to Section 2(g) hereof (in the case of the Warrant Shares, prior to registration of the Warrant Shares under the 1933 Act or the date on which the Warrant Shares may be sold pursuant to Rule 144 without any restriction as to the number of securities as of a particular date that can then be immediately sold), will be given by the Company to its transfer agent and that the Securities shall otherwise be freely transferable on the books and records of the Company as and to the extent provided in this Agreement and the Registration Rights Agreement. Nothing in this Section shall affect in any way the Holder's obligations and agreement set forth in Section 2(g) hereof to comply with all applicable prospectus delivery requirements, if any, upon re-sale of the Securities. If Holder provides the Company with (i) an opinion of counsel in form, substance and scope customary for opinions in comparable transactions, to the effect that a public sale or transfer of such Securities may be made without registration under the 1933 Act and such sale or transfer is effected or (ii) Holder provides reasonable assurances that the Securities can be sold pursuant to Rule 144, the Company shall permit the transfer, and, in the case of the Warrant Shares, promptly instruct its transfer agent to issue one or more certificates, free from any restrictive legend, in such name and in such denominations as specified by Holder.
 
8. Transfer and Registration.
 
(a) Transfer Rights. Subject to the provisions of Section 12 of this Warrant, this Warrant may be transferred on the books of the Company, in whole or in part, in person or by attorney, upon surrender of this Warrant properly completed and endorsed. This Warrant shall be canceled upon such surrender and, as soon as practicable thereafter, the person to whom such transfer is made shall be entitled to receive a new Warrant or Warrants as to the portion of this Warrant transferred, and Holder shall be entitled to receive a new Warrant as to the portion hereof retained.
 
(b) Registrable Securities. The Common Stock issuable upon the exercise of this Warrant has registration rights pursuant to that certain Registration Rights Agreements between the Company and Technology Properties Limited Inc. dated of even date herewith.
 
9. Anti-Dilution Adjustments.
 
(a) Stock Dividend. If the Company shall at any time declare a dividend payable in shares of Common Stock, then Holder, upon Exercise of this Warrant after the record date for the determination of holders of Common Stock entitled to receive such dividend, shall be entitled to receive upon Exercise of this Warrant, in addition to the number of shares of Common Stock as to which this Warrant is exercised, such additional shares of Common Stock
 

 
as such Holder would have received had this Warrant been exercised immediately prior to such record date and the Exercise Price will be proportionately adjusted.
 
(b) Distribution. If at any time after the Issue Date hereof, the Company shall declare or make any distribution of its assets (or rights to acquire its assets) or shares of its capital stock (other than Common Stock) to Holders of Common Stock of the Company as a partial liquidating dividend, by way of return of capital or otherwise (including any dividend or distribution to the Company's shareholders in cash or shares or rights to acquire shares of capital stock of any other public or private company, including but not limited to a subsidiary or spin-off of the Company (a “Distribution”)), then the Holders of this Warrant shall be entitled, to immediately receive the amount of such distribution (in kind) which would have been payable to the Holder with respect to the shares of Common Stock issuable upon a full exercise of this Warrant (without regard to any contractual, legal or regulatory limitations on the amount of such conversion), had such Holder been the holder of such shares of Common Stock on the record date for determination of shareholders entitled to such Distribution.
 
(c) Recapitalization or Reclassification. If the Company shall at any time effect a recapitalization, reclassification or other similar transaction of such character that the shares of Common Stock shall be changed into or become exchangeable for a larger or smaller number of shares, then upon the effective date thereof, the number of shares of Common Stock which Holder shall be entitled to purchase upon Exercise of this Warrant shall be increased or decreased, as the case may be, in direct proportion to the increase or decrease in the number of shares of Common Stock by reason of such recapitalization, reclassification or similar transaction, and the Exercise Price shall be, in the case of an increase in the number of shares, proportionally decreased and, in the case of decrease in the number of shares, proportionally increased. The Company shall give Holder the same notice it provides to holders of Common Stock of any transaction described in this Section 9(c).
 
(d) Intentionally Left Blank.
 
(e) Notice of Consolidation or Merger. In the event of a merger, consolidation, exchange of shares, recapitalization, reorganization, or other similar event, as a result of which shares of Common Stock shall be changed into the same or a different number of shares of the same or another class or classes of stock or securities or other assets of the Company or another entity or there is a sale of all or substantially all the Company's assets (a “Corporate Change”), then this Warrant shall be exerciseable into such class and type of securities or other assets as Holder would have received had Holder exercised this Warrant immediately prior to such Corporate Change; provided, however, that Company may not affect any Corporate Change unless it first shall have given thirty (30) business days notice to Holder hereof of any Corporate Change.
 
(f) Exercise Price Adjusted. As used in this Warrant, the term “Exercise Price” shall mean the purchase price per share specified in Section 3 of this Warrant, until the occurrence of an event stated in subsection (a), (b), (c) or (d) of this Section 9, and thereafter shall mean said price as adjusted from time to time in accordance with the provisions of said subsection. No such adjustment under this Section 9 shall be made unless such adjustment would
 

 
change the Exercise Price at the time by $.01 or more; provided, however, that all adjustments not so made shall be deferred and made when the aggregate thereof would change the Exercise Price at the time by $.__ or more. No adjustment made pursuant to any provision of this Section 9 shall have the net effect of increasing the Exercise Price in relation to the split adjusted and distribution adjusted price of the Common Stock. The number of shares of Common Stock subject hereto shall increase proportionately with each decrease in the Exercise Price.
 
(g) Adjustments: Additional Shares, Securities or Assets. In the event that at any time, as a result of an adjustment made pursuant to this Section 9, Holder shall, upon Exercise of this Warrant, become entitled to receive shares and/or other securities or assets (other than Common Stock) then, wherever appropriate, all references herein to shares of Common Stock shall be deemed to refer to and include such shares and/or other securities or assets; and thereafter the number of such shares and/or other securities or assets shall be subject to adjustment from time to time in a manner and upon terms as nearly equivalent as practicable to the provisions of this Section 9.
 
10. Fractional Interests.
 
No fractional shares or scrip representing fractional shares shall be issuable upon the Exercise of this Warrant, but on Exercise of this Warrant, Holder may purchase only a whole number of shares of Common Stock. If, on Exercise of this Warrant, Holder would be entitled to a fractional share of Common Stock or a right to acquire a fractional share of Common Stock, such fractional share shall be disregarded and the number of shares of Common Stock issuable upon exercise shall be the next higher number of shares.
 
11. Reservation of Shares.
 
From and after the date hereof, the Company shall at all times reserve for issuance such number of authorized and unissued shares of Common Stock (or other securities substituted therefor as herein above provided) as shall be sufficient for the Exercise of this Warrant and payment of the Exercise Price. If at any time the number of shares of Common Stock authorized and reserved for issuance is below the number of shares sufficient for the Exercise of this Warrant and payment of the Exercise Price (based on the Exercise Price in effect from time to time), the Company will promptly take all corporate action necessary to authorize and reserve a sufficient number of shares, including, without limitation, calling a special meeting of stockholders to authorize additional shares to meet the Company's obligations under this Section 11, in the case of an insufficient number of authorized shares, and using its best efforts to obtain stockholder approval of an increase in such authorized number of shares. The Company covenants and agrees that upon the Exercise of this Warrant, all shares of Common Stock issuable upon such exercise shall be duly and validly issued, fully paid, nonassessable and not subject to preemptive rights, rights of first refusal or similar rights of any person or entity.
 
12. Restrictions on Transfer.
 
(a) Registration or Exemption Required. This Warrant has been issued in a transaction exempt from the registration requirements of the Act by virtue of Regulation D and
 

 
exempt from state registration under applicable state laws. The Warrant and the Common Stock issuable upon the Exercise of this Warrant may not be pledged, transferred, sold or assigned except pursuant to an effective registration statement or an exemption to the registration requirements of the Act and applicable state laws.
 
(b) Assignment. If Holder can provide the Company with reasonably satisfactory evidence that the conditions of (a) above regarding registration or exemption have been satisfied, Holder may sell, transfer, assign, pledge or otherwise dispose of this Warrant, in whole or in part. Holder shall deliver a written notice to Company, substantially in the form of the Assignment attached hereto as Exhibit B, indicating the person or persons to whom the Warrant shall be assigned and the respective number of warrants to be assigned to each assignee. The Company shall effect the assignment within ten (10) days, and shall deliver to the assignee(s) designated by Holder a Warrant or Warrants of like tenor and terms for the appropriate number of shares.
 
13. Benefits of this Warrant.
 
Nothing in this Warrant shall be construed to confer upon any person other than the Company and Holder any legal or equitable right, remedy or claim under this Warrant and this Warrant shall be for the sole and exclusive benefit of the Company and Holder.
 
14. Arbitration: Governing Law.
 
This Agreement shall be governed by and construed in accordance with the laws of the State of New York applicable to agreements made in and wholly to be performed in that jurisdiction, except for matters arising under the Act or the Securities Exchange Act of 1934, which matters shall be construed and interpreted in accordance with such laws. Any controversy or claim arising out of or related to this Agreement or the breach thereof, shall be settled by binding arbitration in New York, New York in accordance with the Expedited Procedures (Rules 53-57) of the Commercial Arbitration Rules of the American Arbitration Association (“AAA”). A proceeding shall be commenced upon written demand by Company or any Lender to the other. The arbitrator(s) shall enter a judgment by default against any party, which fails or refuses to appear in any properly noticed arbitration proceeding. The proceeding shall be conducted by one (1) arbitrator, unless the amount alleged to be in dispute exceeds _____ dollars ($__), in which case three (3) arbitrators shall preside. The arbitrator(s) will be chosen by the parties from a list provided by the AAA, and if they are unable to agree within ten (10) days, the AAA shall select the arbitrator(s). The arbitrators must be experts in securities law and financial transactions. The arbitrators shall assess costs and expenses of the arbitration, including all attorneys' and experts' fees, as the arbitrators believe is appropriate in light of the merits of the parties' respective positions in the issues in dispute. Each party submits irrevocably to the jurisdiction of any state court sitting in New York, New York or to the United States District Court sitting in New York for purposes of enforcement of any discovery order, judgment or award in connection with such arbitration. The award of the arbitrator(s) shall be final and binding upon the parties and may be enforced in any court having jurisdiction. The arbitration shall be held in such place as set by the arbitrator(s) in accordance with Rule 55. With respect to any arbitration proceeding in accordance with this section, the prevailing party's reasonable attorney's fees and expenses shall be borne by the non-prevailing party.
 

 
Although the parties, as expressed above, agree that all claims, including claims that are equitable in nature, for example specific performance, shall initially be prosecuted in the binding arbitration procedure outlined above, if the arbitration panel dismisses or otherwise fails to entertain any or all of the equitable claims asserted by reason of the fact that it lacks jurisdiction, power and/or authority to consider such claims and/or direct the remedy requested, .then, in only that event, will the parties have the right to initiate litigation respecting such equitable claims or remedies. The forum for such equitable relief shall be in either a state or federal court sitting in New York, New York. Each party waives any right to a trial by jury, assuming such right exists in an equitable proceeding, and irrevocably submits to the jurisdiction of said New York court. New York law shall govern the proceeding as well as the interpretation and construction of this Agreement and the transaction as a whole.
 
15. Loss of Warrant.
 
Upon receipt by the Company of evidence of the loss, theft, destruction or mutilation of this Warrant, and (in the case of loss, theft or destruction) of indemnity or security reasonably satisfactory to the Company, and upon surrender and cancellation of this Warrant, if mutilated, the Company shall execute and deliver a new Warrant of like tenor and date.
 
16. Notice or Demands.
 
Notices or demands pursuant to this Warrant to be given or made by Holder to or on the Company shall be sufficiently given or made if sent by certified or registered mail, return receipt requested, postage prepaid, and addressed, until another address is designated in writing by the Company, to the address set forth in Section 2(b) above. Notices or demands pursuant to this Warrant to be given or made by the Company to or on Holder shall be sufficiently given or made if sent by certified or registered mail, return receipt requested, postage prepaid, and addressed, to the address of Holder set forth in the Company's records, until another address is designated in writing by Holder.
 

 
IN WITNESS WHEREOF, the undersigned have executed this Warrant as of the __th day of __, 2005.
 
 
PATRIOT SCIENTIFIC CORPORATION,
a Delaware corporation
 
By:__________________________________
Name:________________________________
Title:_________________________________
   
 
____________________________________,
a _______________ corporation
 
 
By:__________________________________
Name:________________________________ 
Title:_________________________________ 




EXHIBIT A
 
EXERCISE FORM FOR WARRANT
 
TO: PATRIOT SCIENTIFIC CORP.
 
The undersigned hereby irrevocably exercises the right to purchase ________________ of the shares of Common Stock (the “Common Stock”) of Patriot Scientific Corp., a Delaware corporation (the “Company”), evidenced by the attached warrant (the “Warrant”), and herewith makes payment of the exercise price with respect to such shares in full, all in accordance with the conditions and provisions of said Warrant.
 
1. The undersigned agrees not to offer, sell, transfer or otherwise dispose of any of the Common Stock obtained on exercise of the Warrant, except in accordance with the provisions of Section 8(a) of the Warrant.
 
2. The undersigned requests that stock certificates for such shares be issued free of any restrictive legend, if appropriate, and a warrant representing any unexercised portion hereof be issued, pursuant to the Warrant in the name of the undersigned and delivered to the undersigned at the address set forth below:
 

Dated:_________________


Signature


Print Name


Address

NOTICE
 
The signature to the foregoing Exercise Form must correspond to the name as written upon the face of the attached Warrant in every particular, without alteration or enlargement or any change whatsoever.
 

 
 


EXHIBIT B
 
ASSIGNMENT
 
(To be executed by the registered holder
 
desiring to transfer the Warrant)
 
FOR VALUE RECEIVED, the undersigned holder of the attached warrant (the “Warrant”) hereby sells, assigns and transfers unto the person or persons below named the right to purchase ________ shares of the Common Stock of Patriot Scientific Corp., evidenced by the attached Warrant and does hereby irrevocably constitute and appoint ______________________ attorney to transfer the said Warrant on the books of the Company, with full power of substitution in the premises.
 
Dated:_____________    __________________________

Signature

Fill in for new registration of Warrant:

_____________________________________
Name

_____________________________________
Address

_____________________________________
Please print name and address of assignee
(including zip code number)

________________________________________________________________________

NOTICE
 
The signature to the foregoing Assignment must correspond to the name as written upon the face of the attached Warrant in every particular, without alteration or enlargement or any change whatsoever.
 

________________________________________________________________________
 

 
EXHIBIT J

REGISTRATION RIGHTS AGREEMENT

REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of ________, 200__, by and between PATRIOT SCIENTIFIC CORPORATION, a Delaware corporation (The “Company”), and _______, a _________ corporation (the “Buyer” or “____”).

WHEREAS:

A. In connection with the transactions contemplated by the Master Agreement by and among the Company, ___, and _______, dated as of ________, 200__ (the “Master Agreement”), the company has agreed, upon the terms and subject to the conditions contained in the Master Agreement and the Warrant Agreement between the Company and ___, dated as of the date hereof (the “Warrant Agreement”), to issue to ___ warrants (the “Warrants”) to purchase ________ shares of common stock of the Company, par value of $_____ (the “Common Stock”); and

B. To induce _____ to execute and deliver the Master Agreement and the Warrant Agreement, the Company has agreed to provide certain registration rights under the Securities Act of 1933, as amended, and the rules and regulations thereunder, or any similar successor statute (collectively, the “1933 Act”), and applicable state securities laws;

NOW, THEREFORE, in consideration of the premises and the mutual covenants contained herein, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and _________ hereby agree as follows:

1. DEFINITIONS.

a. As used in this Agreement, the following terms shall have the following meanings:

(i) “BUSINESS DAY” shall have the meaning set forth in the Master Agreement.

(ii) “BUYER” shall mean ____ or any transferee pursuant to Section 9 herein.

(iii) “REGISTER,” “REGISTERED,” and “REGISTRATION” refer to a registration effected by preparing and filing a Registration Statement or Statements in compliance with the 1933 Act and pursuant to Rule 3415 under the 1933 Act or any successor rule providing for offering securities on a continuous as basis (“RULE 415”), and the declaration or ordering of effectiveness of such Registration statement by the United States Securities and Exchange Commission (the “SEC”).

(iv) “REGISTRATION SECURITIES” means (a) any shares of Common Stock (the “Warrant Shares”) issued or issuable upon exercise of or otherwise pursuant to the Warrants and (b) any shares of capital stock or issuable as a dividend on or in exchange for or otherwise with respect to the foregoing.

1

(v) “REGISTRATION STATEMENT(S)” means a registration statement(s) of the Company under the 1933 Act.

2. REGISTRATION.

a. MANDATORY REGISTRATION. The Company shall prepare and, on or prior to ________, 200__ (the “FILING DATE”) file with the SEC a Registration Statement on Form S-3 (or, if Form S-3 is not then available, on such form of Registration Statement as is then available to effect a registration of the Registrable Securities, subject to the consent of the Buyer, which consent will not be unreasonably withheld) covering the resale of the Registrable Securities, which Registration Statement, to the extent allowable under the 1933 Act and the rules and regulations promulgated thereunder (including Rule 415), shall state that such Registration Statement also covers such indeterminate number of additional shares of Common Stock as may become issuable upon exercise of or otherwise pursuant to the Warrants to prevent dilution resulting from stock splits, stock dividends or similar transactions. The number of shares of Common Stock initially included in such Registration Statement shall be no less than 100% of the aggregate number of Warrant Shares that are then issuable upon exercise of or otherwise pursuant to the Warrants, without regard to any limitation on the Buyer’s ability to exercise the Warrants. The Company acknowledges that the number of shares initially included in the Registration Statement represents a good faith estimate of the maximum number of shares issuable upon exercise of or otherwise pursuant to the Warrants. Registration Statement (and each amendment or supplement thereto, and each request for acceleration of effectiveness thereof) shall be provided to (and subject to the approval of) the Buyer and its counsel prior to its filing or other submission.

b. [INTENTIONALLY OMITTED].

c. PAYMENTS BY THE COMPANY. The Company shall use its best efforts to obtain effectiveness of the Registration Statement or as soon as practicable, but in any event not later than __________, 200__ (the “REGISTRATION DEADLINE”). If (i) the Registration Statement covering the Registrable Securities required to be filed by the Company pursuant to Section 2(a) hereof is not declared effective by the SEC by the Registration Deadline, or (ii) after the Registration Statement has been declared effective by the SEC, sales of all of the Registrable Securities cannot be made pursuant to the Registration Statement, or (iii) the Common Stock is not listed or included for quotation on the Over the Counter Electronic Bulletin Board (the “OTC-BB”), the Nasdaq National Market (“NNM”), the Nasdaq Small Cap Market (“NASDQ SMALL CAP”), the New York Stock Exchange (the “NYSE”) or the American Stock Exchange (the “AMEX”), then the Company will make payments to the Buyer in such amounts and at such times as shall be determined pursuant to this Section 2(c) as partial relief for the damages to the Buyer by reason of any such delay in or reduction of its ability to sell the Registrable Securities (which remedy shall not be exclusive of any other remedies available at law or in equity). The Company shall pay to the holder of the Warrants an amount equal to the aggregate, exercise price paid for such Registrable Securities upon exercise of the Warrants (“OUTSTANDING AMOUNT”) multiplied by the Applicable Percentage (as defined below) times the number of months (prorated for partial months) after the Registration Deadline and prior to the date the Registration Statement is declared effective by the SEC.

2

The term “APPLICABLE PERCENTAGE” means ________ (___). (For example, if the Registration Statement becomes effective one (1) month after the Registration Deadline, the Company would pay $________ for each $________ of Outstanding Amount. If thereafter, sales of all of the Registrable Securities could not be made pursuant to the Registration Statement for an additional period of one (1) month, the Company would pay an additional $________ for each $________ Outstanding Amount. Such amounts shall be paid in cash within five (5) days after the end of each period that gives rise to such obligations, PROVIDED that, if any such period extends for more than thirty (30) days, interim payments shall be made for each such thirty (30) day period.

d. PIGGY-BACK REGISTRATIONS. If at any time prior to the expiration of the Registration Period (as hereinafter defined) the Company shall determine to file with the SEC a Registration Statement relating to an offering for its own account or the account of others under the 1933 Act of any of its equity securities (other than on Form S-4 or Form S-8 or their then equivalents relating to equity securities to be issued solely in connection with any acquisition of any entity or business or equity securities issuable in connection with stock option or other employee benefit plans), the Company shall send the Buyer written notice of such determination and, if within fifteen (15) days after the effective date of such notice, the Buyer shall so request in writing, the company shall include in such Registration Statement all or any part of the Registrable Securities the Buyer requests to be registered, except that if, in connection with any underwritten public offering for the account of the Company, the managing underwriter(s)’ thereof shall impose a limitation on the number of shares of Common Stock which may be included in the Registration Statement because, in such underwriter(s)’ judgment, marketing or other factors dictate such limitation is necessary to facilitate public distribution, then the Company shall be obligated to include in such Registration Statement only such limited portion of the Registrable Securities with respect to which the Buyer has requested inclusion hereunder as the underwriter shall permit;

PROVIDED, HOWEVER, that the Company shall not exclude any Registrable Securities unless the Company has first excluded all outstanding securities, the holders of which are not entitled by contract to inclusion of such securities in such Registration Statement or are not entitled to pro rata inclusion with the Registrable Securities; and

PROVIDED, FURTHER, HOWEVER, that, after giving effect to the immediately preceding proviso, any exclusion of Registrable Securities shall be made pro rata with holders of other securities having the contractual right to include such securities in the Registration Statement other than holders of securities entitled to inclusion of their securities in such Registration Statement by reason of demand registration rights. No right to registration of Registrable Securities under this Section 2(d) shall be construed to limit any registration required under Section 2(a) hereof. If an offering in connection with which the Buyer is entitled to registration under this Section 2(d) is an underwritten offering, then the Buyer shall, unless otherwise agreed by the Company, offer and sell such Registrable Securities in an underwritten offering using the same underwriter or underwriters and, subject to the provisions of this Agreement, on the same terms and conditions as other shares of Common Stock include in such underwritten offering. Notwithstanding anything to the contrary set forth herein, the registration rights of the Buyer pursuant to this Section 2(d) shall only be available in the event the Company fails to timely file, obtain effectiveness or maintain effectiveness of any Registration Statement to be filed pursuant to Section 2(a) in accordance with the terms of this Agreement.

3

e. ELIGIBILITY FOR FORM SB-2. The Company represents and warrants that it meets the registrant eligibility and transaction requirements for the use of Form SB-2 for registration of the sale by the Buyer of the Registrable Securities and the Company shall file all reports required to be filed by the Company with the SEC in a timely manner so as to maintain such eligibility for the use of Form SB-2.

3. OBLIGATION OF THE COMPANY.

In connection with the registration of the Registrable Securities, the Company shall have the following obligations:

a. The Company shall prepare promptly, and file with the SEC as soon as practicable after the date of the Closing under the Master Agreement (the “CLOSING DATE”) (but no later than the Filing Date), a Registration Statement with respect to the number of Registrable Securities provided in Section 2(a), and thereafter use its best efforts to cause such Registration Statement relating to Registrable Securities to become effective as soon as possible after such filing (but in no event later than the Registration Deadline), and keep the Registration Statement effective pursuant to Rule 415 at all times until such date as is the earlier of (i) the date on which all of the Registrable Securities have been sold and (ii) the date on which the Registrable Securities (in the opinion of counsel to the Buyer) may be immediately sold to the public without registration or restriction (including without limitation as to volume by each holder thereof) under the 1933 Act (the “REGISTRATION PERIOD”), which Registration Statement (including any amendments or supplements thereto and prospectuses contained therein) shall not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein, or necessary to make the statements therein not misleading.

b. The Company shall prepare and file with the SEC such amendments (including post-effective amendments) and supplements to the Registration Statements and the prospectus used in connection with the Registration Statements as may be necessary to keep the Registration Statements effective at all times during the Registration Period, and, during such period, comply with the provisions of the 1933 Act with respect to the disposition of all Registrable Securities of the Company covered by the Registration Statements until such time as all of such Registrable Securities have been disposed of in accordance with the intended methods of disposition by the seller or sellers thereof as set forth in the Registration Statements. In the event that on any Business Day (the “REGISTRATION TRIGGER DATE”) the number of shares available under a Registration Statement filed pursuant to this Agreement is insufficient to cover all of the Registrable Securities issued or issuable upon exercise of or otherwise pursuant to the Warrants, without giving effect to any limitations on the Buyer’ ability to exercise the Warrants, the Company shall amend the Registration Statement, or file a new Registration Statement (on the short form available therefore, if applicable), or both, so as to cover ________ (_____ %) of all of the Registrable Securities so issued or issuable (without giving effect to any limitations on exercise contained in the Warrants) as of the Registration Trigger Date, in each case, as soon as practicable, but in any event within twenty (20) Business Days after the necessity therefore arises (based on the market price of the Common Stock and other relevant factors on which the Company reasonably elects to rely), provided, however that the Company shall have a sufficient number of authorized and unissued shares. In the event the Company does not have a sufficient number of authorized and unissued shares, the Company shall use its best efforts to obtain all necessary shareholder approvals and to make all necessary filings to increase its authorized shares as promptly as practicable and, within twenty (20) Business Days after the necessary increase in its authorized shares shall become effective, amend the Registration Statement or file a new Registration Statement as set forth above. The Company shall use its best efforts to cause such amendments and/or new Registration Statement to become effective as soon as practicable following the filing thereof, but in any event within sixty (60) days of the Registration Trigger Date or as promptly as practicable in the even the Company is required to increase its authorized shares. The provisions of Section 2(c) above shall be applicable with respect to the Company’s obligations under this Section 3(b).

4

c. The Company shall furnish to the Buyer and its legal counsel (i) promptly after the same is prepared and publicly distributed, filed with the SEC, or received by the Company, one copy of each Registration Statement and any amendment thereto, each preliminary prospectus and prospectus and each amendment or supplement thereto, and, in the case of the Registration Statement referred to in Section 2(a), each letter written by or on behalf of the Company to the SEC or the staff of the SEC, and each item of correspondence from the SEC or the staff of the SEC, in each case relating to such Registration Statement (other than any portion of any thereof which contains information for which the Company has sought confidential treatment), and (ii) such number of copies of a prospectus, including a preliminary prospectus, and all amendments and supplements thereto and such other documents as the Buyer may reasonably request in order to facilitate the disposition of the Registrable Securities owned by the Buyer. The Company will immediately notify the Buyer by facsimile of the effectiveness of each Registration Statement or any post-effective amendment. The Company will promptly respond to any and all comments received from the SEC, with a view towards causing each Registration Statement or any amendment thereto to be declared effective by the SEC as soon as practicable and shall file an acceleration request as soon as practicable, but no later than three (3) business days (the “ACCELERATION REQUEST DEADLINE”), following the resolution or clearance of all SEC comments or, if applicable, following notification by the SEC that any such Registration Statement or any amendment thereto will not be subject to review.

d. The Company shall use reasonable efforts to (i) register and qualify the Registrable Securities covered by the Registration Statements under such other securities or “blue sky” laws of such jurisdictions in the United States to which the Buyer is subject, (ii) prepare and file in those jurisdictions such amendments (including post-effective amendments) and supplements to such registrations and qualifications as may be necessary to maintain the effectiveness thereof during the Registration Period, (iii) take such other actions as may be necessary to maintain such registrations and qualifications in effect at all times during the Registration Period, and (iv) take all other actions reasonably necessary or advisable to qualify the Registrable Securities for sale in such jurisdictions;

e. [INTENTIONALLY OMITTED].

5

f. As promptly as practicable after becoming aware of such event, the Company shall notify the Buyer of the happening of any event, of which the Company has knowledge, as a result of which the prospectus included in any Registration Statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading, and use its best efforts promptly to prepare a supplement or amendment to any Registration Statement to correct such untrue statement or omission, and deliver such number of copies of such supplement or amendment to the Buyer as the Buyer may reasonably request; provided that, for not more than twenty (20) consecutive days (or a total of not more than sixty (60) days in any twelve (12) month period), the Company may delay the disclosure of material non-public information concerning the Company (as well as prospectus or Registration Statement updating) the disclosure of which at the time is not, in the good faith opinion of the Company, in the best interests of the Company (an “ALLOWED DELAY”); provided, further, that the Company shall promptly (i) notify the Buyer in writing of the existence of (but in no event, without the prior written consent of the Buyer, shall the Company disclose to the Buyer any of the facts or circumstances regarding) material non-public information giving rise to an Allowed Delay and (ii) advise the Buyer in writing to cease all sales under such Registration Statement until the end of the Allowed Delay, provided the above actions are consistent with the requirements of the 1933 Act and/or the Securities Exchange Act of 1934, as amended (the “1934 Act”) or other applicable law. Upon expiration of the Allowed Delay, the Company shall again be bound by the first sentence of this Section 3(f) with respect to the information giving rise thereto.

g. The Company shall use its least efforts to prevent the issuance of any stop order or other suspension of effectiveness of any Registration Statement, and, if such an order is issued, to obtain the withdrawal of such order at the earliest possible moment and to notify the Buyer who holds Registrable Securities being sold (or, in the event of an underwritten offering, the managing underwriters) of the issuance of such order and the resolution thereof.

h. The Company shall permit a single firm of counsel designated by the Buyer to review such Registration Statement and all amendments and supplements thereto (as well as all requests for acceleration of effectiveness thereof) a reasonable period of time prior to their filing with the SEC (not less than three (3) Business Days but not more then five (5) Business Days) and not file any document in a form to which such counsel reasonably objects and will not request acceleration of such Registration Statement without prior notice to such counsel.

i. The Company shall make generally available to its security holders as soon as practicable, but not later than ninety (90) days after the close of the period covered thereby, an earnings statement (in form complying with the provisions of Rule 158 under the 1933 Act) covering a twelve-month period beginning not later than the first day of the Company’s fiscal quarter next following the effective date of the Registration Statement.

j. At the request of the Buyer participating in an underwritten offering pursuant to Section 2(d), the Company shall furnish, on the date that Registrable Securities are delivered to an underwriter for sale in connection with any Registration Statement pursuant to Section 2(d), (i) an opinion, dated as of such date, from counsel representing the Company for purposes of such Registration Statement, in form, scope and substance as is customarily given in an underwritten public offering, addressed to the underwriters, if any, and the Buyer and (ii) a letter, dated such date, from the Company’s independent certified public accountants in form and substance as is customarily given by independent certified public accountants to underwriters in an underwritten public offering, addressed to the underwriters, if any, and the Buyer.

6

k. The Company shall make available for inspection by (i) the Buyer, and (ii) one firm of attorneys and one firm of accountants or other agents retained by the Buyer (collectively, the “INSPECTORS”) all pertinent financial and other records, and pertinent corporate documents and properties of the Company (collectively, the “RECORDS”), as shall be reasonably deemed necessary by each Inspector to enable each Inspector to exercise its due diligence responsibility, and cause the Company’s officers, directors and employees to supply all information which any Inspector may reasonably request for purposes of such due diligence;

PROVIDED, HOWEVER, that each Inspector shall hold in confidence and shall not make any disclosure (except to the Buyer) of any Record or other information which the Company determines in good faith to be confidential, and of which determination the Inspectors are so notified, unless (a) the disclosure of such Records is necessary to avoid or correct a misstatement or omission in any Registration Statement, (b) the release of such Records is ordered pursuant to a subpoena or other order from a court or government body of competent jurisdiction, or (c) the information in such Records has been made generally available to the public other than by disclosure in violation of this or any other agreement. The Company shall not be required to disclose any confidential information in such Records to any Inspector until and unless such Inspector shall have entered into confidentiality agreements (in form and substance satisfactory to the Company) with the Company with respect thereto, substantially in the form of this Section 3(k). The Buyer agrees that it shall, upon learning that disclosure of such Records is sought in or by a court or governmental body of competent jurisdiction or through other means, give prompt notice to the Company and allow the Company, at its expense, to undertake appropriate action to prevent disclosure of, or to obtain a protective order for, the Records deemed confidential. Nothing herein (or in any other confidentiality agreement between the Company and the Buyer) shall be deemed to limit the Buyer’s ability to sell Registrable Securities in a manner which is otherwise consistent with applicable laws and regulations.

l. The Company shall hold in confidence and not make any disclosure of information concerning the Buyer provided to the Company unless (i) disclosure of such information is necessary to comply with federal or state securities laws, (ii) the disclosure of such information is necessary to avoid or correct a misstatement or omission in any Registration Statement, (iii) the release of such information is ordered pursuant to a subpoena or other order from a court or governmental body of competent jurisdiction, or (iv) such information has been made generally available to the public other than by disclosure in violation of this or any other agreement. The Company agrees that it shall, upon learning that disclosure of such information concerning the Buyer is sought in or by a court or governmental body of competent jurisdiction or through other means, give prompt notice to the Buyer prior to making such disclosure, and allow the Buyer, at its expense, to undertake appropriate action to prevent disclosure of, or to obtain a protective order for, such information.

m. The Company shall use its best efforts to (i) cause all the Registrable Securities covered by the Registration Statement to be listed on each national securities exchange on which securities of the same class or series issued by the Company are then listed, if any, if the listing of such Registrable Securities is then permitted under the rules of such exchange, or (ii) to the extent the securities of the same class or series are not then listed on a national securities exchange, secure the designation and quotation, of all the Registrable Securities covered by the Registration Statement on the NNM or, if not eligible for the NNM on the Nasdaq Small Cap or, if not eligible for the Nasdaq Small Cap, on the Over the Counter electronic bulletin board and, without limiting the generality of the foregoing, to arrange for at least two market makers to register with the National Association of Securities Dealers, Inc. (“NASD”) as such with respect to such Registrable Securities.

7

n. The Company shall provide a transfer agent and registrar, which may be a single entity, for the Registrable Securities not later than the effective date of the Registration Statement.

o. The Company shall cooperate with the Buyer who holds Registrable Securities being offered and the managing underwriter or underwriters, if any, to facilitate the timely preparation and delivery of certificates (not bearing any restrictive legends) representing Registrable Securities to be offered pursuant to such Registration Statement and enable such certificates to be in such denominations or amounts, as the case may be, as the managing underwriter or underwriters, if any, or the Buyer may reasonably request and registered in such names as the managing underwriter or underwriters, if any, or the Buyer may request, and, within three (3) business days after a Registration Statement which includes Registrable Securities is ordered effective by the SEC, the Company shall deliver, and shall cause legal counsel selected by the Company to deliver, to the transfer agent for the Registrable Securities (with copies to the Buyer) an appropriate instruction and an opinion of such counsel in the form required by the transfer agent in order to issue the Registrable Securities free of restrictive legends.

p. At the request of the holders of a majority-in-interest of the Registrable Securities, the Company shall prepare and file with the SEC such amendments (including post-effective amendments) and supplements to a Registration Statement and any prospectus used in connection with the Registration Statement as may be necessary in order to change the plan of distribution set forth in such Registration Statement.

q. The Company shall not, and shall not agree to, allow the holders of any securities of the Company to include any of their securities in any Registration Statement under Section 2(a) hereof or any amendment or supplement thereto under Section 3(b) hereof without the consent of the holders of a majority-in-interest of the Registrable Securities. In addition, the Company shall not offer any securities for its own account or the account of others in any Registration Statement under Section 2(a) hereof or any amendment or supplement thereto under Section 3(b) hereof without the consent of the holders of a majority-in-interest of the Registrable Securities.

r. The Company shall take all other reasonable actions necessary to expedite and facilitate disposition by the Buyer of Registrable Securities pursuant to a Registration Statement.

s. The Company shall comply with all applicable laws related to a Registration Statement and offering and sale of securities and all applicable rules and regulations of governmental authorities in connection therewith (including without limitation the 1933 Act and the 1934 Act and the rules and regulations promulgated by the SEC).

8

4. OBLIGATIONS OF THE BUYER.

In connection with the registration of the Registrable Securities, the Buyer shall have the following obligations:

a. It shall be a condition precedent to the obligations of the Company to complete the registration pursuant to this Agreement with respect to the Registrable Securities of the Buyer that the Buyer shall furnish to the Company such information regarding itself, the Registrable Securities held by it and the intended method of disposition of the Registrable Securities held by it as shall be reasonably required to effect the registration of such Registrable Securities and shall execute such documents in connection with such registration as the Company may reasonably request. At least three (3) business days prior to the first anticipated filing date of the Registration Statement, the Company shall notify the Buyer of the information the Company requires from each the Buyer.

b. The Buyer, by the Buyer’s acceptance of the Registrable Securities, agrees to cooperate with the Company as reasonably requested by the Company in connection with the preparation and filing of the Registration Statements hereunder, unless the Buyer has notified the Company in writing of the Buyer’s election to exclude all of the Buyer’s Registrable Securities from the Registration Statements.

c. In the event of an underwritten offering pursuant to Section 2(d) in which any Registrable Securities are to be included, the Buyer agrees to enter into and perform the Buyer’s obligations under an underwriting agreement, in usual and customary form, including, without limitation, customary indemnification and contribution obligations, with the managing underwriter of such offering and take such other actions as are reasonably required in order to expedite or facilitate the disposition of the Registrable Securities, unless the Buyer has notified the Company in writing of the Buyer’s election to exclude all of the Buyer’s Registrable Securities from such Registration Statement.

d. The Buyer agrees that, upon receipt of any notice from the Company of the happening of any event of the kind described in Section 3(f) or 3(g), the Buyer will immediately discontinue disposition of Registrable Securities pursuant to the Registration Statement covering such Registrable Securities until the Buyer’s receipt of the copies of the supplemented or amended prospectus contemplated by Section 3(f) or 3(g) and, if so directed by the Company, the Buyer shall deliver to the Company (at the expense of the Company) or destroy (and deliver to the Company a certificate of destruction) all copies in the Buyer’s possession, of the prospectus covering such Registrable Securities current at the time of receipt of such notice.

e. No Buyer may participate in any underwritten registration hereunder unless the Buyer (i) agrees to sell the Buyer’s Registrable Securities on the basis provided in any underwriting arrangements in usual and customary form entered into by the Company, (ii) completes and executes all questionnaires, powers of attorney, indemnities, underwriting agreements and other documents reasonably required under the terms of such underwriting arrangements, and (iii) agrees to pay its pro rata share of all underwriting discounts and commissions and any expenses in excess of those payable by the Company pursuant to Section 5 below.

9

5. EXPENSES OF REGISTRATION.

All reasonable expenses, other than underwriting discounts and commissions, incurred in connection with registrations, filings or qualifications pursuant to Sections 2 and 3, including, without limitation, all registration, listing and qualification fees, printers and accounting fees, the fees and disbursements of counsel for the Company, and the reasonable fees and disbursements of one counsel selected by the Buyer pursuant to Sections 2(b) and 3(h) hereof shall be borne by the Company.

6. INDEMNIFICATION.

In the event any Registrable Securities are included in a Registration Statement under this Agreement:

a. To the extent permitted by law, the Company will indemnify, hold harmless and defend (i) the Buyer, (ii) the directors, officers, partners, managers, members, employees, agents and each person who controls any Buyer within the meaning of the 1933 Act or the Securities Exchange Act of 1934, as amended (the “1934 ACT”), if any, (iii) any underwriter (as defined in the 1933 Act) for the Buyer in connection with an underwritten offering pursuant to Section 2(d) hereof, and (iv) the directors, officers, partners, employees and each person who controls any such underwriter within the meaning of the 1933 Act or the 1934 Act, if any (each, an “INDEMNIFIED PERSON”), against any joint or several losses, claims, damages, liabilities or expenses (collectively, together with actions, proceedings or inquiries by any regulatory or self-regulatory organization, whether commenced or threatened, in respect thereof, “CLAIMS”) to which any of them may become subject insofar as such Claims arise out of or are based upon: (i) any untrue statement or alleged untrue statement of a material fact in a Registration Statement or the omission or alleged omission to state therein a material fact required to be stated or necessary to make the statements therein not misleading; (ii) any untrue statement or alleged untrue statement of a material fact contained in any preliminary prospectus if used prior to the effective date of such Registration Statement, or contained in the final prospectus (as amended or supplemented, if the Company files any amendment thereof or supplement thereto with the SEC) or the omission or alleged omission to state therein any material fact necessary to make the statements made therein, in light of the circumstances under which the statements therein were made, not misleading; or (iii) any violation or alleged violation by the Company of the 1933 Act, the 1934 Act, any other law, including, without limitation, any state securities law, or any rule or regulation thereunder relating to the offer or sale of the Registrable Securities (the matters in the foregoing clauses (i) through (iii) being, collectively, “VIOLATIONS”). Subject to the restrictions set forth in Section 6(c) with respect to the number of legal counsel, the Company shall reimburse the Indemnified Person, promptly as such expenses are incurred and are due and payable, for any reasonable legal fees or other reasonable expenses incurred by them in connection with investigating or defending any such Claim. Notwithstanding anything to the contrary contained herein, the indemnification agreement contained in this Section 6(a): (i) shall not apply to a Claim arising out of or based upon a Violation which occurs in reliance upon and in conformity with information furnished in writing to the Company by any Indemnified Person or underwriter for such Indemnified Person expressly for use in connection with the preparation of such Registration Statement or any such amendment thereof or supplement thereto; (ii) shall not apply to amounts paid in settlement of any Claim if such settlement is effected without the prior written consent of the Company, which consent shall not be unreasonably withheld; and (iii) with respect to any preliminary prospectus, shall not inure to the benefit of any Indemnified Person if the untrue statement or omission of material fact contained in the preliminary prospectus was corrected on a timely basis in the prospectus, as then amended or supplemented, such corrected prospectus was timely made available by the Company pursuant to Section 3(c) hereof, and the Indemnified Person was promptly advised in writing not to use the incorrect prospectus prior to the use giving rise to a Violation and such Indemnified Person, notwithstanding such advice, used it. Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of the Indemnified Person and shall survive the transfer of the Registrable Securities by the Buyer pursuant to Section 9.

10

b. [Intentionally Omitted].

c. Promptly after receipt by an Indemnified Person under this Section 6 of notice of the commencement of any action (including any governmental action), such Indemnified Person shall, if Claim in respect thereof is to be made against any the Company under this Section 6, deliver to the Company a written notice of the commencement thereof, and the Company shall have the right to participate in, and, to the extent the Company so desires, to assume control of the defense thereof with counsel mutually satisfactory to the Company and the Indemnified Person, as the case may be.

PROVIDED, HOWEVER, that an Indemnified Person shall have the right to retain its own counsel with the fees and expenses to be paid by the Company, if, in the reasonable opinion of counsel retained by the Company, the representation by such counsel of the Indemnified Person and the Company would be inappropriate due to actual or potential differing interests between such Indemnified Person and any other party represented by such counsel in such proceeding. The Company shall pay for only one separate legal counsel for the Indemnified Persons, and such legal counsel shall be selected by Buyer, if the Buyer is entitled to indemnification hereunder. The failure to deliver written notice to the Company within a reasonable time of the commencement of any such action shall not relieve the Company of any liability to the Indemnified Person under this Section 6, except to the extent that the Company is actually prejudiced in its ability to defend such action. The indemnification required by this Section 6 shall be made by periodic payments of the amount thereof during the course of the investigation or defense, as such expense, loss, damage or liability is incurred and is due and payable.

7. CONTRIBUTION.

To the extent any indemnification by the Company is prohibited or limited by law, the Company agrees to make the maximum contribution with respect to any amounts for which it would otherwise be liable under Section 6 to the fullest extent permitted by law.

11

8. REPORTS UNDER THE 1934 ACT.

With a view to making available to the Buyer the benefits of Rule 144 promulgated under the 1933 Act or any other similar rule or regulation of the SEC that may at any time permit the Buyer to sell securities of the Company to the public without registration (“RULE 144”), the Company agrees to:

a. make and keep public information available, as those terms are understood and defined in Rule 144;

b. file with the SEC in a timely manner all reports and other documents required of the Company under the 1933 Act and the 1934 Act so long as the Company remains subject to such requirements (it being understood that nothing herein shall limit the Company’s obligations under Section 4(c) of the Securities Purchase Agreement) and the filing of such reports and other documents is required for the applicable provisions of Rule 144; and

c. furnish to the Buyer so long as the Buyer owns Registrable Securities, promptly upon request, (i) a written statement by the Company that it has complied with the reporting requirements of Rule 144, the 1933 Act and the 1934 Act, (ii) a copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company, and (iii) such other information as may be reasonably requested to permit the Buyers to sell such securities pursuant to Rule 144 without registration.

9. ASSIGNMENT OF REGISTRATION RIGHTS.

The rights under this Agreement shall be automatically assignable by the Buyers to any transferee of all or any portion of Registrable Securities if: (i) the Buyer agrees in writing with the transferee or assignee to assign such rights, and a copy of such agreement is furnished to the Company within a reasonable time after such assignment, (ii) the Company is, within a reasonable time after such transfer or assignment, furnished with written notice of (a) the name and address of such transferee or assignee, and (b) the securities with respect to which such registration rights are being transferred or assigned, (iii) following such transfer or assignment, the further disposition of such securities by the transferee or assignee is restricted under the 1933 Act and applicable state securities laws, (iv) at or before the time the Company receives the written notice contemplated by clause (ii) of this sentence, the transferee or assignee agrees in writing with the Company to be bound by all of the provisions contained herein, and (v) such transfer shall have been made in accordance with the applicable requirements of the Securities Purchase Agreement.

10. AMENDMENT OF REGISTRATION RIGHTS.

Provisions of this Agreement may be amended and the observance thereof may be waived (either generally or in a particular instance and either retroactively or prospectively), only with written consent of the Company, the Buyer (to the extent such Buyer still owns Registrable Securities) and Buyers who hold a majority interest of the Registrable Securities. Any amendment or waiver effected in accordance with this Section 10 shall be binding upon the Buyer and the Company.

12

11. MISCELLANEOUS.

a. A person or entity is deemed to be a holder of Registrable Securities whenever such person or entity owns of record such Registrable Securities. If the Company receives conflicting instructions, notices or elections from two or more persons or entities with respect to the same Registrable Securities, the Company shall act upon the basis of instructions, notice or election received from the registered owner of such Registrable Securities.

b. Any notices required or permitted to be given under the terms hereof shall be sent by certified or registered mail (return receipt requested) or delivered personally or by courier (including a recognized overnight delivery service) or by facsimile and shall be effective five days after being placed in the mail, if mailed by regular United States mail, or upon receipt, if delivered personally or by courier (including a recognized overnight delivery service) or by facsimile, in each case addressed to a party. The addresses for such communications shall be:

If to the Company: To the address set forth immediately below such Company’s name on the signature pages hereto.

With copy to:

Otto Sorensen, Esq.
Luce, Forward, Hamilton and Scripps, LLP
600 West Broadway, Suite 2600
San Diego, CA 92191
Tel (619) 699-2534
Fax (619) 232-8311

If to a Buyer: To the address set forth immediately below such Buyer’s name on the signature pages hereto.

Each party shall provide notice to the other party of any change in address.

c. Failure of any party to exercise any right or remedy under this Agreement or otherwise, or delay by a party in exercising such right or remedy, shall not operate as a waiver thereof.

d. This Agreement shall be governed by and construed in accordance with the internal laws of the State of New York. Any controversy or claim arising out of or related to this Debenture or the breach thereof, shall be settled by binding arbitration in New York, NY in accordance with the Expedited Procedures (Rules 53-57) of the Commercial Arbitration Rules of the American Arbitration Association (“AAA”). A proceeding shall be commenced upon written demand by Company or the Buyer to the other. The arbitrator(s) shall enter a judgment by default against any party, which fails or refuses to appear in any properly noticed arbitration proceeding. The proceeding shall be conducted by one (1) arbitrator, unless the amount alleged to be in dispute exceeds ________ ($________), in which case three (3) arbitrators shall preside. The arbitrator(s) will be chosen by the parties from a list provided by the AAA, and if they are unable to agree within ten (10) days, the AAA shall select the arbitrator(s). The arbitrators must be experts in securities law and financial transactions. The arbitrators shall assess costs and expenses of the arbitration, including all attorneys’ and experts’ fees, as the arbitrators believe is appropriate in light of the merits of the parties’ respective positions in the issues in dispute. Each party submits irrevocably to the jurisdiction of any state court sitting in New York, NY or to the United States District Court sitting in New York for purposes of enforcement of any discovery order, judgment or award in connection with such arbitration. The award of the arbitrator(s) shall be final and binding upon the parties and may be enforced in any court having jurisdiction. The arbitration shall be held in such place as set by the arbitrator(s) in accordance with Rule 55. With respect to any arbitration proceeding in accordance with this section, the prevailing party’s reasonable attorney’s fees and expenses shall be borne by the non-prevailing party.

13

Although the parties, as expressed above, agree that all claims, including claims that are equitable in nature, for example specific performance, shall initially be prosecuted in the binding arbitration procedure outlined above, if the arbitration panel dismisses or otherwise fails to entertain any or all of the equitable claims asserted by reason of the fact that it lacks jurisdiction, power and/or authority to consider such claims and/or direct the remedy requested, then, in only that event, will the parties have the right to initiate litigation respecting such equitable claims or remedies. The forum for such equitable relief shall be in either a state or federal court sitting in New York, NY. Each party waives any right to a trial by jury, assuming such right exists in an equitable proceeding, and irrevocably submits to the jurisdiction of said New York court. New York law shall govern both the proceeding as well as the interpretation and construction of the Debenture and the transaction as a whole.

e. This Agreement and the Securities Purchase Agreement (including all schedules and exhibits thereto) constitute the entire agreement among the parties hereto with respect to the subject matter hereof and thereof. There are no restrictions, promises, warranties or undertakings, other than those set forth or referred to herein and therein. This Agreement and the Securities Purchase Agreement supersede all prior agreements and understandings among the parties hereto with respect to the subject matter hereof and thereof.

f. Subject to the requirements of Section 9 hereof, this Agreement shall inure to the benefit of and be binding upon the successors and assigns of each of the parties hereto.

g. The headings in this Agreement are for convenience of reference only and shall not limit or otherwise affect the meaning hereof.

h. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original but all of which shall constitute one and the same agreement. This Agreement, once executed by a party, may be delivered to the other party hereto by facsimile transmission of a copy of this Agreement bearing the signature of the party so delivering this Agreement.

i. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents, as the other party may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.

14

j. Except as otherwise provided herein, all consents and other determinations to be made by the Buyer pursuant to this Agreement shall be made by Buyers holding a majority of the Registrable Securities, determined as if the all of the Debentures then outstanding have been converted into for Registrable Securities.

k. The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Buyer by vitiating the intent and purpose of the transactions contemplated hereby. Accordingly, the Company acknowledges that the remedy at law for breach of its obligations hereunder will be inadequate and agrees, in the event of a breach or threatened breach by the Company of any of the provisions hereunder, that the Buyer shall be entitled, in addition to all other available remedies in law or in equity, to an injunction or injunctions to prevent or cure breaches of the provisions of this Agreement and to enforce specifically the terms and provisions hereof, without the necessity of showing economic loss and without any bond or other security being required.

l. The language used in this Agreement will be deemed to be the language chosen by the parties to express their mutual intent, and no rules of strict construction will be applied against any party.

m. In the event that any provision of this Agreement is invalid or unenforceable under any applicable statute or rule of law, then such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform with such statute or rule of law. Any provision hereof which may prove invalid or unenforceable under any law shall not affect the validity or enforceability of any other provision hereof.

n. The initial number of Registrable Securities included in any Registration Statement and each increase to the number of Registrable Securities included therein shall be allocated pro rata among the Buyers based on the number of Registrable Securities held by the Buyer at the time of such establishment or increase, as the case may be. In the event an Buyer shall sell or otherwise transfer any of such holder’s Registrable Securities, each transferee shall be allocated a pro rata portion of the number of Registrable Securities included in a Registration Statement for such transferor. Any shares of Common Stock included on a Registration Statement and which remain allocated to any person or entity which does not hold any Registrable Securities shall be allocated to the remaining Buyers, pro rata based on the number of shares of Registrable Securities then held by the Buyers. For the avoidance of doubt, the number of Registrable Securities held by a Buyer shall be determined as if all the Debentures and Warrants then outstanding and held by a Buyer were converted into or exercised for Registrable Securities.

o. There shall be no oral modifications or amendments to this Agreement. This Agreement may be modified or amended only in writing.

[INTENTIONALLY LEFT BLANK]

15


IN WITNESS WHEREOF, the undersigned Buyer and the Company have caused this Agreement to be duly executed as of the ____ day of ________, 200__.

PATRIOT SCIENTIFIC CORPORATION
________________________________
   
   
By: _____________________________
By: _____________________________
   (Name & Title)
   (Name & Title)

ADDRESS:

PATRIOT SCIENTIFIC CORPORATION
 _____________________________
10989 Via Frontera
 _____________________________
San Diego, California 92127
 _____________________________
Telephone No. (858) 674-5000
 _____________________________
Facsimile No. (858) 674-5005
 _____________________________
 
 
16

EX-10.41 5 v046258_ex10-41.htm
EXHIBIT 10.41
 

 
COMMERCIALIZATION AGREEMENT
 
by and among
 
P-NEWCO
 
and
 
TECHNOLOGY PROPERTIES LIMITED
 
and
 
PATRIOT SCIENTIFIC CORPORATION
 

 

 

 

 
***
Indicates material omitted pursuant to an application for confidential treatment and that material has been filed separately with the Commission.
 


 
TABLE OF CONTENTS
 
Page
   
ARTICLE 1 GRANT
1
ARTICLE 2 COMMERCIALIZATION
2
ARTICLE 3 COVENANTS
3
ARTICLE 4 PAYMENT ***
4
ARTICLE 5 TERM
5
ARTICLE 6 TERMINATION
5
ARTICLE 7 REPRESENTATIONS AND WARRANTIES
6
ARTICLE 8 GENERAL
7
 
EXHIBIT A
GRANT & SCHEDULE OF PATENTS
SCHEDULE 1
SCHEDULE OF PATENTS
SCHEDULE 2
PROJECT DESCRIPTION ***
SCHEDULE 3
SCHEDULE OF OUTSTANDING ACTIVITIES/RIGHTS/CLAIMS
 

 
COMMERCIALIZATION AGREEMENT

This Commercialization Agreement (“Commercialization Agreement”) is entered into by and among [P-Newco], a Delaware limited liability corporation (“P-Newco”), Patriot Scientific Corporation, a Delaware corporation (“Patriot”), having its principal place of business at 10989 Via Frontera, San Diego, California 92127, and Technology Properties Limited Inc., a California Corporation (“TPL”), having its principal place of business at 21730 Stevens Creek Boulevard, Ste. 201, Cupertino, California 95014. Capitalized terms used but not defined herein shall have the meanings given to such terms in that certain agreement dated as of June 7, 2005 (the “Master Agreement”).
 
WHEREAS, Patriot, TPL and Charles H. Moore (“Moore”) collectively hold all rights with respect to certain microprocessor implementation and architecture patents set forth on Schedule 1 (the “MSD Patents”);
 
WHEREAS, Moore has transferred complete authority for the management of Moore’s rights to the MSD Patents to TPL;
 
WHEREAS, Patriot, TPL and Moore have entered into the Master Agreement, pursuant to which Patriot and TPL are entering into licenses with P-Newco and T-Newco, respectively, with respect to certain of their rights in the MSD Patents (collectively, the “Newco Licenses”);
 
WHEREAS, Patriot, TPL, P-Newco and T-Newco have entered into a Merger Agreement, pursuant to which T-Newco merged with and into P-Newco, with P-Newco continuing as the surviving entity and holding all of the rights with respect to the MSD Patents formerly held by P-Newco and T-Newco;
 
WHEREAS, pursuant to the Master Agreement, P-Newco, Patriot and TPL are entering into this Commercialization Agreement providing for the commercialization of P-Newco’s interests in the MSD Patents by TPL in return for the commitment of TPL to diligently pursue the commercialization; and
 
WHEREAS, concurrently herewith Patriot and TPL are entering into that certain Limited Liability Company Operating Agreement of P-Newco (the “Operating Agreement”), governing the rights and obligations of Patriot and TPL with respect to their membership interests in P-Newco and the distribution of the proceeds received from the commercialization program contemplated by this Commercialization Agreement.
 
NOW THEREFORE, for and in consideration of the mutual covenants herein contained as well as other good and valuable consideration the receipt and sufficiency of which is hereby acknowledged, the parties hereto covenant and agree that:
 
ARTICLE I
GRANT
 
1.1 Pursuant to the Master Agreement, P-Newco and TPL shall enter into the grant attached hereto as Exhibit A (the “Grant”).
 

 
ARTICLE II
COMMERCIALIZATION
 
2.1 TPL shall exert reasonable best efforts to implement the activities (the “Commercialization”) described at Schedule 2 and to conduct the project described therein (“Project”) in accordance with the project description (the “Project Description”) including the Business Plan then in effect.
 
(a) The first Business Plan is made a part of the Project Description as Attachment I to Schedule 2, and shall remain in full force and effect until replaced by agreement of P-Newco and TPL.
 
(b) TPL shall have no obligation to pursue or fund any effort to prosecute, maintain, enforce or defend any element of the MSD Patents other than as specifically provided for in Schedule 2.
 
2.2 By these presents, P-Newco appoints, authorizes, and directs TPL to take any and all action for the term of this Commercialization Agreement, with respect to all matters that are related to P-Newco’s rights to the MSD Patents, including without limitation:
 
(a) entering into settlement and/or license agreements related to the MSD Patents which meet the Commercialization guidelines set forth in Section II of Schedule 2;
 
(b) with the prior written consent of the P-Newco Management Committee, entering into any settlement and license agreements related to the MSD Patents which do not meet the guidelines set forth in Section II of Schedule 2;
 
(c) to sue in the name of TPL, Moore, Patriot and/or P-Newco and to pursue for the use and benefit of the parties hereto as their respective interests appear: (i) all remedies of whatsoever kind or nature with respect to the protection, use, and enforcement of the MSD Patents; (ii) the collection of all claims for damages, profits, and awards relating to the past, present, or future use or ownership of the MSD Patents; and (iii) all equitable relief available in connection therewith; and
 
(d) to otherwise manage and control by license, sublicense, or other agreement the practice and/or use of the MSD Patents by third parties.
 
2.3. TPL may utilize the services of its various licensing personnel who may be lawyers to implement the Commercialization of the MSD Patents. Such services shall for no purpose be deemed to be legal services or to give rise to a lawyer-client relationship between TPL and/or TPL affiliates or Representatives on the one hand, and P-Newco and/or Patriot or any of their respective affiliates or Representatives on the other hand. Without limiting the foregoing, neither TPL nor any TPL Representative shall for any purpose be deemed to have:
 
 
(i)
Provided legal services or advice to;
 
 
(ii)
Undertaken the representation of; or
 
 


 
(iii)
Entered into a lawyer-client relationship with,
 
P-Newco, Patriot or any of P-Newco’s or Patriot’s respective affiliates or Representatives.
 
ARTICLE III
COVENANTS
 
3.1 Within sixty (60) days after the close of each calendar quarter TPL shall deliver to P-Newco: (i) an operating statement reflecting the Project’s financial activity over the past quarter; (ii) a calculation of the Gross Cash Proceeds (as defined in the Operating Agreement) resulting from the Project; and (iii) an itemization of all TPL Direct Reimbursable Expenses (as defined below).
 
(a) Within thirty (30) days after P-Newco’s receipt thereof, Patriot shall deliver to TPL written notice detailing all objections to such materials and calculations on an individual item-by-item basis. Any objection not so noticed shall be deemed to be waived.
 
(b) Costs related to verifying reported time and expense charges and/or auditing reports or activities shall be paid in advance by the entity (either Patriot or TPL) supporting such request for verification or audit.
 
3.2 As requested by TPL, Patriot and P-Newco shall have a continuing obligation to exert their respective reasonable best efforts to support the Project, cooperate with TPL in the execution of its obligations, and to provide such support in the manner described herein and in the Master Agreement.
 
3.3 Upon reasonable request, P-Newco and Patriot shall promptly execute and deliver all documents, instruments, and things necessary or useful in the conduct of TPL’s activities hereunder, and Patriot and P-Newco agree to cooperate in any litigation with respect to the MSD Patents, including providing any reasonable assistance in connection with such litigation or joining as a party thereto, as requested by TPL, provided that neither Patriot nor P-Newco shall be required to provide financial support except as otherwise provided in the Commercialization Agreement.
 
3.4 Patriot and P-Newco shall each avoid and refrain from any and all activity of any kind or nature which may impede, impair, frustrate or otherwise interfere with the activities of TPL in the execution the Project, and shall:
 
(a) Exert their respective reasonable best efforts to impose the covenants of this Commercialization Agreement, the Master Agreement and the transactions contemplated hereby and thereby on their respective directors, officers, employees, consultants, attorneys, agents and other affiliates or Representatives; and
 
(b) Be responsible hereunder for each and every failure in the good and faithful performance of this Commercialization Agreement and transaction by themselves and/or their respective directors, officers, employees, consultants, attorneys, agents and other affiliates or Representatives (other than TPL).
 
3.5 With the exception of the agreements and transactions entered into pursuant to the Project, P-Newco, Patriot and TPL shall not transfer, assign, license, or otherwise convey any
 

 
interest in, or grant any security interest with respect to, any portion of their interest in the MSD Patents during the term of this Commercialization Agreement without the written consent of all parties hereto, other than to entities which are owned and controlled by the transferring Person and who assume and agree to pay and perform all of the transferor’s obligations hereunder.
 
3.6 Upon the termination of this Commercialization Agreement, Patriot shall be entitled to receive a copy of third party “DeCaps” (as such term is commonly understood to mean in the industry) related to the Commercialization and third party expert analyses thereof; and TPL does hereby consent to the deliveries thereof by such third party experts. In the event any of the foregoing are not provided by such third parties, TPL will provide Patriot with copies of such documents in its possession. In addition, a Patriot Representative shall be entitled to view such “DeCaps” on a quarterly basis, but shall not be entitled to make copies thereof. With the exception of TPL’s obligations pursuant to Section 3.1 and this Section 3.6, TPL shall not be obligated to share any other materials related to the Commercialization, including without limitation any attorney work product generated during the term of this Commercialization Agreement or thereafter, which for all intents and purposes shall be deemed to be privileged, proprietary and exclusive to TPL.
 
3.7. P-Newco and Patriot shall on a continuing basis provide TPL all leads, information, and materials which Patriot encounters or discovers which may relate to the rights to the MSD Patents transferred by Patriot and TPL to P-Newco pursuant to the Newco Licenses, shall exert their respective reasonable best efforts to support the Commercialization activities of TPL hereunder, and shall refrain from all contact with third parties regarding the MSD Patents except as is specifically approved and/or requested in writing by TPL. The foregoing shall not affect the exercise of the retained rights of Patriot or TPL under the Newco Licenses.
 
ARTICLE IV
PAYMENT
 
4.1 TPL shall cause all Gross Cash Proceeds generated from the Commercialization efforts to be paid directly to P-Newco.
 
4.2 Upon the submission of customary and appropriate invoices and other supporting documentation, P-Newco shall reimburse TPL for the payment of all legal and third-party expert fees and other related third-party costs and expenses, including without limitation those incurred in connection with patent maintenance and prosecution and third party “DeCaps” and third party expert analysis relating thereto (the “TPL Direct Reimbursable Expenses”) incurred by TPL in connection with the Project and in conformity with the applicable Business Plan, as well as all TPL Direct Reimbursable Expenses not in conformity with the applicable Business Plan, to the extent approved by the P-Newco Management Committee. All such reimbursement shall be made prior to the due date indicated on the invoice.
 
4.3 P-Newco shall make payment to TPL of $500,000 no later than three (3) days prior to the start of each fiscal quarter from the Working Capital Fund to cover indirect and other expenses related to the Project which do not constitute TPL Direct Reimbursable Expenses (“TPL Other Project Expenses”). Advances to TPL made pursuant to this Section 4.3 shall be nonaccountable and nonrecoupable, but shall offset the amounts owed TPL pursuant to Section 6.1(a)(iv)(b) of the Operating Agreement in the manner contemplated by such Section 6.1(a)(iv)(b). At such time as the
 

 
Working Capital Fund exceeds [***] after the first [***] has been generated pursuant to the Commercialization, such quarterly payment shall be increased (but not decreased) to one-eighth of the amount of the Working Capital Fund.
 
4.4 To the extent that P-Newco does not have sufficient funds from the Working Capital Fund at the time any payment is due pursuant to this Article IV, TPL shall refrain from enforcing any collection rights against P-Newco for such payments until the earlier of (a) such time as funds become available in the Working Capital Fund, or (b) termination of this Commercialization Agreement.
 
ARTICLE V
TERM
 
5.1 This Commercialization Agreement shall continue for the useful life of the MSD Patents, which shall be deemed to be the greater of the period of time during which any of the MSD Patents is either (i) susceptible to legal protection, or (ii) reasonably perceived to have commercial value.
 
5.2 In the event that facts or events are discovered or occur which materially reduce TPL’s evaluation of the useful life or commercial value of the MSD Patents, or the viability of the Project, TPL may reduce the term of this Commercialization Agreement accordingly by providing P-Newco with ninety (90) days written notice, provided that TPL shall not reduce the term of this Commercialization Agreement to less than six (6) months.
 
5.3 After the expiration of the term provided for above, neither party shall have any further obligation hereunder other than the administration of all outstanding transactions as under Article VI below, and the obligations of confidentiality undertaken by the parties.
 
ARTICLE VI
TERMINATION
 
6.1 TPL may terminate this Commercialization Agreement upon the failure of Patriot or P-Newco to substantially perform any of their material obligations to be performed hereunder, including without limitation the payment obligations pursuant to Article IV of this Commercialization Agreement.
 
6.2 P-Newco may terminate this Commercialization Agreement if:
 
(a) TPL has failed to close transactions in accordance with the Performance Milestones set forth in Section IV of Schedule 2, and
 
 
(i)
there has been no material breach by Patriot or P-Newco of this Commercialization Agreement, the Master Agreement, the Newco Licenses or the Operating Agreement; and
 
 
(ii)
there has been no event or occurrence which negatively and materially impacts the viability or value of the MSD Patents; and
 
 


 
(iii)
the failure of TPL is not reasonably attributable to the conduct of P-Newco, Patriot and/or their respective affiliates or Representatives (other than TPL); or
 
(b) TPL enters into a liquidation under Chapter 7 of the United States Bankruptcy Code; or
 
(c) TPL enters into a reorganization under Chapter 11 of the United States Bankruptcy Code, and TPL ceases to be a debtor in possession during the pendency of such bankruptcy proceeding.
 
Each of the events referred to in Sections 6.1 and 6.2 shall be referred to as a “Termination Event.” In no event shall the conduct of Moore be deemed to constitute a Termination Event.
 
6.3 Upon termination pursuant to this Article VI:
 
(a) All rights to the MSD Patents arising under the Grant or this Commercialization Agreement shall be transferred to P-Newco subject to all outstanding rights under licenses, agreements, or awards theretofore made and entered into by or with TPL prior to such expiration or termination which, for all purposes, shall continue and be administered by TPL under TPL’s then current reasonable hourly fee schedule as if this Commercialization Agreement were still in full force and effect.
 
(b) All amounts due to TPL with respect to TPL Direct Project Expenses and TPL Other Project Expenses shall be paid from Gross Cash Proceeds as such funds are received.
 
(c) At the option of Patriot, TPL, or P-Newco, all of the rights and privileges of whatsoever kind or nature granted by it shall immediately and without further action whatsoever revert in their entirety to each of Patriot, TPL, or P-Newco, as the case may be, and all licenses granting such rights and privileges shall be deemed to be for all purposes cancelled.
 
(d) In the event of a termination by P-Newco or Patriot, all claims for loss and/or damages shall be deemed to be liquidated and discharged with respect to each party upon its completion of the dissolution, distributions and the documentation and transfers contemplated by Article 8 of the Operating Agreement, provided, however, that claims based on conduct which is intentional, willful, or grossly negligent shall survive.
 
ARTICLE VII
REPRESENTATIONS AND WARRANTIES
 
7.1 P-Newco and Patriot acknowledge, represent, and warrant to TPL that:
 
(a) TPL and its Representatives have prepared this Commercialization Agreement at the request of P-Newco and Patriot and such preparation by TPL shall not be used as basis for construing the terms hereof against TPL or otherwise;
 

 
(b) Neither TPL nor its Representatives have for any purpose undertaken the representation of or entered into a lawyer/client relationship with Patriot or P-Newco or any of their Representatives;
 
(c) P-Newco and Patriot release, acquit, and agree to hold TPL and its Representatives harmless with respect to all claims of whatsoever kind or nature by or on behalf of P-Newco and Patriot and related to the preparation, execution, and delivery of this Commercialization Agreement; and,
 
(d) P-Newco and Patriot have sought and received the advice of independent counsel and are in no way relying on any advice or representations of TPL or its Representatives.
 
7.2 Patriot and TPL each represent and warrant to one another that:
 
(a) It is the sole owner of all right, title and interest in and to its portion of the MSD Patents, excepting only the rights reflected at the Schedule of Outstanding Activities/Rights/Claims attached as Schedule 3; and
 
(b) There are no outstanding agreements, rights or interests which are inconsistent with the provisions of this Commercialization Agreement or which could give rise to such rights or interests.
 
7.3 P-Newco represents and warrants to TPL that:
 
(a) It is the sole owner, and for the term of this Commercialization Agreement will remain the sole owner, of all right, title, and interest in and to those certain rights to the MSD Patents transferred by Patriot and TPL to P-Newco pursuant to the P-Newco License and T-Newco License; and
 
(b) There are no outstanding agreements, rights or interests which are inconsistent with the provisions of this Commercialization Agreement or which could give rise to such rights or interests.
 
ARTICLE VIII
GENERAL
 
8.1 In no event shall any right, duty or privilege arising hereunder be assigned by either party to an entity which it does not own and control without the prior written consent of the other parties. Any attempted or purported assignment without such consent shall be voidable at the option of the non-consenting party.
 
8.2 Any covenant requiring a party to perform or provide an act or service shall be construed to impose upon such party the burden of the cost thereof unless otherwise provided for herein.
 
8.3 Section titles are intended only to aid and assist the reader and are not intended to be descriptive of the contents of the section or to be used for construction or interpretation.
 

 
8.4 The failure of any provision of this Commercialization Agreement by virtue of its being construed as invalid or otherwise unenforceable shall render the entire Commercialization Agreement cancelable at the option of the party asserting the enforceability of the said provision.
 
8.5 All notices shall be in writing and effective upon delivery or upon posting by certified mail, return receipt requested, addressed as follows (or such other address as may be hereafter designated):
 
If to Patriot:

Patriot Scientific Corporation
10989 Via Frontera
San Diego, CA 92127
Attn: President
Fax: (858) 674-5005

with a copy to:

Luce, Forward, Hamilton & Scripps LLP
600 West Broadway, Suite 2600
San Diego, CA 92101
Attn: Otto E. Sorensen, Esq.
Fax: (619) 232-8311

If to TPL:

Technology Properties Limited
21730 Stevens Creek Blvd., Suite 201A
Cupertino, CA 95014
Attn: Daniel E. Leckrone, Chairman
Fax: (408) 296-6637

with a copy to:

Gibson, Dunn & Crutcher LLP
333 S. Grand Avenue
Los Angeles, California 90071
Attn: Andrew E. Bogen, Esq.
Fax: (213) 229-6159

If to P-Newco:
 
8.6 This Commercialization Agreement together with its exhibits and attachments, the Stipulated Final Judgment, the Master Agreement, the Newco Licenses, the Operating Agreement
 

 
and the Escrow Agreement contains the entire agreement between the parties and supersedes any and all other agreements between them relating to the subject matter hereof.
 
8.7 With the exception of the Grant attached hereto as Exhibit A and the obligation to share certain materials pursuant to Section 3.6, this Commercialization Agreement shall create no rights or licenses to any intellectual property between or among the parties, nor shall it create any obligation to share technology, trade secrets, know-how, show-how and other proprietary developments and discoveries conceived or reduced to practice during the course of the Project.
 
8.8 Any provision of this Commercialization Agreement may be amended or waived if, and only if, such amendment or waiver is in writing and signed, in the case of an amendment, by all parties hereto, or in the case of a waiver, by the party against whom the waiver is to be effective.
 

 
IN WITNESS WHEREOF, the parties have hereunto set their hands and seal as of the date of the execution hereof by the last signatory hereto.
 
PATRIOT SCIENTIFIC CORPORATION, a
Delaware corporation

__________________________________________
By:
Its:


TECHNOLOGY PROPERTIES LIMITED, a California corporation

 
__________________________________________
By: Daniel E. Leckrone
Its: Chairman


P-NEWCO, a Delaware limited liability company

 
__________________________________________
By:
Its: Patriot Member

 
__________________________________________
By:
Its: TPL Member
 


EXHIBIT A
GRANT
(NEWCO TO TPL)


This Grant (“Grant”) is entered into by and between Newco (sometimes “Newco”) on the one hand, and Technology Properties Limited (“TPL”), on the other hand, and is made and entered into for the purpose of implementing that certain Commercialization Agreement (“ComAg”) entered into between the parties contemporaneously herewith.
 
NOW THEREFORE, for and in consideration of the mutual cove-nants herein contained as well as of other good and valuable consideration the receipt and sufficiency of which is hereby acknowledged, it is covenanted and agreed by and between the parties hereto that:
 
1. Subject Matter.
 
1.1 The patents described in the Schedule of Patents at Attachment I hereof, sometimes collectively referred to as the “Project Patents.”
 
2. Grant.
 
2.1 Pursuant to the provisions of section 2.1 of the Licenses made a part hereof as Attachment I (PTSC to Newco) and Attachment II (TPL to Newco), Newco hereby grants unto Technology Properties Limited the exclusive, personal and non-transferable, worldwide right to:
 
2.1.1 To grant licenses and sub-licenses to make, have made, use, sell, and import products and/or services utilizing the Project Patents, for all fields of use and for all applications;
 
2.1.2 To sue in the name of Technology Properties Limited or jointly with Patriot Scientific Corporation, Charles H. Moore and/or Newco if required by law, and to pursue for the use and benefit of Technology Properties Limited: (i) all remedies of whatsoever kind or nature with respect to the protection, use, and enforcement of the Project Patents; (ii) the collection of all claims for damages, profits, and awards relating to the past, present, or future use or ownership of the Project Patents; and (iii) all equitable relief available in connection therewith; and,
 
2.1.3 To otherwise manage and control by license, sublicense, or other agreement the practice and/or use of the Project Patents by third parties.
 
Accordingly, Newco divests itself of all rights with respect to the activities and/or rights described at 2.1.1., 2.1.2., and 2.1.3. above, and Newco retains no such right.
 
2.2 The grant at Section 2.1 above shall be subject to (a) the terms and conditions of the Patent License Agreement between Patriot and Intel Corporation, dated as of June 1, 2005, and (b) the rights retained by PTSC and TPL under the provisions of section 2.2 of the said Attachments I and II, respectively.
 

 
3. General.
 
3.1 In no event shall any right, duty, or privilege arising hereunder be assigned by either party to an entity which it does not own and control, without the prior written consent of the other party. Any attempted or purported assignment without such consent shall be voidable at the option of the non-consenting party.
 
3.2 Any covenant requiring a party to perform or provide an act or service shall be construed to impose upon such party the burden of the cost thereof unless otherwise provided for herein or in the ComAg.
 
3.3 Section titles are intended only to aid and assist the reader and are not intended to be descriptive of the contents of the section or to be used for construction or interpretation.
 
3.4 The failure of any provision of this Agreement by virtue of its being construed as invalid or otherwise unenforceable shall render the entire Agreement cancelable at the option of the party asserting the enforceability of the said provision.
 
3.5 All notices shall be in writing and effective upon delivery or upon posting by certified mail, return receipt requested, addressed as follows (or such other address as may be hereafter designated):
 

 
If to TPL:

Daniel E Leckrone, Chm
21730 Stevens Creek Blvd
Cupertino, CA 95014
Telephone: 408-446-4222
Facsimile: 408-446-5444

If to Newco:

Daniel E Leckrone, Chm
21730 Stevens Creek Blvd
Cupertino, CA 95014
Telephone: 408-446-4222
Facsimile: 408-446-5444

AND

Patriot Scientific Corporation
10989 Via Frontera
San Diego, CA 92127
Attn: President
Fax: (858) 674-5005

AND

Robert K. Neilson
Relational Advisors LLC
11975 El Camino Real, Suite 300
San Diego, California 92130
Fax: (858) 704-3341

3.6 This Agreement together with its exhibits and attachments contains the entire agreement between the parties and supersedes any and all other agreements between them relating to the subject matter hereof.
 
3.7 This Agreement shall be construed in accordance with and governed by the internal laws (without reference to choice or conflict of laws) of the State of California.
 

 
IN WITNESS WHEREOF, the parties have hereunto set their hands and seals as of the date of the execution hereof by the last signatory hereto.
 
NEWCO
 
 
By:__________________________________________
Robert K. Neilson
 
Date:__________________________________________
TECHNOLOGY PROPERTIES LTD.
 
 
By:__________________________________________
Daniel E. Leckrone, Chairman
 
Date:__________________________________________

 
Attachment I - Schedule of Patents
 
(See next page)
 

 
EXHIBIT A
SCHEDULE OF PATENTS

A. PROJECT PATENTS - US
                   
NUMBER
 
NAME
 
FILED
 
ISSUED
 
EXPIRY
US
5,440,749
 
Hi Perf, Lo cost Micro Arch
 
3 AUG 89
 
8 AUG 95
 
8 AUG 12
US
5,530,890
 
Hi Perf, Lo cost Micro Arch
 
7 JUN 95
 
25 JUN 96
 
25 JUN 13
US
5,659,703
 
Micro Sys with Hierarchical stack
 
7 JUN 95
 
19 AUG 97
 
19 AUG 14
US
5,784,584
 
Multiple Instructions within Groups
 
7 JUN 95
 
21 JUL 98
 
21 JUL 15
US
5,809,336
 
Hi Perf Variable Speed Sys Clock
 
7 JUN 95
 
15 SEP 98
 
15 SEP 15
US
5,604,915
 
Load Dependent Bus Timing
 
7 JUN 95
 
18 FEB 97
 
18 FEB 14
US
6,598,148
 
Hi Perf Microprocessor
 
29 JUL 98
 
22 JUL 03
 
3 AUG 09
     
Having Variable Speed Sys Clock
           
                   
B. PROJECT PATENT APPLICATIONS PENDING - US
                   
SN 09/051,263     RISC Microprocessor Architecture   8 AUG 98   _ _ _ _   3 AUG 09
 
 C. PROJECT PATENTS - NON US (Preliminary)
 
DE
69033568.7
 
Hi Perf, Lo Cost Micro
 
2 AUG 90
 
14 JUN 00
 
2 AUG 10
DE
69033568T2
 
Preisguenstiger Hochleistungsmikro
 
2 AUG 90
 
1 MAR 01
 
- - - -
DE
69033568C0
 
Preisguenstiger Hochleistungsmikro
 
2 AUG 90
 
20 JUL 00
 
- - - -
EP
0786730
 
Hi Perf, Lo Cost Micro
 
2 AUG 90
 
14 JUN 00
 
2 AUG 10
EP
786730A1
 
Hi Perf, Lo Cost Micro
 
2 AUG 90
 
30 JUL 97
 
- - - -
EP
497772A4
 
Hi Perf, Lo Cost Micro
 
2 AUG 90
 
4 AUG 93
 
- - - -
EP
497772A1
 
Hi Perf, Lo Cost Micro
 
2 AUG 90
 
12 AUG 92
 
- - - -
EP
0870226
 
RISC Microprocessor Architecture
 
_ _ _ _
 
_ _ _ _
 
- - - -
FR
0786730
 
Hi Perf, Lo Cost Micro
 
2 AUG 90
 
14 JUL 00
 
- - - -
WO
9715001
 
RISC Microprocessor Arch
 
_ _ _ _
 
_ _ _ _
 
- - - -
WO
9102311A3
 
Hi Perf, Lo Cost Micro
 
2 AUG 90
 
21 MAR 91
 
- - - -
WO
9102311A1
 
Hi Perf, Lo Cost Micro
 
2 AUG 90
 
1 FEB 91
 
- - - -
JP
5502125T2
 
_ _ _ _ _ _
 
2 AUG 90
 
15 APR 93
 
- - - -
JP
2966085B2
 
Hi Perf, Lo Cost Micro
 
2 AUG 90
 
13 AUG 99
 
2 AUG 10
AU
6067290A1
 
Hi Perf, Lo Cost Micro
 
2 AUG 90
 
11 MAR 91
 
- - - -

The schedule of Patents shall include the items listed above, as well as all progenitors and progeny thereof, and all additions, changes, amendments, modifications, actions, counterparts, continuations, continuations-in-part, extensions, reissues, divisionals and/or renewals of such items, progenitors, and/or progeny.
 

 
SCHEDULE 1
SCHEDULE OF PATENTS

A. MSD PATENTS - US
 
Number     Name   Filed   Issued   Expiry
US
5,440,749
 
Hi Perf, Lo cost Micro Arch
 
3 AUG 89
 
8 AUG 95
 
8 AUG 12
US
5,530,890
 
Hi Perf, Lo cost Micro Arch
 
7 JUN 95
 
25 JUN 96
 
25 JUN 13
US
5,659,703
 
Micro Sys with Hierarchical stack
 
7 JUN 95
 
19 AUG 97
 
19 AUG 14
US
5,784,584
 
Multiple Instructions within Groups
 
7 JUN 95
 
21 JUL 98
 
21 JUL 15
US
5,809,336
 
Hi Perf Variable Speed Sys Clock
 
7 JUN 95
 
15 SEP 98
 
15 SEP 15
US
5,604,915
 
Load Dependent Bus Timing
 
7 JUN 95
 
18 FEB 97
 
18 FEB 14
US
6,598,148
 
Hi Perf Microprocessor
Having Variable Speed Sys Clock
 
29 JUL 98
 
22 JUL 03
 
3 AUG 09

B. PROJECT PATENT APPLICATIONS PENDING - US
 
Number
Name
Filed
Issued
Expiry
SN
09/051,263
RISC Microprocessor Architecture
8 AUG 98
- - - -
3 AUG 09

C. MSD PATENTS - NON US (Preliminary)
 
Number   Name Filed Issued Expiry
DE
69033568.7
Hi Perf, Lo Cost Micro
2 AUG 90
14 JUN 00
2 AUG 10
DE
69033568T2
Preisguenstiger Hochleistungsmikro
2 AUG 90
1 MAR 01
- - - -
DE
69033568C0
Preisguenstiger Hochleistungsmikro
2 AUG 90
20 JUL 00
- - - -
EP
0786730
Hi Perf, Lo Cost Micro
2 AUG 90
14 JUN 00
2 AUG 10
EP
786730A1
Hi Perf, Lo Cost Micro
2 AUG 90
30 JUL 97
- - - -
EP
497772A4
Hi Perf, Lo Cost Micro
2 AUG 90
4 AUG 93
- - - -
EP
497772A1
Hi Perf, Lo Cost Micro
2 AUG 90
12 AUG 92
- - - -
EP
0870226
RISC Microprocessor Architecture
- - - -
- - - -
- - - -
FR
0786730
Hi Perf, Lo Cost Micro
2 AUG 90
14 JUL 00
- - - -
WO
9715001
RISC Microprocessor Arch
- - - -
- - - -
- - - -
WO
9102311A3
Hi Perf, Lo Cost Micro
2 AUG 90
21 MAR 91
- - - -
WO
9102311A1
Hi Perf, Lo Cost Micro
2 AUG 90
1 FEB 91
- - - -
JP
5502125T2
_ _ _ _ _ _
2 AUG 90
15 APR 93
- - - -
JP
2966085B2
Hi Perf, Lo Cost Micro
2 AUG 90
13 AUG 99
2 AUG 10
AU
6067290A1
Hi Perf, Lo Cost Micro
2 AUG 90
11 MAR 91
- - - -

The schedule of Patents shall include the items listed above, as well as all progenitors and progeny thereof, and all additions, changes, amendments, modifications, actions, counterparts, continuations, continuations-in-part, extensions, reissues, divisionals and/or renewals of such items, progenitors, and/or progeny.
 

 
SCHEDULE 2
PROJECT DESCRIPTION

I. OBJECTIVES & ACTIVITIES
 
 
A.)
Develop and execute a commercialization program for the rights to the MSD Patents transferred by Patriot and TPL to P-Newco pursuant to the Newco Licenses which:
 
 
i.)
Establishes the MSD Patents as an income-producing, commercially valuable asset; and
 
 
ii.)
Builds long-term Project value; and
 
 
iii.)
Minimizes risks to Project assets.
 
 
B.)
Promote the commercialization program by encouraging the implementation and use of the MSD Patents through licenses, and various relationships.
 
 
C.)
Transform selected unauthorized use of the MSD Patents into strategically and commercially valuable authorized use.
 
 
D.)
Pursue licensing discussions with multiple simultaneous identified prospects.
 
 
E.)
Pursue parallel litigation on a selective strategic basis.
 
 
F.)
Negotiate and document agreements relating to the Project and the MSD Patents.
 
 
G.)
***
 
 
H.)
***
 
 
I.)
***
 
II. COMMERCIALIZATION GUIDELINES
 
 
A.)
***
 
 

 
III. ADDITIONAL ACTIONS
 
 
A.)
***
 
 
B.)
***
 
 
C.)
***
 
IV. ***
 
***
 
V. BUSINESS PLAN
 
 
A.)
A Business Plan detailing the implementation of the Project is attached hereto as Attachment I and will remain in full force and effect until duly amended or replaced.
 
 


ATTACHMENT 1 TO SCHEDULE 2

BUSINESS PLAN

 
I. ***
 
 

 
SCHEDULE 3
SCHEDULE OF OUTSTANDING ACTIVITIES/RIGHTS/CLAIMS
 

AGREEMENT
DATE
TPL
 
1. Moore - TPL Commercialization Agreement
22 OCT 02
2. P-Newco - TPL - PTSC Commercialization Agreement
25 MAY 05
3. TPL - Intel License Agree ment
28 JUN 04
   
PTSC
 
1. PTSC - AMD License Agreement
_________
2. P-Newco - TPL - PTSC Commercialization Agreement
25 MAY 05
3. ________________________
 
 
 

EX-10.42 6 v046258_ex10-42.htm
EXHIBIT 10.42
 

 

 

LIMITED LIABILITY COMPANY
 
OPERATING AGREEMENT
 
OF
 
[P-NEWCO],
 
A DELAWARE LIMITED LIABILITY COMPANY
 
 
 

 
 
TABLE OF CONTENTS
 
Page
     
ARTICLE 1
DEFINITIONS
1
     
ARTICLE 2
FORMATION OF LIMITED LIABILITY COMPANY
7
2.1
Formation
7
2.2
Name; Principal Place of Business
7
2.3
Registered Office and Registered Agent
7
2.4
Agreement; Effect of Inconsistencies With the Act or the Code
7
2.5
Business
8
2.6
Term
8
2.7
Qualification
8
     
ARTICLE 3
MEMBERSHIP
8
3.1
Members
8
3.2
Representations and Warranties
9
3.3
Incorporation of Representations and Warranties
9
3.4
Resignation or Withdrawal of a Member.
10
3.5
Effect of Certain Events on Membership.
10
3.6
Restrictions on Transfers of Interests
10
3.7
No Authority as Agent
11
     
ARTICLE 4
MANAGEMENT
11
4.1
Management of the Company by Management Committee
11
4.2
Appointment of Management Committee.
11
4.3
Responsibilities of the Management Committee
13
4.4
Officers
13
4.5
Liability of Committee Members and Officers
14
4.6
Records, Audits and Reports
14
 
   
ARTICLE 5
CAPITAL CONTRIBUTIONS
15
5.1
Initial Capital Contributions
15
5.2
Percentage Interests
15
5.3
Working Capital Contributions.
15
5.4
Failure to Make Contributions
15
5.5
Capital Accounts
16
 
   
ARTICLE 6
DISTRIBUTIONS, ALLOCATIONS AND TAX MATTERS
17
6.1
Application of Gross Cash Proceeds.
17
6.2
Allocation of Net Profits
18
6.3
Allocation of Net Losses
18
6.4
General Rules for Allocations
18
6.5
Special Allocations to Capital Accounts.
18
6.6
Tax Allocations; Section 704(c) of the Code.
19
6.7
Tax Matters Member.
20
6.8
Section 754 Election
20
6.9
Returns and Other Elections
20
6.10
Partnership Tax Treatment
21
 
 
 
-i-

 
 
 
 
   
ARTICLE 7
INDEMNIFICATION AND LIMITATION OF LIABILITY
21
7.1
Indemnification.
21
7.2
Limitation of Liability
22
7.3
Savings Clause
22
 
   
ARTICLE 8
DISSOLUTION AND WINDING UP
23
8.1
Dissolution
23
8.2
Winding Up
23
8.3
Reversion of Rights
23
8.4
Order of Payment Upon Liquidation
23
8.5
Antecedent Activities.
23
8.6
Limitations on Payments Made in Dissolution
24
8.7
Certificate of Cancellation
24
8.8
Effect of Filing Certificate of Cancellation
24
 
   
ARTICLE 9
MISCELLANEOUS
24
9.1
Amendment
24
9.2
Governing Law and Severability
25
9.3
Counterparts
25
9.4
Titles and Subtitles
25
9.5
Notices
25
9.6
Entire Agreement
25
9.7
Power of Attorney
26
9.8
Related Party Transactions
26
9.9
Dispute Resolution
26
9.10
No Partition
26
9.11
Bankruptcy
26

SCHEDULE 1 - INITIAL CAPITAL CONTRIBUTIONS
 
SCHEDULE 2 - PERCENTAGE INTERESTS
 
EXHIBIT A - CONSENT OF CHARLES H. MOORE TO LIMITED LIABILITY OPERATING AGREEMENT OF P-NEWCO, A DELAWARE LIMITED LIABILITY COMPANY
 
 
-ii-

 
 
LIMITED LIABILITY COMPANY
OPERATING AGREEMENT FOR
[P-NEWCO],
A DELAWARE LIMITED LIABILITY COMPANY
 
This Limited Liability Company Operating Agreement (this “Operating Agreement”) of [P-Newco], a Delaware limited liability company (the “Company”), is made as of June 7, 2005, by and between PATRIOT SCIENTIFIC CORPORATION, a Delaware corporation (“Patriot”), and TECHNOLOGY PROPERTIES LIMITED INC., a California corporation (“TPL”) (collectively, the “Members”).
 
RECITALS
 
WHEREAS, Patriot has formed the Company as a limited liability company under the Delaware Limited Liability Company Act, 6 Del. C. § 18-101, et seq., as amended (the “Act”), for the purposes of effecting the transactions contemplated by the Master Agreement (as defined below);
 
WHEREAS, prior to the capital contributions and the issuance of the Percentage Interests described in Article 5 hereof, Patriot has been the sole member of the Company;
 
WHEREAS, the Members wish to enter into this Operating Agreement to provide for the structure, governance and operation of the Company.
 
AGREEMENT
 
NOW THEREFORE, in consideration of the respective covenants and promises contained herein and for other good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, the parties hereto agree as follows:
 
ARTICLE 1
DEFINITIONS
 
The following terms shall have the meanings set forth below for purposes of this Operating Agreement:
 
Act” means the Delaware Limited Liability Company Act.
 
Active Potential Licensees” has the meaning set forth in Section 6.2 of the Master Agreement.
 
Adjusted Capital Account Deficit” means, with respect to any Member for any taxable year or other period, the deficit balance, if any, in such Member’s Capital Account as of the end of such year or other period, after giving effect to the following adjustments: (a) credit to such Capital Account any amounts that such Member is obligated to restore or is deemed obligated to restore as described in the penultimate sentence of Treasury Regulation Section 1.704-2(g)(1) and in Treasury Regulation Section 1.704-2(i); and (b) debit to such Capital Account the items described in Treasury Regulation Sections 1.704-1(b)(2)(ii)(d)(4), (5) and (6).
 
 
-1-

 
 
Adjusted Gross Cash Proceeds” means Gross Cash Proceeds minus TPL Direct Reimbursable Expenses.
 
Affiliate”, with respect to any Person, means any other Person directly or indirectly controlling, controlled by or under common control with, such Person. For purposes of this Operating Agreement, “control” (including with correlative meanings, the terms “controlling”, “controlled by” or “under common control with”) as used with respect to any Person, shall mean the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of such Person, whether through the ownership of voting securities or by contract or otherwise.
 
Annual Business Plan” means, for any Fiscal Year, the Company’s annual financial and operating plan and budget for such Fiscal Year as formally approved by the Management Committee, as such financial and operating plan and budget may be amended from time to time by the Management Committee.
 
Antecedent Activities” means active negotiations with parties identified as Active Potential Licensees pursuant to Section 6.2 of the Master Agreement..
 
Applicable Law” means any domestic or foreign, federal, state or local statute, law, common law, ordinance, rule, administrative interpretation, regulation, order, writ, injunction, directive, judgment, decree, permit or other requirement of any Governmental Authority.
 
Book Value” means, with respect to any asset, the asset’s adjusted basis for federal income tax purposes, except as follows:
 
(a)The initial Book Value of any asset contributed by a Member to the Company shall be the gross fair market value of such asset (not reduced by any associated liabilities), as agreed to by the contributing Member and the Management Committee;
 
(b)The Book Value of the property of the Company shall be adjusted to equal its gross fair market value, as determined by the Management Committee, as of the following times: (i) the acquisition of an additional Interest by any new or existing Member in exchange for more than a de minimis Capital Contribution; (ii) the distribution by the Company to a Member of more than a de minimis amount of property as consideration for an Interest; (iii) the liquidation of the Company within the meaning of Treasury Regulations Section 1.704-1 (b)(2)(ii)(g); and (iv) any other instance in which such adjustment is permitted under Treasury Regulation Section 1.704-1(b)(2)(iv); provided, however, that adjustments pursuant to clauses (i), (ii), and (iv) above shall be made only if the Management Committee reasonably determines that such adjustments are necessary or appropriate to reflect the relative economic interests of the Members in the Company; and
 
(c)The Book Value of any property distributed to a Member shall be adjusted to equal the gross fair market value of such asset on the date of distribution as determined by the Management Committee.
 
The Book Value of any property which has been established or adjusted to reflect gross fair market value hereunder shall thereafter be adjusted by depreciation as provided in Treasury Regulation
 
 
-2-

 
 
Section 1.704-1(b)(2)(iv)(g) and any other adjustment to the value of such property other than depreciation or amortization.
 
Capital Account” means, with respect to any Member, the capital account maintained by the Company for such Member in accordance with Section 5.5.
 
Change of Control” means (a) the merger or consolidation of Patriot with or into another corporation in which Patriot is not the surviving entity, or a reverse triangular merger, or similar transaction, in which Patriot is the surviving entity but the shares of Patriot’s capital stock outstanding immediately prior to the merger are converted into other property, whether in the form of securities, cash, or otherwise, and as a result of which the outstanding capital stock of Patriot prior to such transaction represents less than a majority of the outstanding capital stock of Patriot or the acquirer or successor following such transaction, (b) any sale or transfer of all or substantially all of Patriot’s assets to any other Person, or (c) the sale or transfer of shares of Patriot’s capital stock, warrants, options or instruments convertible into capital stock of Patriot and as a result of which the outstanding capital stock of Patriot on a fully diluted basis assuming conversion of all outstanding instruments convertible into shares of Patriot’s capital stock prior to such transaction represents less than a majority of the outstanding capital stock of Patriot or the acquirer or successor following such transaction.
 
Certificate of Formation” means the Certificate of Formation of the Company as filed with the Secretary of State of the State of Delaware on June [__], 2005, as the same may be amended or restated from time to time.
 
Code” means the Internal Revenue Code of 1986, as amended from time to time, or any successor federal tax statute enacted after the date of this Operating Agreement.
 
Commercialization Agreement” means that certain Commercialization Agreement, dated as of the date hereof, by and among Patriot, TPL and the Company.
 
Company” has the meaning set forth in the Preamble.
 
Company Expenses” means any direct operating expenses of the Company as may be approved by the Management Committee, including any fees or other compensation payable to the Managers or for expenses related to the preparation of Company financial statements, tax reporting and the maintenance of a bank account in the name of the Company, and other similar administrative expenses.
 
Company Minimum Gain” means “partnership minimum gain” as defined in Treasury Regulation Section 1.704-2(d).
 
Damages” means all demands, claims, actions or causes of action, assessments, losses (including reasonably foreseeable lost profits), damages, costs, expenses, liabilities, judgments, awards, fines, sanctions, penalties, charges and amounts paid in settlement (net of insurance proceeds and proceeds from related third party indemnification, contribution or similar claims actually received), including (a) interest at a rate equal to 200 basis points above the prime rate, as in effect from time to time, of Citibank, N.A., on cash disbursements in respect of any of the foregoing, compounded quarterly, from the date each such cash disbursement is made until the Person incurring the same shall have been indemnified in respect thereof, (b) reasonable costs, fees and expenses of
 
 
-3-

 
 
such Person’s Representatives and (c) any reasonable costs, fees and expenses incurred in connection with investigating, defending against, or settling any such claims.
 
Exchange Act” means the Securities Exchange Act of 1934, as amended.
 
Fair Market Value” shall mean, with respect to the Initial Capital Contributions, the fair market value of such asset as determined by the Members.
 
Fiscal Year” means (i) any twelve (12) month period commencing on June 1 and ending on May 31, or (ii) any portion of the period described in clause (i) of this sentence for which the Company is required to allocate Net Profits, Net Losses and other items of Company income, gain, loss or deduction pursuant to Article VI, as the case may be.
 
Governmental Approval” means an authorization, consent, approval, permit or license issued by, or a registration or filing with, any Governmental Authority.
 
Governmental Authority” means any foreign, domestic, federal, territorial, state or local governmental authority, quasi-governmental authority, instrumentality, court, government or self-regulatory organization, commission, tribunal or organization or any regulatory, administrative or other agency, or any political or other subdivision, department or branch of any of the foregoing.
 
Gross Cash Proceeds” means all cash proceeds received pursuant to licenses, judgments, settlements and other payments with respect to the right to make, have made, use, sell, and import products utilizing the MSD Patents.
 
Indemnitees” means the Members, Managers, officers and employees of the Company, as well as their respective Representatives, entitled to indemnification by the Company pursuant to Article VII.
 
Independent Manager” has the meaning set forth in Section 4.2(c).
 
Initial Capital Contributions” has the meaning set forth in Section 5.1.
 
Initial Working Capital Contribution” means the Two Million Dollars ($2,000,000) payable by each of Patriot and TPL, in the aggregate amount of Four Million Dollars ($4,000,000), due upon the execution of this Operating Agreement.
 
JAMS” has the meaning set forth in Section 4.2(c).
 
Liabilities” means, with respect to any Person, any liability or obligation of such Person of any kind, character or description, whether known or unknown, absolute or contingent, accrued or unaccrued, liquidated or unliquidated, secured or unsecured, joint or several, due or to become due, vested or unvested, executory, determined, determinable or otherwise and whether or not the same is required to be accrued on the financial statements of such Person or is disclosed on any schedule to the Master Agreement or this Operating Agreement.
 
Lien” means, with respect to any asset, any mortgage, title defect or objection, lien, pledge, charge, security interest, hypothecation, restriction, encumbrance or charge of any kind in respect of such asset.
 
 
-4-

 
 
Liquidator” has the meaning set forth in Section 8.2.
 
Management Committee” has the meaning set forth in Section 4.1.
 
Manager” means a member of the Management Committee.
 
Master Agreement” means that certain agreement, dated as of May [27], 2005, by and between Patriot and TPL.
 
Member Minimum Gain” means the Company’s “partner nonrecourse debt minimum gain” as defined in Treasury Regulation Section 1.704-2(i)(2).
 
Member Nonrecourse Debt” means “partner nonrecourse debt” as defined in Treasury Regulation Section 1.704-2(b)(4).
 
Member Nonrecourse Deductions” means “partner nonrecourse deductions” as defined in Treasury Regulation Section 1.704-2(i)(2).
 
Members” has the meaning set forth in the Preamble.
 
MSD Patents” means those microprocessor science and design patents identified on Schedule 1 to the Master Agreement.
 
Net Cash Proceeds” has the meaning set forth in Section 6.1(a)(v).
 
Net Profit” or “Net Loss” means, for any Accounting Period, the amount, computed as of the last day thereof, of the net income or loss of the Company determined in accordance with federal income tax principles (but without requiring any items to be stated separately pursuant to Code Section 703), with the following adjustments:
 
(a) Any income of the Company that is exempt from federal income tax shall be included in the computation of Net Profit or Net Loss;
 
(b) Any expenditures of the Company described in Code Section 705(a)(2)(B) or treated as Code Section 705(a)(2)(B) expenditures pursuant to Treasury Regulations Section 1.704-l(b)(2)(iv)(i) shall be included in the computation of Net Profit or Net Loss;
 
(c) Any adjustment in the Book Value of property in accordance with this Agreement and pursuant to Treasury Regulation Section 1.704-1(b)(2)(iv)(f) or (g) shall be taken into account as gain or loss from the disposition of such asset for purposes of computing Net Profit or Net Loss (to the extent such adjustment is not already reflected in the Capital Accounts of the Members);
 
(d) In any situation in which an item of income, gain, loss or deduction is affected by the adjusted tax basis of property, the Book Value of the property shall be used in lieu of adjusted basis (notwithstanding that the adjusted tax basis of such property may differ from its Book Value), and in lieu of depreciation, amortization and other cost recovery deductions taken into account in computing taxable income or loss, there will be taken into account
 
 
-5-

 
 
depreciation for the taxable year or other period as determined in accordance with Treasury Regulation Section 1.704-1(b)(2)(iv)(g); and
 
(e) Any items of income, gain, deduction and loss specially allocated pursuant to Section 6.6 of this Agreement shall not be considered in determining Net Profit or Net Loss.
 
Newco Licenses” means the P-Newco License and the T-Newco License.
 
Nonrecourse Deductions” has the meaning set forth in Treasury Regulation Section 1.704-2(b)(1).
 
Operating Agreement” has the meaning set forth in the Preamble.
 
Patriot” has the meaning set forth in the Preamble.
 
Patriot Appointee” has the meaning set forth in Section 4.2(a).
 
Percentage Interest” means a Member’s percentage interest in the Company, as such Percentage Interest may be adjusted from time to time pursuant to the terms of this Operating Agreement.
 
Person” means an individual, corporation, partnership, limited liability company, joint venture, association, trust, estate or other entity or organization, including a Governmental Authority.
 
P-Newco License” means that certain license agreement entered into between Patriot and the Company.
 
Proceedings” means any actions, suits, claims, hearings, arbitrations, proceedings (public or private) or governmental investigations that have been brought by or against any Governmental Authority or any other Person.
 
Recovery Event” means the moment at which payment is actually received by Patriot, TPL, or the Company as a result of or in connection with any Antecedent Activities.
 
Regulatory Allocations” are those allocations contained in Section 6.5.
 
Representatives” means the officers, directors, employees, attorneys, accountants, advisors, representatives and agents of a Person.
 
Securities Act” means the Securities Act of 1933, as amended.
 
Tax Matters Member” means that Member appointed by the Management Committee with the power to manage and control, on behalf of the Company, any administrative proceeding at the Company level with the Internal Revenue Service relating to the determination of any item of Company income, gain, loss, deduction or credit for federal income tax purposes.
 
T-Newco” means a newly formed Delaware limited liability company, wholly owned by TPL.
 
 
-6-

 
 
T-Newco License” means that certain license agreement entered into between TPL and T-Newco.
 
TPL” has the meaning set forth in the Preamble.
 
TPL Appointee” has the meaning set forth in Section 4.2(b).
 
TPL Direct Reimbursable Expenses” has the meaning set forth in Section 4.2 of the Commercialization Agreement.
 
Transfer” has the meaning set forth in Section 3.6.
 
Treasury Regulations” means the proposed, temporary and final regulations promulgated under the Code in effect as of the date of filing the Certificate of Formation and the corresponding sections of any regulations subsequently issued that amend or supersede those regulations.
 
Working Capital Contribution” means the amount payable to the Company each Fiscal Year by each of the Members for the Company’s working capital requirements pursuant to Section 5.3.
 
Working Capital Fund” means the fund containing the Company’s working capital to be maintained pursuant to Section 5.3(b).
 
ARTICLE 2
FORMATION OF LIMITED LIABILITY COMPANY
 
2.1 Formation. Patriot caused the Certificate of Formation of the Company to be filed with the Delaware Secretary of State on June [__], 2005.
 
2.2 Name; Principal Place of Business. Unless and until amended in accordance with this Operating Agreement and the Act, the name of the Company is “[__________]”. The principal place of business of the Company shall be such place or places as the Management Committee from time to time determines.
 
2.3 Registered Office and Registered Agent. The Company’s initial registered office shall be at the office of its registered agent at 160 Greentree Drive, Suite 101, Dover, Delaware 19904, and the name of its initial registered agent at such address shall be National Registered Agents, Inc. The registered agent may be changed from time to time by filing the address of the new registered office and/or the name of the new registered agent with the Secretary of State of the State of Delaware pursuant to the Act.
 
2.4 Agreement; Effect of Inconsistencies With the Act or the Code. It is the express intention of the Members that this Operating Agreement, together with the Exhibits and Schedules, shall be the sole source of agreement of the parties with respect to the structure, governance and the operation of the Company and, except to the extent a provision of this Operating Agreement expressly incorporates federal income tax rules by reference to sections of the
 
 
-7-

 
 
Code or Treasury Regulations or is expressly prohibited or ineffective under the Act, this Operating Agreement shall govern the structure and operation of the Company, even when inconsistent with, or different than, the provisions of the Act or any other law or rule. To the extent that any provision of this Operating Agreement is prohibited or ineffective under the Act, this Operating Agreement shall be deemed to be amended to the smallest degree possible in order to make this Operating Agreement effective under the Act in accordance with the intent of the parties. In the event the Act is subsequently amended or interpreted in such a way to make any provision of this Operating Agreement that was formerly invalid valid, such provision shall be considered to be valid from the effective date of such interpretation or amendment. Each of the Members shall be entitled to rely on the provisions of this Operating Agreement, and none of the Members shall be liable to the Company or to any of the other Members for any action or refusal to act taken in good faith reliance on the terms of this Operating Agreement. The Members hereby agree that the duties and obligations imposed on the Members as such shall be those set forth in this Operating Agreement, which is intended to govern the relationship among and between the Company and the Members, notwithstanding any provision of the Act or common law to the contrary.
 
2.5 Business. The purpose of the Company is to engage in any activity for which a limited liability company may be organized under the Act.
 
2.6 Term. The term of the Company commenced upon the filing of the Certificate of Formation with the Delaware Secretary of State on June [__], 2005 and shall continue until the Company’s dissolution in accordance with Article VIII of this Operating Agreement.
 
2.7 Qualification. The Management Committee shall cause the Company to be qualified or registered, if and to the extent required, under the applicable laws of any jurisdiction in which such registration may be required, and shall be authorized to execute, deliver and file any certificates and documents necessary to effect such qualification or registration.
 
ARTICLE 3
MEMBERSHIP
 
3.1 Members. The names and addresses of the Members are as follows:
 
Patriot Scientific Corporation
10989 Via Frontera
San Diego, California 92127
Technology Properties Limited Inc.
21730 Stevens Creek Boulevard, Suite 201
Cupertino, California 95014
 

 
 
-8-

 

3.2 Representations and Warranties. Each Member hereby represents and warrants to the Company and the other Member as follows:
 
(a) Such Member is either an individual or a corporation duly organized, validly existing and in good standing under the laws of its state of incorporation with all requisite corporate power and authority to own, lease and operate its properties and assets and to carry on its business as now conducted;
 
(b) Such Member has all requisite power and authority to execute and deliver this Operating Agreement and to perform its obligations hereunder. The execution and delivery by such corporate Member of this Operating Agreement and the consummation of the transactions contemplated hereby have been duly authorized by all necessary corporate action on its part. This Operating Agreement has been duly executed and delivered by such Member and constitutes the legal, valid and binding obligations of such Member, enforceable against it in accordance with its terms, except as enforcement may be limited by equitable principles and by bankruptcy, insolvency, reorganization, moratorium or similar laws relating to creditors’ rights generally;
 
(c) The execution, delivery and performance by such Member of this Operating Agreement and the consummation of the transactions contemplated hereby do not and will not (i) violate the certificate of incorporation or bylaws of such Member, in each case as amended through the date hereof, (ii) conflict with, result in a breach of or constitute (or, with the giving of notice or lapse of time, or both, constitute) a default under, or require the approval or consent of any Person pursuant to, any material agreement, instrument or other document to which such Member is a party or by which it or its properties or assets is bound, or (iii) violate any material provision of any statute, rule or regulation applicable to such Member or binding on it or any of its assets, or (iv) except as set forth in the Newco Licenses, result in the creation or imposition of any Lien on the MSD Patents.
 
(d) Such Member is acquiring its Percentage Interest for investment purposes and not with a view to the resale or distribution thereof;
 
(e) Such Member understands and acknowledges that such Member’s Percentage Interest has not been registered under the Securities Act or any state securities or blue sky laws and may not be sold unless registered under the Securities Act and qualified under applicable state securities or blue sky laws or such sale is made pursuant to an exemption from such registration and qualification requirements;
 
(f) The limitations on Transfer contained in Section 3.6 create an economic risk that such Member is capable of bearing; and
 
(g) Such Member is a “United States person” within the meaning of Section 7701(a)(30) of the Code.
 
3.3 Incorporation of Representations and Warranties. Each of Patriot and TPL hereby reaffirms the representations and warranties made by such Member in the Master Agreement as if such representations and warranties were set forth fully herein.
 
 
-9-

 
 
3.4 Resignation or Withdrawal of a Member.
 
(a) No Member shall resign from membership in the Company or withdraw their interest in the capital of the Company, except (i) in connection with the dissolution of the Company pursuant to the provisions of Article VIII, or (ii) with the prior written consent of all of the other Members.
 
(b) The resignation of a Member shall not (i) relieve such Member of any of its covenants, agreements, duties, obligations or liabilities under this Operating Agreement whether arising prior to, on, or after the date of such resignation (including, without limitation, any contingent obligations based on acts or omissions occurring, or liabilities or obligations incurred, prior to, on or after the date of such resignation), or (ii) directly or indirectly result in the termination of, or relieve such Member (or any Affiliate thereof) of, or otherwise affect, any of the covenants, agreements, duties, obligations or liabilities of such Member (or any Affiliate thereof) under any other agreement to which such Member is a party.
 
3.5 Effect of Certain Events on Membership.
 
(a) Bankruptcy, Foreclosure, or Other Similar Event. In the event of a Member’s bankruptcy, or the foreclosure upon or other similar proceeding with respect to that Member’s interest in the MSD Patents or that Member’s Percentage Interest:
 
 
(i)
any and all rights that Member may have under Section 4.2 of this Operating Agreement shall automatically terminate; and
 
 
(ii)
any and all rights that Member may have under Sections 2.2.1 and 2.2.2 of the P-Newco License or T-Newco License, as the case may be, shall automatically and without further action by any of the parties thereto be irrevocably transferred to the Company.
 
(b) Change of Control. In the event of a Change of Control of Patriot or TPL:
 
 
(i)
any and all rights Patriot or TPL may have under Section 4.2 of this Operating Agreement, as the case may be, shall automatically terminate; and
 
 
(ii)
Patriot or TPL’s rights under Sections 2.2.1 and 2.2.2 of the P-Newco License or T-Newco License, as the case may be, shall automatically and without further action by any of the parties thereto be irrevocably transferred to the Company.
 
3.6 Restrictions on Transfers of Interests. Except as provided in Section 5.4, no Member shall sell, assign, pledge, mortgage or otherwise dispose of or transfer (a “Transfer”) its Percentage Interest in the Company, whether in whole or in part, without the consent of the Management Committee, which consent may be withheld for any or for no reason.
 
 
-10-

 
 
3.7 No Authority as Agent. Except as may be authorized by the Management Committee, or as set forth in the Commercialization Agreement, no Member shall have the authority in its or his capacity as a Member to enter into any transaction on behalf of the Company or to otherwise bind the Company.
 
ARTICLE 4
MANAGEMENT
 
4.1 Management of the Company by Management Committee. The business and affairs of the Company shall be managed by a management committee (the “Management Committee”) consisting of three (3) Managers, which number may not be changed without the written consent of the Members holding at least seventy-five percent (75%) of the Percentage Interests.
 
4.2 Appointment of Management Committee.
 
(a) Patriot Appointment. Patriot shall have the right to appoint one (1) Manager to the Management Committee (the “Patriot Appointee”).
 
(b) TPL Appointment. TPL shall have the right to appoint one (1) Manager to the Management Committee (the “TPL Appointee”).
 
(c) Independent Manager. The Patriot Appointee and the TPL Appointee shall work together in good faith to appoint a mutually acceptable third Manager (the “Independent Manager”). In the event that the Patriot Appointee and the TPL Appointee are unable to appoint a mutually acceptable Manager within 10 days of the resignation or removal of the Independent Manager, either party may apply to the Judicial Arbitration and Mediation Service (“JAMS”) in Santa Clara County, or the nearest county thereto, if necessary, for the appointment of the Independent Manager, and JAMS shall select the Independent Manager from a list of no more than three persons submitted by each party. All costs associated with the selection of the Independent Manager by JAMS pursuant to this Section 4.2(c) shall be paid by the Company.
 
(d) Term of Service. Each Manager (other than the Independent Manager) will serve until his or her death or resignation from the Management Committee, or until his or her removal from the Management Committee by the Member who appointed him or her. The Independent Manager shall serve a five (5) year term (subject to earlier removal as provided below).
 
(e) Initial Managers.  The initial Managers are as follows:
 
Patriot Appointee
David H. Pohl
TPL Appointee
Daniel E. Leckrone
Independent Manager
Robert K. Neilson

 
 
-11-

 

(f) Meetings; Place of Meetings; Telephonic Participation. Meetings of the Management Committee may be held at such times and places within or without the State of Delaware as the Management Committee may from time to time designate or as shall be designated by the Manager or Managers calling the meeting in the notice or waiver of notice of any such meeting. Regular meetings of the Management Committee shall be held not less than once during every calendar quarter. Special meetings of the Management Committee shall be held whenever called by one or more Managers. Notice of the time, place and purpose of each such special meeting shall be sent by facsimile transmission or electronic mail or be delivered personally or mailed to and received by each Manager not less than seventy-two (72) hours before the time at which the meeting is to be held. Notice of any meeting of the Management Committee shall not be required to be given to any Manager who waives such notice in writing or who is present at such meeting, except a Manager who shall attend such meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. At the request of any Manager, any or all Managers may participate telephonically in any meeting of the Management Committee so long as all persons participating in the meeting can hear each other, and such participation shall constitute presence in person at such meeting. Any action required or permitted to be taken at any meeting of the Management Committee may be taken without a meeting, without prior notice and without a vote, if a consent in writing (including by electronic transmission as permitted by Section 18-302 of the Act), setting forth the action so taken, shall be signed or delivered by all Managers. Such written (or electronically transmitted) consent shall be filed with the minutes of proceedings of the Management Committee.
 
(g) Quorum. Two (2) Managers must be present at a meeting of the Management Committee to establish a quorum for the transaction of business.
 
(h) Majority Vote. All actions to be taken by the Management Committee shall require the affirmative vote of at least two (2) of the three (3) Managers.
 
(i) Resignation; Removal; Vacancies; Compensation.
 
 
(i)
Resignation. A Manager may resign at any time by giving written notice to the Members. The resignation of a Manager shall take effect upon receipt of such notice or at such later time as shall be specified in the notice. Unless otherwise specified in the notice, the acceptance of the resignation shall not be necessary to make it effective.
 
 
(ii)
Removal. The Patriot Appointee to the Management Committee may be removed only by Patriot, with or without cause. The TPL Appointee to the Management Committee may be removed only by TPL, with or without cause. The Independent Manager may be removed at any time, with or without cause, by written consent of the Members holding at least seventy-five percent (75%) of the Percentage Interests.
 
 
(iii)
Vacancies. Vacancies on the Management Committee shall be filled by the Member who originally appointed the vacating Manager, or, in the case of the Independent Manager, pursuant to Section 4.2(c) of this Operating Agreement.
 
 
 
-12-

 

 
(iv)
Compensation. No Manager other than the Independent Manager (in the Members’ discretion) shall be eligible to receive separate compensation from the Company for his or her services on the Management Committee; provided, however, that the Managers shall be reimbursed by the Company for the reasonable and actual costs incurred in attending and participating in any meetings of the Management Committee and other costs and expenses reasonably related to fulfilling the duties and obligations of a Manager hereunder.
 
4.3 Responsibilities of the Management Committee. The Management Committee shall have the responsibility, on behalf of the Company:
 
(a) To approve the Annual Business Plan, as well as any modifications thereto.
 
(b) To make any distributions to Members pursuant to Article VI.
 
(c) To make any filings with any Governmental Authority on behalf of the Company.
 
(d) To purchase liability and other insurance to protect the Company’s properties and business and to purchase liability insurance to indemnify or otherwise protect the Members, Managers, officers and employees of the Company.
 
(e) To make certain decisions regarding tax matters pursuant to the terms of this Operating Agreement.
 
(f) To approve the execution by TPL pursuant to the Commercialization Agreement of any license agreement, infringement claim settlement or other agreement with respect to the MSD Patents, the proposed terms of which do not fall within the guidelines for allowable license agreements and infringement claim settlements set forth in Exhibit C to the Commercialization Agreement.
 
(g) To approve any modifications, amendments or waivers of the Commercialization Agreement, and any of the license or other agreements referred to therein to which the Company is a party.
 
(h) To take or authorize such other actions on behalf of the Company as are consistent with Applicable Law and the fiduciary duties of the Managers and the Members.
 
4.4 Officers. The Company shall have a President and Treasurer and such other officers as the Management Committee may determine. Any officer except the President and the Treasurer may hold more than one office concurrently. Except as set forth herein, the officers shall serve at the pleasure of the Management Committee. The Management Committee may determine a reasonable compensation to be paid to each officer so appointed. The officers shall exercise such powers as shall be determined or delegated from time to time by the Management Committee.
 
 
-13-

 
 
(a) President. The Company shall have a President with primary responsibility for and active charge of the management and supervision of the Company’s business and affairs. The President may execute in the name of the Company license agreements, settlement agreements, checks and other similar documents and instruments to the extent that such execution is consistent with and in furtherance of the Annual Business Plan, as well as such other documents and instruments otherwise authorized for execution by the Management Committee. For as long as the Commercialization Agreement is in effect, Robert K. Neilson shall be President of the Company.
 
(b) Treasurer. The Company shall have a Treasurer as the principal financial officer and principal accounting officer of the Company who shall keep full and accurate accounts of receipts and disbursements in books belonging to the Company. The initial treasurer shall be [__________].
 
4.5 Liability of Committee Members and Officers. The Managers and the officers shall not be liable to the Company or to any Member for any Damages suffered or sustained by the Company or any Member, as the case may be, unless the Damage results from the fraud, deceit, gross negligence, willful misconduct, breach of fiduciary duty, a knowing violation of law by a specific Manager or officer or a material breach of such Manager’s or officer’s obligations under this Operating Agreement, in which event only the Manager or officer who engaged in such conduct or behavior (and no other Manager or officer) shall be liable for the full extent of Damages suffered or sustained to the full extent permitted pursuant to this Agreement or provided by Applicable Law.
 
4.6 Records, Audits and Reports. At the expense of the Company, proper and complete records and books of account shall be kept or shall be caused to be kept by the Management Committee (or a designee thereof) in which shall be entered fully and accurately all transactions and other matters relating to the Company’s business in the detail and completeness customary and usual for businesses of the type engaged in by the Company. The books and records shall at all times be maintained at the principal executive offices of the Company and shall be open to the inspection and examination of the Members or their duly authorized agents during business hours. At a minimum, the Company shall keep at its principal place of business:
 
(a) A current list of the full name and last known business, residence or mailing address of each Member and Manager;
 
(b) A copy of the Certificate of Formation and all amendments thereto, together with executed copies of any powers of attorney pursuant to which any amendment has been executed;
 
(c) Copies of the Company’s federal, state and local income tax returns and reports, if any, for the four most recent years;
 
(d) A copy of this Operating Agreement, as amended to date, any correspondence relating to any Member’s obligation to contribute cash, property or services, and copies of any financial statements of the Company for the three most recent years; and
 
 
-14-

 
 
(e) Minutes of every meeting of the Management Committee, or any written consents of the Managers obtained in lieu of a meeting.
 
The Management Committee shall maintain and preserve, during the term of the Company and for a period of five years thereafter, all accounts, books and other relevant Company documents.
 
ARTICLE 5
CAPITAL CONTRIBUTIONS
 
5.1 Initial Capital Contributions. Concurrently with the execution hereof, Patriot and TPL shall enter into the P-Newco License, TPL and T-Newco shall enter into the T-Newco License, T-Newco shall merge with and into the Company and each of the Members shall make the capital contributions set forth on Schedule 1 hereto (collectively, the “Initial Capital Contributions”). The Initial Capital Contributions to the Company of each Member shall be deemed to have a Fair Market Value as set forth opposite such Member’s name on Schedule 1 hereto.
 
5.2 Percentage Interests. Upon making its Initial Capital Contribution, and as a result of the merger contemplated by the Merger Agreement (as defined in the Master Agreement), TPL shall be issued Percentage Interests in the Company such that Patriot will no longer be the sole Member of the Company and the Members shall have the Percentage Interests set forth on Schedule 2 hereto. Percentage Interests shall for all purposes be personal property. A Member has no interest in specific property of the Company.
 
5.3 Working Capital Contributions.
 
(a) Initial Working Capital Contribution. On the date hereof, Patriot and TPL shall each make an Initial Working Capital Contribution to the Company of Two Million Dollars ($2,000,000), for an aggregate Initial Working Capital Contribution of Four Million Dollars ($4,000,000).
 
(b) Future Working Capital Contributions. At any time during the Fiscal Year at the discretion of the Management Committee, Patriot and TPL shall be obligated to make Working Capital Contributions in equal amounts in order to maintain a Working Capital Fund of not more than Eight Million Dollars ($8,000,000), and then only to the extent necessary to bring the balance of the Working Capital Fund to Eight Million Dollars ($8,000,000), provided, however, that neither TPL nor Patriot shall be required to contribute more than Two Million Dollars ($2,000,000) in any Fiscal Year.
 
Except as provided in this Section 5.3, no Member shall be obligated to make any contribution of capital to the Company.
 
5.4 Failure to Make Contributions. The failure of Patriot or TPL to make Working Capital Contributions when due pursuant to Section 5.3 shall result in the following adjustments to that Member’s Percentage Interest:
 
 
-15-

 
 
(a) For each One Dollar ($1) that is not contributed by Patriot or TPL when due pursuant to Section 5.3, one hundred thousandth of a percent (0.00001%) of the outstanding Percentage Interests of the Company shall be deducted from that Member’s Percentage Interest and transferred to the other Member. As an example, if a Member failed to contribute One Million Dollars ($1,000,000) when due pursuant to Section 5.3, ten percent (10%) of the outstanding Percentage Interests of the Company would be deducted from that Member’s Percentage Interest and transferred to the other Member.
 
(b) In the event that Patriot’s Percentage Interest falls below twenty-five percent (25%), Patriot shall lose the right to appoint the Patriot Appointee pursuant to Section 4.2(a), and TPL shall have the right to appoint the Patriot Appointee, such that TPL shall have the right to appoint two (2) of the three (3) Managers. In the event that TPL’s Percentage Interest falls below twenty-five percent (25%), TPL shall lose the right to appoint the TPL Appointee pursuant to Section 4.2(b), and Patriot shall have the right to appoint the TPL Appointee, such that Patriot shall have the right to appoint two (2) of the three (3) Managers.
 
5.5 Capital Accounts. A separate Capital Account shall be established and maintained for each Member.
 
(a) Each Member’s Capital Account will be increased by:
 
 
(i)
The Initial Capital Contribution by the Member to the Company pursuant to Section 5.1;
 
 
(ii)
The Working Capital Contributions by the Member to the Company pursuant to Section 5.3; and
 
 
(iii)
Each Member’s pro rata allocation of the Company’s and each Member’s contributions to the Working Capital Fund.
 
(b) Each Member’s Capital Account will be decreased by:
 
 
(i)
The amount of Net Cash Proceeds distributed to the Member by the Company;
 
 
(ii)
The Fair Market Value of property distributed to the Member by the Company; and
 
 
(iii)
Allocations to the Member of Net Losses.
 
(c) The manner in which Capital Accounts are to be maintained pursuant to this Section 5.5 is intended to comply with the requirements of Section 704(b) of the Code and the Treasury Regulations promulgated thereunder. If, in the opinion of the Management Committee after consultation with the Company’s accountants, the manner in which Capital Accounts are to be maintained pursuant to the preceding provisions of this Section 5.5 should be modified to comply with Section 704(b) of the Code and the Treasury Regulations thereunder, then, notwithstanding anything to the contrary contained in the preceding provisions of this Section 5.5, the method in which Capital Accounts are maintained shall be
 
 
-16-

 
 
so modified without any approval of the Management Committee; provided, however, that any change in the manner of maintaining Capital Accounts shall not materially alter the economic agreement between the Members.
 
(d) No Member shall have any liability to restore all or any portion of a deficit balance in the Member’s Capital Account.
 
ARTICLE  6
DISTRIBUTIONS, ALLOCATIONS AND TAX MATTERS
 
6.1 Application of Gross Cash Proceeds.
 
(a) Application of Gross Cash Proceeds. Within sixty (60) days after the close of each of the Company’s fiscal quarters, the Company shall apply and distribute Gross Cash Proceeds in accordance with the following schedule of priorities:
 
 
(i)
First, for the payment to TPL (or, in the case of any payment to satisfy the obligations of the Company under Section 4.2 of the Commercialization Agreement, directly to the Person identified by TPL) in satisfaction of the Company’s payment obligations under Sections 4.2 and 4.3 of the Commercialization Agreement;
 
 
(ii)
Next, to the payment of any Company Expenses;
 
 
(iii)
Next, for the Working Capital Fund until the Working Capital Fund equals Eight Million Dollars ($8,000,000);
 
 
(iv)
Next,
 
 
(1)
for payment to Patriot of an amount equal to ten percent (10%) of the Gross Cash Proceeds until Patriot shall have received Twenty Million Dollars ($20,000,000); and
 
 
(2)
for payment to TPL of an amount equal to fifteen percent (15%) of the Adjusted Gross Cash Proceeds minus any amounts previously advanced to TPL (and not previously credited against payments to TPL hereunder) pursuant to Section 4.3 of the Commercialization Agreement; and
 
 
(v)
Finally, the remaining Gross Cash Proceeds (such remaining amount, the “Net Cash Proceeds”) to the Members according to their respective Percentage Interests.
 
In the event that funds sufficient to satisfy the payments required to be made pursuant to subsections (iv)(a) and (iv)(b) above are unavailable, such payment obligations shall be pari passu, and any unpaid amounts thereof shall be paid from Gross Cash Proceeds subsequently received by the Company.
 
 
-17-

 
 
(b) Distribution of Company Property. Company property shall be distributed only pursuant to Article VIII.
 
(c) Withholdings. All amounts withheld pursuant to the Code or any provisions of state or local tax law with respect to any payment or distribution to the Members from the Company shall be treated as amounts distributed to the relevant Members pursuant to this Section 6.1.
 
6.2 Allocation of Net Profits. Subject to the provisions of Sections 6.4 and 6.5, Net Profits for any Fiscal Year or other period shall be allocated to the Members according to their Percentage Interests.
 
6.3 Allocation of Net Losses. Subject to the provisions of Sections 6.4 and 6.5, Net Losses for any Fiscal Year or other period shall be allocated to the Members according to their Percentage Interests.
 
6.4 General Rules for Allocations. The rules of this Section 6.4 shall govern all allocations under this Article:
 
(a) Except as otherwise provided in this Operating Agreement, an allocation of Net Profits or Net Losses shall be treated as an allocation between the Members of the same share of each item of income, gain, loss and deduction that is taken into account in computing such Net Profits or Net Losses, as the case may be.
 
(b) If any Member is deemed to have received imputed income with respect to any property licensed or otherwise made available to the Company pursuant to this Operating Agreement, the corresponding imputed expenses to the Company arising out of such arrangement shall be specially allocated to such Member.
 
(c) For purposes of determining the Net Profits or Net Losses allocable to any period, the Net Profits and Net Losses shall be determined on a daily, monthly or other basis, as determined by the Management Committee using any permissible method under Section 706 of the Code and the Treasury Regulations promulgated thereunder.
 
6.5 Special Allocations to Capital Accounts.
 
(a) Notwithstanding anything to the contrary contained in this Article 6, if there is a net decrease in Company Minimum Gain or in any Member Minimum Gain during any taxable year or other period, prior to any other allocation pursuant hereto, such Member shall be specially allocated items of income and gain for such year (and, if necessary, subsequent years) in an amount and manner required by Treasury Regulation Sections 1.704-2(f) or 1.704-2(i)(4). The items to be so allocated shall be determined in accordance with Treasury Regulation Section 1.704-2.
 
 
-18-

 
 
(b) Nonrecourse Deductions for any taxable year or other period shall be allocated (as nearly as possible) under Treasury Regulation Section 1.704-2 to the Members, pro rata in proportion to their respective Percentage Interests.
 
(c) Any Member Nonrecourse Deductions for any taxable year or other period shall be allocated to the Member that made, or guaranteed or is otherwise liable with respect to the loan to which such Member Nonrecourse Deductions are attributable in accordance with principles under Treasury Regulation Section 1.704-2(i).
 
(d) Any Member who unexpectedly receives an adjustment, allocation or distribution described in Treasury Regulation Section 1.704-1(b)(2)(ii)(d)(4), (5) or (6) which causes or increases a negative balance in his or its Capital Account shall be allocated items of income and gain sufficient to eliminate such increase or negative balance caused thereby, as quickly as possible, to the extent required by such Treasury Regulation.
 
(e) No allocation or loss or deduction shall be made to any Member if, as a result of such allocation, such Member would have an Adjusted Capital Account Deficit. Any such disallowed allocation shall be made to the Members entitled to receive such allocation under Treasury Regulation Section 1.704 in proportion to their respective Percentage Interests. If losses or deductions are reallocated under this subsection 6.5(e), subsequent allocations of income and losses (and items thereof) shall be made so that, to the extent possible, the net amount allocated under this subsection 6.5(e) equals the amount that would have been allocated to each Member if no reallocation had occurred under this subsection 6.5(e).
 
(f) For purposes of Section 752 of the Code and the Treasury Regulations thereunder, excess nonrecourse liabilities (within the meaning of Treasury Regulations Section 1.752-3(a)(3)) shall be allocated to the Members pro rata in proportion to their respective Percentage Interests.
 
(g) The allocations contained in Sections 6.5(a), 6.5(c), 6.5(d) and 6.5(e) (the “Regulatory Allocations”) are intended to comply with certain requirements of Treasury Regulation Sections 1.704-1 and 1.704-2. The Regulatory Allocations shall be taken into account in allocating Net Profit and Net Loss and other items of income, gain, loss and deduction among the Members so that to the extent possible, the allocations contained in this Agreement other than the Regulatory Allocations and the Regulatory Allocations made to each Member shall equal the net amount that would have been allocated to each Member had the Regulatory Allocations not occurred. The Management Committee shall take account of the fact that certain of the Regulatory Allocations will occur at a period in the future for purposes of applying this Section 6.5(g).
 
6.6 Tax Allocations; Section 704(c) of the Code.
 
(a) Except as otherwise provided in this Section 6.6, for income tax purposes, each item of income, gain, loss, and deduction of the Company shall be allocated among the Members in accordance with the manner in which the equivalent items of Net Profits and Net Losses were allocated under the preceding sections of this Article VI.
 
(b) In the event the Book Value of a Company asset differs from its adjusted federal income tax basis, then all allocations of income, gain, loss and deduction with respect
 
 
-19-

 
 
to such asset shall take into account any variation between the adjusted tax basis of such asset and its Book Value. Such allocations shall be made under the principles of Sections 704(b) and 704(c) of the Code and the Treasury Regulations thereunder and are intended to eliminate, to the extent possible, disparities that otherwise exist between the balances of the Members’ Capital Accounts, as maintained by the Company, and such balances had the Capital Accounts been maintained in accordance with tax accounting principles. It is intended, for example, that any taxable gain recognized by the Company upon the disposition of property contributed by a Member to the Company shall be allocated to the contributing Member to the extent that the property’s initial Book Value exceeded its adjusted income tax basis on the date of the contribution, with any excess taxable gain being allocated to the Members (including the contributing Member) in a manner that coincides with the corresponding allocation of “book” gain. Any elections, accounting conventions or other decisions relating to such allocations shall be made by the Management Committee in a manner that (i) reasonably reflects the purposes and intention of this Operating Agreement, and (ii) complies with Sections 704(b) and 704(c) of the Code and the Treasury Regulations thereunder. The Management Committee shall determine the method set forth in Treasury Regulation Section 1.704-3c to be used for allocating such terms.
 
6.7 Tax Matters Member.
 
(a) At such time as it deems necessary, the Management Committee shall elect the “Tax Matters Member” of the Company for purposes of Section 6231(a)(7) of the Code. The Tax Matters Member shall have the power to manage and control, on behalf of the Company, any administrative proceeding at the Company level with the Internal Revenue Service relating to the determination of any item of Company income, gain, loss, deduction or credit for federal income tax purposes.
 
(b) The Tax Matters Member shall, within ten (10) days of the receipt of any notice from the Internal Revenue Service in any administrative proceeding at the Company level relating to the determination of any Company item of income, gain, loss, deduction or credit, mail a copy of such notice to the other Members.
 
6.8 Section 754 Election. The Tax Matters Member may, in its discretion, make, on behalf of the Company, an election in accordance with Section 754 of the Code so as to adjust the basis of Company property in the case of a distribution of property within the meaning of Section 734 of the Code, and in the case of a transfer of a Member’s Percentage Interest within the meaning of Section 743 of the Code. Each Member shall, upon the request of the Tax Matters Member, furnish such information as the Tax Matters Member shall deem necessary or appropriate to give effect to such election.
 
6.9 Returns and Other Elections. The Chief Financial Officer shall cause the preparation and timely filing all tax returns required to be filed by the Company pursuant to the Code and all other tax returns deemed necessary and required in each jurisdiction in which the Company does business. Copies of those returns, or pertinent information from the returns, shall be furnished to the Members within a reasonable time after the end of the Company’s fiscal year. All elections permitted to be made by the Company
 
 
-20-

 
 
under federal or state laws shall be made by the Chief Financial Officer, provided that the Management Committee may direct the Chief Financial Officer to make or refrain from making any tax election.
 
6.10 Partnership Tax Treatment. The Members expect and intend that the Company shall be treated as a partnership for all federal and state income tax purposes, and the Members agree that they will not: (a) take a position on any federal, state, local or other tax return, or otherwise assert a position, inconsistent with such expectation and intent; or (b) elect for the Company to be treated as an association for tax purposes or do any other act or thing which could cause the Company to be treated as other than a partnership for federal income tax purposes.
 
ARTICLE 7
INDEMNIFICATION AND LIMITATION OF LIABILITY
 
7.1 Indemnification.
 
(a) To the fullest extent permitted by the Act and by law, the Members, Managers, officers and employees of the Company, as well as their respective Representatives (collectively, “Indemnitees”) shall, in accordance with this Section 7.1, be indemnified, protected, held harmless and defended by the Company from and against any and all Damages and Liabilities by reason of their management of, or involvement in, the affairs of the Company, or rendering of advice or consultation with respect thereto, or which relate to the Company, its properties, business or affairs, if such Indemnitee acted in good faith and in a manner such Indemnitee reasonably believed to be in, or not opposed to, the best interests of the Company.
 
(b) If any Indemnitee shall believe that such Indemnitee is entitled to indemnification pursuant to this Article 7 in respect of any Damages or Liabilities, such Indemnitee shall give the Company prompt written notice thereof. Any such notice shall set forth in reasonable detail and to the extent then known the basis for such claim for indemnification. The failure of such Indemnitee to give notice of any claim for indemnification promptly shall not adversely affect such Indemnitee’s right to indemnity hereunder except to the extent that such failure adversely affects the right of the Company to assert all reasonable defenses to such claim. Each such claim for indemnity shall expressly state that the Company shall have only the thirty (30) calendar day period referred to in the next sentence to dispute or deny such claim. The Company shall have thirty (30) calendar days following its receipt of such notice either (y) to acquiesce in such claim and the responsibility to indemnify the Indemnitee in respect thereof in accordance with the terms of this Article 7 by giving such Indemnitee written notice of such acquiescence or (z) to object to the claim by giving such Indemnitee written notice of the objection. If the Company does not object thereto within such thirty (30) calendar day period, the Company shall be deemed to have acquiesced in such claim and the responsibility to indemnify the Indemnitee in respect thereof in accordance with the terms of this Article 7.
 
(c) In connection with any claim which may give rise to indemnity under this Article 7 resulting from or arising out of any claim or Proceeding against an Indemnitee by a
 
 
-21-

 
 
Person that is not a party hereto, the Company may (unless such Indemnitee elects not to seek indemnity hereunder for such claim), upon written notice sent at any time to the relevant Indemnitee, assume the defense of any such claim or Proceeding if the Company with respect to such claim or Proceeding acknowledges to the Indemnitee the Indemnitee’s right to indemnity pursuant hereto in respect of the entirety of such claim (as such claim may have been modified through written agreement of the parties or arbitration hereunder) and provide assurances, reasonably satisfactory to such Indemnitee, that the Company will be financially able to satisfy such claim in full if such claim or Proceeding is decided adversely. The Company shall select counsel reasonably acceptable to such Indemnitee to conduct the defense of such claim or Proceeding, shall take all steps reasonably necessary in the defense or settlement thereof and shall at all times diligently and promptly pursue the resolution thereof. If the Company shall have assumed the defense of any claim or Proceeding in accordance with this Section 7, the Company shall not (without the written consent of each Indemnitee) consent to a settlement of, or the entry of any judgment arising from, any such claim or Proceeding, unless such settlement or order shall provide for the unconditional release of all Indemnitees. If the Company has so elected to assume the defense, each Indemnitee shall be entitled to participate in (but not control) the defense of any such action, with its own counsel and at its own expense. Each Indemnitee shall, and shall cause each of its Representatives to, cooperate fully with the Company in the defense of any claim or Proceeding being defended by the Company pursuant to this Section 7. If the Company does not assume the defense of any claim or Proceeding resulting therefrom in accordance with the terms of this Section 7, such Indemnitee may defend against such claim or Proceeding in such manner as it may deem appropriate, provided that the Indemnitee may not settle such claim or Proceeding without the written consent of the Company (which consent shall not be unreasonably withheld or delayed), and provided further that the Company shall be obligated to pay Indemnitee’s attorneys’ fees and costs promptly as they are incurred in the defense of such claim or Proceeding.
 
(d) The indemnification provided by this Section 7.1 shall not be deemed to be exclusive of any other rights to which any Person may be entitled under any agreement, or as a matter of law, or otherwise, both as to action in a Person’s official capacity and to action in another capacity.
 
(e) The Management Committee shall have power to purchase and maintain insurance on behalf of the Company, the Managers, the Members, officers, employees or agents of the Company and any other Indemnitees at the expense of the Company, against any liability asserted against or incurred by them in any such capacity whether or not the Company would have the power to indemnify such Persons against such liability under the provisions of this Operating Agreement.
 
7.2 Limitation of Liability. The debts, obligations and liabilities of the Company shall be solely the debts, obligations and liabilities of the Company; and, except as provided under the Act, no Manager or Member shall be obligated personally for any such debt, obligation or liability of the Company solely by reason of being a Manager or Member of the Company.
 
7.3 Savings Clause. If this Article 7 or any portion hereof shall be invalidated on any ground by any court of competent jurisdiction, the Company shall nevertheless indemnify and hold harmless each Indemnitee or any other person indemnified pursuant to this Article 7 as to costs, charges and expenses (including, without limitation, reasonable attorneys’ fees), judgments, fines and amounts paid in settlement with respect to any action, suit or proceeding, whether civil, criminal, administrative or investigative, to the full extent permitted by any applicable portion of this Article 7 that shall not have been invalidated and to the fullest extent permitted by applicable law.
 
 
-22-

 
 
ARTICLE 8
DISSOLUTION AND WINDING UP
 
8.1 Dissolution. The Company shall be dissolved, its assets shall be disposed of, and its affairs wound up on the first to occur of the following:
 
(a) The written agreement of Members holding at least seventy-five percent (75%) of the Percentage Interests to dissolve the Company; or
 
(b) The entry of a decree of judicial dissolution under Section 18-802 of the Act.
 
Except for the foregoing, the Company shall not dissolve on the occurrence of any other event.
 
8.2 Winding Up. Upon the occurrence of any event specified in Section 8.1, the Management Committee promptly shall notify each of the Members, and the Company shall continue solely for the purpose of, and immediately begin the process of, winding up its affairs in an orderly manner, liquidating its assets, and satisfying the claims of its creditors. The Management Committee shall promptly appoint a Person to act as the liquidator of the Company (the “Liquidator”) who shall be responsible for overseeing the winding up and liquidation of the Company pursuant to the terms of this Operating Agreement. The Liquidator shall give written notice of the commencement of winding up by mail to all known creditors and claimants whose addresses appear on the records of the Company.
 
8.3 Reversion of Rights. Upon the occurrence of any event specified in Section 8.1, or upon the valid termination of the Commercialization Agreement by the Company, all of the rights granted by each of Patriot and TPL to the Company pursuant to the P-Newco License and T-Newco License, respectively, shall immediately and without further action by any of the parties thereto revert in their entirety to each of Patriot and TPL, respectively.
 
8.4 Order of Payment Upon Liquidation. Immediately after the reversion of rights contemplated by Section 8.3 above, payment shall be made in the manner contemplated by Section 6.1.
 
8.5 Antecedent Activities.
 
 
 
-23-

 

(a) The occurrence of any Recovery Event within twelve (12) months of a Termination Event, as defined in Section 6.2 of the Commercialization Agreement, shall entitle each of the Members to payment of the proceeds of such Recovery Event in accordance with Section 6.1.
 
(b) The entitlements set forth in Section 8.5(a) shall vest in the Members without further action. All proceeds and incidents of any such Recovery Event shall be transferred by the Member receiving such proceeds within three (3) Business Days (as defined in the Master Agreement) after receipt of such proceeds directly into an independent escrow account approved by Patriot and TPL for distribution pursuant to the terms of this Operating Agreement and the joint instructions of Patriot and TPL.
 
8.6 Limitations on Payments Made in Dissolution. Each Member shall only be entitled to look to the assets of the Company for the return of its Initial Capital Contribution, Working Capital Contribution and positive Capital Account balance and shall have no recourse for its Initial Capital Contribution, Working Capital Contribution, positive Capital Account balance and/or share of Gross Cash Proceeds (upon dissolution or otherwise) against the Management Committee or any other Member in the event the assets of the Company remaining after payment of or due provision for all debts, liabilities and obligations of the Company are insufficient to return such Member’s Initial Capital Contribution and positive Capital Account balance.
 
8.7 Certificate of Cancellation. When all debts, liabilities and obligations have been paid and discharged or adequate provisions have been made therefor and all of the remaining property and assets have been distributed to the Members, a certificate of cancellation shall be executed in duplicate and verified by all three (3) Managers, which certificate shall set forth the information required by the Act. Duplicate originals of the certificate of cancellation shall be delivered to the Secretary of State of the State of Delaware.
 
8.8 Effect of Filing Certificate of Cancellation. Upon the issuance of the certificate of cancellation, the existence of the Company shall cease. The Management Committee shall have the authority to distribute any Company property discovered after dissolution and take such other action as may be necessary on behalf of and in the name of the Company.
 
ARTICLE 9
MISCELLANEOUS
 
9.1 Amendment. The Management Committee shall have the duty and authority to amend the Certificate of Formation as and to the extent necessary to reflect any and all changes or corrections necessary or appropriate as a result of any action taken by the Members in accordance with the terms of this Operating Agreement. Members holding at least seventy-five percent (75%) of the Percentage Interests shall have the authority to amend this Operating Agreement. Notwithstanding anything to the contrary set forth herein, neither the Management Committee nor the Members may amend the Certificate of Formation or this Operating Agreement to decrease the Percentage Interest of a
 
 
-24-

 
 
Member, increase the Working Capital Contributions of a Member or the liability of a Member with respect to the Company without the consent of each Member affected thereby.
 
9.2 Governing Law and Severability. This Operating Agreement shall, in all respects, be construed in accordance with and governed by the laws of the State of Delaware as applied to agreements among Delaware residents entered into and to be performed entirely within Delaware. If any provision of this Operating Agreement becomes or is deemed invalid, illegal or unenforceable in any jurisdiction by reason of the scope, extent or duration of its coverage, then such provision shall be deemed amended to the extent necessary to conform to applicable law so as to be valid and enforceable or, if such provision cannot be so amended without materially altering the intention of the parties, then such provision shall be stricken and the remainder of this Operating Agreement shall continue in full force and effect. Should there ever occur any conflict between any provision contained in this Operating Agreement and any present or future statute, law, ordinance or regulation contrary to which the parties have no legal right to contract, the latter shall prevail, but the provision of this Operating Agreement affected thereby shall be curtailed and limited only to the extent necessary to bring it into compliance with the law. All the other terms and provisions of this Operating Agreement shall continue in full force and effect without impairment or limitation.
 
9.3 Counterparts. This Operating Agreement may be executed simultaneously in multiple counterparts and by facsimile, each of which shall be deemed an original, but all of which taken together shall constitute one and the same instrument.
 
9.4 Titles and Subtitles. The headings of this Operating Agreement are inserted for convenience only and shall not constitute a part of this Operating Agreement in construing or interpreting any provision hereof.
 
9.5 Notices. All notices and other communications required or permitted under this Operating Agreement shall be delivered to the parties at the address appearing on the books of Company, or at such other address that they designate by notice to all other parties in accordance with this section. All notices and communications shall be deemed to have been received unless otherwise set forth herein: (a) in the case of personal delivery, on the date of such delivery; (b) in the case of facsimile transmission, on the date on which the sender receives confirmation by facsimile transmission that such notice was received by the addressee, provided that a copy of such transmission is additionally sent by mail as set forth in (d) below; (c) in the case of overnight air courier, on the second business day following the day sent, with receipt confirmed by the courier; and (d) in the case of mailing by first class certified or registered mail, postage prepaid, return receipt requested, on the fifth business day following such mailing.
 
9.6 Entire Agreement. This Operating Agreement, as well as the Stipulated Final Judgment, Master Agreement, Commercialization Agreement and Newco Licenses, constitutes the entire agreement and
 
 
-25-

 
 
understanding of the parties with respect to the terms and conditions of the transactions referred to herein and therein and supersede all prior and contemporaneous agreements and understandings, oral or written, between the parties relating to such subject matter, other than as provided herein and therein.
 
9.7 Power of Attorney. By signing this Operating Agreement, each Member designates and appoints the Management Committee as their true and lawful attorney, in his name, place and stead, to make, execute, sign and file such instruments, documents or certificates which may from time to time be required by the laws of the United States of America and the State of Delaware and any political subdivision thereof or any other state or political subdivision in which the Company shall do business to carry out the purposes of this Operating Agreement, except where such action requires the express approval of a Member hereunder. The Management Committee shall provide to the Members copies of all documents executed pursuant to the power of attorney contained in this Section 9.7.
 
9.8 Related Party Transactions. The Company shall not, without the approval of the Management Committee, engage in any loans, leases, contracts or other transactions with any Manager, officer or key employee of the Company, any member of any such person’s immediate family, including the parents, spouse, children and other relatives of any such person, or any Person controlled by such person, with the exception of the payments to be made to TPL pursuant to Article IV of the Commercialization Agreement.
 
9.9 Dispute Resolution. All rights and obligations under this Operating Agreement shall be resolved as if all persons and all transactions related to this Operating Agreement had their legal residence, situs, and employment in Santa Clara County, California. Within fifteen (15) days after written notice of the dispute, members of the most senior management of the parties shall meet and exercise their best efforts to resolve any dispute under this Operating Agreement. If the dispute is not resolved to the mutual satisfaction of the parties within thirty (30) days after such notice, the Company, Patriot and TPL shall submit such dispute to expedited binding arbitration before a single arbitrator. The arbitration shall be administered by JAMS pursuant to its Comprehensive Arbitration Rules and Procedures. Judgment on the award, including without limitation injunctive relief, may be entered in any court having jurisdiction. All costs related to such arbitration shall be paid in advance by the Company, including the cost of translating into English all discoverable materials, and of providing contemporaneous translation of all live testimony. All performances due hereunder by the Company, Patriot and TPL shall continue unabated throughout the entire process and a final adjudication in accordance with the terms hereof has been made from which no appeal or review can be undertaken. This clause shall not preclude the parties from seeking provisional remedies in aid of arbitration, including without limitation a temporary or preliminary injunctive relief, from a court of appropriate jurisdiction. The arbitrator may, in the award, allocate all or part of the costs of the arbitration, including the fees of the arbitrator and the reasonable attorneys’ fees of the prevailing party.
 
9.10 No Partition. No Member nor any legal successor of a Member shall have the right to partition the property of the Company or any part thereof or interest therein, or to file a complaint or institute any proceeding at law or in equity to partition the property of the Company or any part thereof or interest therein. Each Member, for such Member and such Member’s legal successor, hereby waives any such rights. The Members intend that, during the term of this Operating Agreement, the rights of the Members and their successors in interest, as among themselves, shall be governed solely by the terms of this Operating Agreement and by the Act.
 
9.11 Bankruptcy. Neither the Management Committee, nor any Manager or Member of the Company, shall be permitted to file a bankruptcy petition on behalf of the Company unless the filing of the bankruptcy petition shall first have been approved in writing by Members holding at least seventy-five percent (75%) of the Percentage Interests of the Company.
 
[signature page follows]
 
 
-26-

 
 
IN WITNESS WHEREOF, the parties hereto have executed this Operating Agreement as of the day and year first above written.
 
PATRIOT SCIENTIFIC CORPORATION,
a Delaware corporation
 
By:________________________________________
Its:________________________________________
 
 
TECHNOLOGY PROPERTIES LIMITED INC.,
a California corporation
 
By:________________________________________
Daniel E. Leckron
Its:  Chairman
 

 
 
-27-

 
 
SCHEDULE 1
 
INITIAL CAPITAL CONTRIBUTIONS
 
 
MEMBER
 
CONTRIBUTIONS
 
AGGREGATE FAIR MARKET VALUE OF CONTRIBUTIONS
Patriot Scientific Corporation
 
· P-Newco License
· $2,000,000
   
Technology Properties Limited Inc.
 
· T-Newco License
· $2,000,000
   

 
 
-28-

 

SCHEDULE 2
 
PERCENTAGE INTERESTS
 

 
MEMBER
 
PERCENTAGE INTEREST
Patriot Scientific Corporation
 
50%
Technology Properties Limited Inc.
 
50%
 

 
 
-29-

 
 
EXHIBIT A
 
 
CONSENT OF CHARLES H. MOORE
TO
LIMITED LIABILITY OPERATING AGREEMENT
OF
P-NEWCO
A DELAWARE LIMITED LIABILITY COMPANY

 
Charles H. Moore (“Moore”) does hereby affirm and acknowledge that:
 
(a) Moore has read and reviewed the accompanying Limited Liability Company Operating Agreement (the “P-Newco Operating Agreement”) for P-Newco, a Delaware Limited Liability Company (“P-Newco”) and is familiar with the contents thereof;
 
(b) Technology Properties Limited Inc., a California Corporation, has full power and authority to enter into the P-Newco Operating Agreement insofar as it affects the interests of Moore in the microprocessor science and design patents set forth on Schedule 1 to the Master Agreement, to which Moore is a party; and
 
(c) Moore consents to the P-Newco Operating Agreement.
 
IN WITNESS WHEREOF, Moore has executed this Consent as of the [__] day of [__________], 2005.
 
CHARLES H. MOORE
 
________________________________________
 
 
 
-30-

 
 

 
EX-23.2 7 v046258_ex23-2.htm
EXHIBIT 23.2
 
CONSENT OF INDEPENDENT REGISTED PUBLIC ACCOUNTING FIRM
 
We consent to the use in this Prospectus constituting a part of this Registration Statement of our report dated August 18, 2005, except for notes 10 and 12, for which the date is September 12, 2005, relating to the financial statements of Patriot Scientific Corporation, which are contained in this Prospectus. We also consent to the reference to us under the caption “Experts” in the Prospectus.

/s/ Mayer Hoffman McCann P.C.


San Diego, California
June 27, 2006
 

 
EX-23.3 8 v046258_ex23-3.htm Unassociated Document
EXHIBIT 23.3

CONSENT OF INDEPENDENT REGISTED PUBLIC ACCOUNTING FIRM
 
We consent to the use in this Prospectus constituting a part of this Registration Statement of our report dated July 8, 2004, relating to the financial statements of Patriot Scientific Corporation, which are contained in this Prospectus. Our report contains an explanatory paragraph regarding the Company’s ability to continue as a going concern. We also consent to the reference to us under the caption “Experts” in the Prospectus.


/s/ Nation Smith Hermes Diamond


San Diego, California
June 27, 2006
 


-----END PRIVACY-ENHANCED MESSAGE-----